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1003-43 Phosphodiesterase-5 Inhibitors Reduce Myocardial 
Infarction, Apoptosis and Improve Post-Ischemic 
Ventricular Function in Female Mice
Fadi N. Salloum, Antonio Abbate, William R. Brown, Ramzi A. Ockaili, Nicholas N. Hoke, 
Rakesh C. Kukreja, Virginia Commonwealth University Medical Center, Richmond, VA
Background: Phosphodiesterase-5 (PDE-5) inhibitors sildenaﬁl (SIL) and vardenaﬁl 
(VAR) induce powerful cardioprotection against ischemia/reperfusion injury (I/R) in male 
animal models. Since the impact of PDE-5 inhibitors on the female cardiovascular system 
following ischemia remains unknown, we interrogated the effect of SIL and VAR on I/R 
in female mice.
Methods: Adult female mice were pretreated (ip, bid) with SIL (0.71 mg/kg), VAR (0.14 
mg/kg) or saline one hr before left coronary artery ligation for 30 min and reperfusion for 
24 hr. At the end of reperfusion, infarct size (IS) was measured using TTC staining and 
apoptosis was measured using TUNEL assay. Left ventricular (LV) function was evaluated 
using echocardiography.
Results: Myocardial IS (mean ± SE) was reduced with SIL (9.1 ± 1.0%) and VAR 
(8.8±1.1%) as compared to saline (39.9±4.5%, P<0.05). The apoptotic index was 9.0 ± 
3.3% for saline, 1.9 + 0.9% and 2.4 ± 0.9% for SIL and VAR, respectively. LV end-diastolic 
and end-systolic diameters increased 7 days post MI with saline. In contrast, no dilatation 
was detected in SIL and VAR groups. Moreover, fractional shortening (FS) decreased 7 
days post MI with saline, but was well preserved with SIL and VAR (Table). Furhtermore, 
survival rate was lower with saline (57%) as compared to SIL (95%) and VAR (100%).
Conclusions: PDE-5 inhibitors induce powerful cardioprotection in female mice. We 
propose that PDE-5 inhibition may be a novel therapeutic strategy against I/R in women 
with coronary artery disease.
*P<0.05 vs. Control
Group LVEDD (mm) LVESD (mm) FS (%)
Control 3.1 ± 0.1 1.6 ± 0.1 46.7 ± 1.4
Saline 3.5 ± 0.1* 2.4 ± 0.2* 30.4 ± 4.1*
SIL 3.0 ± 0.1 1.4 ± 0.1 52.2 ± 2.0
VAR 2.9 ± 0.3 1.4 ± 0.2 52.7 ± 5.1
11:00 a.m.
1003-44 Transient Overexpression of Human Heme Oxygenase-
1 in Transplanted Mesenchymal Stem Cells Results in 
Enhanced Repair of Myocardial Infarction
Toshinari Tsubokawa, Kunimasa Yagi, Atsushi Nohara, Chiaki Nakanishi, Hatsue 
Ueda, Noboru Fujino, Masaaki Kawashiri, Hidekazu Ino, Noritoshi Nagaya, Masakazu 
Yamagishi, Division of Cardiovascular Medicine, Kanazawa University Graduate School 
of Medicine, kanazawa, Japan, Departments of Regenerative Medicine and Tissue 
Engineering, National Cardiovascular Center, Osaka, Japan
Background: Bone marrow-derived mesenchymal stem cells (MSC) could be of great 
therapeutic potential after ischemic myocardial injury. However, intolerance and poor cell 
viability associated with oxidative stress after transplantation has limited the reparative 
capacity. Under these conditions, Heme Oxygenase-1 (HO-1) plays a pivotal role as anti-
oxidative stress molecule.
Methods: Transfer of human HO-1 gene in cultured MSC was performed by lipofection 
method and expression of HO-1 mRNA was analyzed by RT-PCR. To evaluate the effect of 
HO-1 overexpression, MSC or MSCHO-1 were exposed to culture conditions with serum 
deprivation and hypoxia (SD/hypoxia) over different periods of time and characteristics 
of cell damage were analyzed by ﬂow cytometry. In vitro, cell viability was determined by 
MTS assay after exposing MSC or MSCHO-1 to H2O2 as an oxidative stress. VEGF level 
in the supernatant of each cells culture after the load of H2O2 were measured by using 
ELISA. In rat infarction model, MSC (5×106 ±0.4 ×106 cells/rat) or MSCHO-1was injected 
around the infracted border zone, and cardiac examination was performed on 28th day 
after cell transplantation.
Results: The efﬁciency of HO-1 gene transfer was about 80% . HO-1 overexpression 
was observed in MSC and which prevented MSC from SD/hypoxia - induced apoptosis. 
In addition, MSCHO-1 as resistant to cell death under condition of oxidative stress 
(400-500µM H2O2) and secreted a large amount, 2.5-fold more VEGF compared with 
MSC.Transplantation of MSCHO-1 attenuated left ventricular remodeling and improved 
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1003-41 Oral Glyburide, but not Glimepiride, Blocks the Infarct-
Size Limiting Effects of Pioglitazone
Yumei Ye, Yu Lin, Saraswathy Manickavasagam, Regino J. Perez-Polo, Yochai Birnbaum, 
University Of Texas Medical Branch, Galveston
Background: Many patients with diabetes mellitus type 2 (DM2) receive several oral 
hypoglycemic agents, including sulfonylurea-urea drugs. Intravenous glyburide (GLYB), 
a sulfonylurea agent, blocks the protective effects of preconditioning in various animal 
models without affecting myocardial infarct size (IS). However, there are conﬂicting results 
when other sulfonylurea drugs are used. Pioglitazone (PIO) reduces IS in the rat. We 
asked whether oral GLYB and glimepiride (GLIM) affect the IS-limiting effects of PIO. 
Methods: Sprague-Dawley rats received 3-day oral treatment with: PIO (5mg/kg/d); 
PIO+GLYB (10mg/kg/d); PIO+GLIM (4mg/kg/d) or water alone. Drugs were administered 
by oral gavage. Sugar 5% was added to water to prevent hypoglycemia. Rats underwent 
30min coronary artery occlusion and 4h reperfusion (n=6 in each group). Area at risk (AR) 
was assessed by blue dye and IS by triphenyl-tetrazolium-chloride. Results: Body weight 
and the AR size were comparable among groups. IS (% of the AR) was signiﬁcantly 
smaller in the PIO (p<0.001) and PIO+GLIM (p<0.001) groups than in the control group. 
GLYB completely blocked the effect of PIO (p<0.001). GLIM did not affect the protective 
effect of PIO (p=0.993). Conclusions: Oral GLYB, but not GLIM, blocks the IS limiting 
effects of PIO. It is plausible that GLYB affects other pleiotropic effects of PIO and thus 
may attenuate favorable effects on cardiovascular outcomes. In contrast, GLIM does not 
attenuate the protective effect of PIO. 
11:00 a.m.
1003-42 Resolvin E1 Protects the Rat Heart Against Reperfusion 
Injury
Yochai Birnbaum, Yumei Ye, Yu Lin, Saraswathy Manickavasagam, Regino J. Perez-
Polo, Per Gjorstrup, University Of Texas Medical Branch, Galveston, TX, Resolvyx 
Pharmaceuticals, Inc., Bedford, MA
Background: Resolvin E1 (RvE1) is an endogenously formed oxidation product of the 
omega-3 polyunsaturated fatty-acid eicosapentaenoic acid (EPA), originally isolated from 
exudates during the resolution phase of an acute inﬂammation. Its further investigation has 
conﬁrmed multiple actions in the control of inﬂammation including both anti-inﬂammatory 
properties and activation of survival pathways. We asked whether RvE1, administered 
before reperfusion, can limit myocardial infarct size (IS). Methods: Rats were anesthetized 
with ketamine and xylazine and underwent 30 min of coronary artery occlusion and 4h 
of reperfusion. Just before reperfusion rats received i.v. RvE1 (0.03 mg/kg, 0.1 mg/kg or 
0.3 mg/kg) or vehicle alone (control). Area at risk (AR) was assessed by blue dye and IS 
by TTC. Results: RvE1 did not affect heart rate or mean blood pressure. Body weight, 
left ventricular weight and the size of AR were comparable among groups. RvE1 dose-
dependently limited IS (Figure. * p<0.05 vs. control; # p<0.05 vs. RvE1 0.3). Conclusions: 
RvE1 protects against reperfusion injury and limits myocardial infarct size. 




21.1%(MSCHO-1 group) V.S. 36.9%(control group), p<0.05). Capillary density was 
markedly increased in the MSCHO-1 group.
Conclusion: These results demonstrate transplantation of MSC with transient 
overexpression of HO-1 could enhance the reduction of myocardial injury after acute 
ischemia, probably through suppression of the allogenic reaction and graft loss in early 
stages. We suggest the advantage of combined transplantation of cardiac stem cell and 
MSC in salvaging ischemic myocardial injury.
11:00 a.m.
1003-45 Endogenous Thymosin Increases During Acute 
Myocardial Ischemia
Atman P. Shah, Nirat Beohar, Scott Youngquist, Gary Josephson, John P. Rosborough, 
James T. Niemann, Harbor-UCLA Medical Center, Torrance, CA
Background: Efforts to promote tissue repair following myocardial infarction through the 
use of stem cells usually requires isolation and introduction of progenitor cells. Thymosin 
A1 (TA1) and thymosin B4 (TB4) have been shown to promote cell migration and cell 
survival after ischemia. The purpose of this study was to determine the time course of TA1 
and TB4 appearance during acute myocardial ischemia.
Methods: 15 anesthetized and instrumented domestic swine underwent balloon occlusion 
of the proximal LAD. LAD occlusion was conﬁrmed angiographically in all animals. During 
occlusion, venous blood samples were collected from the right atrium at 5 min intervals for 
30 min. Plasma levels of TA1, TB4, and MMP-9 (matrix metalloproteinase-9, selected as a 
marker for remodeling and repair) were measured by ELISA. Changes in concentrations 
over time were assessed with one way RMANOVA on ranks with Dunnett’s test.
Results: Changes in TA1, TB4, and MMP-9 are shown in the ﬁgure (median, 25%-75% 
IQR) from baseline to 30 minutes of occlusion. TA1 and MMP-9 were statistically increased 
over control at 20 minutes and TB4 was increased over control at 15 minutes (p<0.05).
Conclusion: Endogenous thymosins increase shortly after the onset of myocardial 
ischemia and increase in parallel to proteases involved in remodeling. The thymosins may 
represent an endogenous mechanisms to recruit undifferentiated stem cells in response 
to myocardial ischemia. 
11:00 a.m.
1003-46 Inhibiting Protease-Activated Receptor 4 Activation 
Limits Myocardial Ischemia/Reperfusion Injury in Rat 
Hearts by Unmasking Adenosine Signaling
Jennifer L. Strande, Jidong Su, Xiangping Fu, Anna Hsu, Garrett J. Gross, John E. 
Baker, Medical College of Wisconsin, Milwaukee, WI
Background: Harnessing endogenous cardioprotectants is a novel therapeutic strategy 
to combat ischemia/reperfusion (I/R) injury. Thrombin causes whereas exogenous 
adenosine prevents I/R injury. We hypothesized that blocking thrombin activation with 
a Protease-Activated Receptor 4 (PAR4) antagonist would unmask the cardioprotective 
effects of endogenous adenosine.
Methods/Results: PAR4 mRNA and protein were detected in the rat heart by RT-
PCR and immunoblot analysis. We then assessed the potential protective role of two 
structurally unrelated PAR4 antagonists, tc-Y-NH2 and P4pal10 in an in vivo and in vitro 
rat model of myocardial I/R injury. P4pal10 (0.1-100 µg/kg) treatment before ischemia 
decreased infarct size (IS) by 31% in the in vivo model at an optimal dose of 10 µg/
kg. P4pal10 also signiﬁcantly decreased IS by 21% and 19% respectively when given 
after the onset of ischemia or at reperfusion. Tc-Y-NH2 (1-10 µM) treatment immediately 
before ischemia decreased IS by 51% in the in vitro model and increased recovery in 
ventricular function by 26% following I/R at a optimal concentration of 5 µM. To assess if 
the cardioprotective effects of PAR4 blockade were due to endogenous adenosine acting 
on adenosine receptors, isolated hearts were treated with a non-selective adenosine 
receptor blocker (8-SPT) with tc-Y-NH2 before ischemia. 8-SPT abolished the protective 
effects of tc-Y-NH2 but did not affect IS when given alone. Survival pathways known to 
be up-regulated by adenosine were then explored. The cardioprotective effects of tc-Y-
NH2 were abolished by inhibition of Akt (wortmannin), ERK1/2 (PD98059), NOS (L-NMA) 
and KATP channels (glibenclamide). PD98059, L-NMA and glibenclamide alone had no 
effect on cardioprotection in vitro. Furthermore, inhibition of mitochondrial KATP channels 
(5-HD) and sarcolemmal KATP channels (HMR 1098) abolished P4pal10-induced 
cardioprotection in vivo.
Conclusion: Thrombin receptor blockade by PAR4 inhibition provides protection against 
injury from myocardial I/R by unmasking adenosine receptor signaling and supports the 
hypothesis of a coupling between thrombin receptors and adenosine receptors which 
may play a major role in cardioprotection.
11:00 a.m.
1003-47 Ranolazine Attenuates Palmitoyl-L-Carnitine Induced 
Ventricular Diastolic Dysfunction
Yuzhi Wu, Luiz Belardinelli, John Shryock, CV Therapeutic, Palo Alto, CA
Background: Palmitoyl-L-carnitine (PC), an ischemic metabolite, alters Na+ channel 
function and causes cellular Na+ and Ca2+ overload. Ranolazine (Ran) is anti-anginal 
drug and a selective blocker of late sodium current. This study was to determine if Ran 
attenuates PC-induced diastolic dysfunction (increased wall stiffness, reduced vascular 
conductance and ischemia).
Methods: Guinea pig isolated hearts perfused at constant ﬂow (Langendorff method) 
were used to study left ventricular end-diastolic pressure (LVEDP), coronary perfusion 
pressure (CPP), and cardiac lactate and adenosine release. Hearts were treated with 
4 uM PC for 30 min followed by 30 min treatment with Ran or vehicle. To measure wall 
stiffness, hearts were exposed to no drug (control), PC, or PC + 10uM Ran for 30min; 
the incremental increase of LVEDP caused by an increase of intraventricular volume was 
measured.
Results: PC increased LVEDP, wall stiffness (see Figure), CPP, and lactate and adenosine 
release. Ran (10 µM) signiﬁcantly reduced the PC-induced increase in LVEDP by -61 
± 5 % (n=6, p<0.001) and reduced wall stiffness (Figure). Ran (10 µM) attenuated the 
PC-induced increase of CPP by -27 ± 3% (n=6-7, p<0.05). Ran (10 µM) reduced the 
PC-induced increase of lactate and adenosine release by (-50 ± 7 and -75 ± 4 %), 
respectively (n=6, pa 0.05 for both).
Conclusion: Ran attenuated PC-induced ventricular diastolic dysfunction, as indicated by 
reduction of wall stiffness (positive lusitropic effect), ischemic metabolites, and CPP
11:00 a.m.
1003-48 Killer Immunoglobulin-like Receptor Genotype and the 
Risk of Acute Coronary Syndromes
Phillip A. Horwitz, Trudy L. Burns, John A. Spertus, Lan Xiao, Thomas M. Morgan, Paul 
W. Naumann, Jonathan W. Heusel, University of Iowa, Iowa City, IA, Mid America Heart 
Institute and University of Missouri–Kansas City, Kansas City, MO
Background: Chronic inﬂammation is a known risk factor for acute coronary syndromes 
(ACS). Killer immunoglobulin-like receptors (KIR) regulate both tolerance and activation 
of natural killer (NK) and T cells. KIR genes are encoded in a cluster of polymorphic genes 
and exist as either activating or inhibitory receptors with opposing effects on immune 
cell activation. KIR genotypes have been associated with a variety of human diseases 
characterized by chronic inﬂammation. Our objective was to investigate the association 
between KIR genotype and risk of ACS.
Methods: We conducted a case-control study on 192 Caucasian subjects with ACS 
and 192 controls. Case subjects were prospectively enrolled after admission for ACS. 
Controls were randomly selected from a cohort of outpatients without prior manifestations 
of coronary artery disease undergoing blood draws for routine clinical testing. KIR 
genotypes were determined by PCR-based ampliﬁcation of 15 distinct KIR genes. KIR 
genotype frequencies, clinical and demographic variables were compared between cases 
and controls using chi-square and Student’s t tests. Logistic regression models were used 
for multivariable analyses after adjusting for known cardiac risk factors.
Results: Mean age was 63±12 and 61±13 years for cases and controls, respectively 
(p=0.17). 68% of cases and 56% of controls were male (p=0.01). Prevalence of the 
inhibitory KIR genes 3DL1(95.3 vs. 89.1%; p=0.02) and 2DL3 (93.8 vs. 88.0; p=0.05) were 
higher and the activating KIR 2DS3 lower (19.8 vs. 31.3%; p=0.01) in case vs. control 
subjects. Prevalence of the inactive variant of the activating KIR 2DS4n was also higher in 
cases (83.9 vs. 73.4%; p=0.01). In multivariable analysis, the adjusted odds of activating 
KIR 2DS3 were signiﬁcantly lower in ACS cases relative to controls (OR 0.42; 95%CI 
0.22-0.82). Other signiﬁcant covariates associated with case status were male sex, less 
education, smoking, no alcohol use, and a family history of premature atherosclerosis.
Conclusions: KIR gene frequencies differ in ACS patients compared to controls, 
suggesting that KIR gene products may inﬂuence T- and NK- cell activation, vascular 
inﬂammation and the risk of ACS development.




















1003-49 Endothelin-1 receptor blockade and left ventricular 
unloading immediately prior to reperfusion result in 
equivalent myocardial salvage compared to reperfusion 
alone in a rabbit myocardial infarction model
Sophie Tamareille, James Amirian, Patricia Felli, Fenghua Li, William Barry, Richard 
Smalling, The University of Texas at Houston Medical School, Houston, TX, The 
University of Utah Health Science Center, Salt Lake City, UT
Background: Previous work has shown that during acute ischemia/reperfusion (I/R), left 
ventricular (LV) unloading reduces endothelin-1 (ET-1) release and is cardioprotective. 
We have also found that ET-1 release is associated with calcium overload related cell 
death. We tested the hypothesis that ET-1 released during acute myocardial infarction 
might mediate I/R injury by stimulating an increase in intracellular calcium concentration 
([Ca2+]i) and triggers the apoptotic cascade.
Methods: 24 anesthetized rabbits were subjected to 1 hour of left circumﬂex coronary 
artery occlusion followed by 3 hours of reperfusion. Unloading was initiated 15 min prior 
to reperfusion and maintained during the entire period of reperfusion (unloaded group, 
n=6). A control group (n=6) was subjected to reperfusion alone. 12 animals were treated 
with ET-1 receptor antagonist BQ123 with or without unloading. In parallel, isolated rabbit 
cardiomyocytes were subjected to simulated I/R with or without ET-1 or BQ123 and 
intracellular Ca2+ was assessed with ﬂow cytometry.
Results: Just prior to reperfusion, LV unloading signiﬁcantly decreased LV end-diastolic 
pressure. LV support signiﬁcantly reduced ET-1 release from the heart at 2 hours of 
reperfusion (21.37±2.83 pg/mL vs 54.34±11.34 pg/mL, P=0.03). Infarct size, expressed 
as % of zone at risk, was signiﬁcantly reduced in the unloaded group (3.39±1.35%) 
and in the BQ123 treated groups with or without unloading (4.61±1.09 and 5.06±3.81 
respectively) compared to controls (17.50±4.52%). LV unloading caused a signiﬁcant 
reduction in the % of apoptotic cells (2.75±0.38% vs 5.84±1.97%, P=0.003) associated 
with a signiﬁcant increase in the anti-apoptotic Bcl-2 protein expression in the ischemic 
region. In isolated ventricular myocytes subjected to simulated I/R, BQ123 signiﬁcantly 
reduced both ET-1-induced [Ca2+]i increase and cell death.
Conclusions: Our results suggest that the molecular basis of reperfusion injury involves 
endothelin-1 release which stimulates calcium overload and apoptosis. Intravenous ET-1 
receptor blockade prior to reperfusion should be evaluated as an adjunct to reperfusion 
therapy in STEMI patients.
11:00 a.m.
1003-50 Human Umbilical Cord Stem Cells Decrease Myocardial 
Cytokines, Inﬂammatory Cells, and Infarct Size
Robert J. Henning, Ujwala Eadula, Masood Shariff, Felipe Alvarado, Mark Vasko, 
Vincent DeLostia, JAMES A.HALEY MEDICAL CENTER/UNIVERSITY OF SOUTH 
FLORIDA, TAMPA, FLORIDA
We investigated whether human umbilical cord blood stem cells (HUCBC) can decrease 
cytokines, inﬂammatory cells and infarct (MI) size. We ligated the left coronary artery in 
rats and injected 4X106 HUCBC in Isolyte or Isolyte alone into each MI. We measured 
cytokine proteins in HUCBC (N=15) and Isolyte (N=15) treated LVs at 2, 6, 12, 24, and 
72 hrs after MI. We counted LV CD3, CD4, CD8 T cells and CD11b macrophages by 
ﬂow cytometry at 24 and 72 hrs after MI treatment with HUCBC (24 hrs N=17; 72 hrs 
N=19) or Isolyte (24 hrs N=17; 72 hrs N=19). MI size was determined by tetrazolium stain. 
RESULTS: In Isolyte treated rats, LV cytokines increased above controls from 2 to 72 
hrs after MI : TNFA increased from 6.7+0.8% to 52.3+4.6%, monocyte chemoattractant 
protein (MCP) from 9.5+1.1% to 39.8+2.0%, fractalkine from 11+1.5% to 28.1+1.3%, 
monocyte inﬂammatory protein (MIP) from 10.3+1.6% to 23.9.0+1.5%, interleukin (IL)-1B 
from 6.1+0.04% to 19.0+1.2%, ciliary factor (CNTF) from 12.1+0.02% to 21.9+1.1%, and 
interferon-G (INF-G) from 8.7+0.3% to 26.0+1.7% (all p<0.001). In HUCBC treated MIs, 
TNFA, MCP-1, fractalkine, MIP, IL-1 B, CNTF, and INF-G did not signiﬁcantly change. 
The percentage of CD3, CD4 and CD11b in 50,000 myocytes was less in HUCBC than 
in Isolyte LVs at 24 hrs (p<0.01) and the decreases in CD3 and CD4 persisted at 72 hrs 
(p<0.01) (Table). MI sizes averaged 10+1% in HUCBC treated LVs in contrast to Isolyte 
LVs that averaged 28+1% (p<0.01). CONCLUSION: HUCBC decrease MI cytokines, 
inﬂammatory cells and infarct size. 
CELL COUNT % BY FLOW CYTOMETRY: HUCBC vs. ISOLYTE
TIME TREATMENT CD3 CD4 CD8 CD11B
24 Hrs Post MI
ISOLYTE 11.50±1.61 7.50±1.52 2.47±0.50 2.39±0.27
HUCBC 5.64±1.02 2.94±0.70 1.60±0.33 1.67±0.24
SHAM 4.51±1.12 3.00±0.90 1.44±0.34 0.67±0.12
72 Hrs Post MI
ISOLYTE 8.01±1.18 5.07±0.80 2.57±0.28 2.40±0.47
HUCBC 4.12±0.53 2.32±0.39 2.19±0.28 1.80±0.26
SHAM 4.11±1.08 2.76±0.84 1.39±0.28 0.67±0.09
11:00 a.m.
1003-51 Injection of an Acellular Matrix Emulsion Enhances 
Angiogenesis and Improves Cardiac Function by 
Mobilizing Bone Marrow C-kit Cells after Ischemia and 
Reperfusion
Zhi-Qing Zhao, John D. Puskas, Di Xu, Ning-Ping Wang, Robert A. Guyton, Jakob 
Vinten-Johansen, Robert Matheny, Emory University, Atlanta, GA
Background: Recruitment of bone marrow-derived c-kit cells has been associated with 
tissue angiogenesis and repair after myocardial infarction. The purpose of this study 
was to test the hypothesis that injection of an acellular extracellular matrix emulsion 
in ischemic myocardium enhances angiogenesis and preserves cardiac function by 
mobilizing bone marrow c-kit cells. Methods: Thirty six rats were subjected to 45 minutes 
coronary occlusion followed by 3, 7 and 21 days of reperfusion with and without emulsion 
injection, respectively. Histological examination was performed by immunohistological 
staining and cardiac function was analyzed using echocardiography. Results: Emulsion 
(50 µl) was injected into the area at risk myocardium after reperfusion and localization of 
emulsion was conﬁrmed with Masson’s trichome staining. At 21 days after reperfusion, the 
population of c-kit positive cells in the bordering emulsion area and within emulsion area 
increased to a signiﬁcant extent relative to the Control (32±0.6* vs. 15±3/1000 nuclei). 
Along with this change, strong immunoreactivity of VEGF with emulsion injection was 
detected in emulsion area. Angiogenesis in emulsion area was signiﬁcantly enhanced 
relative to the Control, evidenced by increased density value of A-SMA-positive vessels 
(70±10* vs. 20±4/HPF) and vWF-positive vessles (95±14* vs. 34±8/HPF), respectively. 
Echocardiography showed improvements with emulsion in end-systolic volume (0.3±0.1* 
vs. 0.6±0.3 ml)), fractional shortening (33±5* vs. 24±6%) and ejection fraction (67±6* 
vs. 53±10%). The wall thickness of the infarcted middle anterior septum with emulsion 
was also signiﬁcantly greater than that in the Control (0.19±0.02* vs. 0.15±0.02cm). 
Conclusion: Intramyocardial injection of acellular matrix emulsion into the ischemic/
reperfused myocardium enhances tissue angiogenesis and preserves cardiac function by 
recruiting bone marrow c-kit positive cells. * p<0.05 Emulsion vs. Control.
11:00 a.m.
1003-52 Pregnancy-associated plasma protein-A in cardiac and 
non-cardiac patients
Kasper Iversen, Ane Teisner, Borge Teisner, Peer Grande, Peter Clemmensen, 
Rigshospitalet, Copenhagen, Denmark, The London Bridge Fertility, Gynaecology and 
Genetics Centre, London, United Kingdom
Background: Pregnancy-associated plasma protein-A (PAPP-A) is a new biomarker in 
acute coronary syndromes that detect vulnerable plaques and potentially points out high-
risk patients. Large studies of serial measurements of PAPP-A in patients with acute 
coronary syndromes are needed, so we assessed the levels of PAPP-A in a large patient 
cohort with acute coronary syndromes and compared it to healthy individuals and patients 
admitted with non-cardiac disease.
Methods: Serial measurements (1-5 samples) of PAPP-A were performed in 354 patients with 
ST-elevation myocardial infarction, 123 patients with non ST-elevation myocardial infarction 
and 415 patients with low-risk acute coronary syndrome. Single measurement of PAPP-A was 
performed in 1448 patients with non-cardiac disease and in 100 healthy volunteers. PAPP-A 
was analysed with a novel ELISA technique with a detection limit of 4.0 mIU/l.
Results: Considering the peak PAPP-A value from each patient, 91% of patients with 
myocardial infarction, 74% of patients with low-risk acute coronary syndrome, 19 % of 
patients with non-cardiac disease and 1% of healthy volunteers had detectable PAPP-A, 
p<0.01 for all comparisons. In the ﬁgure the percentage of patients with PAPP-A above 
different cut-off levels are shown.
Conclusion: PAPP-A is elevated across the entire spectrum of acute coronary syndromes 
and considerably higher than in patients with non-cardiac disease. PAPP-A is promising 
as a marker of the unstable plaque in coronary disease. 





1003-53 Postconditioning Markedly Reduces Reperfusion 
- Induced Ventricular Arrhythmias - Even in the 
Senescent Heart
Joan Dow, Anil Bhandari, Robert A. Kloner, Heart Institute, Good Samaritan Hospital, 
Los Angeles, CA, Keck School of Medicine at University of Southern California, Los 
Angeles, CA
Background: Studies suggest that in elderly populations, the cardioprotective effects of 
ischemic preconditioning are lost. Previously we observed that ischemic postconditioning 
markedly reduced reperfusion induced ventricular arrhythmias in young adult rats. 
Whether postconditioning’s beneﬁt is lost in senescent hearts is unknown. Therefore, the 
purpose of this study was to determine if postconditioning’s beneﬁcial effect on ventricular 
arrhythmias is maintained in elderly hearts. Methods: Young adult rats (3 to 4 months old) 
or old rats (24 to 25 months old) were randomized to four groups: Young adult control, 
young adult postconditioning, old control, and old postconditioning. Young control (n = 11) 
and old control (n = 8) groups received 5 minutes of left coronary artery occlusion followed 
by 5 minutes of reperfusion while young postconditioning (n = 11) and old postconditioning 
(n = 10) were subjected to 5 minutes of occlusion; but then a postconditioning regimen 
of 4 cycles of 20 seconds of reperfusion/20 seconds of reocclusion prior to sustained 5 
minutes of reperfusion. Results: Postconditioning reduced the number of young rats that 
developed reperfusion-induced ventricular tachycardia (VT); (4 in young postconditioning) 
compared to 11 in young control (p = 0.004); the number of episodes of VT (4.8 ± 3.1 
vs. 11.6 ± 1.3; p = 0.01); the number of rats with sustained VT q 10 sec (2 vs. 11; p = 
0.0002); and the % of time during reperfusion spent in VT (2.7% ± 1.8% vs. 18.9 ± 4.0%; 
p = 0.002). In old rats postconditioning also reduced the number of rats that developed 
VT (4 in old postconditioning vs. 8 in old control; p = 0.01); the number of episodes of 
VT (1.3 ± 0.7 vs. 7.0 ± 2.3; p = 0.01); the number with sustained VT (0 vs. 4; p = 0.02); 
and the % time during reperfusion spent in VT (0.33% ± 0.15% vs. 3.8 ± 1.3%; p = 
0.03). Conclusions: Thus although overall amount of VT was less in old vs. young adult 
rats, postconditioning still markedly lowered ventricular arrhythmias in old rats. Unlike 
some studies that suggest that the beneﬁts of preconditioning are lost in elderly subjects, 
postconditioning robustly reduced ischemia/reperfusion induced ventricular tachycardia 
in the senescent heart.
11:00 a.m.
1003-54 Effect of Beta-blockade on Regional Function and 
Myocardial Cytokine Levels in Chronic Ischemic 
Cardiomyopathy: An Experimental Evaluation
Dai-Trang Le, Marco Pascotto, Ibrahim Sari, Thanjavur Bragadeesh, Antonio Micari, 
Helmy Siragy, Sanjiv Kaul, OHSU, Portland, OR
Background: The mechanisms of the beneﬁcial effects of B-blockers in ischemic 
cardiomyopathy (IC) have not been fully elucidated. We hypothesized that the beneﬁcial 
effects of B-blockers in IC are related to their anti-inﬂammatory properties. Methods: We 
induced ischemic left ventricular (LV) dysfunction by placing ameroid constrictors around 
the proximal coronary arteries in 29 chronically instrumented dogs. Microcatheters 
were placed in the LV myocardium for interstitial ﬂuid collection for myocardial cytokine 
measurement. After LV dysfunction developed, the dogs were randomized to 3 groups: 
placebo (n= 8); metoprolol (n = 11); and carvedilol (n=10). Percent wall thickening (%WT) 
and myocardial and plasma TNF-A, IL-6, and IL-1B levels were measured before and at 
1, 2, and 3 months after initiation of drug therapy. 
WT (%) Baseline 1 month 2 months 3 months
Placebo 22.5 ± 8.0 21.9 ± 6.0 23.3 ± 5.2 22.1 ± 5.4
Metoprolol 27.3 ± 6.3* 25.7 ± 4.4* 27.7 ± 4.9* 28.4 ± 5.9†
Carvedilol 24.4 ± 6.4 28.7 ± 5.2* 31.0 ± 5.8† 32.0 ± 5.3†‡
TNF-A (pg/mL)
Placebo 59.8 ± 36.5 80.6 ± 44.5 70.1 ± 38.9 52.0 ± 28.4
Metoprolol 43.3 ± 21.9 57.5 ± 3.5 47.0 ± 20.5 43.1 ± 24.3
Carvedilol 60.3 ± 35.2 47.6 ± 23.4* 46.1 ± 33.1 50.4 ± 8.8
IL-6 (pg/mL)
Placebo 0.48 ± 0.30 0.67 ± 0.25 0.59 ± 0.25 0.59 ± 0.27
Metoprolol 0.33 ± 0.16 0.39 ± 0.17† 0.37 ± 0.18* 0.28 ± 0.19†
Carvedilol 0.34 ± 0.12 0.39 ± 0.18† 0.42 ± 0.15 0.42 ± 0.24
IL1-B (pg/mL)
Placebo 60.0 ± 13.0 61.3 ± 15.8 51.6 ± 15.7 60.9 ± 6.0
Metoprolol 50.1 ± 15.0 54.1 ± 11.4 51.0 ± 14.7 50.4 ± 8.8†
Carvedilol 52.7 ± 12.7 57.1 ± 9.6 50.1 ± 13.6 47.5 ± 3.5*
*p<0.05 vs. Placebo; †p<0.01 vs. Placebo; ‡ p<0.05 vs Metoprolol
Results: There was no difference in %WT and myocardial cytokine levels prior to drug 
therapy. At 1, 2, and 3 months after treatment, %WT improved in dogs receiving B-
blockers compared with placebo, which was associated with a decrease in myocardial 
TNF-A, IL-6, and IL-1B levels. In comparison, plasma cytokine levels did not change 
between the groups. Conclusion: We have shown that in a multivessel chronic ischemia 
model, improvement of LV function was associated with suppression of myocardial and 
not circulating pro-inﬂammatory cytokines. Our results suggest that myocytes or cells 
in the extracellular matrix may play an important role in perpetuating the inﬂammatory 
state of IC.
11:00 a.m.
1003-55 Therapeutic Beneﬁts of Umbilical Cord Blood-derived 
Mesenchymal Stem Cells in Ischemic Cardiac Injury
Yong Sook Kim, Youngkeun Ahn, Moon Hwa Hong, Hye Jeong Park, Jin Sook Kwon, Hyun 
Ju Lee, Chang Hun Song, Kye Hun Kim, Young Joon Hong, Ju Han Kim, Hyung Wook 
Park, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Chonnam National University 
Hospital, Gwangju, South Korea, Chosun University Hospital, Gwangju, South Korea
Background: We designed this study to demonstrate the therapeutic potential of umbilical 
cord blood (UCB)-mesenchymal stem cells (MSCs) cellular properties.
Methods: MSCs were isolated from UCB and characterized. Cell migration was assayed 
by wound healing assay, and angiogeneic potential of MSC was evaluated by in vitro 
tube formation. The expressions of Ang-1, VEGF isoforms, ie VEGF121, VEGF165, and 
VEGF189, CARP, and STAT-3 were determined by RT-PCR or Western blot analysis. For 
in vivo study, myocardial infarction was induced by ligation of left anterior descending 
coronary artery for 30 min followed by release in rats, and MSCs were injected around 
the infarcted area. Before and 2 weeks after surgery, the echocardiograph and histologic 
analysis were performed.
Results: The mRNA and protein expression level of CARP in UCB-MSCs were higher 
than those of BM-MSCs. UCB-MSCs were transfected with CARP siRNA for 72 hours to 
reduce the CARP protein level to 30% of basal level. In wound healing assay, it was delayed 
in CARP siRNA transfected UCB-MSCs compared with that of control UCB-MSCs. Cell 
invasion after CARP siRNA transfection were signiﬁcantly delayed to 1.4-fold compared 
with control UCB-MSCs (P<0.05). Endothelial growth medium (EGM) was used to trigger 
the angiogeneic events. Tube formation was triggered by EGM, whereas attenuated by 
AG490, an inhibitor of STAT3. EGM increased the expression level of Ang-1, VEGF121, 
VEGF165, and phosphorylation of STAT3. AG490 blocked the tube formation, while 
restored by H2O2 (0.2 mM). From these data, CARP could be a responsible factor for the 
cell behavior such as migration and invasion, and STAT3 could be responsible for tube 
formation of UCB-MSCs. In animal study, Masson’s trichrome staining showed ﬁbrosis 
was decreased in UCB-MSC-treated infarcted myocardium compared with control one. In 
echocardiograph ﬁndings, FS was 43.1%, and EF was 79.3% in UCB-MSC injected rats 
(control FS; 17.2%, and control EF; 40.6%).
Conclusions: Our results demonstrated that UCB-MSCs could contribute to therapeutic 
application to cardiovascular diseases thanks to their mobility and angiogenetic 
potentials.
11:00 a.m.
1003-56 Lnk Gene Deﬁciency Contributes to Cardiac Repair 
post Myocardial Infarction by Equivalently Enhancing 
Regenerative Capacity of BM-derived Progenitor Cells 
and Resident Cardiac Stem/Progenitor Cells
Hiroto Iwasaki, Miki Horii, Sang Mo Kwon, Atsuhiko Kawamoto, Akira Oyamada, Ayumi 
Yokoyama, Hiromi Nishimura, Masaaki Ii, Takayuki Asahara, Kobe Institute of Biomedical 
Research and Innovation / RIKEN Center for Developmental Biology, Kobe, Japan
Background: Lnk is a negative regulator of self-renewal capacity of hematopoietic stem 
cells (HSCs). We have previously reported that gene deﬁciency of Lnk augments cardiac 
myoangiogenesis post myocardial infarction (MI) via enhancing proliferation of both bone 
marrow (BM)-derived progenitor cells (BMPCs) and resident cardiac stem/progenitor 
cells (CSPCs). However, proportional contribution of each cell population to cardiac repair 
remains unknown. Methods and Results: The c-kit+/lineage-/GFP+ BM cells isolated from 
Lnk-/-/GFP mice or wild type (WT)/GFP mice were used for BM transplantation (BMT) into 
irradiated Lnk-/- mice or WT mice. Four weeks after BMT, MI was induced by ligating LAD 
of each mouse. Echocardiography and a micro-tip catheter examination 4 weeks after MI 
revealed signiﬁcant preservation of LV function in Lnk-/- mice undergoing BMT from Lnk-
/-
 mice (KO->KO) than all other groups, while in Lnk-/- mice receiving WT BM (WT->KO) 
and WT mice receiving Lnk-/- BM (KO->WT) than WT mice receiving WT BM (WT->WT) 
[(1) Fractional shortening: WT->WT, 20.8±1.7; WT->KO, 31.8±0.5; KO->WT, 35.3±1.1; 
KO->KO, 39.5±1.7%, P<0.05, (2) Regional wall motion score: WT->WT, 26.0±0.4; WT-
>KO, 20.3±0.7; KO->WT, 20.3±0.6; KO->KO, 18.4±0.4, P<0.05, (3) +dP/dt: WT->WT, 
6508±604; WT->KO, 8783±444; KO->WT, 10015±414; KO->KO, 11279±358 mmHg/sec, 
P<0.05]. Necropsy examination disclosed signiﬁcant augmentation of capillary density in 
KO->KO mice than WT->WT or WT->KO mice, while in KO->WT or WT->KO mice than 
WT->WT mice (WT->WT, 651±176; WT->KO, 941±176; KO->WT, 1036±73; KO->KO, 
1123±177 /mm2, P<0.05) and inhibition of LV ﬁbrosis area in KO->KO mice than all other 
groups, while in WT->KO or KO->WT mice than WT->WT mice (WT->WT, 20.1±6.2; WT-
>KO, 9.5±5.0; KO->WT, 9.1±3.7; KO->KO, 5.4±2.9%, P<0.05). All parameters in WT->KO 
mice were similar as those in KO->WT mice. Conclusions: In Lnk deﬁcient mice, BM-
derived BMPCs and resident CSPCs equivalently contributed to cardiac repair in MI. Both 
BM and heart would be considered as the target organ/ tissue of the novel therapeutic 
modality for cardiac regeneration.




















1003-57 Human Amniotic Membrane-derived Mesenchymal 
Stem Cell Acquired Immune Tolerance by HLA-G 
Expression and Differentiated into Cardiomyocyte in 
vivo
Hiroko Tsuji, Yukinori Ikegami, Shunichiro Miyoshi, Naoko Hida, Nobuhiro Nishiyama, 
Ikuko Togashi, Hikaru Nakamizo, Hironori Asada, Taro Uyama, Mamoru Tanaka, Kaoru 
Segawa, Junko Inoue, Kazuhiro Minegishi, Hitoshi Ishimoto, Satoshi Ogawa, Yasunori 
Yoshimura, Akihiro Umezawa, Keio University school of Medicine, Tokyo, Japan, 
National Research Institute for Child Health and Development, Tokyo, Japan
Background: We have previously reported that human amniotic membrane-derived 
mesenchymal stem cell (HAMC) had a potential of “working” cardiomyogenic 
transdifferentiation in vitro (68%). In the present study, we aim to show the induction of 
immune tolerance by transplanted HAMC and survival of transdifferentiated cardiomyocyte 
from HAMC in vivo.
Methods & Results: Flowcytometric surface marker analysis revealed that HAMC was 
negative for HLA-DR and weakly positive for HLA-A, B, and C. Marked expression of HLA-
G in vitro was shown by Western blot analysis. EGFP-labeled HAMCs (approximately 
200,000) were transplanted into the border zone of infarcted heart of wistar rat (xerograft), 
and immunohistochemical analysis was performed to determine the survival of EGFP-
positive transdifferentiated cardiomocytes. Six weeks after the transplantation, many 
rod-like and EGFP-positive transdifferentiated cardiomocytes with clear striation of 
sarcomeric a-actinin (Fig) and cardiac troponin-I (>2,000) were survived. Enzyme-linked 
immunoassay of sera revealed that 4 of 24 rats transplanted with HAMCs were positive 
for soluble HLA-G.
Conclusions: Since HLA-G has been known to suppress natural killer cell-mediated graft 
rejection, the transplanted HAMCs which transdifferentiated into cardiomyocytes in vivo 
might acquire immune tolerance by HLA-G expression. In allotransplantation, HAMC 
can be a promising cell source for cardiac stem cell therapy because of the absence of 
immune response to HAMC. 
11:00 a.m.
1003-58 Decreased Parasympathetic Tone Worsens Left 
Ventricular Remodeling Following Myocardial Infarction
Xiaorong Zhou, Mazen Khalil, Kwangdeok Lee, Kai Wang, Marc S. Penn, Cleveland 
Clinic, Cleveland, OH
It has been demonstrated that the efferent vagus nerve inhibits pro-inﬂammatory cytokine 
release and protects against systemic inﬂammation. The inﬂammatory response following MI 
impacts left ventricular remodeling and ultimately cardiac function. In this study we tested the 
effects of parasympathetic tone on left ventricular remodeling. We hypothesized that unilateral 
vagotomy would worsen left ventricular remodeling after MI. Methods and result: C57/BL 
wild type mice at age 8 weeks underwent sham surgery or left-unilateral cervical vagotomy. 
After one month the animals from both groups underwent left coronary artery ligation. 
Animals were sacriﬁced at 3, 21 days after MI. The echocardiography was performed before 
vagotomy, after vagotomy (the day before AMI), and at day 3, 21 after AMI. H-E and Mason’s 
trichrome staining were performed to evaluate cellular inﬁltrate and collagen deposition. One 
month after unilateral vagotomy there were no differences in cardiac function or dimensions 
compared to sham operated animals (EF: 75.00±8.89 vs 76.10±10.53, P=NS). Similarly, 
unilateral vagotomy had no effect on ejection fraction (EF) 3 days after AMI (50.00±22.00 
vs 54.00±19.84, P=NS). However, 21 days after AMI, there was a signiﬁcant increase in left 
ventricular dilation and decreased EF in the vagotomy group when compared to the sham 
vagotomy group (41.00±14.99 vs 56.00±21.21, P<0.05). There was a signiﬁcant increase in 
cellular inﬁltrate in the infarct zone of those animals that underwent vagotomy when compared 
to sham (40±23 vs. 21±6 leukocytes per high-power ﬁeld, P<0.05). Mason’s trichrome staining 
showed that the infarct zone had a greater area of collagen in the vagotomized animals 
compared to sham (55.63%±18.95 vs 33.72%±10.98, P<0.05). Conclusion: The unilateral 
vagotomy signiﬁcantly increases the myocardial inﬂammatory response following AMI leading 
to increased collagen deposition and decreased cardiac function. These data suggest that 
parasympathetic tone at baseline signiﬁcantly impacts ventricular remodeling and suggests 
a potential mechanism for the poorer outcomes observed in patients with a history of MI and 
evidence of decreased parasympathetic tone.
11:00 a.m.
1003-59 Predictors of Sudden Cardiac Death Change With Time 
After Myocardial Infarction: Results From the VALIANT Trial
Jonathan P. Piccini, Karen S. Pieper, Scott D. Solomon, Sana Al-Khatib, Frans Van de 
Werf, Marc A. Pfeffer, John JV McMurray, Robert M. Califf, Eric J. Velazquez, Duke 
Clinical Research Institute, Duke University Medical Center, Durham, NC
Background. The risk of sudden cardiac death (SCD) changes with time following 
myocardial infarction (MI). Little is known about whether predictors of SCD also vary with 
time after MI.
Methods. The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) enrolled 14,703 
patients with acute MI, complicated by heart failure (HF), left ventricular (LV) dysfunction, 
or both. Landmark analysis and Cox proportional hazards modeling were used to predict 
SCD (SCD and resuscitated SCD) during the initial hospitalization, from discharge to 30 
days, 30 days to 6 months, and 6 months to 3 years.
Results. The cumulative incidence of SCD was 7.3% (n=1046). Reduced creatinine 
clearance (CrCl), hypotension, and tachycardia were strong predictors of SCD prior to 
discharge and in the ﬁrst 30 days after MI (Table). While tachycardia and reduced CrCl 
remained predictors of SCD up to 3 years after MI, recurrent HF, diabetes, and a history 
of MI prior to enrollment were strong predictors of later events. Interestingly, quantitative 
evidence of LV dysfunction was not a signiﬁcant predictor until after 30 days of follow-up 
and, even then, was less predictive than several other clinical variables.
Conclusion. Both the incidence and predictors of SCD change with time after MI. Initially, 
indices of hemodynamic instability are strong predictors of SCD, however, with continued 
follow-up, prior MI, initial CrCl, and clinical HF are more robust risk stratiﬁers. 
11:00 a.m.
1003-60 Ranolazine’s Mechanism of Action for Reducing 
Myocardial Infarct Size Is Independent of Changes in 
Coronary Collateral Blood Flow
Sharon L. Hale, Robert A. Kloner, Heart Institute, Good Samaritan Hospital, Los Angeles, 
CA, Keck School of Medicine, University of Southern California, Los Angeles, CA
Background: The antianginal drug ranolazine is a selective inhibitor of the late sodium 
current relative to peak sodium channel current, and via this mechanism may decrease 
sodium-dependent intracellular calcium overload during ischemia and reperfusion. It 
has been suggested that one mechanism by which ranolazine protects the ischemic/
reperfused heart is by reducing intracardiac diastolic pressure during ischemia, which 
then decreases capillary compression and thereby improves perfusion. The goal of this 
study was to test whether ranolazine causes changes in regional myocardial blood ﬂow 
(RMBF) during ischemia and/or reperfusion in a myocardial occlusion model. Methods: 
Ten minutes before coronary artery occlusion (CAO), anesthetized rabbits were assigned 
to vehicle (n = 13) or ranolazine (2 mg/kg I.V. bolus plus 60 µg/kg/min I.V. infusion, n=14). 
Hearts received 60 minutes of CAO and 3 hours reperfusion. RMBF was measured with 
radioactive microspheres, risk zone with blue dye and necrosis by tetrazolium staining. 
Results: Ischemic risk zone was comparable in the two groups (29±2% of the left ventricle 
in ranolazine group and 26±2 in the vehicle group, p = ns). Ranolazine reduced infarct size 
(46±4 % of risk zone versus 60±5% vehicle, P <0.03). However, RMBF was similar in both 
groups in the risk zone during ischemia (0.14±0.08 ml/min/g ranolazine and 0.14±0.06 
vehicle, p=ns) and at 3 hours reperfusion (0.29±0.06 ranolazine and 0.32±0.03 vehicle). 
Body temperatures and rate-pressure products were similar in both groups. Conclusions: 
Ranolazine was effective in reducing myocardial infarct size by 23%. The mechanism by 
which it did this was independent of improving regional blood ﬂow during ischemia or 
reperfusion, and unrelated to changes in the rate-pressure product. Therefore, it is likely 
that ranolazine’s protective effect involves a direct cellular mechanism.





1003-61 Myocardial Hibernation in the Absence of Augmented 
Glucose Metabolism in Diabetic Hearts
Joaquin B. Gonzalez, Sharat Koul, Alice Chen, Zbigniew Malecki, George J. Crystal, 
Song-Jun Kim, Advocate Illinois Masonic Medical Center, Chicago, IL
Background: Myocardial hibernation (MH) is a state of persistent regional ventricular 
dysfunction in patients with coronary artery disease which is reversible with 
revascularization. In our previous study, a porcine model of persistent stunning was used 
to recapitulate the phenotype of MH, i.e., reduced but stable regional dysfunction and 
glycogen deposition. It has been proposed that a shift to glucose metabolism is integral 
to achieve protection against ischemia in hibernating myocardium. If this were the case, 
diabetic hearts would be expected to have an impaired ability to hibernate.
Methods: Ten swine were divided into control (CON; n=5) and streptozotocin (STZ)-
treated (100 mg/kg; n=5) groups. The animals were chronically instrumented to measure 
coronary blood ﬂow (CBF) and regional wall thickening (WT); catheters were implanted in 
the aorta and coronary sinus to calculate myocardial glucose extraction (MGE). Persistent 
myocardial stunning leading to hibernation was induced by six repetitive episodes of 90-
min coronary stenosis (CS) (30% reduction in baseline CBF) followed by full reperfusion 
every 12 hrs.
Results: Plasma glucose was elevated in STZ group, compared to CON group (489±87 
vs. 100±3 mg/dl, p<0.01). MGE was increased 2-fold in CON group during 1st CS (and 
remained elevated prior to and during 6th CS), whereas MGE was not affected by 
stunning protocol in STZ group; glycogen deposition was prominent in CON group but 
negligible in STZ group. Nevertheless, the decreases in WT in CON and STZ groups 
during 1st CS were similar (-46±10% vs. -50±9%, respectively), as were those just prior 
to 6th CS (-28±9% and -17±4%, respectively). Both groups showed no further decrease 
in WT during 6th CS. Expression of cell survival proteins [X-linked inhibitor of apoptosis 
protein (XIAP) and heat-shock protein 70 (Hsp70)] was 2-fold increased in hibernating 
myocardium from both groups.
Conclusions: Diabetic myocardium retains the ability to resist the effects of repetitive 
ischemia and reperfusion, 2) augmented glucose metabolism and glycogen deposition 
are not essential for myocardial hibernation; and 3) upregulation of survival proteins may 
play a critical role in the development of this state.
11:00 a.m.
1003-62 Outcomes After Pimecrolimus-Elution From a Durable 
Polymer on a Stainless Steel Stent. First-in-Human 
Study Discordance With Preclinical Studies
John A. Ormiston, Mark W. Webster, Patrick Gladding, James T. Stewart, Peter N. 
Ruygrok, Robert Hattrick, Patrick Kay, Auckland City Hospital, Auckland, New Zealand
Background; Pimecrolimus has multiple anti-inﬂammatory effects, but does not bind to 
mTOR, and therefore does not directly affect cell cycle regulation. It may limit restenosis 
without adversely affecting re-endothelialization, and hence may limit late stent 
thrombosis. The trial stainless steel stent was coated with 400 mcg pimecrolimus and an 
outer layer of parylene C (UnicoatTM) to control drug release (Avantec Vascular Corp., 
Sunnyvale, CA). Porcine studies (12 weeks) with bare metal, polymer only, different doses 
of drug with polymer showed low injury and inﬂammatory scores, mature endothelialized 
intima, no granulomas, thrombosis, or aneurysm. Historical controls with the same metal 
stent are from the IMPACT trial.
Methods: This prospective registry enrolled 15 patients with 3-3.5 mm diameter de novo 
lesions <14mm length.
Results: By 6 months, there was ischemia driven target vessel revascularization in 7 of 
13 patients (54%). 
Pimecrolimus n=15 Bare metal n=50 P value
BASELINE
Lesion length, mm 6.22+1.93 11.80+3.95 <0.05
Ref diameter, mm 2.86+0.55 2.72+0.47
POST-PROCEDURE
In-stent min lumen diam, mm 2.76+0.43 2.56+0.40
In-lesion diam stenosis, % 20.4+15.4 19.5+14.0
6 MONTH
In-stent late loss, mm 1.44+0.89 0.85+0.55 <0.05
In-lesion restenosis, % 61 27 <0.01
Conclusions:Preclinical porcine studies with this pimecrolimus DES showed good luminal 
patency with low injury and inﬂammation scores; however the porcine studies did not 
predict the increase in late loss and restenosis observed in this ﬁrst-in-man study, that 
was greater than historical bare metal controls. This emphasizes the difference between 
species and argues for caution in ﬁrst-in-human trials and justiﬁes a small initial cohort
11:00 a.m.
1003-63 Functional Improvement After Bone Marrow-Derived 
Mononuclear Versus Nonmodiﬁed Mesenchymal Stem 
Cell Therapy in Chronic Myocardial Infarction
Myrielle Mathieu, Bachar El Oumeiri, Philippe Thoma, Thierry Metens, Karim Touihri, 
Ielham Hadad, Lynn Ray, Naïma Mazouz, Naïma Mazouz, Aurore de lavareille, Philippe 
Willemsen, Robert Naeije, Guy Heyndrickx, Jozef Bartunek, Kathleen MC Entee, Free 
university of Brussels, Brussels, Belgium, OLV, Aalst, Belgium
Background: Stem cell therapy may facilitate cardiac repair after myocardial infarction 
(MI) but the optimal cell type remains discussed. The present study was designed as 
randomized, investigator-blinded, placebo controlled head-to-head comparison of 
autologous bone-marrow mononuclear cells (BMNC) and nonmodiﬁed mesenchymal 
stem cells (MSC) in a large animal model of chronic MI.Methods: Twenty-four dogs 
underwent the ligation of the left coronary artery. Eleven weeks later, they received 
intramyocardial injections of either placebo (n = 8), BMNC (227.106 ± 32.106 cells, n = 8) 
or culture expanded nonmodiﬁed-MSC (232.106 ± 40.106 cells, n = 8). Echocardiography, 
magnetic resonance imaging (MRI), conductance catheter and histopathology were used 
to assess cardiac function, remodelling and viability before therapy (Baseline), and 9 and 
16 weeks after cell injections. The echocardiographic wall motion score (WMS) index 
was used to assess the regional systolic function.Results: While left ventricular ejection 
fraction remained unchanged, the WMS index showed a sustained improvement in the 
BMNC group (from 1.8 + 0.1 at baseline to 1.6 + 0.07 at 9 weeks and 1.5 + 0.07 at 16 
weeks, both p<0.001). In the MSC group, the WMS index improved moderately at late 
follow-up (from 1.9 + 0.08 at baseline to 1.7 + 01 at 16 weeks p<0.05). End systolic 
elastance increased only in the BMNC transfer (from 2.23 + 0.25 mmHg/ml to 4.42 + 0.55 
mmHg/ml at 9 weeks, p<0.05). This was associated with a reduction in the MRI infarct 
size (from 13 + 0.67 % at baseline to 10 + 1.17% at 16 weeks p<0.05) and an increased 
semi-quantitative arterial density in the infarct zone as compared to MSC group (p<0.01). 
No changes in contractility and infarct size were noted in the MSC group. Conclusions: 
In the canine model of chronic MI, stem cell therapy with BMNC appears to be superior 
to treatment with culture-expanded non-modiﬁed MSC to improve cardiac contractility, 
regional systolic function, myocardial viability and vascularity after healed MI.
11:00 a.m.
1003-64 Novel Pharmacological Compounds as Triggers of 
Preconditioning In Vivo
Ioanna Andreadou, Theano Fotopoulou, Maria Koufaki, Andrew Tsotinis, Anastasia 
Zoga, Anastasia Pyriochou, Dimitrios Farmakis, Efstathios K. Iliodromitis, Dimitrios T. 
Kremastinos, Attikon University Hospital, Athens, Greece
Background: Potential triggers of preconditioning currently in clinical use include adenosine 
and its analogues and KATP channel openers, such as nicorandil. We assessed the effect 
of new compounds with aromatic heterocycles, such as indole, quinoline and purine and 
the pharmacophoric nitroxy ester group. The indole and quinoline derivatives possess 
structural features of nitrate containing KATP channel openers.
Methods: Male rabbits were randomly divided into 4 groups and subjected to 30 min 
of ischemia and 3 h of reperfusion with the following prior interventions Controls, no 
intervention; group A, administration of indole analogue; group B, administration of 
quinoline analogue; group C, administration of the N6,N9-substituted adenine analogue, 
C6. Compounds were administered in a total dose of 4 mg, 40 min and 1 min before 
sustained ischemia. Myocardial infarct size was determined with TTC staining and 
ﬂuorescent microspheres. Blood samples were drawn at different time points for 
malondialdehyde (MDA) determination as a lipid peroxidation index and for cGMP. In 
order to test whether combined treatment of compounds A and C with the mito KATP 
blocker 5-hydroxydecanoic acid (5-HD) alters the infarct size, 2 additional groups were 
assessed in the ﬁrst series of experiments.
Results: Reduction of the infarct size was observed in all treated groups (20.5±5.2%, 
22.4±4.7%, 19.8±3.1% vs 47.4±2.6% in control, p<0.05). Combined indole and 5-HD 
treatment abolished infarct size reduction while combined adenine analogue and 5-HD did 
not. All tested compounds reduce the circulating MDA level at the 20th min of reperfusion 
(p<0.05). MDA was signiﬁcantly elevated at the 20th min of ischemia in groups A and B 
compared to baseline. cGMP circulating levels were signiﬁcantly elevated in groups A and 
B at the 20th min of ischemia compared to controls.
Conclusion: The administration of the new compounds reduced infract size and triggered 
preconditioning in vivo. The indole and quinoline analogues accomplish it via c-GMP, 
mitoKATP channel opening and free radical production, while the adenine analogue acts 
independently of the mitoKATP channels opening.
11:00 a.m.
1003-65 Myelosuppressives Improve Cardiac Dysfunction 
After Myocardial Infarction by Activating Cell Survival 
Signaling, Mobilizing CD34 Positive Cells and 
Attenuating Fibrosis and Apoptosis
Hiroaki Ushikoshi, Yu Misao, Takamasa Ohno, Yiwen Li, Ngin Cin Khai, Genzou 
Takemura, Takako Fujiwara, Hisayoshi Fujiwara, Shinya Minatoguchi, Gifu University 
Graduate School of Medicine, Gifu, Japan, Kyoto Women’s University, Kyoto, Japan
Background: Leukocytosis is a well-known effect of myocardial infarction (MI). Recently 
we reported that myelosuppressives improve left ventricular (LV) function following 
reperfusion-induced MI. However, the role of myelosuppressives in permanently 
occluded large MI remains unknown. Here we aimed to elucidate the beneﬁcial effects of 
5-ﬂuorouracil (5FU) and cyclophosphamide (Cy) using a murine model. Methods: (1) In 



















vitro: Primary cultured ventricular cardiomyocytes and cardiac ﬁbroblasts were incubated 
in the presence or absence of 5FU and Cy, and cell growth was evaluated. (2) In vivo: 
An MI model was created by permanent coronary occlusion. On the next day after MI, 
5FU (100 mg/kg), Cy (50mg/kg) or saline (control, C) were injected intraperitoneally. 
Cardiac function, histological changes, cell signaling and apoptosis were evaluated. To 
detect circulating CD34+ cells, FACS analysis was performed. Results: (1) 5FU and Cy 
inhibited cardiac ﬁbroblast proliferation in a dose-dependent manner in vitro. (2) 5FU 
and Cy increased peripheral CD34+ cells (5FU: 30.5 ± 5.5 /µl, Cy: 21.8 ± 4.6 /µl vs. C: 
11.2 ± 6.1 /µl, p < 0.05). Myelosuppressives also reduced the area of MI (5FU: 27.9 ± 
4.3%, Cy: 30.4 ± 5.3% vs. C: 39.6 ± 8.6%, p < 0.05) at one week after MI and improved 
cardiac function (by LVEF; 5FU: 42.9 ± 6.4%, Cy: 38.8 ± 6.9% vs. C: 28.2 ± 6.2%, p < 
0.05). Heart weight (p < 0.01) also decreased four weeks after MI. Histological ﬁndings 
showed an enhancement of angiogenesis at the border area (by capillary density, p < 
0.01), a decreased ﬁbrosis area (p < 0.05) in 5FU treated hearts, and decreased Ki-
67/TUNEL positive cells in the MI area of both groups (5FU: 1.8 ± 1.0 %, Cy: 0.9 ± 
0.8 % vs. C: 4.4 ± 1.1 %, p < 0.01). Finally, immunoblotting revealed upregulated SDF-
1/CXCR4 axis, ANP, Bcl2 and activated Akt, indicating enhanced survival signaling in 
treated hearts. Conclusions: Upregulation of cell survival signaling, mobilization of 
CD34+ cells and attenuation of ﬁbrosis and apoptosis may play important roles in the 
beneﬁcial effects caused by myelosuppressives in acute-MI. These ﬁndings suggest that 
myelosuppressives are good candidates for protective therapy of the post-MI heart.
11:00 a.m.
1003-66 Impaired Glucose Tolerance Is Associated With 
Endothelial Damage Following Acute Myocardial 
Infarction
Shahirose S. Jessani, Vellore J. Karthikeyan, Teri Millane, Gregory YH Lip, University 
department of medicine, City hospital, Birmingham, United Kingdom, Department of 
medicine, Basildon, United Kingdom
Background: Impaired glucose tolerance (IGT) post acute myocardial infarction (AMI) 
is largely ignored despite evidence of poorer clinical outcome. We hypothesized that 
endothelial damage following AMI, measured by a rise in von Willebrand factor (vWF), 
would be more pronounced in patients with IGT compared to those with normal glucose 
tolerance (NGT).
Method: Consecutive non-diabetic patients with AMI underwent oral glucose tolerance 
testing 3-5 days after admission. We established existing endothelial cell damage by 
measuring vWF levels in the fasting state, and investigated the effect on the endothelium 
of a 75 g glucose load. vWF levels were measured by enzyme linked immunosorbent 
assay (ELISA).
Results: 125 patients [mean (SD) age 59 (12.5) yrs; 107 (86%) male] were studied. 
Baseline mean vWF levels were higher in IGT patients versus those with NGT (p < 0.001) 
(Table 1). The change in vWF levels in response to oral glucose tolerance test correlated 
with the change in plasma glucose levels (Spearman, r = 0.302, p< 0.001).
Conclusion: IGT post AMI is associated with signiﬁcant endothelial damage when 
compared with NGT. Further endothelial damage appears to occur in response to a rise 
in plasma glucose levels. Interestingly, the degree of endothelial damage in subjects with 
IGT appears comparable to that observed in frank diabetes. IGT is not currently actively 
sought in this population, let alone treated - a change in clinical practice is warranted.













Age (years) 57.4 (12.4) 61.0 (12.9) 57.9 (11.9)
Male, n (%) 43 (82.7) 43 (89.5) 21 (84)




125.4 (19.4)a 145.9 (29.4)*a b 145.4 (17.7)*a b
Between group analyses by ANOVA with Tukey post hoc test. 
Pre and post glucose challenge vWF analysis by paired t- test. 
* Signiﬁcantly higher (p < 0.001) compared to NGT; 
a Signiﬁcantly higher vWF at 2-hour post glucose challenge (p < 0.0001). 
b Signiﬁcantly higher vWF compared to NGT (p < 0.01).
11:00 a.m.
1003-67 Fibroblast Growth Factors Promote the Proliferation 
of Bone-Marrow Mesenchymal Stem Cells Through 
the Activation of the PI3K/Akt and ERK1/2 Signaling 
Pathways
Seung-Cheol Choi, Su-Jin Kim, Ji-Hyun Choi, Chi-Yeon Park, Wan-Joo Shim, Do-Sun 
Lim, Korea University Medical College, Seoul, South Korea
Background: Bone-marrow mesenchymal stem cells (BMMSCs) have the capacity for 
self-renewal, differentiation into a variety of cell types including cardiac and endothelial 
lineages, and thus represent an attractive source for myocardial regeneration. Despite this 
promise, little is known about the mechanisms underlying the proliferation of BMMSCs. 
The purpose of this study is to identify the factors and signaling pathways involved in the 
proliferation of Sca-1+ BMMSCs. Methods: Sca-1+ BMMSCs were puriﬁed by magnetic-
activated cell sorting (MACS) system from bone marrow of ICR mice. The effect of cytokines, 
growth factors, and signal pathways involved in the proliferation of Sca-1+ BMMSCs was 
analyzed by BrdU incorporation assay and Western blotting. Results: Flow cytometry 
analysis revealed that Sca-1+ BMMSCs were enriched to > 90% after sorting four rounds 
with the MACS system. Among the cytokines and growth factors examined in this study, 
ﬁbroblast growth factor 2 (FGF-2) and FGF-4 signiﬁcantly stimulated the proliferation 
of Sca-1+ BMMSCs (Control, 1±0.05 vs. FGF-2, 4.34±0.22 vs. FGF-4, 3.62±0.26, P < 
0.05), as determined by BrdU incorporation. PI3K/Akt, ERK1/2 and JAK/STAT3 pathways 
were investigated after stimulation with FGF-2 or FGF-4. No changes were observed in 
total ERK1/2 and Akt; however, the pERK1/2 and pAkt levels were up-regulated within 
15 min for the FGF-2- or FGF-4-treated Sca-1+ BMMSCs. Moreover, the pERK1/2 and 
pAkt up-regulation induced by FGFs was completely abolished by the pretreatment with 
the MEK1/2 inhibitor U0126 and the PI3K/Akt inhibitor, LY294002. However, no change 
in pJAK2 or total JAk2 levels was observed in Sca-1+ BMMSCs induced by FGFs. As 
a consequence of PI3K/Akt and ERK1/2 activation, the up-regulation of c-Jun, the 
downstream target of ERK1/2 in Sca-1+ BMMSCs after stimulation with FGF-2- or FGF-4 
was observed after 12 or 24 h. Moreover, the activation of c-Jun was signiﬁcantly reduced 
by U0126 in FGF-2 or FGF-4-treated Sca-1+ BMMSCs. Conclusions: Taken together, the 
data suggest that FGF-2 and FGF-4 promote the proliferation of Sca-1+ BMMSCs through 
the activation of the ERK1/2 and PI3K/Akt signaling pathways.
11:00 a.m.
1003-68 Is Sarco(endo)plasmic Reticulum Ca2+-ATPase 
(SERCA) Inhibition Detrimental or Beneﬁcial for 
Postischemic Myocardial Function and Injury? 
Evidence From SERCA2a-deﬁcient Mice
M.A. Hassan Talukder, Li Zuo, Anuradha Kalyanasundaram, Velayutham Murugesan, 
Muthu Periasamy, Jay L. Zweier, The Ohio State University, Columbus, OH
Intracellular Ca2+ overload with reduced activity of SERCA2a is one of the important 
mediators of ischemia/reperfusion (I/R) injury. While upregulation of SERCA function 
is well documented to improve postischemic cardiac function, there are also reports 
where pharmacological inhibition of SERCA improved postischemic myocardial function. 
Therefore, to address this issue, I/R studies were performed in isolated hearts from 
heterozygous SERCA-knockout (HT) and wild-type (WT) mice. Both myocardial stunning 
(20-min I) and infarction (30-min I) models were investigated for 60-min R. Rhod-2 
spectroﬂuorometry was used to measure cytosolic Ca2+ ﬂuorescence (CaF), and EPR 
spin trapping to measure free radicals during R. Table shows that with R following 20-min 
I, there was no signiﬁcant difference in the postischemic contractile function between 2 
strains. However, following 30-min I, postischemic contractile function was signiﬁcantly 
lower in HT hearts with larger myocardial infarction. Compared to WT, basal systolic CaF 
was signiﬁcantly lower and diastolic CaF was signiﬁcantly higher in HT hearts. After 30-
min I, diastolic CaF was markedly elevated in HT hearts. Postischemic coronary free 
radicals were similar in both strains. Thus, these ﬁndings provide direct evidence that 
functional SERCA2a level plays a crucial role in postischemic Ca2+ overload, myocardial 
contractile function and salvage. SERCA2a inhibition does not improve rather it worsens 
postischemic myocardial performance.
Parameters at baseline and with global ischemia and reperfusion







Baseline (PI) LVDP (mmHg) 114±9 (5) 89±8 (5) 84±11 (6) 76±5 (6)
LVEDP (mmHg) 3.1±0.6 (5) 5±0.8 (5) 3.3±0.8 (6) 3.1±0.7 (5)
D-CaF (RU) ND ND 367±28 (5) 646±17 (5)**
Peak systolic CaF(~fold 
increase from D-CaF) ND ND ~1.7-fold (5) ~1.4-fold (5)*
Global Ischemia D-CaF (RU) ND ND 1432±60 (5) 1783±12 (5)***
Reperfusion (60-
min) LVEDP (mmHg) 16±4 (5) 33±6 (5)* 18±2 (6) 47±10 (6)*
LVDP (%PI) 93±7 (5) 80±3 (5) 68±4 (6) 37±6 (6)**








(RU), diastolic Ca2+ 
ﬂuorescence in 
relative units











1003-69 Ranolazine Prevents Ischemia-Induced ST Segment 
Changes and Left Ventricular Mechanical Dysfunction 
in Rabbits
Wei-Qun Wang, Chelsea Robertson, Paige Ivey, Arvinder K. Dhalla, Luiz Belardinelli, CV 
Therapeutics, Inc, Palo Alto, CA
Background: Ranolazine (Ran) is an anti-anginal drug that improves Na+ and Ca++ 
homeostasis during ischemia in vitro. This study was undertaken to determine whether 
Ran prevents left ventricular dysfunction induced by ischemia in vivo.
Methods: In anesthetized female rabbits (n=62) regional myocardial ischemia (15 min) 
was caused by ligation of the left anterior descending coronary artery and followed by 
45 min of reperfusion. Epicardial ECG (epi-ECG), fractional shortening (FS, measured 
by piezoelectric crystals), and regional myocardial blood ﬂow (RMBF, measured by color 
microspheres) were examined. Ran was given 30 min prior to ischemia.
Results: Ran (1, 4 and 8 µM) dose-dependently prevented the ischemia-induced ST 
elevation (2.3 ± 0.8, 0.8 ± 0.6 and 0.4± 1.0 mV, p<0.05 for Ran 8 µM vs control 4.1± 
1.1mV). The end-diastolic (EDL) and end-systolic segment length (ESL) of the ischemic 
region were signiﬁcantly prolonged (2.1 ± 0.2 and 3.3 ± 0.3 mm, respectively), and FS of 
the ischemic region was signiﬁcantly impaired with either akinesis (4/7) or systolic bulging 
(3/7) occurring during ischemia. Ran (4µM) signiﬁcantly prevented a) the prolongation 




of EDL (-0.1 ± 0.2 mm) and ESL (0.3 ± 0.3 mm), b) the reduction in FS (Figure A), and 
c) myocardial akinesis (0/7) and systolic bulging (0/7). RMBF for ischemic region was 
signiﬁcantly improved by Ran at 8 µM (Figure B).
Conclusion: Ran prevents ischemia induced myocardial electrical and mechanical 
dysfunction, and improves blood supply to the ischemia region. 
11:00 a.m.
1003-70 A Novel EBV Encoded Protein Is Associated With ICAM 
Expression in Patients With Acute Myocardial Infarction
Glen E. Cooke, Amanda Lesinski, Mackenzie Taylor, James Green, Christopher Jones, 
Min Chen, W. James Waldman, Marshall V. Williams, Jr., Deborah A. Knight, Philip F. 
Binkley, Ronald Glaser, The Ohio State University, Columbus, OH
Background:We have identiﬁed a novel early Ebstein Barr Virus (EBV) protein (dUTPase) 
produced during virus replication. We have further shown that this protein can induce 
the upregulation of several pro-inﬂammatory cytokines including TNFalpha and IL-6, two 
cytokines that have been shown to be related to cardiovascular disease. We have also 
shown that depression/stress can reactivate latent EBV.
Methods:To determine whether this protein, and thus EBV, may play a role in coronary 
atherosclerosis, we measured cytokines by ELISA and antibody titres to EBV dUTPase 
in 297 consecutive patients undergoing percutaneous coronary intervention for stable 
angina, unstable angina, or acute myocardial infarction.
Results:Acute myocardial infarction was associated with the highest measures of IL-6 
(ANOVA p = 0.05; 4.6 + 2.6pg/mL in patients with acute myocardial infarction vs 3.2 
+ 2.3pg/mL in stable angina). Similarly, Intracellular Adhesion Molecule 1 (ICAM1) was 
signiﬁcantly higher in patients with acute MI (ANOVA p < 0.05; 304 + 116pg/mL in AMI 
versus 265 + 86pg/mL in stable angina ). However, the highest values of ICAM1 were 
found in patients having an acute MI and who were antibody positive for dUTPase 
(ANOVA p = 0.008; 369 + 183pg/mL in AMI and positive for dUTPase versus 249 + 70 
pg/mL in stable angina and negative for dUTPase antibody).
Conclusions:These data indicate that: 1. pro-inﬂammatory cytokines are expressed to 
the greatest degree in acute myocardial infarction as compared to stable ischema; 2. 
EBV acting through early viral proteins may play a role in the stimulation of the pro-
inﬂammatory mechanisms that precipitate AMI.
11:00 a.m.
1003-71 Do Selected Markers of Inﬂammatory Response During 
the Acute Phase of ST-Segment Elevation Myocardial 
Infarction Relate to Outcome?
Pierre Theroux, Paul W. Armstrong, David J. Moliterno, Franz-Josef Neumann, Amanda 
L. Stebbins, Kenneth W. Mahaffey, Judith S. Hochman, Christian W. Hamm, Christopher 
B. Granger, APEX AMI Investigators, Montreal Heart Institute, Montreal, QC, Canada, 
Duke Clinical Research Institute, Durham, NC
Background: Inﬂammation portends accelerated progression in chronic cardiovascular 
disease. During acute STEMI, inﬂammation may be causative and/or consequential. We 
evaluated this in a case-control APEX-AMI substudy where pexelizumab was given to 
STEMI undergoing primary PCI < 6 hrs of symptoms.
Methods: Comprehensive biomarkers were evaluated in 201 patients (cases) with death, 
shock or heart failure < 90 days and 584 controls matched for age, sex, and site of MI. 
Blood was obtained early after symptoms (median 2.7 hrs) before study drug and PCI. 
The 12 biomarkers in at least 800 pts (C-reactive protein (CRP), NT pro-BNP, Il-6, Il-4, Il-
10, IL-12, IL-1B, TNFA, interferon gamma (IFNG), IL-1 receptor antagonist (ra), MBL, and 
interferon-inducible protein (IP-10)) were entered into multivariable models and related 
to outcomes.
Results: Biomarkers were all elevated and univariable and multivariable associations 
with the 90 day composite of death, shock and heart failure are below. Higher levels 
of pro-inﬂammatory cytokine (IL-6), T cell-focused chemokine IP-10, anti-inﬂammatory 
cytokine IL-1ra and NTpro-BNP all independently predicted adverse outcome in all 
models tested. 
Biomarker Univariable relationship Multivariable modelHazard ratio P value Hazard ratio (95% CI) P value
IL-6 2.64 (per 10 ng/ml) <0.0001 2.14 (1.39, 3.30) 0.0005
IP-10 0.8 (per 200 Units) 0.0031 0.76 (0.66-0.89) 0.0006
NT proBNP 1.28 (per 100 g/ml) <0.0001 1.27 (1.11, 1.47) 0.0007
IL-1ra 1.58 (per 200 units) <0.0001 1.19 (0.99-1.42) 0.05
IL-12 1.00 (per 5 ng/ml) NS -- NS
IL-10 1.16 (per 10 ng/ml) <0.0005 -- NS
CRP 1.31 (per 5 ng/ml) <0.0001 -- NS
IFNG 1.04 (per 5 ng/ml) 0.04 -- NS
Conclusions: The acute phase of STEMI is associated with a marked systemic 
inﬂammatory response detectable in selected markers within a few hours of symptoms. 
This reaction is strongly associated with an adverse outcome, complementing the 
predictive value of CRP in multivariable models.
11:00 a.m.
1003-72 Induction of HO-1 Reduces the Metabolic and Nitro/
Oxidative Effects of Ischemia-Reperfusion in Diabetic 
Rat Hearts
Danilo Neglia, Cecilia Vecoli, Daniela Giannessi, Maristella Maltinti, Virginia Ottaviano, 
Simona Baldi, Michela Novelli, Pellegrino Masiello, Aldo Paolicchi, Renata Barsacchi, 
Nader G. Abraham, Antonio L’Abbate, CNR Institute of Clinical Physiology, Pisa, Italy
Background. Ischemia/reperfusion damage could be exacerbated in diabetic hearts by 
myocardial overexpression of inducible nitric oxide synthase (iNOS) resulting in increased 
interaction of NO with superoxide (O2-) and production of peroxynitrite (ONOO-). In this 
study we tested the hypothesis that cobalt protoporphyrin (CoPP), inducer of heme 
oxygenase-1 (HO-1), may ameliorate ischemia-reperfusion myocardial damage by 
reducing iNOS expression and the production of ONOO- and NOx.
Methods. Isolated perfused hearts (Langendorff model) from 22 rats with STZ-Nicotinamide 
induced diabetes were subjected to an ischemia/reperfusion protocol: 20 min at control 
perfusion pressure (80 cmH2O) followed by 30 min at low perfusion pressure (20 cm H2O) 
and 30 min of reperfusion at control pressure. Rats were pretreated (3 weeks) with CoPP 
(n=11) or vehicle (n=11). Lactate and NOx were measured in the coronary perfusate during 
all the experiments. O2- and malonildialdehyde (MDA) myocardial levels as well as HO-1 and 
iNOS protein expression were measured in the cardiac tissue at the end the experiments.
Results. Lactate release in the coronary efﬂuent was documented during low perfusion 
pressure followed by release of NOx at reperfusion. CoPP pretreatment reduced the 
extent of metabolic ischemia and the production of ONOO- as expressed by the integral 
under the lactate and the NOx concentration curves, respectively (p<0.0001 CoPP vs 
no-CoPP). In CoPP-treated animals oxidative stress as measured by myocardial O2- and 
MDA levels was reduced (p<0.001 CoPP vs no-CoPP). In CoPP-treated rats cardiac HO-
1 was increased (p<0.001) but iNOS was decreased (p<0.05).
Conclusion. Induction of HO-1 in the diabetic rat prevents the increase in metabolic and 
nitro/oxidative stress and may present a strategy to lessen myocardial damage following 
ischemia-reperfusion injury.
11:00 a.m.
1003-73 Regional Myocardial Temperature During Coronary 
Occlusion in the Wwine: Comparison With 
Electrocardiographic Changes
Amany Ahmed, Muhammad S. Munir, Igor V. Stupin, Jill Robertson, Koovapudi J. 
Shankar, Sreedevi Gondi, Ibrahim Aboshady, Marlos R. Fernandes, Christiano O. 
Cardoso, Fred Baimbridge, Ed Sobash, Alan M. Brewer, S. Ward Casscells, Texas Heart 
Institute, Houston, TX
Background: EKG ﬁndings of ischemia can be confounded by conduction blocks, 
electrolytes, medications, and effusions, hence making it vital to ﬁnd complementary 
diagnostic tools. We hypothesized that coronary artery occlusion (CO) would initially 
increase temperature (T) of the myocardium, followed by a decreased T due to cessation 
of oxidative metabolism.
Methods: We placed 2 T sensors ~2mm sub-endocardial (SE) and 4mm mid-myocardial 
(MM) in the LAD territory of 7 pigs. EKG and T data were acquired using a data acquisition 
system. Serial, timed balloon occlusions of the LAD were done for 3 and 5 minutes, with 
3 minutes of reﬂow.
Results: 
12 occlusions (total 14) were associated with an initial rise (ascending phase) in T; with 
a mean $T of 0.04±0.03ºC in the SE, and a mean $T of 0.07±0.04ºC in the MM. When 
the peak T rise in MM was compared to the SE (p = 0.006). With ongoing occlusion, a 
drop (descending phase) in T occurred, resulting in a mean $T of -0.11±0.07ºC in the SE, 
and a mean $T of -0.14±0.11ºC in the MM. Onsets of $T following CO were observed 
instantaneously, and preceded ischemic EKG changes by mean of 35±29s.



















Conclusions: The myocardium exhibited a detectable temperature response to ischemia 
in the SE and the MM, prior to surface EKG changes. There was transmural heterogeneity 
during the ascending phase of this response, with a higher peak in the MM. Temperature 
monitoring may become a complement to EKG analysis for improved detection of 
ischemia; either intra-operatively or via pacemaker leads.
11:00 a.m.
1003-74 Increased Vulnerability to Ischemia-Reperfusion Injury 
in UCP3 Null Mouse Hearts
Cevher Ozcan, Monica Palmeri, Raymond R. Russell, III, Yale University School of 
Medicine, New Haven, CT
Background: Uncoupling of mitochondrial oxidative phosphorylation by endogenous 
uncoupling proteins (UCP) has emerged as a cardioprotective mechanism by preventing 
cardiac cell death under metabolic or oxidative stress. However, it is not clear whether 
lack of myocyte UCP3 is associated with increased vulnerability to oxidative stress and 
contributes to the development of detrimental ischemia-reperfusion injury.
Methods: This was tested in a model of left coronary artery (LCA) ligation induced 
ischemia-reperfusion injury by using multi parametric measurements including infarct 
size, area at risk, ST changes, heart rate and rhythm in 8-10 week-old male UCP3 null 
(UCP3-/-) mice compared with age- and gender- matched wild type mice. Hearts were 
subjected to 20-min ischemia by complete occlusion of the LCA followed by 2 hours of 
reperfusion. The infarct size and area at risk were measured with triphenyltetrazolium 
chloride staining.
Results: The infarct area in UCP3-/- mice was signiﬁcantly larger than in wild type mice 
following ischemia-reperfusion (30.8+/-6.6% vs. 12.4+/-1.2%, p=0.009). Accordingly, 
there were signiﬁcant differences in the infarct area to area at risk ratio (0.52+/-0.07 
versus 0.27+/-0.03, p=0.004). However the area at risk was similar in both groups 
(61.9+/-3.2 versus 48.7+/-9.5%, p=0.08). Reperfusion arrhythmias, including bradycardia, 
atrioventricular block and ventricular arrhythmias, were more pronounced in UCP3-/- 
mice while the overall heart rate response to ischemia reperfusion injury was similar. LCA 
ligation was associated with a greater ST segment elevation in UCP3-/- mice than in wild 
type mice in addition to persistent ST segment depression during reperfusion suggesting 
a component of no-reﬂow in the UCP3-/- mice.
Conclusions: Thus there is increased myocardial vulnerability to ischemia-reperfusion 
injury in mouse hearts lacking UCP3. We conclude that UCP3 in cardiomyocytes prevents 
myocardial damage during oxidative stress. The regulation of mitochondrial UCP3 by 
pharmacological or genetic means may be a new potential therapeutic target for effective 
myopreservation in oxidative stress.
11:00 a.m.
1003-75 Real-Time Magnetic Resonance Imaging (MRI) of the 
Time Course of Myocardial Injury and Cell Death in a 
Canine Model of Regional Ischemia and Reperfusion
Patrick M. Burns, Patrick N. Kearns, Yoshinori Nishijima, Pedro Vargas-Pinto, Yu Ding, 
Mihaela Jekic, Jiarui Lian, Hung-Yu Lin, Kun Huang, Orlando P. Simonetti, Jay L. Zweier, 
The Ohio State University, Columbus, OH
Background:Questions remain regarding when cell death occurs in the ischemic and 
reperfused heart. Therefore, we developed a technique for real-time MRI of myocardial 
function and infarction in hearts subjected to regional ischemia and reperfusion.
Methods:Left anterior descending artery was occluded in 7 dogs via an intracoronary 
balloon and a coronary sinus catheter was placed. Myocardial signal enhancement was 
measured every 10 min with a constant infusion of gadolinium during 90 min of ischemia 
followed by 120 min of reperfusion, and again at 24 and 48 hours post-reperfusion. Wall 
motion was measured by cine MRI.
Results:At occlusion the at-risk region became akinetic whilst the remote myocardium 
showed increased inotropy. During ischemia, myocardial signal intensity showed no 
increase. Upon reperfusion, infarct region end-diastolic thickness increased by >80% 
(13.5 ± 2.1 vs. 7.4 ± 0.9 mm), immediately followed by an increase in infarct signal 
intensity to 244% of remote (124.6 ± 18.7 vs. 51.1 ± 11.9) and infarct area reached a 
peak after 60 min reperfusion. CPK measured across the coronary circulation showed no 
change during ischemia, but increased upon reperfusion returning to baseline by 48 hr.
Conclusions:We observed myocardial injury and cell death occur primarily upon 
reperfusion with continued necrosis and enzyme leak for up to 120 min after the onset of 
reﬂow. These results demonstrate that reperfusion injury occurs with a critical window of 
cell death during the ﬁrst two hours of reﬂow. 
11:00 a.m.
1003-76 Identiﬁcation of Characteristic Expression Proﬁling of 
Acute Coronary Syndromes Associated With STEMI : 
Large-Scale Diagnostic Markers for STEMI
Pum-Joon Kim, Ki-Bae Seung, Ki Yuk Jang, Sang Hong Baek, Hae Ok Jung, Woo 
Seung Shin, Hun Jun Park, Ju Yeal Baek, Seong Gyu Yoon, Man Won Park, Yoon Seok 
Koh, Suk Woo Nam, Kyu Bo Choi, The Catholic University of Korea, Kangnam St’ Mary’s 
Hospital, Seoul, South Korea
Background:The purpose of this study is to identify characteristic transcriptomic proﬁle of AMI 
and recapitulate genetic elements whose expression is markedly elevated in AMI, as well as 
to suggest large-scale molecular markers which allow diagnosing AMI in early times.
Methods:To deﬁne testing group for early AMI detection, peripheral bloods from patients 
presented with 2 hours of pain onset were included as AMI. To assess and identify 
characteristic molecular proﬁling of AMI, total RNA of peripheral blood was subjected 
to human whole genome expression array (Human-6 V2, Illumina, USA) in 10 patients 
at 2.0±0.5h after onset of AMI and compared with healthy subjects or 2 weeks follow-up 
samples from the same patients.
Results:Unsupervised hierarchical clustering analysis of gene expression proﬁling 
resulted in distinct molecular signature between AMI and healthy, follow-up groups. 
Large-scale genetic elements included S 100 calcium binding protein P, MMP 9, TNF-A 
induced protein 6,IL-2 receptor B, and BCL6, and many of them were previously reported 
as genetic marker for ischemic stroke.
Conclusions:We present characteristic molecular signature of AMI by using whole 
genomic expression analysis and suggest large-scale genetic elements as early 
diagnostic marker or surrogate makers for guiding AMI from the peripheral blood of 
patients. These data provide insight into inﬂammatory responses after AMI, and should 
be helpful in understanding pathogenesis and development of new treatment for AMI. 
11:00 a.m.
1003-77 Heart-Kidney Connection: Renal Fibrosis and Activation 
of Renal Molecular Remodeling After Myocardial 
Infarction in the Absence of Heart Failure
Fernando L. Martin, Brenda K. Huntley, Gerald E. Harders, Horng H. Chen, Alessandro 
Cataliotti, John C. Burnett, Jr., Mayo Clinic, Rochester, MN
Background: Studies in human myocardial infarction (MI) suggest that even in the 
absence of heart failure (HF) alterations in renal function may occur and contribute to 
poor outcomes. After MI a decline in renal function may be seen acutely by mechanisms 
which are unclear. The long term consequences of MI upon renal function and structure 
remain poorly deﬁned. We hypothesized that even without preexisting renal disease, renal 
functional and structural changes would be present following MI. Methods: Cardiorenal 
function and structure were assessed in Wistar rats, Sham (S; n=10) and MI groups (n=9) 
3 weeks after MI. GFR was determined by inulin clearance. Blood was obtained for PRA 
and aldosterone. Hearts and kidneys were harvested for histological analysis. Cardiac 
function was assessed by echo. Genome-wide microarray analysis was performed on 
kidney cortex (KC) and medulla (KM) (Affymetrix GeneChip® Rat Genome 230 2.0). 
Results: EF decreased after MI (S:62.8±2.3, MI:42.8±6.5 %, p<0.01) and LVEDd 
increased (p<0.005) PRA and aldosterone activation were absent. Blood pressure (BP) 
was not different between groups. There was no HF as sodium and water excretion was 
maintained. GFR tended to decrease (S:2.9±0.3, MI:2.4±0.2 ml/min, NS). Picrosirius Red 
staining for collagen in the KC and KM after MI showed greater ﬁbrosis especially in the 
RM (KC S:1.1±0.2, MI:3.5±0.6 %, p<0.001 and KM S:1±0.2, MI:18.8±6 %, p<0.005). 
Microarray analysis revealed that 303 genes signiﬁcantly changed in KM and 407 genes 
in the KC after MI (1.5 fold, P<0.05). Gene dysregulation was related to cell proliferation, 
metabolic processes and cell communication (Z value>2). Conclusion: We conclude that 
experimental MI results in renal structural remodeling characterized by renal cortical and 
medullary ﬁbrosis with a mild reduction in GFR and extensive modulation of molecular 
pathways related to renal growth and metabolism. This investigation provides evidence for 
a heart-kidney connection after MI by mechanisms which remain to be deﬁned. We also 
conclude that therapies for MI targeting the heart also should be evaluated for properties 
of renoprotection.





1003-78 Paracrine Cytoprotective Effects of Inner Chorion-
Derived Human Mesenchymal Stem Cells
Kazuhiko Harada, Noritoshi Nagaya, Shunsuke Ohnishi, Shin Ishikane, Michihiro 
Fujiwara, Tomoaki Ikeda, Department of Biochemistry, National cardiovascular center 
research institute, Suita, Japan, Department of regenerative medicine and Tissue 
engineering, National cardiovascular center research, Suita, Japan
Background:The fetal membrane, which includes amnion and chorion, is considered 
an ideal source for regenerative medicine, although it is normally discarded after birth. 
Mesenchymal stem cells (MSC) have been identiﬁed in the fetal membrane; however, little 
information is available regarding the biological difference of MSC derived from different 
layers of the fetal membrane. We assessed the hypothesis that the different layers of MSC 
would exert different effects in response to biological stress.
Methods:We mechanically and enzymatically separated the human fetal membrane into 
three layers; amnion and inner and outer layers of chorion, and isolated MSC from each 
layer. MSC were identiﬁed by adherence, surface antigen expression and multi-lineage 
differentiation. We examined the amount of growth factor from MSC culture and effects of 
conditioned medium from MSC culture by MTS assay, TUNEL assay and measurement 
of caspase-3 activity.
Results:MSC obtained from all three layers were similar in morphological appearance and 
surface antigen expression, and comparably differentiated into adipocytes and osteocytes. 
The amount of growth factor secretion from MSC culture was different according to the 
origin of MSC: hepatocyte growth factor and insulin-like growth factor-1 were secreted 
mainly from the inner chorion, while vascular endothelial growth factor was secreted 
mainly from the outer chorion and basic ﬁbroblast growth factor was secreted mainly 
from the amnion. Conditioned media obtained from inner and outer chorion-derived MSC 
protected against the growth inhibition in endothelial cells and cardiomyocytes, whereas 
conditioned medium obtained from amnion-derived MSC protected only cardiomyocytes. 
Moreover, conditioned medium obtained from inner chorion-derived MSC had an anti-
apoptotic effect on both endothelial cells and cardiomyocytes under biological stress.
Conclusions:MSC can be isolated from three different layers of the fetal membrane, and 
exert different paracrine effects in response to biological stress. Particularly, inner chorion-
derived MSC have potent cytoprotective effects on endothelial cells and cardiomyocytes.
11:00 a.m.
1003-79 Development of Monitoring Systems for 
Cardiomyogenic and Endothelial Differentiation
SEUNG-CHEOL CHOI, JI-HYUN CHOI, CHI-YEON PARK, WAN-JOO SHIM, DO-SUN 
LIM, Korea University Medical College, Seoul, South Korea
Background: It has been shown that adult stem cells derived from various organs can 
transdifferentiate into cardiomyocytes and endothelial cells and contribute to myocardial 
repair. However, the concept of stem cell plasticity has been challenged by recent 
ﬁndings demonstrating cell fusion, but not transdifferentiation. Therefore, questions 
and controversies with regard to the mechanisms of myocardial regeneration still 
exist. This study is to develop the reporter-vector systems for monitoring of stem cells 
transdifferentiating into cardiomyogenic or endothelial lineage. Methods: For monitoring 
of cardiomyogenic differentiation, atrial natriuretic factor (785-bp), cardiac troponin 
I (408-bp), myosin heavy chain (363-bp) and myosin light chain (327-bp) fragment of 
promoter regions were ampliﬁed using the genomic DNA isolated from C57BL/6 mice and 
cloned into pDsRed vector. A 844-bp fragment of Flk1 and a 1,061-bp fragment of Tie2 
promoter regions were ampliﬁed and cloned into pEGFP vector to monitor endothelial cell 
differentiation. The reporter vectors were transfected into bone marrow mesenchymal stem 
cells (BMMSCs) and P19 embryonic stem cells, and cardiac or endothelial differentiation 
was induced by 5-azacytidine or VEGF treatment. Results: The differentiation of 
BMMSCs and P19 embryonic stem cells along the cardiomyogenic or endothelial 
lineage was speciﬁcally monitored by the appearance of cardiac- or endothelial-speciﬁc 
promoter-driven EGFP or DsRed as determined by immunocytochemistry. Furthermore, 
dual-reporter systems for simultaneous tracking of DsRed driven by the cardiac-speciﬁc 
promoters and EGFP driven by the endothelial-cell-speciﬁc promoters were constructed, 
and their speciﬁcity in monitoring of cardiac and endothelial differentiation was conﬁrmed 
in BMMSCs and P19 embryonic stem cells. Conclusions: These results showed that 
the reporter-vector systems based on tissue-speciﬁc promoters can be used to monitor 
stem cells differentiating into cardiac or endothelial lineage. By combining noninvasive 
molecular imaging technology, these can be used to track stem cell location and fate after 
transplantation into infarcted myocardium.
11:00 a.m.
1003-80 The Cardioprotective Role of Osteopontin-1 in the 
Pathogenesis of Murine Ischemic Cardiomyopathy
Georg D. Duerr, Martin Zoerlein, Daniela Dewald, Bettina Mesenholl, Prisca Schneider, 
Alexander Ghanem, Susan Rittling, Armin Welz, Oliver Dewald, University Clinical 
Center Bonn, Bonn, Germany
Background: Repetitive brief ischemia and reperfusion (I/R) is associated with ventricular 
dysfunction in development of ischemic cardiomyopathy. We investigated the role of 
matricellular protein and macrophage maturation marker osteopontin-1 (OPN) in our 
closed-chest murine model of repetitive I/R.
Methods: Daily 15 minutes LAD occlusion followed by reperfusion was performed for 3, 5 
and 7 consecutive days (d) in C57/Bl6 wildtype (WT) and OPN KO mice (n=8/group). Hearts 
were examined echocardiographically and processed for histological and mRNA studies.
Results: OPN mRNA expression was induced 15 fold in Taqman RT-PCR after 3d I/R in 
WT mice followed by a transient chemokine induction and macrophage inﬁltration. This 
led to extensive interstitial ﬁbrosis with global and regional left ventricular dysfunction 
and without myocardial infarction after 7d I/R. In contrast, OPN KO mice showed 
microinfarctions in the ischemic region after 3d I/R followed by a scar formation. Total 
collagen area was comparable between the strains. The microinfarctions in OPN KO 
mice showed dense collagen deposition and a strong macrophage inﬁltration after 5d I/R 
(27.9±12.7 cells/ﬁeld, F4/80). The non-infarcted ischemic area in OPN KO mice showed 
only loose interstitial collagen deposition and lower macrophage density (7.0±1.6/
ﬁeld) when compared to WT mice (33.3±8.2/ﬁeld; p<0.05). Anterior wall thickening 
was signiﬁcantly lower in OPN KO hearts (32.1±6.1% vs. WT 51.8±5.6%; p<0.05), but 
fractional shortening was comparable between the strains. mRNA induction of CCL2 and 
CCL4 was signiﬁcantly decreased in OPN KO hearts and accompanied by up to 5 fold 
lower induction of glutathione peroxidase 1, heme oxygenase 1 and zinc-storage proteins 
metalothionein 1 & 2.
Conclusions: The cardioprotective mechanism of OPN seems to involve a cascade where 
sufﬁcient induction of free radical scavenger enzymes, metallothionein and chemokines is 
leading to macrophage inﬁltration and subsequent interstitial ﬁbrosis without myocardial 
infarction. OPN may therefore prevent cardiomyocyte loss through modulation of 
inﬂammatory response and interstitial remodelling in murine ischemic cardiomyopathy.
11:00 a.m.
1003-83 Myocardial perfusion changes in the ﬁrst week after 
STEMI strongly inﬂuence left ventricular size and 
function at 6 months follow-up: results from the 
Acute Myocardial Infarction Contrast Imaging (AMICI) 
multicenter trial
Stefania Funaro, Emanuela Berardi, Emanuele Canali, Mariapina Madonna, 
Antonella Mattatelli, Alessandra Labbadia, Antonio Scarà, Leda Galiuto, Luciano 
Agati, Department of Cardiology, La Sapienza University, Rome, Italy, Department of 
Cardiology, Catholic University Sacred Heart, Campobasso, Italy
Background: Clinical signiﬁcance of microvascular damage (MD) changes after 
reperfusion is still under discussion. At this aim we studied the correlation between MD 
changes in the ﬁrst week after STEMI and LV functional outcome at 6 month F/U.
Methods: 110 STEMI patients were enrolled in the AMICI multicenter trial. MD was 
assessed using myocardial contrast echocardiography on day 1 after reperfusion (T1) 
and at pre-discharge (T2). The following echo parameters were calculated at T1,T2 and 
at 6 months F/U: contrast defect length (CDL%), wall motion abnormalities (WMA%), 
ejection fraction (EF%) and end diastolic volume (EDV).
Results: During the ﬁrst week after STEMI, CDL% reduced (Group 1) in 31% of patients 
(from 29±14 to 14±15), didn’t change (group 2) in 21% (from 28±13 to 28±13) and 
increased (Group 3) in 13% (from 28±8 to 36±7). Microvascular perfusion was normal 
(Group 4) at T1 and T2 in 35% of patients. At T1, there weren’t statistical differences in 
MD extent between Groups 1, 2 and 3 (CDL% 29±14, 28±13, 28±8, respectively, ns). At 
T1, WMA% and EF%, were less compromised in group 4 than in the remaining groups 
(WMA%: 48±18, 45±15, 54±11, 21±17 respectively, p<0.05 and EF%: 44±9, 42±6, 42±7, 
53±7 respectively p<0.05) while EDV was similar in the 4 groups (110±30, 109±9, 118±26, 
100±25 respectively). At F/U, patients with normal perfusion had the best outcome with a 
signiﬁcant reduction in WMA% and EDV (- 30 % and -7 % respectively) and a signiﬁcant 
improvement in EF (+ 8 %). Among patients with microvascular damage at T1 only those 
with CDL% reduction showed WMA% and EDV reduction (-33 % and - 3 % respectively) 
and EF% improvement (+ 9 %). In patients with stable MD, no changes in WMA or EF 
might be detected at F/U. Finally a signiﬁcant EDV increase (+ 22 %) was detected in 
patients with increased MD after STEMI.
Conclusions: Patients with normal microvascular perfusion after STEMI had smaller 
infarct size and better systolic function with signiﬁcant reduction in EDV at F/U. Similar 
results were observed in patients showing MD reduction in the ﬁrst week after STEMI. 
The persistence or worsening of MD was strongly connected to a bigger infarct size with 
a more depressed EF% and a signiﬁcant EDV increase at F/U.
11:00 a.m.
1003-84 Reverse Remodeling During Healing After Reperfused 
Myocardial Infarction Through Matrix and Cytokine 
Modulation With Vasopeptidase Inhibition
Arivazhagan Palaniyappan, Vijayan Menon, Halliday Idikio, Richard R. Uwiera, Bodh I. 
Jugdutt, University of Alberta, Edmonton, AB, Canada
Background: Angiotensin II and matrix metalloproteinases (MMPs) and tissue inhibitors of 
MMPs (TIMPs) modulate cardiac remodeling and nitric oxide synthases (NOSs) modulate 
function. We hypothesized that decreased effects of angiotensin II induced by dual inhibition 
of neutral endopeptidase and the angiotensin-converting enzyme with the vasopeptidase 
inhibitor omapatrilat or the the angiotensin type 1 receptor blocker candesartan improves 
MMP-9/TIMP-3 balance and decreases iNOS, reverses left ventricular (LV) remodeling 
and limits dysfunction during healing after reperfused myocardial infarction (RMI).
Methods: We randomized Sprague-Dawley rats 24 hours after RMI (1 hour of left anterior 
descending coronary occlusion followed by reperfusion) to 3 weeks of oral placebo, 
omapatrilat (10 mg/kg), or candesartan (30 mg/kg). A sham group had no occlusion. 
We measured LV function and remodeling (2D-echocardiography/Doppler), MMP activity 
(zymography), and MMP, TIMP and NOS proteins (Western blots) in the ischemic and 
non-ischemic zones, and infarct size at 3 weeks.
Results: Compared to sham, RMI in placebo induced ST-segment elevation, infarction 
(25% LV; 60% risk), LV dysfunction (decreased ejection fraction and diastolic function) 
and remodeling (increased LV diastolic and systolic volumes; infarct expansion and 
thinning). Compared to placebo, both omapatrilat and candesartan limited LV dysfunction 
and remodeling with improved (P<0.001) LV ejection fraction, volumes and diastolic 
dysfunction, and less (P<0.001) infarct expansion and thinning. Compared to the non-



















infarct zone, MI induced nearly 1.8-fold increases (P<0.001) in MMP-9 and MMP-2 
(activity and protein) and TIMP-3 protein, nearly 2-fold increases in iNOS, nNOS and 
eNOS in the ischemic zone and these changes were normalized (P<0.001) by omapatrilat 
and candesartan. Both drugs also improved the MMP-9/TIMP-3 balance (not MMP-2/
TIMP-1) and normalized myeloperoxidase and transforming growth factor B1 in the 
ischemic zone.
Conclusions: Modulation of MMP-9/TIMP-3 balance, angiotensin II and iNOS with 
omapatrilat and candesartan induces reverse LV remodeling and limits dysfunction during 
healing after RMI.
11:00 a.m.
1003-85 Cell Distribution by both Endomyocardial and 
Epicardial Injections in Porcine Chronic Myocardial 
Infarction Model
Dongming Hou, Fernando Tondato, Pendyala Lakshmana, Nic Chronos, Keith Robinson, 
Saint Joseph’s Research Institute, Atlanta, GA
Background: Unrestricted somatic stem cells (USSCs) obtained from human cord blood 
have intrinsic pluripotent differentiation potential. However the fate of cells transplanted 
into the chronic infarcted heart has not been extensively studied. We evaluated myocardial 
distribution of USSCs by both endomyocardial and epicardial injection technique in a 
swine model.
Methods: Myocardial infarction (MI) was induced by coronary artery embolization in 7 
pigs. 28 days after MI, 2x106/kg hUSSCs labeled by 111Indium (n=7) were delivered 
either via intramyocardial injection catheter (Endo, n=4), or via thoracotomy direct 
epicardial injection (Epi, n=3). 20 injections were throughout the infarct and border zones 
in a grid-like pattern (0.1 ml each site). The Endo delivery was under intracardiac Echo 
guidance. Animals were terminated after 24hrs. The radioactive biodistribution in heart 
and other organs were assessed by G-emission counting.
Results: Lung, liver, spleen and kidney were weighted and sampled with ~1 cm3 in 3 
locations. For hearts, the regions of infracted, border, and rim of adjacent normal tissue, 
in addition to remote LV, LA, RV, RA, mitral and aortic valves, were also cut and weighed. 
Quantitative data showed that average overall cardiac retention was 17±16% for both 
delivery modalities. The retention rate in the infarction and remote zones were 10±8% 
and 6±6% for Endo, 15±16% and 3±2% for Epi group (P>0.05) respectively. Epicaridal 
delivery was more variable. The majority of transplanted cells were detected out side the 
heart, primarily in lung (25±5%) and liver (40±9%).
Conclusions: The majority of delivered USSCs are sequestered into the lungs and 
liver at 24 hours. The ﬁndings support the notion that backstreaming into or outside of 
ventricular chamber, as well as unintentional injection into intramyocardial veins are 
signiﬁcant sources of cell loss by this method. The clinical implications of these ﬁndings 
are potentially signiﬁcant, as these proangiogenic cells may have undesirable effects 
in non-target organs and the poor retention efﬁciency may hinder therapeutic efﬁcacy. 
Development of improved delivery and retention efﬁcacy is the goal of future study.
11:00 a.m.
1003-86 Protein Kinase C-D inhibitor protects against acute 
myocardial infarction by intravenous administration 
either during ischemia or reperfusion
Eiketsu Sho, Jin Dong, Zhen Jin, Yong Sun Lee, Steve Harrison, Dirk Mendel, KAI 
Pharmaceuticals, South San Francisco, CA
Background: Historical studies have shown that a selective DPKC inhibitor peptide 
(KAI-9803) reduces reperfusion-induced myocardial damage in a pig acute myocardial 
infarction (AMI) model when delivered locally into the intracoronary artery at the onset 
of reperfusion. The goal of this study is to study the therapeutic effects of KAI-9803 
administered by intravenous (IV) infusion in a rodent AMI model either during ischemia 
or reperfusion.
Methods: Transient left coronary artery occlusion was induced in male Sprague Dawley 
rats for 30min followed by 24hrs of reperfusion. KAI-9803 or saline was administered as a 
30-min IV infusion via the femoral vein either starting at the onset of ischemia, the onset 
of reperfusion, or at 30-min or 90-min after initiation of reperfusion. The infarct sizes were 
evaluated at 24hrs of reperfusion. Histological studies were performed at the end of IV 
infusion to evaluate myocyte and capillary protection and early inﬂammatory reactions 
following treatment.
Results:Thirty minutes of IV infusion with KAI-9803 both during ischemia and at the 
beginning of reperfusion resulted in 40% reduction in infarct size after 24hrs of reperfusion. 
Delayed treatment resulted in a reduced protective effect with a 30% or 23% reduction 
in infarct size when treatment started at 30 or 90 min of reperfusion, respectively. 
Histological analysis of the early time course of reperfusion showed KAI-9803 protects 
against capillary damage (2382 ± 234/mm2 vs. 1389 ± 126/mm2 capillary density with 
treatment during ischemia; 2338 ± 113/mm2 vs. 1270 ± 166/mm2 capillary density with 
treatment beginning at reperfusion, p<0.01). This protection was reduced when the 
treatment started after 90 min of reperfusion. Inﬂammatory cell inﬁltration started ~60-90 
min after reperfusion and was limited by treatment with KAI-9803 (246 ± 17/mm2 vs. 399 
± 34/mm2 inﬂammatory cell density at 120-min reperfusion, p<0.01).
Conclusions: IV infusion of KAI-9803 either during ischemia or within 90 minutes of the 
start of reperfusion can protect against myocardial damage. DPKC inhibition may not only 
reduce myocyte damage, but can also protect against microvascular damage and limit the 
acute inﬂammatory reaction.
11:00 a.m.
1003-88 Decreased levels of inﬂammatory cytokines and 
circulating endothelial progenitor cells after 
implantation of paclitaxel-eluting stents
Wojciech Wojakowski, Andrzej Ochala, Beata Ksiazek, Maciej Kazmierski, Andrzej Pyrlik, 
Joanna Ciosek, Iwona Mroz, Marek Krol, Katarzyna Maslankiewicz, Barbara Korzeniowska, 
Rafal Wyderka, Michal Tendera, Medical University of Silesia, Katowice, Poland
Background: Increased levels of inﬂammatory markers are predictors of adverse 
cardiac events and restenosis in patients undergoing PCI. Paclitaxel-eluting stents 
(PES) signiﬁcantly lower the risk of restenosis. Paclitaxel can modulate the activity of 
immune cells leading to altered levels in systemic inﬂammatory markers and transcription 
of inﬂammation- and apoptosis related genes. We hypothesized that in patients with 
stable CAD undergoing the elective PCI, implantation of PES leads to suppression of 
procedure-associated increase of inﬂammatory cytokines, circulating progenitor cells 
and inﬂammatory genes in circulating MNC in comparison to bare metal stents (BMS). 
Aim: to assess the inﬂuence of paclitaxel-elutins stents on procedure-related increase 
of hematopoietic cytokines, circulating CXCR4+ and CD34+CD133+VEGFR2+ progenitor 
cells and expression of inﬂammatory genes in comparison to BMS in patients undergoing 
elective PCI. Methods: 28 patients undergoing elective one-vessel PTCA with implantation 
of PES and 26 with BMS were enrolled. Blood samples were drawn at before PTCA, 24 
hours and 4 weeks after PTCA. Results: PTCA with BMS lead to increased levels of 
MCP-1, IL-10, sCD40L and hsCRP after 24, however there was no increase in patients 
treated with PES [MCP-1 (510±112 vs. 362±71 pg/mL, p<0.05); IL-10 (4.4±2.1 vs. 3.1±1.3 
pg/mL, p<0.05); sCD40L (4.97±2.4 vs. 3.2±1.5 pg/mL, p<0.03); hsCRP (3.4±1.1 vs. 
2.8±0.9 pg/mL, p<0.05). Number of circulating CD34+CD133+VEGFR2+ EPC (1.7±1.0 
cells/µL) increased 24 hours after PTCA in patients with BMS (3.9±1.6 cells/µL), but not 
with PES (2.0±0.9 cells/µL). No changes in levels of chemoattractants SCF, G-CSF, VEGF 
and SDF-1 were found after 24 hours and 4 weeks. No differences in levels of cytokines 
and EPC were found after 4 weeks between PES and BMS. Microarrays were used 
for the evaluation of transcriptional activity of inﬂammatory genes in circulating MNC. 
Conclusion: Implantation of paclitaxel-eluting stents has anti-inﬂammatory effect on 
PTCA-related increase of cytokine levels and may have unfavorable effect by suppression 
of the mobilization of progenitor cells.
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1010-41 Hydrogen Sulﬁde (H2S) Preconditions the Myocardium 
Against Myocardial Ischemia-Reperfusion Injury via 
Up-regulation of Anti-Apoptotic Signaling
Susheel Gundewar, Saurabh Jha, Sang Yong Ji, Arun Ramachandran, Denise J. Nunez, 
Iris Toedt-Pingel, Sandeep Patel, John W. Calvert, John W. Elrod, David J. Lefer, Albert 
Einstein College of Medicine, Bronx, NY
Background: Hydrogen sulﬁde (H2S) is an important endogenously produced gaseous 
signaling molecule with a diverse physiological proﬁle. Moreover, the emergence of H2S 
as a potent cardioprotective mediator, either through its exogenous administration or 
through the up-regulation of its endogenous production, necessitates the elucidation of 
its cytoprotective mechanisms. Therefore, we evaluated several potential mechanisms of 
H2S mediated myocardial preconditioning. Methods: H2S donor (100 µg/kg), or vehicle 
was administered (i.v.) to mice. Hearts were excised 24 hr after H2S administration and 
left ventricular tissue was processed for a glutathione assay or for Western blot analysis. 
In a separate group, mice were treated with H2S and then 24 hr later subjected to transient 
myocardial ischemia for a period of 45 min followed by reperfusion for 24 hr, at which time 
the hearts were excised and evaluated for infarct size using 2,3,5-triphenyltetrazolium 
chloride (TTC) staining. Results: H2S increased the protein expression of the anti-
apoptogen, Bcl-2, in both the cytosolic and mitochondrial cellular compartments. 
However, H2S did not increase the protein levels or activation of eNOS, MnSOD or 
glutathione. Mice treated with H2S donor did exhibit a 42% reduction (p < 0.001) in infarct 
size relative to area-at-risk compared to vehicle. Conclusion: These ﬁndings suggest that 
activation of anti-apoptotic signals could be an important mechanism of H2S mediated 
cardioprotection. 
3:00 p.m.
1010-42 Delayed Ischemic Preconditioning of the Swine Heart 
by Gene Delivery of H11 Kinase
Li Chen, You-Tang Shen, Ping Zhang, Stephen F. Vatner, Christophe Depre, Department 
of Cell Biology and Molecular Medicine, University of Medicine & Dentistry of New 
Jersey, Newark, NJ
Background: H11 kinase (H11K) is a small heat shock protein expressed predominantly in 
the heart, the expression of which increases in various forms of ischemic heart disease, 
both in animal models and in patients. We hypothesized that over-expression of the H11K 
gene delivered into the potential area-at-risk (AAR) would reduce the extent of irreversible 
damage upon subsequent ischemia-induced myocardial infarction.
Methods: Domestic pigs were instrumented with a left ventricular pressure gauge, 
catheters and hydraulic occluder around the left circumﬂex (LCX) coronary artery. An 
adenovirus harboring the H11K sequence was injected to the potential AAR (n=5). Control 
pigs were injected with virus expressing LacZ (n=5). Three days after injection, the LCX 
artery was occluded for 60 min, followed by 3 days of reperfusion. A similar protocol in 3 
pigs injected with H11K was performed in the presence of N (G)-nitro-L-arginine methyl 
ester (L-NAME), a NO synthase inhibitor. Additional 4 pigs injected with H11K were used 
for determination of gene expression, as well as, cell survival pathway.
Results: H11K-injected myocardium showed a 4-fold increase in H11K protein expression 
compared to control (p<0.01). Although the AAR was similar between groups, infarct size, 
expressed as a fraction of AAR, was reduced signiﬁcantly (p<0.05) in the H11K-injected 
group (32±5%) compared to the LacZ group (50±5%). H11K-injected myocardium 
showed a signiﬁcant (p<0.05) 2- to 4-fold increase in the expression of the inducible 
isoform of NO synthase and cyclooxygenase-2, both mediators of the 2nd window of 
ischemic preconditioning. Pigs with injected H11K virus, but pretreated with L-NAME, no 
longer demonstrated the cardiac protection, i.e. infarct size was 67±11%, similar to that 
observed in pigs injected with LacZ and pretreated with L-NAME (72%).
Conclusion: Pre-emptive conditioning of the swine heart by H11K activates cell survival 
mechanisms that recapitulate the mechanisms of delayed preconditioning, and markedly 
decreases infarct size following lethal ischemia in a NO-dependent mechanism, which 
places H11K as a potential tool for the treatment of ischemic heart disease.
3:00 p.m.
1010-43 Non-Invasive In Vivo Tracking Of Percutaneously 
Intramyocardially Injected Autologous Porcine 
Mesenchymal Stem Cells Modiﬁed For Transgene 
Expression Of PET Reporter Gene Using Serial PET 
Imaging
Mariann Gyongyosi, Jeronimo Blanco, Terez Marian, Lajos Tron, Ors Petnehazy, Zsolt 
Petrasi, Rayyan Hemetsberger, Imre Pavo jr, Dara Kraitchman, Johann Wojta, Kurt 
Huber, Dietmar Glogar, Medical University of Vienna, Vienna, Austria, The Johns 
Hopkins University, School of Medicine, Baltimore, MD
Background: Reporter gene imaging offers the ability to non-invasively serially track 
stem cell fate. To-date most studies have been performed in small animals. Methods: 
Myocardial infarction (MI) was created by percutaneous balloon occlusion of the LAD 
in farm pigs. Bone marrow (BM) was harvested and mesenchymal stem cells (MSCs) 
were selected and modiﬁed for transgene expression of the trifusion protein (lentiviral 
vector expressing renilla luciferase, red ﬂuorescent protein and herpes simplex truncated 
thymidine kinase (LV-RL-RFP-tTK) as positron emission tomography (PET) reporter 
gene. In vitro assays of [18F]-FHBG uptakes of the LV-RL-RFP-tTK MSCs revealed a 
minimum number of 0.1 million cells were detectable with PET. Sixteen days after AMI, 
baseline magnet resonance imaging (MRI) of the heart was performed in all animals and 
the BM-LV-RL-RFP-tTK MSCs were injected intramyocardially using NOGA guidance in 
the infarct border zone (total 2.6+/-0.4 million cells) in 6 pigs, while 7 animals served 
as control. Thirty hours and 7 days after MSC-LV-RL-RFP-tTK treatment, PET imaging 
were performed after intravenous injection of 6 mCi [18F]-FHBG followed by control MRI. 
Results: PET demonstrated diffuse distribution of the injected MSC-LV-RL-RFP-tTK in 
the pig heart in the anterior wall and septum at 30h and decreased tracer activity in the 
injections sites with pericardial and pleura uptake at 7 days. MRI revealed a trend of 
a decreased end-diastolic volume (EDV) (82.5+/-6.8 vs. 79.0+/-4.4 ml) and infarct size 
(29.4+/-5.5 vs. 25.3+/-1.4%) and an increased ejection fraction (EF) (43.8+/-2.4 to 47.0+/-
3.5%) in Group-MSC in contrast to controls (EDV: 80.0+/-6.2 vs. 88.0+/-7.7 ml, infarct 
size: 29.5+/-5.2 vs. 30.2+/-4.1%, EF: 43.7+/-5.9vs 43.5+/-2.3%). The infarct size was 
signiﬁcantly smaller in Group-MSC as compared to controls at 26 days post-MI (p=0.032). 
Histology conﬁrmed the presence of the viable MSCs (12.9+/-3.4% of the injected cells) 
in the myocardium 10 days after intramyocardial delivery. Conclusion: Reporter gene 
imaging enables the non-invasive PET imaging on clinical scanners of the persistence of 
viable MSCs in the peri-infarcted myocardium at 10 days post-delivery.
3:00 p.m.
1010-44 Anemia as a Predictor of Myocardial Infarction, Need for 
Coronary Revascularization, and In-Hospital Mortality 
in Women Presenting With Chest Pain
Miret Habashy-Ibrahim, Bruce Bernstein, W. David Hager, Rodrigo M. Lago, Anita 
M. Kelsey, Saint Francis Hospital and Medical Center, Hartford, CT, University of 
Connecticut Health Center, Farmington, CT
Background: Cardiovascular (CV) disease is the leading cause of death in women. Studies 
have shown that lower levels of hemoglobin (Hgb) may be a risk factor for adverse CV 
outcomes in women. The clinical impact of anemia (Hgb < 12g/dL) in women undergoing 
catherization for chest pain has not been evaluated. We examined the association 
between Hgb and CV disease outcomes and in-hospital death from any cause in this 
population.
Methods: We conducted a retrospective study of 428 women undergoing cardiac 
catheterization for chest pain between 2005 and 2006 and evaluated the risk of 
myocardial infarction (MI), revascularization (percutaneous coronary intervention or 
coronary artery bypass surgery), and death. Logistic regression analysis adjusted for 
age, type 2 diabetes, chronic kidney disease and hypertension was performed to identify 
predictors of adverse CV outcomes.
Results: The overall incidence of anemia was 33% (139 out of 428). Only Age (OR 1.02, 
95% CI 1.01-1.04) and anemia (OR 1.87, 95% CI 1.16-3.02) were found to be independent 
predictors of adverse CV outcomes and death. In this population, anemia was a stronger 
predictor of MI, revascularization, or death than age, type 2 diabetes, chronic kidney 
disease or hypertension . Conclusion: Women with anemia undergoing angiography 
for chest pain have an increased likelihood of adverse CV outcomes compared to non-
anemic women. This result corroborates previous ﬁndings and may indicate the need for 
more aggressive risk stratiﬁcation of anemic women. 




















1010-45 Human adipose tissue-derived stem cell preserved 
heart function in athymic nude rats following 
permanent ischemia
Liying Cai, Brian H. Johnstone, Todd G. Cook, Keith L. March, Indiana Center for 
Vascular Biology and Medicine, Indianapolis, IN, Krannert Institute of Cardiology, 
Indianapolis, IN
Backgroud: The use of stem cells for repair of myocardium damaged by cardiac insult 
has gained much interest as a new therapeutic approach. Previously, we demonstrated 
that adipose stem cells (ASCs) promote reperfusion and tissue repair in ischemic skeletal 
muscle.
Methods and Results: ASCs were harvested from human subcutaneous adipose tissue 
samples obtained following lipoaspiration. ASCs conditioned media (CM) promote 
proliferation and migration of mature and progenitor endothelial cells in vitro. Growth 
and metabolic activity of human microvascular endothelial cells (HMVEC) cultured in 
growth-factor deﬁcient minimal medium (MM) increased 1.7-fold when supplemented 
with a 1:1 mixture of ASC CM (p<0.01). Angiogenic formation and migration of 
HMVECs were enhanced by 2.1 and 2.0-fold, separately, when ASC CM was added 
to MM (p<0.01). Intramyocardial injection of ASCs into periinfarct zone of athymic nude 
rat hearts following permanent LAD ligation, signiﬁcantly preserved cardiac function in 
vivo by serial echocardiography. 28 days after cell treatment, ASC-treated rats exhibited 
better LV ejection fraction of 56.56±6.78% (mean±SEM), compared to saline control as 
37.22±2.96% (p<0.04). Fractional shortening was also improved, as 32.46±4.71% of 
ASC-treated rats VS 18.91±1.73% of control (p<0.04). LV volume both at end-diastolic 
and end-systolic stages were lower in ASC group (311.17±17.29µl and 139.15±20.96µl, 
respectively) than saline group (390.76±29.80µl and 248.61±26.48µl) (p<0.03). Anterior 
wall thinning was attenuated in ASC group (1.60±0.08mm VS control 1.18±0.17mm, at 
end-diastolic stage, p<0.03). Trichrome staining of heart showed ASC treatment had 
lowered ﬁbrosis percentage as 33.81±5.75% (VS control 25.97±5.56%, p<0.05). Human 
ASCs were detected in the border zone of heart by immunoﬂuorescence 28 days after 
injection.
Conclusion: We demonstrated ASCs have a great potential as cell therapy to preserve 
heart function following ischemic insult. Given the abundance cell source, this approach 
may be useful in patients with ischemic heart disease.
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1010-46 Nonuniform Struts Distribution as the New Potential 
Mechanism of Stent Thrombosis After Drug-Eluting 
Stent Implantation
Maksymilian P. Opolski, Radoslaw M. Pracon, Gary S. Mintz, Teruo Okabe, Jerzy 
Pregowski, Sung Yun Lee, Eva van der Waal, Probal Roy, Kimberly A. Smith, Rebecca 
Torguson, Zhenyi Xue, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron 
Waksman, Neil J. Weissman, Washington Hospital Center, Washington, DC
Background: Relation of nonuniform struts distribution to stent thrombosis (ST) has not 
been reported previously. The aim of the study was to compare stent struts distribution in 
the setting of ST and control patients.
Methods: We retrospectively analyzed postprocedural intravascular ultrasound (IVUS) 
images of 13 patients (14 DES thrombosis lesions) and a control group of 27 patients (30 
lesions) matched for history of chronic renal failure and DES type. In addition to standard 
IVUS measurements the number of visualized struts and the maximum interstrut angles 
were measured at one millimeter intervals. The nonuniform struts distribution index (SDI) 
was deﬁned as the maximum interstrut angle divided by the number of struts. Subacute ST 
was deﬁned during the ﬁrst 30 days after stent implantation, while late ST after 30 days.
Results: Compared with the control, IVUS studies in the ST group showed a larger 
maximum interstrut angle (60.8 ± 8.3 vs 55.7 ± 4.8, p=0.014), smaller minimum stent 
area (4.6 ± 1.1 vs 5.6 ± 1.7mm2, p = 0.0489) and smaller mean lumen area (5.6 ± 1.3 vs 
6.8 ± 1.8mm2, p=0.041). SDI was signiﬁcantly higher in the ST group (7.9 ± 1.8 vs 6.8 ± 
0.9, p=0.010). Maximum interstrut angle tended to be larger in late ST group (>30 days) 
than in patients with subacute ST (<30 days), (66.1 ± 10.8 vs 57.8 ± 5.0, p=0.071).
Conclusion: In conclusion, nonuniform struts distribution which may represent partial 
stent fracture at the time of DES implantation suggests a new potential mechanism of 
ST in drug-eluting stents.
COMPARISON OF ST AND CONTROL GROUP
ST CONTROL p
NO OF STRUTS 8,44±0,55 8,67±0,57 0,201
MAX INTERSTRUT ANGLE 60,77±8,28 55,73±4,81 0,014
SDI 7,87±1,83 6,76±0,90 0,010
MEAN LUMEN AREA 5,59±1,32 6,71±1,78 0,041
STENT AREA 5,75±1,38 6,81±1,78 0,054
MIN STENT AREA 4,62±1,12 5,61±1,65 0,049
PLAQUE AREA 7,74±2,88 7,48±2,92 0,787
MEAN VESSEL AREA 13,33±3,78 14,20±4,40 0,528
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1010-47 Role of Oxygen and ROS in Bone Marrow Derived 
Progenitor Cells Accumulation in Infarcted Hearts: 
Implications for Ventricular Aneurysm Formation
Nicanor I. Moldovan, Mirela I. Anghelina, Omer I. Butt, Tiangshen Wang, Jay L. Zweier, 
Ohio State University, Columbus, OH
Background. We tested the hypothesis that bone marrow progenitor cells (BMPC) 
contribute to a repairing process spontaneously taking place in the infarcted hearts. We 
also studied the pattern of their distribution in regions prone to ventricular aneurysms, 
compared to that of oxygen and reactive oxygen species (ROS). Methods. We performed 
coronary ligation for 7 days (n=6), or sham-operation (n=6) in C57/B6 mice transplanted 
with bone marrow from LacZ-expressing (Rosa) donors. We also measured pO2 at the core 
of the infarcts by implanting EPR O2-sensitive (LiPc) probes. We assessed the formation 
of ROS by ﬂuorescent staining with CM-DCF-DA (for H2O2) and hydroethidine (for 
superoxide). We determined the pattern of BMPC engraftment by whole-organ incubation 
with X-gal, followed by sectioning and immunostaining. Results. In the border zone, we 
found an abundance of LacZ+ cells co-expressing, in a mosaic pattern, the progenitors 
markers c-Kit, Oct3/4 or ABC-G2. Cardiomyocyte markers troponin I and connexin 43 were 
found in proliferating cell clusters, and in small cardiomyoblasts functionally integrated 
with mature LacZ- cardiomyocytes. At the core of the infarct, we also found a lack of 
organized microvessels, yet an abundance of extravascular erythrocytes percolating 
a loosely-organized tissue, in pockets corresponding to excessive ventricular thinning 
and/or aneurysms. These erythrocytes apparently mediated oxygen diffusion, as directly 
demonstrated by recovery of local oxygenation to a pre-infaction level (~20 mm Hg), after 
the third day of ischemia. Remarkably, a similar spatial distribution was found for ROS, as 
detected by the ﬂuorescent probes. Conclusions. At one week post-infarction, we found 
substantial BMPC engraftment showing cardiogenic differentiation, in a pattern inversely 
correlated to that of extravascular erythrocytes and ROS in aneurysm-prone areas. These 
data suggest that ventricular rupture is likely to occur in regions where BMPC cannot 
perform their maintenance and/or repairing activity, due to the damaging effects of ROS 
occurring from passive ‘reperfusion’ of myocardium by percolated erythrocytes.
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1010-48 Role of Antiretroviral Therapy and HIV Infection in 
Atherosclerosis
Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell, S. Craig Kalapus, 
Steven G. Deeks, University of California, San Francisco, San Francisco, CA, San 
Francisco General Hospital, San Francisco, CA
Background: HIV patients are at higher risk for atherosclerosis. In order to deﬁne the 
pathogenesis of HIV-associated atherosclerosis, we studied carotid intima-media 
thickness (IMT) in a unique group of HIV-infected patients able to fully control HIV 
replication in the absence of therapy (“HIV controllers”). These patients were compared to 
treated patients both with and without detectable viral loads, and to controls.
Methods: We measured carotid IMT by high resolution ultrasound in 363 HIV patients and 
92 controls. HIV patients were stratiﬁed based on treatment and viral load. We adjusted for 
traditional risk factors and HIV characteristics. The primary outcome was mean maximal 
IMT of 12 pre-selected segments.
Results: The median age was 47 years (IQR: 41-53); 84% were male. The median IMT was 
higher in each of the four HIV infected sub-groups compared to controls (see table); these 
differences remained signiﬁcant after controlling for traditional risk factors. Increasing 
duration of protease inhibitor use was associated higher carotid IMT (Spearman’s rho: 
0.21, p<0.001).
Conclusions: After adjustment for traditional risk factors, both HIV infection and duration 
of exposure to protease inhibitors were independently associated with higher levels of 
subclinical atherosclerosis. The treatment-independent effect of HIV infection on IMT 
appeared to be due to factors other than HIV replication or advanced immunodeﬁciency, 
as evidenced by high IMT in our HIV controllers.
Median IMT in HIV Groups and Controls
Median IMT 
(mm)
P value (for each HIV subgroup 
compared to controls)
Uninfected (n=92) 0.72
HIV+, ART-, VL<75 (n=24) 0.89 <0.001
HIV+, ART-, VL>75 (n=91) 0.82 <0.001
HIV+, ART+, VL<75 (n=180) 0.96 <0.001
HIV+, ART+, VL>75 (n=68) 0.90 <0.001
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1010-49 Increased Monocytic Expression of Urokinase Receptor 
in Acute Coronary Syndrome
Wei Chen, Wen Ling Zhu, Shu Yang Zhang, Lian Feng Chen, Xuan Wang, Tai Bo Chen, 
Zhen Yu Liu, Hong Zhi Xie, Quan Fang, Peking Union Medical College Hospital,Chinese 
Academy of Medical Sciences, Beijing, People’s Republic of China
Background:Studies have suggested that urokinase receptor (uPAR) is highly expressed 
in atheromatous plaques and plays a crucial role in inﬂammation by modulating cell 
migration and matrix degradation. We hypothesized that uPAR is also increased in the 
circulating monocytes of patients with acute coronary syndrome (ACS) compared to 
patients with chronic stable angina (CSA) and may be a marker of clinical instability.
Methods:Consecutive angina patients were prospectively assessed including 157 ACS 
(58 ST elevation myocardial infarction, 26 non-ST elevation myocardial infarction, 73 
unstable angina) and 43 CSA. The percentage of uPAR positive monocytes and the mean 




ﬂuorescence intensity index (MFI Index) of uPAR were measured by ﬂow cytometer.
Results:The percentage of uPAR positive monocytes was signiﬁcantly higher in patients 
with ACS (49.03±31.73)% than in patients with CSA (12.15±14.02) %, p<0.001. Within 
ACS subgroups, monocytic uPAR expression peaked at 59.13% in ST elevation myocardial 
infarction, and was elevated to 57.24% and 39.06% in non-ST elevation myocardial 
infarction and unstable angina, respectively. uPAR MFI Index was increased from 1.99 
of CSA to 4.48 of ACS,p<0.01. Age, body mass index, high sensitive C reactive protein 
and plasma cholesterol concentrations did not correlate with uPAR positive percentage 
and MFI Index.
Conclusions: Increased uPAR in circulating monocytes was documented in patients with 
ACS. These ﬁndings suggest a potential role of increased uPAR as a marker of monocyte 
activity and atheromatous vulnerability.
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1010-50 Myocardial Infarction and Chronic Obstructive 
Pulmonary Disease in the Community
Francesca Bursi, Robert Vassallo, Susan Weston, Jill Killian, Veronique Roger, Mayo 
Clinic, Rochester, MN
Background: Chronic obstructive pulmonary disease (COPD) and myocardial infarction 
(MI) share risk factors and pathophysiological features. Yet, there is limited data on the 
prevalence of COPD in patients with MI and on its impact on outcome.
Methods: The medical records of all Olmsted County residents with MI deﬁned by 
standardized criteria (cardiac pain, biomarkers, and Minnesota coding of the ECG) were 
reviewed to ascertain COPD and evaluate outcomes.
Results: 3259 incident MIs occurred in Olmsted County between 1979 and 2005 (mean 
age 68 ± 14, 43% women). A clinical diagnosis of COPD was noted among 406 (13%). 
The prevalence of COPD increased over time: in 2000-2005 the prevalence of COPD was 
16%, twice the prevalence of 8% in 1979-1985, (4% increase/year). After a mean follow-
up of 4.8 years, 1436 patients died. Survival at 5 years was markedly reduced among 
patients with COPD (44%, 95% CI 39%-49%) compared to those without COPD (68%, 
95% CI 66%-69%), p<0.01 (ﬁgure). After adjusting for age, sex, smoking, hypertension, 
comorbidity, NSTEMI, CK levels, Killip class and treatment of MI, COPD was associated 
with a large increase in the risk of death (adjusted HR 1.39, 95% CI 1.17-1.64; p <0.01).
Conclusions: Among a large geographically deﬁned community of patients with MI, 
COPD was frequent and was associated with a large increase in the risk of death. As the 
prevalence of COPD is increasing over time, its strong association with death underscores 
the public health impact of this condition among patients with MI. 
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1010-51 Impact of Stress Testing Prior to PCI or Medical 
Management on Outcomes of Patients With Persistent 
Total Occlusion After Myocardial Infarction: Analysis 
From the Occluded Artery Trial (OAT)
Warren J. Cantor, Gervasio A. Lamas, Eugenia Nikolsky, Camille A. Pearte, Vankelpuran 
S. Srinivas, Sandra A. Forman, Venu Menon, John R. Ross, Sérgio B. Baptista, Peter 
Meciar, Zygmunt Sadowski, Judith S. Hochman, University of Toronto, Toronto, ON, 
Canada, New York University School of Medicine, New York, NY
Background: In the Occluded Artery Trial, 2201 pts with an occluded infarct-related artery 
(IRA) were randomized to percutaneous coronary intervention (PCI) or medical treatment 
(MED). There was no difference in the primary endpoint of death, re-MI or heart failure 
(CHF). We examined the prognostic impact of pre-randomization stress testing.
Methods: Stress testing was required by protocol except for pts with single vessel disease and 
akinesis / dyskinesis of the infarct zone. Severe inducible ischemia was an exclusion criterion 
for OAT. We compared outcomes based on performance and results of stress testing.
Results: 598 (27%) pts (297 PCI, 301 MED) underwent stress testing. Radionuclide 
imaging or stress echocardiography was performed in 40%. Pts who had stress testing 
were younger with higher ejection fractions, and had lower rates of death (7.8% vs. 
13.2%), Class IV CHF (2.4% vs. 5.5%), and the primary endpoint (13.9% vs. 18.9%) than 
pts without stress testing (all p<0.01). Mild-moderate ischemia was observed in 40% of 














Death, MI or 
Class IV CHF 14.8% 13.1% 0.67 0.93
Death 6.8% 8.5% 0.48 0.28
Nonfatal MI 8.1% 5.9% 0.47 0.84
Class IV CHF 1.8% 2.7% 0.48 0.47
Among pts with inducible ischemia, outcomes were similar for PCI and MED (all p>0.1).
Conclusions: In OAT, pts who underwent stress testing had better outcomes than pts 
who did not, likely related to differences in age and LV function. Mild-moderate inducible 
ischemia was not related to outcomes. The lack of beneﬁt for PCI over MED was consistent 
regardless of whether stress testing was performed or inducible ischemia was present.
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1010-52 Plasma Adiponectin and Resistin Levels as Predictors 
of Mortality in Patients with Acute Myocardial Infarction
Sang Hak Lee, Jung-Sun Kim, Eui Young Choi, Sungha Park, Seok-Min Kang, 
Donghoon Choi, Jong-Won Ha, Yangsoo Jang, Namsik Chung, Yonsei Cardiovascular 
Center, Seoul, South Korea
Background: Adiponectin and resistin are adipocyte-derived cytokine and related to 
insulin resistance, inﬂammation and development of vascular disease. Prior reports 
showed that they are correlated to cardiovascular event in healthy or low-risk population. 
However, their prognostic importance in acute myocardial infarction (MI) is unclear. The 
purpose of this study was to determine the predictive value of adiponectin and resistin in 
patients with acute MI.
Methods: Adiponectin and resistin were measured in 397 consecutive patients (age: 62 
± 12 years, male: 72%) with acute MI who were enrolled in Infarction Prognosis Study. 
The patients were then followed up prospectively for the occurrence of all-cause mortality. 
Potential determinants of mortality were identiﬁed by univariate and multivariate analyses 
with Cox regression model.
Results: Twenty-eight patients (7.1%) died during the follow up (12 ± 7 months). The 
survival rates for patients with the lower, middle, and upper tertile of plasma adiponectin 
level were 98, 94, and 87% (p=0.002 by log rank test), while those of plasma each 
tertile of resistin level were 94, 98, and 87% (p=0.002 by log rank test). Age, history 
of hypertension, mode of treatment, left ventricular systolic dysfunction, fasting plasma 
glucose level, plasma adiponectin and resistin levels were signiﬁcantly associated 
with mortality in univariate analyses. Multivariate regression analyses identiﬁed three 
independent variables that were predictive of mortality: hypertension (OR=2.75, CI: 1.08-
6.95, p=0.03), adiponectin (OR=7.40, CI: 1.69-32.3, p=0.01), resistin (OR=2.45, CI: 0.95-
6.34, p=0.02).
Conclusions: In patients with acute MI, plasma adiponectin and resistin levels are 
predictive of mortality, independent of other risk factors. In particular, high adiponectin 
level showed positive correlation to mortality in this population.
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1010-53 Adaptive Remodeling of Culprit Artery Following 
Sirolimus Eluting Stent Implantation in Acute 
Myocardial Infarction: Its Effect on Late Stent 
Malapposition
Mitsunori Harada, Soichiro Kumagai, Shinji Mokuno, Atsushi Tanaka, Shinji Kamiya, 
Takayuki Saito, Yuji Yamanaka, Toshihiro Obayashi, Kariya Yoyota General Hospital, 
Kariya, Japan
Background: Late stent malapposition (LSM), which is mainly caused by chronic positive 
remodeling of the vessel, occurs in one third of cases following sirolimus eluting stent (SES) 
implantation in acute myocardial infarction (AMI). Recent intravascular ultrasound (IVUS) 
study has shown that positive remodeling is a predominant pattern of lesion remodeling in 
AMI. However, it remains unknown whether acute positive remodeling of the culprit artery 
causes LSM following SES implantation in patients with AMI. Methods: We investigated 
preinterventional IVUS images of 40 consecutive patients with AMI who underwent IVUS-
guided SES implantation (stent to artery ratio>1.1). IVUS analysis included qualitative and 
quantitative measurements of external elastic membrane (EEM), lumen and plaque area at 
reference and lesion. Positive remodeling was deﬁned as lesion / mean reference EEM>1.0. 
LSM was deﬁned as separation of at least 1 stent strut from the intima, with evidence of 
blood ﬂow behind the strut, where post-stent implantation IVUS had revealed complete 
apposition of the stent to the vessel wall. Twenty nine patients with positive remodeling 
were enrolled in this study. Serial IVUS analysis was performed at baseline and 8-month 
follow-up. Results: Soft plaque with spotty calciﬁcation was more frequent in patients with 
positive remodeling than in those without (75.9% versus 40.0%, p=0.04). No difference was 
seen between lumen area immediately after stenting and that at follow-up (9.6±2.8mm² 
to 9.5±2.4mm², p=NS). Both EEM and plaque area decreased signiﬁcantly (23.9±4.8mm² 
to 19.4±4.1mm², p=0.04, 14.4±3.2mm² to 9.8±2.1mm², p=0.003, respectively). There was 
a good correlation between EEM and plaque area (r=0.866, p<0.0001). LSM occurred 
in 4 patients (13.8%) at follow-up. Conclusion: The infarct-related artery with positive 
remodeling shrank in response to plaque regression to adapt itself to the implanted SES. 
Acute positive remodeling did not increase LSM following SES implantation in patients with 
AMI probably due to adaptive remodeling of the culprit artery.




















1010-54 Comparison of Clopidogrel Responsiveness between 
Chronic Renal Failure Patients and Normal Renal 
Function Subjects Using VerifyNowTM P2Y12 Assay
Weon Kim, Sang-Hyun Park, Won-Yu Kang, Sun-Ho Hwang, Wan Kim, Cardiovascular 
Center, Gwangju veterans Hospital, Gwangju, South Korea
BACKGROUND: Effective antiplatelet regimen is an emerging issue in the drug-eluting 
stent (DES) era. Stent thrombosis was increased in chronic renal failure (CRF) which may 
be attributed to poor response to clopidogrel. The mechanisms leading to poor clopidogrel 
effects are not fully elucidated and are likely multifactorial.
METHODS: We conducted a prospective, randomized, open-label trial to evaluate the 
difference of clopidogrel responsiveness according to clopidogrel dose in CRF patients. 
23 normal renal function patients with standard dose clopidogrel 75mg daily (Group 1, 
67±9 years ) and 37 CRF subjects (63±7 years) divided into two groups according to 
clopidogrel dose (Group 2: 18 subjects with 75mg, Group 3: 19 subjects with 150mg daily) 
were enrolled. All patients were administered clopidogrel for 30 days. The primary efﬁcacy 
variable was mean PRU (P2Y12 Reaction unit) and % inhibition difference between each 
groups using VerifyNowTM P2Y12 Assay.
RESULTS: There were no signiﬁcant PRU difference between each three groups ( 
239±87 PRU in group 1, 307±86PRU in group 2, 302±95 PRU in group 3, p= 0.056). But, 
comparing normal subject group with CRF group, signiﬁcantly increased in CRF group 
(239±87 in control, 304±89 PRU in CRF, p=0.016). There was good positive correlation 
between serum creatinine and PRU (r=0.438, p=0.003) and fair negative correlation 
between serum creatinine and % platelet inhibition (r=-0.334, p=0.025). And, the duration 
of dialysis and PRU were correlated positively (Spearman’s rho=0.320, p=0.03).
CONCLUSION: The plavix resistance was more increased in CRF patients than non-CRF 
patients. The PRU and % platelet inhibition were correlated with serum creatinine level 
and the duration of dialysis.
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1010-55 Timing of Coronary Artery Bypass Grafting Following 
Non-ST-Elevation Acute Coronary Syndrome and 
Mortality
Marc W. Deyell, Jianguo Zhang, David B. Ross, William A. Ghali, Brenda Hemmelgarn, 
University of Calgary, Calgary, AB, Canada, University of Alberta, Edmonton, AB, Canada
Background: Despite advances in management of non-ST-segment elevation acute 
coronary syndromes (NSTEACS), there is little data regarding optimal timing of coronary 
artery bypass surgery (CABG) following NSTEACS. The purpose of this study was to 
determine the association between time to CABG following NSTACS and short and long-
term mortality. Methods: The cohort consisted of all patients who underwent isolated 
CABG within 60 days of hospitalization for NSTEACS, in the province of Alberta, Canada, 
from 2000 to 2004. Subjects were identiﬁed using the Alberta Provincial Project for 
Outcome Assessment in Coronary Artery Disease (APPROACH) database. Patients 
who underwent emergency CABG were excluded. The time to CABG was deﬁned as the 
number of days from initial hospital admission to CABG surgery, and was categorized 
as being within: 3-7 days (group 1); 8-14 days (group 2); or 15-60 days (group 3). The 
primary outcome was all-cause mortality, both short term (at 30 days) and long term 
(follow-up to December 31st, 2005). Logistic regression and Cox proportional hazards 
models were used to determine the association between time to CABG and short and 
long-term mortality, respectively, adjusting for comorbidities and severity of CAD. Results: 
A total of 1454 patients were included with 213 (14.6%) in group 1, 637 (43.8%) in group 2 
and 707 (48.6%) in group 3. Median follow-up was 3.7 years. In the ﬁnal adjusted models 
there was a non-signiﬁcant trend towards increased mortality at 30 days in group 1 (odds 
ratio 2.62; 95% conﬁdence interval 0.66, 7.53), using group 3 as a reference. However, 
there were no signiﬁcant differences in mortality between the three groups with long-term 
follow-up, with hazard ratios (95% conﬁdence interval) for death of 0.69 (0.35, 1.35) for 
group 1 and 0.99 (0.71, 1.37) for group 2. Conclusions: We found no association between 
timing of CABG after NSTEACS and mortality. There was no evidence of increased 
mortality associated with CABG performed early after presentation with NSTEACS.
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1010-56 High Sensitivity C-Reactive Protein is an Independed 
Predictor of Coronary Events in Emergency 
Department Patients With Chest Pain
Michael P. Chrissoheris, Hanna B. Slim, Joyce Oen-Hsiao, Costin Ionescu, Amir F. 
Mohani, Ronan Ali, Amenuve Bekui, Thomas J. Donohue, Andre Ghantous, Hospital of 
Saint Raphael, New Haven, CT
Background: High sensitivity C-reactive protein (hs-CRP) is a marker of coronary events 
in patients presenting with acute coronary syndromes. It is not known if hs-CRP can 
predict subsequent coronary events in low risk patients with chest pain presenting to the 
Emergency Department (ED).
Methods: 296 Consecutive patients presenting to the ED with chest pain and admitted for 
observation were enrolled. In addition to standard clinical evaluation, a single measurment 
of hs-CRP level was performed. Patients with hsCRPq10mg/l (“non-cardiac” range) 
were excluded. Primary end-point was the combined events of myocardial infarction, 
revascularization and cardiovascular death during index admission and out to 30-days 
post discharge.
Results: Sixty one patients reached the primary endpoint 
Variables No Event (N=235) Event (=61) p-value
Age (mean yrs) 60 66 0.0004
Gender (%male) 48.3 68.8 0.005
Smoking (current or past, %) 56.03 77.59 0.0008
Hypertension (%) 72.2 86.8 0.018
Statin use 42.8 60.6 0.013
Known CAD (%) 34.18 62.3 0.00001
hsCRP <1mg/l 75 (26.8%) 12 (19.6%)
0.038hsCRP 1-3mg/l 75 (31.9%) 16 (26.2%)
hsCRP >3 <10mg/l 85 (36.1%) 33 (54.1%)
TIMI score 1.6 2.8 0.00001
Multiple logistic regression showed that an hs-CRP level in the highest tertile was an 
independed predictor for the development of the primary end-point, with an odds ratio of 
2.7 (1.1-6.6 p=0.023).
Conclusions: Among presumed low risk patients presenting to an ED with chest pain, a 
single measurment of hs-CRP independedly predicted the presence of unstable coronary 
disease.
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1010-57 Recent Trends of Gender-age Interaction and Its 
Relation to In-hospital Mortality in Patients with Acute 
Myocardial Infarction - Analysis of 30 Years of Data 
from a Single Center
Yoritaka Otsuka, Nobuaki Kokubu, Takuya Taniguchi, Nobuhito Yagi, Yoichiro Kasahara, 
Yu Kataoka, Mitsuru Abe, Yuji Yasuga, Atsushi Kawamura, Hiroyuki Yokoyama, Yoichi 
Goto, Hiroshi Nonogi, Hitonobu Tomoike, National Cardiovascular Center, Suita, Japan
Background: The longevity of the Japanese women is world’ highest and further increasing. 
Such a constant aging and westernization of life style should affect the morbidity and 
mortality of the ischemic heart disease. However, little is known about recent trends of 
gender-age interaction in patients with acute myocardial infarction (AMI). We investigated 
recent trends of gender-age interaction and its relation to in-hospital mortality in patients 
with AMI using a 30-year database of National Cardiovascular Center.
Methods: Consecutive patients (n = 4,766) admitted due to AMI to this hospital from 1977 
to 2006 were divided into 3 groups (Group A; n = 1,740 from 1977 to 1989, Group B; n = 
1,735 from 1990 to 1999, and Group C; n = 1,291 from 2000 to 2006). The data of these 
3 groups were analyzed.
Results: The mean age of both men and women with AMI increased from year 1977 to 
2006 (men; 61.7 years for Group A vs 64.0 years for Group B vs 65.8 years for Group C, 
women; 67.8 years vs 69.8 years vs 72.6 years, p < 0.05). The proportion of women with 
AMI increased in the same time frame (20.1 % vs 21.8% vs 27.8%, p < 0.05). Particularly, 
the ratio of elderly women (q 80 years old) was signiﬁcantly higher than that of elderly 
men (men vs women: 4.2% vs 9.7% for Group A, 6.9% vs 17.9% for Group B, 11.6% vs 
27.9% for Group C). Although in-hospital mortality of both men and women decrease by 
reperfusion therapy with passage of time, in-hospital mortality for elderly women (q 80 
years old) with AMI (14.6%) was still higher than that for elderly men (8.4%), younger 
men (< 80 years old) (3.1%), and younger women (5.2%) with AMI in Group C (the most 
recent years of admission).
Conclusions: These data show that there are steady trends towards higher mean age and 
greater proportion of elderly women in Japanese patients with AMI in recent 30 years. In-
hospital mortality of elderly women with AMI remains high and additional strategies may 
be needed for these patients.
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1010-58 Revascularization but not early invasive management is 
associated with a good prognosis in patients with non-
ST-segment elevation acute coronary syndrome
Alexander Hirsch, Fons Windhausen, Jan G.P. Tijssen, Anthonius J.M. Oude Ophuis, P. 
Marc van der Zee, Jan Hein Cornel, Freek W.A. Verheugt, Robbert J. de Winter, on behalf 
of the ICTUS investigators, Academic Medical Center, Amsterdam, The Netherlands
Background In several observational studies revascularization was associated with 
a substantial reduction in mortality in patients with non-ST-elevation acute coronary 
syndrome (NSTE ACS). These results have strengthened the belief that routine early 
angiography and revascularization leads to a reduction in mortality.
Objective To investigate the association between actual in-hospital revascularization and 
long-term outcome in patients with NSTE ACS included in the ICTUS trial and to compare 
these results to the outcomes of randomized treatment strategies.
Methods In the ICTUS trial 1200 patients with NSTE ACS and an elevated troponin T 
were randomized to an early invasive or selective invasive strategy. For this analysis 
the outcome measures were death from hospital discharge until 4-year follow-up and 
death or spontaneous myocardial infarction (MI) until 3 years among patients who were 
revascularized during hospital admission compared to non-revascularized patients.
Results Among the 1189 patients discharged alive, 58% patients underwent 
revascularization during initial hospitalization. Mortality after 4 years was 4.8% in 
revascularized patients and 10.0% in non-revascularized patients. The cumulative event 
rates for death or MI at 3 years were 7.7% and 15.1% respectively. In multivariate Cox 
regression analyses, in-hospital revascularization was independently associated with a 
reduction in 4-year mortality and 3-year event rate of death or MI (HR 0.60; 95% CI 
0.37-0.96 and 0.45; 0.31-0.66). However, when intention-to-treat analysis was performed, 
no differences in event rates were observed between the early invasive and selective 
invasive strategy; 7.0% vs. 6.9% for death at 4 years (HR 1.10; 0.70-1.74) and 12.6% vs. 
8.9% for death or MI at 3 years (HR 1.27; 0.88-1.85).




Conclusions Although coronary revascularization itself was associated with lower 
mortality and fewer myocardial infarctions, no beneﬁt of an early invasive strategy was 
observed. The conclusion that an early invasive strategy leads to a better outcome than 
a selective invasive strategy cannot be drawn from the observation that revascularized 
patients have an improved prognosis in non-randomized studies.
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1010-59 NO IMPROVEMENT IN TIME TO TREATMENT OF 
ACUTE MYOCARDIAL INFARCTION IN RURAL NATIVE 
AMERICAN PATIENTS: TEMPORAL TRENDS 1999-2006
Eric A. Brody, Andrew C. Duarte, Adeline June-Tsosie, Justin L. Sewell, Beth R. Malasky, 
James Ranger-Moore, Elizabeth Cudilo, Phyllis Sanderson, Neil S. Freund, University of 
Arizona, Tucson, AZ
Background: Acute myocardial infarction (AMI) is a leading cause of morbidity and 
mortality in Native American (NA) communities. Time to presentation in NA with AMI 
in a large national database is minimally longer than in the general U.S. population but 
does not reﬂect the rural population served by the Native American Cardiology Program 
(NACP). This prospective study was designed to examine the time to treatment (T2T) of 
rural NA patients and any longitudinal trends in T2T over an 8 year period.
Methods: Three hundred twenty-two NA patients with AMI were evaluated at rural 
facilities and transferred to NACP from February 1999 through June 2006. Data obtained 
included T2T (symptom onset to arrival at initial treating facility) measured continuously 
for patients presenting within 12 hours, and as a count of patients arriving after 12 hours. 
Three longitudinal trends were evaluated: T2T among patients arriving at <12 hours, and 
proportion of patients presenting <6 vs. >6 and <12 vs. >12 hours.
Results: T2T information was available on 293 patients. The overall median and mean 
times to presentation were 360 and 572 minutes. Cox proportional hazards model 
suggested no signiﬁcant changes in T2T by year (p = 0.880) in the cohort presenting 
under twelve hours. Binary logistic regression indicated no signiﬁcant changes in the 
proportions of patients coming in < vs. >6 (p = 0.939) or <12 vs. >12 (p = 0.986) hours 
over the eight years of the study.
Conclusions: Based on the above data, time to presentation in rural NA patients with 
AMI is longer than nationally reported and has not improved. This T2T delay places NA 
patients at risk for worse outcomes and increased mortality. Public education about the 
importance of rapid clinical presentation and symptoms of AMI would reduce the burden 
of AMI in NA communities.
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1010-60 Dramatic Time-to-Treatment Delay in Rural Native 
Americans with Acute Myocardial Infarction
Eric A. Brody, Andrew C. Duarte, Adeline June-Tsosie, Justin L. Sewell, Beth R. Malasky, 
James Ranger-Moore, Elizabeth Cudilo, Phyllis Sanderson, Neil S. Freund, James M. 
Galloway, University of Arizona, Tucson, AZ
Background: National database studies have reported a signiﬁcant but minor delay in 
presentation of Native American (NA) patients with acute myocardial infarction (AMI). The 
Native American Cardiology Program (NACP) experience is a strong clinical impression 
of a markedly greater delay in rural NA patients. In order to clarify the magnitude and 
causes of this delay for potential intervention, the NACP prospectively studied rural NA 
patients and their presentations to emergency facilities.
Methods: Three hundred twenty-two NA patients with AMI were evaluated at rural facilities 
and transferred to NACP from February 1999 through June 2006. Data obtained included 
demographics, ECG ﬁndings, patient symptoms, complications, laboratory ﬁndings and 
reasons for delayed presentation if applicable.
Results: Time to treatment (T2T) data was available for 293 patients. One hundred six 
patients (36%) presented greater than 12 hours (delayed) following onset of symptoms. 
Of these delayed patients, 64% presented greater than 24 hours after symptom 
onset. The overall median and mean times to presentation were 360 and 572 minutes 
respectively. Only 11% of the total cohort presented within the ﬁrst hour after symptom 
onset. Distance traveled to medical facilities did not contribute to treatment delay (21.6 
miles for delayed patients versus 21.2 miles for those presenting within 12 hours) 
although travel over unimproved roads was more common in the delayed group. Diabetes 
mellitus and advanced age predicted delayed presentation. The most common reason 
sited for delayed presentation was the patient’s own misunderstanding of symptoms (69% 
of delayed patients). Other potential causes of delay (traditional healer consultation, road 
conditions, telephone access, and EMS availability) were investigated and much less 
frequently reported.
Conclusions: This analysis reveals a dramatic delay in presentation of rural NA patients 
with AMI. Misinterpretation of symptoms was conﬁrmed to be the predominant cause 
of patient delay. These ﬁndings clearly underscore the need for community-based 
education among rural NA’s in an effort to increase thrombolytic eligibility and to improve 
cardiovascular outcomes.
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1010-61 Reduced Beneﬁt of Delayed Coronary Artery Bypass 
Graft Surgery in Acute Coronary Syndromes
Jorge M.S Ferreira, Carlos Aguiar, Ana Almeida, Jose Santos, Luis Santos, On Behalf of 
Investigators of Portuguese Registryof ACS, Hospital Santa Cruz, Carnaxide, Portugal
Background: In Pts with ACS, early coronary revascularization is increasingly used, but 
the optimal timing remains uncertain, especially in Pts eligible for CABG. A clinical registry 
of ACS revealed that many Pts submitted to coronariography and with a suitable coronary 
anatomy, do not proceed to CABG during the initial hospitalization and are discharged 
with a planned procedure. We aimed to evaluate the beneﬁt of this unselected delayed 
CABG (Cases = Planned CABG after discharge), in comparison with Pts submitted to 
CABG during the initial hospitalization (Controls).
Methods: A clinical registry of ACS with 44 centres prospectivelly enrolled 18.543 Pts 
since 2002. Our study included 612 Cases and 385 Controls after exclusion of Pts with 
cardiogenic shock and cardiac rupture. Baseline characteristics, in-hospital medications, 
LV function and angiographic features were similar in both groups except for recurrent 
angina (Cases 9% vs Controls 19%, p<0.001) and left main disease (Cases 14% vs 
Controls 31%, p<0.001). The study endpoint was death or MI at 6 months.
Results: CABG was performed in 61% of Cases with a median time delay of 37 d (vs 10 
d in Controls, p<0.001). Mortality after CABG was similar in both groups (3.9% in Cases 
and 3.3% in Controls). Cumulative MI free survival at 6 months was 83.3% in Cases and 
92.1% in Controls (p<0.01)
Conclusions: Our study demonstrates a reduced beneﬁt of a post-discharge surgical 
coronary revascularization practice in comparison with an earlier in-hospital procedure. 
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1010-62 Impact of the Degree of Platelet Function on Thrombin 
Generation Proﬁles in Patients with Type 2 Diabetes 
Mellitus
Dominick J. Angiolillo, Bhaloo Desai, Yoshie Suzuki, Liudmila Rozum, Ronald Charlton, 
Steven B. Shoemaker, Mohammed Aslam, Binu Jacob, Piera Capranzano, Martin Z. 
Zenni, Marco A. Costa, Luis A. Guzman, Theodore A. Bass, University of Florida College 
of Medicine-Jacksonville, Jacksonville, FL
Background: Although antiplatelet agents reduce platelet activation and aggregation 
processes, there is a broad interindividual variability in the effects achieved and elevated 
platelet reactivity is associated with thrombotic risk. Activated platelets not only lead to the 
formation of aggregates, but also play a pivotal role in triggering the coagulation cascade 
by inducing thrombin generation. The aim of this study was to evaluate if the presence 
of elevated platelet reactivity despite the use of dual antiplatelet therapy is associated 
accelerated thrombin generation.
Methods: Type 2 diabetes mellitus (T2DM) patients are characterized by hyper-reactive 
platelets and were selected to assess the study aim. A total of 50 T2DM patients with 
documented coronary artery disease in a steady state (>1 month) maintenance phase of 
aspirin (100mg/day) and clopidogrel (75 mg/day) treatment were studied. Peak platelet 
aggregation was assessed using light transmittance aggregometry in platelet rich plasma 
following 20µmol/L adenosine diphosphate stimuli. Patients were divided in to 2 groups 
according to the degree of platelet reactivity: Group A (>50% aggregation) and Group B 
(<50% aggregation).The onset of thrombin induced platelet-ﬁbrin clot formation, a marker 
of the speed of thrombin generation, and the time to the maximum rate of thrombin 
generation were determined by thrombelastography.
Results: Platelet aggregation was 54±15% in the overall diabetic population. Group A and 
Group B were composed of 30 and 20 patients, respectively. Peak platelet aggregation 
was signiﬁcantly higher in Group A than Group B (66±8% vs 39±8%; p<0.001). The 
speed of thrombin generation (5.6±1.4 min vs 7.2±1.8 min; p=0.002) and the time to 
the maximum rate of thrombin generation (6.8±1.6 min vs 8.7±2.2 min; p=0.001) were 
signiﬁcantly accelerated in Group A compared to Group B patients.
Conclusions: T2DM patients with elevated platelet reactivity are characterized by 
accelerated rates of thombin generation. These ﬁndings may contribute to the enhanced 
thrombotic risk of patients who persist with elevated platelet reactivity despite the use of 
standard dual antiplatelet treatment regimens.
3:00 p.m.
1010-63 Chronic Kidney Disease is an Early Independent 
Predictor of in-Hospital Death in Patients with Acute 
Myocardial Infarction even that with preserved left 
ventricular function
Rudyney Azevedo, José Marconi de Souza, Marcos D. Ferreira, Aurelia Mussi, Edson 
Stefanini, Antonio Carlos C. Carvalho, Federal University of Sao Paulo, Sao Paulo, Brazil
Background Chronic kidney disease (CKD) is an independent predictor of events 
after acute myocardial infarction (AMI). The purpose of this study was to assess renal 
dysfunction after AMI in a real world situation and to examine the inﬂuence of ejection 
fraction (EF) on the relationship CKD and in-hospital death.
Methods Our study population consisted of 613 consecutive patients with AMI (with or 
without ST segment elevation), evaluated within 24 hours after the onset of symptoms, 
mean age 61.9 (±13.1) years, admitted to the CCU of a University Hospital from January 
1999 to December 2004. Previous diseases, medication in use and coronary risk factors 
were recorded. The Modiﬁcation of Diet in Renal Disease (MDRD) study equation was 



















used to calculate the estimated glomerular ﬁltration rate.Patients were classiﬁed into CKD 
stages based on eGFR (tab). Multivariable stepwise Cox analysis was performed.
Results Of 613 patients, 68 (11.0%) had in-hospital death during index MI. Of these, 
32 (47.0%) had preserved EF and 36 (52.9%) had depressed EF. CKD was associated 
with older age, female gender, diabetes, hypertension, and history of CHF. Prevalence of 
death was higher with increasing CKD Stage (tab). In a logistic regression model eGFR 
was independently correlated with in-hospital death.
Conclusions The renal impairment in a real world situation is a signiﬁcant early 
independent risk factor for death among patients whom had a myocardial infarction with 
or without left ventricular systolic dysfunction. 
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1010-64 The Impact of Inﬂammatory Status on the Release of 
sCD40L in Coronary Atherosclerosis: Evidence for a 
Critical Role of the Underlying Disease State
Dimitris Tousoulis, Charalambos Antoniades, Aggeliki Nikolopoulou, Katerina Koniari, 
Carmen Vasiliadou, Nikolas Koumallos, Kiriakoula Marinou, Gerasimos Siasos, 
Gerasimos Siasos, Costas Tsiouﬁs, Christodoulos Stefanadis, 1st Cardiology 
Department, Hippokration Hospital, Athens Medical School, Athens, Greece
Background: The soluble form of CD40-ligand is released from activated platelets during 
the acute phase of myocardial infarction (AMI). Although sCD40L is considered to be part 
of the physiological immune response, the mechanisms regulating its release in different 
disease states remain unknown.
Methods: This study enrolled 596 subjects: 201 pts with stable coronary artery disease 
(CAD), 109 pts with AMI (recruited by their admission to the hospital) and 286 healthy 
controls. Circulating sCD40L, interleukin 6 (IL-6), vascular cells adhesion molecules 
(sVCAM-1) and intercellular adhesion molecules (sICAM-1) were measured
Results: Patients with AMI had signiﬁcantly higher levels of sCD40L (18.8±1.2 ng/ml) 
and IL-6 (9.1±0.5pg/ml) compared to CAD (7.0±0.5 ng/ml and 5.0±0.4pg/ml p<0.01 
for both) or controls (4.6±0.2ng/ml and 2.1±2.3pg/ml p<0.01 for both vs CAD or AMI). 
Similarly, SICAM-1 and sVCAM-1 levels were higher in CAD (316±8 and 753±39 ng/
ml) and AMI (360±18 and 806±52 ng/ml) compared to controls (287±6.5 and 631±270 
ng/ml, p<0.05 for both vs CAD and AMI). IL-6 was the only independent predictor of 
sCD40L in healthy individuals (B(SE):0.491(0.096), p=0.0001). However, in CAD or AMI, 
only diabetes mellitus (B(SE):2.689(1.082), p=0.044 and B(SE):10.406(3.215), p=0.002 
respectively) and smoking (B(SE):3.470(1.111), p=0.002 and B(SE):9.694(2.478), 
p=0.0001 respectively) (but not IL-6), were independently associated with sCD40L.
Conclusions: IL-6 is an independent predictor of sCD40L levels in healthy individuals. 
However, diabetes mellitus and smoking (but not IL-6 or adhesion molecules) are the 
only independent predictors of sCD40L levels in CAD and AMI patients. These ﬁndings 
suggest that the complex interaction between proinﬂammatory cytokines and sCD40L 
release is largely dependent on the underlying disease state.
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1010-65 Sex-Based Differences in Mortality Following Acute 
Coronary Syndromes
Jeffrey S. Berger, Dianne Gallup, Matthew Roe, Paul W. Armstrong, R John Simes, 
Harvey D. White, Frans Van de Werf, Eric J. Topol, Christopher B. Granger, Robert 
A. Harington, Robert M. Califf, Richard C. Becker, Pamela S. Douglas, Duke Clinical 
Research Institute, Durham, NC
Background: There is conﬂicting information about whether sex-differences modulate short-
term mortality following acute coronary syndromes (ACS). We investigated the relationship 
between sex and mortality using a large database spanning the full spectrum of ACS.
Methods: Data from patients in 11 independent randomized ACS trials from 1993 to 2006 
were pooled. This included 136,247 patients, of whom 38,048 (28%) were women. There 
were 102,004 (26% women) with ST-segment elevation myocardial infarction [STEMI], 
14,466 (29% women) with non-STEMI [NSTEMI], and 19,777 (40% women) with unstable 
angina [UA]). After multivariable adjustment with previously validated STEMI and NSTEMI/UA 
mortality models, we compared 30-day mortality of women versus men (C-index=0.81).
Results: The overall mortality at 30 days was 9.6% among women and 5.3% among 
men (P<0.01). After multivariable adjustment women still had signiﬁcantly increased 
risk of death (OR 1.26, 95% CI 1.20-1.33). Importantly a signiﬁcant interaction existed 
between sex and type of ACS (P<0.001). A clear gradient existed such that in STEMI 
patients, 30-day mortality was signiﬁcantly higher in women compared to men (12.3% vs 
5.3%; adjusted OR 1.36, 95% CI 1.28-1.43), yet in patients with NSTEMI, no signiﬁcant 
difference in mortality was found (6.4% vs 4.3%; adjusted OR 0.89, 95% CI 0.74-1.07). By 
contrast, in unstable angina, women had a signiﬁcantly lower 30-day mortality rate than 
men (2.4% vs 2.8%; adjusted OR 0.64, 95% CI 0.51-0.80).
Conclusions: Sex-based differences in 30-day mortality rates exist in ACS but have a 
striking variation depending on which syndrome is present. Whereas STEMI conferred an 
increased risk in women, no signiﬁcant difference was noted in NSTEMI, and UA actually 
conferred a lower risk of death. Appreciating these differences and understanding their 
pathophysiology may lead to both better management and improved overall prognosis.
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1010-66 Comparison of Infarct Size and Cardiac Function in 
Patients With and Without Diabetes Mellitus After 
Primary Percutaneous Coronary Intervention for Acute 
Myocardial Infarction
Stanley Chia, O. Christopher Raffel, Faisal Merchant, Fred Senatore, Ik-Kyung Jang, 
EVOLVE Investigators, Massachusetts General Hospital, Boston, MA
Background: Patients with diabetes mellitus have worse clinical outcomes compared to 
non-diabetics after primary percutaneous coronary intervention (PCI) for acute ST-elevation 
myocardial infarction (STEMI). Whether the poor prognosis is directly related to differences 
in infarct size and cardiac function is unknown. We investigated the impact of diabetes 
mellitus on infarct size and left ventricular ejection fraction (LVEF) after primary PCI.
Methods: We evaluated 387 patients (69 diabetic: 318 non-diabetic) from the EVOLVE 
(EValuation Of MCC-135 for Left VEntricular Salvage in Acute Myocardial Infarction) 
study, a randomized double blind, placebo-controlled trial comparing the efﬁcacy of 
intracellular calcium modulator as an adjunct to primary PCI in patients with ﬁrst STEMI. 
Infarct size and left ventricular ejection fraction (LVEF) were assessed after 5 and 30 days 
using single-photon emission computed tomography.
Results: Diabetic patients (11 type I; 58 type II) were more often female (33 vs 20%), 
hypertensive (65 vs 44%), dyslipidemic (49 vs 32%) and had higher BMI (30 vs 28 kg/m2; 
all P<0.05) compared to non-diabetics. There were no differences between those with 
or without diabetes with regard to distribution of infarct-related artery, post-procedural 
Thrombolysis In Myocardial Infarction (TIMI) ﬂow grades 3 (83 vs 86%) or corrected TIMI 
frame counts. Compared to non-diabetics, patients with diabetes had signiﬁcantly larger 
infarct size when assessed 5 days post-PCI (median: 10 vs 6%, P=0.004). At 30 days, 
LVEF was also worse in diabetic patients (50 vs 53%, P<0.05). In a subgroup of patients 
who had Tc-99m sestamibi injected prior to reperfusion (10 diabetic: 82 non-diabetic), the 
estimated myocardial salvage post-PCI did not differ between the two groups.
Conclusion: Although diabetic patients have similar high rates of TIMI ﬂow grade 3 after 
primary PCI compared to non-diabetics, they were more likely to have larger infarct size 
as well as reduced LVEF. The differences in myocardial infarct size and cardiac function 
despite successful primary PCI in diabetic patients may contribute to worse long-term 
outcomes.
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1010-67 Predictors of Beneﬁt Using an Early Invasive Strategy 
in the Management of Unstable Angina/Non ST-
Elevation Myocardial Infarction
Jayanta Das, George A. Diamond, Shervin Eshaghian, Sameer Amin, Prediman K. 
Shah, Sanjay Kaul, Cedars Sinai Medical Center, Los Angeles, CA
Background: The 2007 AHA/ACC treatment guidelines recommend early invasive (EI) 
management of unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI), 
in patients with high-risk features.
Objective: To identify key correlates of clinical beneﬁt associated with EI strategy.
Methods: Regression analyses were performed to assess association of 5 variables (see 
table) with outcomes in 8 trials - TIMI IIIB, MATE, FRISC II, TACTICS-TIMI 18, VINO, RITA 
3, and ICTUS (N=9,640). Analyses with and without VANQWISH were performed given 
its outlier status. Strength of the association was determined by r2 (the square of the 
correlation coefﬁcient) and statistical signiﬁcance adjudged at P<0.05.
Results: A statistically signiﬁcant association between treatment beneﬁt and baseline 
mortality in the control arm was seen. A modest, but nonsigniﬁcant, association 
was observed regarding difference in between-group revascularization rate. Time to 
angiography, frequency of cardiac biomarker elevation, and ST segment depression 
exhibited no effect on treatment beneﬁt. Similar trends, albeit weaker associations, were 
observed with inclusion of VANQWISH.
Conclusions: The strongest predictors of beneﬁt with early invasive strategy were control 
group mortality and difference in revascularization rate. Treatment decisions should be 
based on a global assessment of patient risk (as afforded by TIMI, PURSUIT or GRACE 
risk scores) rather than a single biomarker determination or admission ECG. 
 
Variable
8 trials (- VANQWISH) 9 trials (+ VANQWISH)
r2 P value r2 P value
Mortality in control group 0.83 0.002 0.23 0.19
Difference in revascularization 0.31 0.150 0.39 0.06
Time to angiography 0.04 0.610 0.06 0.53
Biomarker elevation (troponin) 0.02 0.768 0.06 0.55
ST segment depression 0.07 0.570 0.07 0.52





1010-68 Prognosis and Treatment of Acute Coronary Syndrome 
in Patients With no In-hospital Coronary Angiography: 
Six Months Follow-up in the EMMACE-2 Prospective 
Cohort Study
Raffaele Bugiardini, Christine Morrell, Rajiv Das, Julian H. Barth, Alistair S. Hall, 
EMMACE-2 Investigators, Leeds Institute for Genetics Health and Therapeutics, Leeds, 
United Kingdom, University of Bologna, Bologna, Italy
Background: Patients with acute coronary syndrome (ACS) do not necessarily undergo 
coronary angiography. The size, medical treatment and prognosis of this group has not been 
assessed in a contemporary prospective cohort. Our objective therefore was to investigate 
the above variables among patients admitted with ACS from a U.K. community area.
Methods: The Evaluation of Methods and Management of Acute Coronary Events 
(EMMACE-2) registry enrolled patients hospitalized with unstable angina and myocardial 
infarction during a 6-month period in 11 adjacent hospitals in the West Yorkshire region. 
The in-hospital administration of evidence based therapy (aspirin, beta-blocker, statins 
and ACE-inhibitors) was compared between patients who did and did not undergo cardiac 
catheterization. The effect of therapy on 6-month mortality was evaluated with logistic 
regression models.
Results: The cohort consisted of 1,883 patients without cardiac catheterization and 601 
patients with cardiac catheterization. Aspirin (71.8% vs 82.8%, p <0.001), beta-blockers 
(55.2% vs 77.0%, p <0.001), statins (71.1% vs 92.8%, p <0.001) and ACE-inhibitors 
(58.8% vs 64.4%, p <0.006) were less likely to be administered to patients with no-cardiac 
catheterization than to those with cardiac catheterization. The rate of death over a 6-
month period for patients who did not undergo cardiac catheterization was remarkably 
higher than that of patients who underwent cardiac catheterization (23.7% vs 4.3%; p 
<0.001). The risk reduction of evidence based therapies on 6-month mortality was of 
greatest magnitude and statistical signiﬁcance (p <0.001) in those patients with no-
cardiac catheterization [aspirin: OR 0.48 (95% CI: 0.36-0.63); beta-blocker: OR 0.41 
(95% CI: 0.31-0.55); statins: OR 0.43 (95% CI 0.33- 0.58); ACE-inhibitor: OR 0.46 (95% 
CI 0.35-0.60)].
Conclusions: We observed that patients who did not undergo cardiac catheterization are 
also much less likely to be treated with evidence based therapies for ACS. Simplistically, 
aggressive medical treatment must be applied more consistently to patients identiﬁable 
by the active clinical decision not to investigate with cardiac catheterization.
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1010-69 Genetic Polymorphisms and the Cardiovascular Risk of 
Cyclooxygenase-2 Inhibitors
Christine St.Germaine, James Hanley, Peter Bogaty, Luce Boyer, Jamie C. Engert, 
James M. Brophy, McGill University, Montreal, QC, Canada
Background The cardiovascular safety of cyclooxygenase-2 (COX-2) selective non-
steroidal anti-inﬂammatory drugs (NSAIDs) is of concern, although the majority of users 
remain free of adverse outcomes. A gene-drug interaction may contribute to the variation 
in individual response to COX-2 inhibitors.
Methods In a case-only study of 460 patients selected from a cohort admitted for 
myocardial infarction or unstable angina, we genotyped 84 tagging single nucleotide 
polymorphisms (SNPs) spanning seven candidate genes plus 21 additional SNPs of 
interest identiﬁed by literature review. Strictly adjudicated phenotypes and a detailed 
drug history, including exposure to COX-2 inhibitors, were available for all patients. We 
identiﬁed 115 exposed patients who reported treatment with rofecoxib (n=43), celecoxib 
(n=49), or another NSAID (n=23) within 10 days prior to hospital admission and selected 
345 unexposed subjects matched for age, sex and hospital center. P-values were not 
adjusted for multiple testing.
Results We observed statistically signiﬁcant gene-drug interactions between NSAID 
exposure and 16 SNPs. Furthermore, when the study group was limited to subjects 
exposed to rofecoxib (n=43) or celecoxib (n=49) and the matched unexposed subjects 
(n=276), the association between coxib exposure and genotype strengthened and 
remained signiﬁcant for 4 SNPs. Using the homozygous major allele as a reference, the 
homozygous minor allele yielded statistically signiﬁcant case-only odds ratios for a SNP 
in the C-Reactive Protein (CRP) gene (COR=3.6; 95% conﬁdence interval [CI], 1.6 - 6.7.9; 
P=0.001) as well as two SNPs in the cyclooxygenase-1 (COX-1) gene (COR=6.9; 95% 
CI, 1.4 - 35.7; P=0.02 and COR=6.9; 95% CI, 1.3 - 35.6; P=0.02). Within the Klotho gene, 
the heterozygote of one SNP yielded a statistically signiﬁcant case-only odds ratio of 2.3 
(95% CI, 1.4-4.0; P=0.002).
Conclusions Genetic polymorphisms within the COX-1, CRP and Klotho genes are 
candidates for gene-drug interactions inﬂuencing the cardiovascular outcomes of users 
of NSAIDs and COX-2 inhibitors. These ﬁndings suggest that genetic susceptibility may 
contribute to coronary instability in some users of this class of drugs.
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1010-70 Short-Term Prognostic Implications of 
Electrocardiographic Versus Echocardiographic Left 
Ventricular Hypertrophy in Patients With a First Non-ST-
Elevation Acute Myocardial Infarction
Jose A. Barrabes, Jaume Figueras, Josefa Cortadellas, Rosa M. Lidon, Sonia Ibars, 
Hospital Universitari Vall d’Hebron, Barcelona, Spain
Background: Left ventricular hypertrophy (LVH) has adverse prognostic implications in 
patients with acute myocardial infarction (AMI), yet its deﬁnition varies. In 453 consecutive 
patients with a ﬁrst non-ST elevation AMI, we assessed the value of three different criteria 
for LVH on the admission ECG in predicting in-hospital complications and, in 296 of them, 
the prognostic information added by echocardiographic LVH.
Methods: LVH was deﬁned as Sokolow-Lyon voltage q3.5 mV, a Cornell voltage of 2.8 
mV, a Cornell product >244 µV·s, or as an LV mass index (g/m2, corrected ASE formula) 
>150 in men or >120 in women.
Results: The percentage of patients having LVH was 5% by Sokolow-Lyon, 5% by 
Cornell voltage and 6% by Cornell product, 10% met either of these criteria and 24% 
had echocardiographic LVH. Taking echocardiography as a reference, sensitivity for 
detection of LVH increased from 13 to 26% by combining the ECG criteria. There was a 
poor agreement (kappa <0.2) between these criteria or between electrocardiographic and 
echocardiographic LVH. Rates or complications were as follows: death, 6%, reinfarction, 
4%, angina, 16%, and severe heart failure, 12%. LVH tended to be related to in-hospital 
death (11 vs. 5% in patients meeting or not the Cornell product criterion, respectively, 
P=NS), was not associated with recurrent ischemic events (18 vs. 18%, P=NS) and was 
closely related to heart failure occurrence (36 vs. 10%, P<0.001), with the strongest 
association found for the Cornell product criterion. This association persisted after 
adjusting for the baseline clinical predictors (odds ratio 3.4, 95% CI 1.4-8.4) and the 
prediction was not further improved by considering echocardiographic LVH. Compared 
to the remaining patients, those with LVH had a similar CK-MB peak (109±25 vs. 133±8 
ng/ml, P=NS) and similar prevalence of multivessel disease (45 vs. 40%, P=NS).
Conclusions: The adverse short-term implications of LVH in patients with non-ST elevation 
AMI are related to a higher risk of heart failure but not to more ischemic events. Agreement 
between ECG and echocardiographic LVH is poor, but the latter does not seem to have an 
incremental value over electrocardiographic LVH in predicting complications.
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1010-71 Does an Early Invasive Strategy in NSTEMI 
Management Result in Long-Term Beneﬁt?
Jayanta Das, George A. Diamond, Shervin Eshaghian, Sameer Amin, Prediman K. 
Shah, Sanjay Kaul, Cedars Sinai Medical Center, Los Angeles, CA
Background: Two prior meta-analyses have yielded a signiﬁcant advantage for early 
invasive (EI) compared to selective invasive (SI) management for acute coronary 
syndromes (ACS), at a mean follow-up of 17 to 24 months.
Objective: To determine whether the beneﬁts of EI strategy are sustained beyond 2 years.
Methods: We examined 9 studies with short-term (6-21m) and 3 studies with long-term 
(3-5y) follow-up. A random-effects meta-analysis was used to derive risk ratios (RR) for 
death, nonfatal MI (NF MI) and composite of death or MI. Posterior probabilities (Pr) that 
relative risk difference in outcomes is greater than a threshold value for clinical importance 
(d>5%, 10%, 15%, 20%) were derived from Bayesian analysis using an uninformative 
prior (mean =0, SD = 10) and empirical evidence. Heterogeneity was assessed using 
Cochran’s Q (P<0.1) and I2 (>50%).
Results: At 6-21m, EI strategy was associated with signiﬁcant beneﬁt in nonfatal MI 
but not in other outcomes. The Pr of beneﬁt in nonfatal MI ranged from 97% (d>5%) to 
44% (d>20%). At 3-5 years, no signiﬁcant advantage was seen in any outcome with EI 
strategy, and the Pr of beneﬁt in nonfatal MI ranged from 26% (d>5%) to 14% (d>20%). 
Signiﬁcant heterogeneity was observed in outcomes at both time points.
Conclusions: Evidentiary support for EI strategy for ACS is modest at short-term and does not 
appear to be sustained long-term. Given the increased cost and the attendant complications, 
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1010-72 Relationship between Longitudinal Morphology 
of Ruptured Plaques and TIMI Flow Grade in 
Acute Coronary Syndrome: A Three-Dimensional 
Intravascular Ultrasound Imaging Study
Atsushi Tanaka, Toshio Imanishi, Shigeho Takarada, Satoshi Ueno, Takashi Tanimoto, 
Hideyuki Ikejima, Nobuo Nakamura, Kumiko Hirata, Yu Arita, Hironori Kitabata, Akio 
Kuroi, Manabu Kashiwagi, Hideo Kataiwa, Hiroto Tusjioka, Takashi Kubo, Keishi 
Okouchi, Kazushi Takemoto, Masato Mizukoshi, Takashi Akasaka, Wakayama Medical 
University, Wakayama, Japan
Background: Plaque rupture plays a key role in the onset of acute coronary syndrome 
(ACS). However, there have been few in vivo studies that have addressed the longitudinal 
morphology of plaque rupture. In this study, we investigated the relationship between 
longitudinal morphology reconstructed from pre-intervention intravascular ultrasound 
(IVUS) images and TIMI ﬂow grade at initial angiograms in the acute phase of ACS.
Methods: Our patient population comprised 72 ACS patients in whom we obtained 
successful reconstructed longitudinal images. Based on the site of the maximum aperture 
of rupture in the longitudinally reconstructed IVUS images, patients were divided into 
three groups: Plaques with rupture in the proximal shoulder (proximal-type; n=28), mid 



















portion (mid-type; n=18), or distal shoulder (distal-type; n=26) of the plaque, respectively.
Results: There were no differences in terms of coronary risk factors or the angiographic 
ﬁndings. The proximal-type group more frequently showed TIMI 0 on initial angiogram 
(proximal-type 86%, mid-type 50%, and distal-type 31%, p=0.002). A multivariable logistic 
regression model revealed that the presence of a proximal-type rupture correlated with 
presentation of ST elevation MI (p=0.019, odds ratio 8.12, 95 % CI 1.404- 49.996).
Conclusions:Longitudinal morphological features in a ruptured plaque may affect 
the formation of obstructive thrombus in ACS. Our results suggest that longitudinal 
morphology may be an important determinant of coronary artery occlusion.
3:00 p.m.
1010-73 Impact of Baseline Thrombolysis in Myocardial 
Infarction Grade on Mortality in Non-ST-Segment 
Elevation Myocardial Infarction Patients Treated With 
Early Invasive Strategy
Young B. Song, Joo-Yong Hahn, Sang Yeub Lee, Bong Gun Song, Soo Jin Cho, Jin-Ho 
Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Sang Hoon Lee, Division of Cardiology, 
Cardiac and Vascular Center, Samsung Medical Center, Seoul, South Korea
Background: Baseline vessel patency is known to be associated with outcomes after 
primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial 
infarction (STEMI). However, the prevalence of coronary occlusion and impact of baseline 
Thrombolysis In Myocardial Infarction (TIMI) grade on mortality in non-ST-segment 
elevation myocardial infarction (NSTEMI) is not well known.
Methods: From October 2005 to May 2007, 8,565 patients completed registration in the 
Korean Acute Myocardial Infarction Registry. NSTEMI was present in 3,372 patients 
(39.4%) and STMEI in 5,074 patients (59.2%). We evaluated an impact of baseline 
TIMI grade on 1-month mortality in 1,168 NSTEMI patients treated with early invasive 
strategy.
Results: In NSTEMI patients treated with early invasive strategy, baseline TIMI grade 
was as follows: grade 0 in 355 patients (30.4%); grade 1 in 153 (13.1%); grade 2 in 
177 (15.2%); and grade 3 in 483 (41.4%). Baseline characteristics were not signiﬁcantly 
different between patients with baseline TIMI grade 0 to 1 ﬂow (group I) and those with 
baseline TIMI grade 2 to 3 ﬂow (group II) except age (60 in group I versus 64 in group 
II, p = 0.001). Patients in group I were signiﬁcantly more likely to have a left circumﬂex 
(LCx) artery culprit lesion and less likely to have left anterior descending (LAD) artery 
involvement compared with group II (LCx: 34.5% versus 23.0% and LAD: 34.3% versus 
48.2%, p <0.001). Total mortality at 1-month was 3.3%. Patients in group I demonstrated 
a higher 1-month mortality than those in group II (4.7% versus 2.1%, p = 0.01). In 
multivariate analysis, baseline TIMI grade 0 to 1 ﬂow was an independent predictor of 
1-month mortality (OR 2.87, 95% CI 1.33 to 6.18, p = 0.006) with age (OR per 10 years 
1.76, 95% CI 1.18 to 2.62, p = 0.006) and Killip class (OR 5.82, 95% CI 2.71 to 12.47, 
p < 0.001).
Conclusions: In NSTEMI patients treated with early invasive strategy, baseline TIMI grade 
is an independent predictor of 1-month mortality.
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1010-74 Alcohol Intake and Risk of Incident Atrial Fibrillation in 
Women: A Prospective Cohort Study
David Conen, Usha B. Tedrow, Julie E. Buring, Christine M. Albert, Brigham and 
Women’s Hospital, Boston, MA
Background: Recent studies suggest that high levels of alcohol intake increase the risk 
of incident atrial ﬁbrillation in men, but the relationship between more moderate levels of 
alcohol intake and atrial ﬁbrillation is less clear, especially among women.
Methods: We assessed the relationship between alcohol intake and incident atrial 
ﬁbrillation in a prospective cohort of 38934 women, who were free of cardiovascular 
disease and atrial ﬁbrillation at study entry and who provided complete information on 
baseline alcohol consumption. Women were then classiﬁed into 1 of 4 categories of 
alcohol consumption: Non-drinkers, <1 drink per day, 1-<2 drinks per day and at least 
2 drinks per day. Multivariable Cox proportional hazards models were constructed to 
evaluate the independent relationship between categories of alcohol intake and the risk 
of incident atrial ﬁbrillation.
Results: Mean ± SD age and body mass index were 55 ± 7 years and 26 ± 5 kg/m2, 
respectively. During a median follow-up of 12.3 years, 1250 new cases of incident atrial 
ﬁbrillation were reported. Age-adjusted incidence rates across the 4 categories of alcohol 
intake were 2.9, 2.6, 2.1 and 3.6 events per 1000 person-years of follow-up. Compared 
to non-drinking women (referent), the age-adjusted hazard ratios (95% conﬁdence 
interval) for women drinking <1 drink/day, 1-<2 drinks/day and at least 2 drinks per day 
were 0.93 (0.83-1.04), 0.70 (0.54-0.91) and 1.28 (1.00-1.64). After adjustment for age, 
body mass index, systolic blood pressure, history of hypertension, smoking, diabetes, 
hypercholesterolemia and race, the corresponding risk estimates were 1.0 (referent), 0.97 
(0.86-1.10), 0.77 (0.59-1.00) and 1.36 (1.05-1.77).
Conclusions: This prospective study provides evidence of a nonlinear relationship between 
alcohol consumption and risk of incident atrial ﬁbrillation in women. While women drinking 
at least 2 drinks of alcohol per day have an increased risk of incident atrial ﬁbrillation, 
the risk of atrial ﬁbrillation might be reduced in women consuming moderate amounts 
of alcohol.
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1010-75 Incremental Prognostic Value of Combining 
Inﬂammatory, Cardiorenal and Metabolic Biomarkers 
in Acute Myocardial Infarction: Data from Infarction 
Prognosis Study (IPS) Registry
Jung-Sun Kim, Jong-Won Ha, Jaedeok Kim, Byung Ho Lee, Sung Ai Kim, Chansoo Kim, 
Sungha Park, Eui-Young Choi, Sang-Hak Lee, Sung Min Kang, Donghoon Choi, Yangsoo 
Jang, Namsik Chung, Division of Cardiology, Yonsei University, Seoul, South Korea
Background: Inﬂammatory (hsCRP and ﬁbrinogen), cardiorenal (NT-proBNP and 
BUN) and metabolic biomarkers (FBS) have been known as predictors of MACE, 
respectively. Therefore, we sought to evaluate the incremental prognostic value of 
inﬂammatory, cardiorenal and metabolic biomarker in AMI. Methods: Three hundred 
thirty-ﬁve consecutive patients with AMI (242 men, 163 STEMI, mean age 63 ± 12) were 
prospectively enrolled in Infarction Prognosis Study (IPS) registry. Subjects were divided 
into 3 groups based on number of biomarkers were above each cut-off values (hsCRP: 
10 mg/L, ﬁbrinogen: 400 mg/dl, BUN: 20 mg/dl, NT-porBNP: 500 pg/ml, FBS: 110 mg/
dl)(Group 1: < 2, Group 2: 2-4, Group 3: q 4). Mean follow-up duration were 12 month 
(range, 1 to 24)
Results: Of the 335 patients, MACE (cardiac death, non-fatal MI, re-admission due 
to unstable angina or heart failure) was developed in 37 patients (11 %). MACE was 
occurred in 2 (2 %) of 118 patients of group 1, 15 (10 %) of 144 patients of group 2 and 20 
(27 %) of 73 patients of group 3 (p< 0.001). Even after adjusting for the conventional risk 
factors [age, gender, BMI, HTN, DM, smoking, LVEF, type of AMI], group 3 had a 5.4-fold 
higher risk for MACE than group 1. (Group 2: HR 2.5 [95% CI 0.54-12.2], P = 0.241 and 
Group 3: HR 5.4 [1.09-26.5], P = 0.038).
Conclusion: Combination of inﬂammatory, cardiorenal and metabolic biomarkers has 
graded incremental effects in predicting cardiovascular events in patients with AMI, 
independent of conventional clinical risk factors. 
3:00 p.m.
1010-76 Impact of Diabetes Mellitus on Intravascular Ultrasound 
Findings in Patients with Acute Myocardial Infarction 
with Plaque Ruptures
Young Joon Hong, Myung Ho Jeong, Jong Won Chung, Doo Sun Sim, Jae Youn Moon, 
Ju Han Kim, Hyun Ju Yoon, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, 
Chonnam National University Hospital, Gwangju, South Korea
Background:Plaque rupture and subsequent thrombus formation is the most important 
mechanism leading to an acute myocardial infarction (AMI). Previous pathological study 
showed diabetic patients had a larger content of lipid-rich atheroma and macrophage 
inﬁltration compared with nondiabetic patients. This is consistent with a greater probability 
of coronary plaque rupture in diabetic patients. However, data on the intravascular 
ultrasound (IVUS) ﬁndings in diabetic patients with AMI with plaque rupture are lacking.
Methods: The aim of this study was to assess the impact of diabetes mellitus on IVUS 
ﬁndings in 112 AMI patients (58 ST segment elevation and 54 non-ST segment elevation 
MI; 47 diabetic and 65 nondiabetic patients) with plaque ruptures. IVUS ﬁndings included 
ruptured plaque (a cavity that communicated with the lumen with an overlying residual 
ﬁbrous cap fragment), multiple ruptured plaques (different plaque ruptures separated by 
a >5-mm length of artery containing smooth lumen contours), and a thrombus (discrete 
intraluminal ﬁlling defects).
Results: Baseline high-sensitivity C-reactive protein (4.6±4.6 mg/dl vs. 2.4±4.2 mg/
dl, p=0.050) and triglyceride levels (158±84 mg/dl vs. 127±52 mg/dl, p=0.041) were 
signiﬁcantly higher in diabetic patients compared with non-diabetic patients. Reference 
segment plaque burden was greater in diabetic patients compared with non-diabetic 
patients (37±10% vs. 31±12%, p=0.006). The presence of multiple plaque ruptures (60% 
vs. 29%, p=0.001) and thrombus (72% vs. 52%, p=0.032) were more common in diabetic 
patients compared with non-diabetic patients. Plaque cavity was signiﬁcantly larger 
(2.6±1.6 mm2 vs. 2.2±1.2 mm2, p=0.046) and ruptured plaque length was signiﬁcantly 
longer (3.0±1.6 mm vs. 2.5±1.3 mm, p=0.031) in diabetic patients compared with non-
diabetic patients.
Conclusions: Diabetic AMI patients with IVUS-evident plaque ruptures have more plaque 
vulnerability (more frequent multiple plaque ruptures and more thrombus) accompanied 
with higher inﬂammatory status compared with non-diabetic AMI patients with plaque 
ruptures.





1010-77 An Invasive Management Strategy is the Only 
Therapeutic Intervention Associated with Improved 
Survival in Acute Coronary Syndrome complicated by 
Hemodynamic Compromise
Benjamin K. Dundon, Luan T. Huynh, Stephen G. Worthley, Ashish Soman, David B. 
Brieger, Derek P. Chew, University of Adelaide, Adelaide, Australia, Flinders University, 
Adelaide, Australia
Introduction: The presentation of Acute Coronary Syndrome (ACS) is commonly 
complicated by heart failure or other hemodynamic compromise. Therapeutic trials 
targeting such high-risk patients remain limited however. We sought to assess the impact 
of contemporary management strategies on clinical outcomes in ACS complicated by 
hemodynamic compromise.
Methods: The Australian Collaborative Acute Coronary Syndromes Prospective Audit 
(ACACIA, n=3402, PML0051) is a prospective multi-centre registry of ST-segment 
elevation myocardial infarction and intermediate- to high-risk non-ST-segment elevation 
ACS patients from 39 Australian metropolitan and rural sites. ACS patients presenting 
with Hemodynamic Compromise [HC] (deﬁned as Killip Class q2, Systolic Blood Pressure 
<100mmHg) were the focus of this investigation. Patient characteristics, management 
and clinical outcomes were assessed.
Results: 647 patients fulﬁlled the pre-speciﬁed analysis criteria. Patients with HC were 
older (mean 69.8 vs 63.2yrs, p<0.0001), with a higher prevalence of diabetes (31.9 vs 
21.2%, p<0.0001) and renal impairment (mean eGFR 64.1 vs 73.3mL/min, p<0.0001). The 
presence of HC at hospital presentation was associated with markedly increased in-hospital 
(HR 6.3, 95% CI 2.9-9.4 p<0.0001) and 12-month (HR 5.1, 3.8-6.8 p<0.0001) mortality, 
with incremental Killip Class predicting worsening survival (p=0.03). After multivariate 
adjustment, survival analysis revealed that an invasive management strategy was the only 
therapy associated with improved in-hospital (HR 0.41, 0.22-0.74 p=0.003) and 12-month 
survival (HR 0.43, 0.31-0.60 p<0.0001), with beneﬁt seen across all Killip grades.
Conclusion: In this large real-world study, an invasive management strategy was the 
only therapeutic intervention associated with improved outcomes in ACS complicated 
by HC at hospital presentation. Further efforts are necessary to improve the provision of 
recommended therapies in such high-risk ACS patients.
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1010-78 Abnormal glucose metabolism in acute myocardial 
infarction - association with NT-proBNP and prognosis
Dan E. Høfsten, Brian B. Løgstrup, Jacob E. Møller, Kenneth Egstrup, Department of 
Medical Research, Funen Hosptal, Svendborg, Denmark, Department of Cardiology, 
Rigshospitalet, Copenhagen, Denmark
Background: Abnormal glucose metabolism is common in patients with acute myocardial 
infarction (MI), and is associated with impaired prognosis, paticularly due to post-MI 
congestive heart failure (HF). We hypothesized that increased neurohormornal activation, 
expressed by elevated levels of of N-terminal B-type natriuretic peptide (NT-proBNP) 
could signal an important pathophysiological pathway.
Methods: NT-proBNP levels were assessed in 197 consecutive patients during admission 
for acute MI. Values were log-transformed for statistical analysis. Using echocardiography, 
we also assessed left ventricular systolic function using a regional 16-segment wall motion 
score index (WMSI), and diastolic function using the ratio of early transmitral ﬂow velocity 
to early diastolic mitral annulus velocity (E/e’). Patients without a previous diagnosis of 
diabetes (DM), underwent a standardized 75g oral glucose tolerance test and were, using 
WHO criteria, categorised as having normal glucose tolerance (NGT), impaired glucose 
homeostasis (IGH), or newly detected DM. Patients were followed a median of 21 months 
(IQR: 16-28 months). Primary endpoint was death or hospitalization for heart failure.
Results: The prevalence of NGT, IGH, new DM, and known DM was 35%, 28%, 23%, and 
14% respectively. Using linear regression, we found a signiﬁcant linear increase in NT-
proBNP levels with increasing degree of dysglycemia (Ptrend<0.001). After adjustment for 
age, gender, pre-existing HF, WMSI, E/e’, and Killip class at admission, this association 
remained statistically signiﬁcant (Ptrend=0.02) also after exclusion of patients with a prior 
history of DM (Ptrend=0.04). After adjustment for the same variables, both NT-proBNP 
and glucose metabolism independently predicted outcome in multivariable survival 
analysis (P<0.01 for both variables).
Conclusions: In acute MI, abnormal glucose metabolism is associated with increased 
neurohormonal activation beyond what can be explained from estimates of left ventricular 
dysfunction and clinical signs of HF. However, estimates of glucose metabolism and NT-
proBNP both provide independent additional prognostic information in such patients.
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1010-79 Plaque rupture and morphological characteristics 
of the culprit lesion in acute coronary syndromes 
without signiﬁcant angiographic lesion: analysis by 
intravascular ultrasound
Marie-Jeanne ALIBELLI-CHEMARIN, H orma OULDZEIN, Jr., Remy CAGNAC, Jr., 
Jerome Roncalli, Sr., Didier CARRIE, Sr., Jacques PUEL, Sr., Meyer ELBAZ, Sr., 
Federation of Cardiology Rangueil Hospital, Toulouse, France
Background: The main purpose of this study was to assess the morphological 
characteristics of the culprit lesion with plaque rupture, by intravascular ultrasound 
(IVUS), after acute coronary syndrome (ACS) without signiﬁcant angiographic stenosis 
(% stenosis < 50%). The second purpose was to quantitatively assess the culprit lesion 
and the arterial remodeling. 
Methods: IVUS was performed in 68 patients (46.8 years +/- 11.9) after ACS (21 ST + 
and 47 ST -) without signiﬁcant angiographic lesion (% stenosis: 31% +/- 15). IVUS was 
performed 3 days after ACS, before any interventional procedure. A plaque rupture was 
recognized as a cavity within plaque, communicating with the arterial lumen and having 
an overlying residual ﬁbrous cap fragment. At the culprit lesion, qualitative analysis has 
deﬁned the type of plaque and quantitative analysis has evaluated plaque plus media 
area, plaque volume, plaque burden and arterial remodeling index. Patients were divided 
into two groups: Group I with plaque rupture and Group II without rupture. After qualitative 
analysis of plaque, we studied plaque plus media, plaque volume, plaque burden and 
remodeling index.
Results: Patients were divided into 2 groups: Group I with rupture (25 patients 36.8%), 
Group II without rupture (43 patients 63.2%). All patients with rupture showed soft or mixed 
plaque but no calciﬁed plaque. The average length of plaque was 19.3 ± 9.0 in Group I 
vs 17.6 ± 8.9 mm (ns). In Group I, plaque rupture was associated with a larger plaque 
burden (49.8% ± 12.3 vs 39.8% ± 12.1, p<0.0005), a more signiﬁcant plaque plus media 
area (7.44 mm² ± 2.9 vs 5.24 mm² ± 2.4, p<0.001), a greater plaque volume (151.9 mm3 
± 103.4 vs 99.2 mm3 ± 81.6 p<0.007) and a higher ratio of plaque volume over length 
(8.0 mm3/mm ± 3.8 vs 5.6 mm3/mm ± 3.7, p<0.003). In group I, positive remodeling was 
more frequent than intermediate remodeling (p< 0.03) or negative remodeling (p<0.005). 
In group II, there was no signiﬁcant difference between the 3 types of remodeling.
Conclusions: The plaque ruptures responsible for ACS frequently appear on voluminous 
plaques with a large plaque burden and positive arterial remodeling. 
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1010-80 Genetic Variability Of Platelet Glycoprotein Ia 
Determined The Release Of Soluble CD40-Ligand And P 
Selectin During Myocardial Infarction
Charalambos Antoniades, Dimitris Tousoulis, Carmen Vasiliadou, Kyriakoula Marinou, 
George Latsios, Nikolas Koumallos, Elli Stefanadi, Kostas Toutouzas, Gerasimos 
Siasos, Nikos Papageorgiou, Christodoulos Stefanadis, University of Athens, Athens, 
Greece
Background: Platelet glycoprotein Ia (GPIa) mediates platelet adhesion to collagen, a 
major step in platelets activation during the acute phase of myocardial infarction (MI). 
Activated platelets release the soluble forms of CD40-ligand (sCD40L) and P-selectin 
(P-Sel). We investigated the role of genetic polymorphisms C807T and G1648A on GPIa 
gene, on the risk for MI and the release of sCD40L and sP-sel during the acute phase of 
MI and one year after the event.
Methods: The study population consisted of 630 young subjects (aged 49.0±3.0 years): 
219 pts with premature MI and 411 controls. A sub-population of 67 pts and 232 matched 
controls was followed-up prospectively for 1 year. Distribution of C807T and G1648A were 
determined by PCR, and plasma sCD40L and P-Sel by ELISA.
Results: The genotypes distribution were for 807TT/CT/CC: 34/112/73 in pts and 33/229/149 
in controls (p<0.05) and for 1648GG/AG/AA: 161/50/8 in pts and 315/84/12 in controls 
(p=NS). The adjusted risk for MI in 807TT was 2.301(1.189-4.540) p=0.011. During the 
acute phase of MI, both sCD40L and P-sel were higher in 807CT+TT (12.77±1.22pg/ml 
and 68.2±4.9ng/ml) compared to CC (7.12±0.93pg/ml and 39.9±3.67ng/ml respectively, 
p<0.01 for both). One year after the event, although sCD40L and P-sel were decreased 
in all genotypes, they remained higher in CT+TT (8.73±0.97pg/ml and 51.1±3.6ng/ml) 
compared to CC(4.35±0.93pg/ml and 37.2±2.6ng/ml respectively, p<0.01 for both). In 
controls, sCD40L and P-sel was not different in CC (4.19±0.48pg/ml and 31.1±3.1ng/ml 
respectively) compared to CT+TT (5.3±0.33pg/ml and 35.8±1.8 p=ns for both). G1648A 
had no effect on sCD40L and P-sel levels.
Conclusions: Genetic polymorphism C807T on platelet GPIa is a risk factor for premature 
MI, and it affects the release of sCD40L and P-selectin during the acute phase of MI. The 
effect of this genotype on sCD40L and p-sel is still present one year after the event. These 
ﬁndings suggest that C807T polymorphism may modify platelets activation in patients with 
coronary atherosclerosis, especially during the acute phase of myocardial infarction.
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1010-83 Natural History of the Thin-Cap Fibroatheroma 
Assessed by Optical Coherence Tomography in vivo
Ryotaro Yamada, Hiroyuki Okura, Teruyoshi Kume, Takahiro Kawamoto, Yoji Neishi, 
Eiji Toyota, Yoshinori Miyamoto, Koichiro Imai, Nozomi Watanabe, Kiyoshi Yoshida, 
Kawasaki Medical School, Kurashiki, Japan
Background:The precursor lesion for plaque rupture is known as thin cap ﬁbroatheroma 
(TCFA). However, natural history of TCFA in vivo is still unclear. Therefore, the purpose 
of this study was to evaluate natural history of TCFA in vivo by using optical coherence 
tomography (OCT) and intravasucular ultrasound (IVUS) during 6 months follow-up.
Methods:Forty-ﬁve coronary arterial segments from 15 patients with acute coronary 
syndrome were examined by OCT and IVUS. TCFA and thick cap ﬁbroatheroma were 
detected and followed up for 6 months. TCFA was deﬁned as a plaque with a minimum 
ﬁbrous cap thickness < 65µm by OCT and thick-cap ﬁbroatheroma >= 65µm.
Results:Twelve TCFAs were identiﬁed in 7 patients (47 %). Among these patients, 
4 (57%) had 1 TCFA, 3 (43%) had 2 TCFAs, and 1 (14%) had 3 TCFAs. Three of 12 
TCFAs were treated with stenting because of signiﬁcant stenosis. Six TCFAs were 
followed up serially by angiography and IVUS. There were no signiﬁcant differences in 
volumetric IVUS assessment between TCFA and thick cap ﬁbroatheroma at the initial 
examination. However, plaque burden of TCFA was signiﬁcantly higher than that of thick 
cap ﬁbroatheroma 6 month later (Table).
Conclusions:This is the ﬁrst report to reveal natural history of TCFA assessed by 
OCT. Further large long-term investigation will be needed for a more comprehensive 
pathophysiologic approach towards natural history of vulnerable plaque. 




















1010-84 Early Phase of Gadolinium Enhancement and T2-
weighting Imaging on Cardiac Magnetic Resonance can 
Detect Ischemic Stunned Myocardium
Yoko Masukata, Teruo Noguchi, Jun Tanaka, Rika Kawakami, Hiroshi Nonogi, Yoichi 
Goto, Naoaki Yamada, National Cardiovascular Center, Suita, Japan
Background: Although late gadolinium-enhancement (LGE) by cardiac magnetic 
resonance (CMR) can visualize myocardial infarction, this technique cannot distinguish 
stunned myocardium (SM) from normal myocardium. To address this, we measured the 
signal intensity (SI) of stunned myocardium at the early phase of LGE (i.e., 2-5 min after 
contrast injection) and to evaluate the usefulness of T2-weighting image (T2WI). Methods: 
Cardiac cine, T2WI, and LGE were performed in 20 patients with ischemic SM and 10 
age-mated controls. LGE was evaluated at 2, 5, 10, 20 minutes after contrast injection. To 
measure SI in myocardium, we put region of interest on the myocardium segments #1, 2, 
3, 4, 5 of the American Heart Association, and on blood pool, and calculated myocardium-
blood pool ratio. Results: In SM group, conventional LGE representing myocardial 
infarction was not observed. However, at the early phase LGE SM region was visualized 
as hyperenhancement, whereas such hyperenhancement was not observed in controls. 
Myocardium-blood pool ratio in SM was signiﬁcantly higher than that in controls. This 
hyperenhancement region agreed well with the region of high signals on T2WI. Follow-up 
CMR demonstrated complete resolution of abnormal wall motion and disappearance of 
hyperenhancement at the early phase of LGE and on T2WI within one month. Conclusion: 
Stunned myocardium is visualized by the early phase of LGE and T2WI. Thus, combination 
of these techniques is useful to detect a reversible myocardial damage. 
3:00 p.m.
1010-85 Prehospital Wireless Transmission of STEMI 
Electrocardiograms to a Cardiologist Reduces Door-
to-PCI Times to Less than One-Half of the ACC/AHA 
Guidelines
Benjamin A. Lee, George L. Adams, Paul T. Campbell, Janet Patterson, Charles 
Maynard, Galen S. Wagner, Duke University Medical Center, Durham, NC
Background Percutaneous coronary intervention (PCI) for STEMI reduces morbidity and 
mortality if performed rapidly. However, the ACC/AHA <90 minute goal for door-to-PCI 
time is infrequently accomplished.
Methods The Timely Intervention in Myocardial Emergency - NorthEast (TIME-NE) 
study enrolled 422 STEMI patients during three two-year phases: 1) pre-intervention 
- transmission of electrocardiograms (ECGs) unavailable, 2) intervention - study of 
wireless ECG transmission to a cardiologist’s hand-held computer, and 3) follow-up - 
ECG transmission available in routine clinical practice. This study tests the hypothesis 
that pre-hospital ECG transmission to a cardiologist reduces door-to-PCI times not only 
during the study period, but also into follow-up routine clinical practice.
Results A pre-hospital ECG transmission system at NorthEast Medical Center 
reduced door-to-PCI times for both EMS-transport and self-transport patients. The 
door-to-PCI times were signiﬁcantly lower for the ECG Transmission group vs. the No 
ECG Transmission (p <0.0001) and Self-transport (p <0.0001) groups during both the 
Intervention and Follow-up phases. Despite fewer ECG transmissions during the Follow-
up phase than during the Intervention phase, a median time reduction of 25 minutes was 
maintained (Transmission vs. No transmission).
Conclusion Pre-hospital ECG transmission to a cardiologist reduces door-to-PCI time for 
patients with STEMI to less than half of the ACC/AHA recommended goal of 90 minutes. 
Pre-intervention Intervention Follow-up
Time Period 2001-2003 2003-2005 2005-2007
Self-transport Patients
- Number of Patients 73 94 73
- Door-to-PCI Time 
in minutes (median) 106 96 82
EMS Patients
No ECG Transmission
- Number of Patients 48 37 58
- Door-to-PCI Time 
in minutes (median) 101 78 65
ECG Transmission
- Number of Patients ~ 24 15
- Door-to-PCI Time 
in minutes (median) ~ 50 39
3:00 p.m.
1010-86 Beneﬁts of Drug Eluting versus Bare Metal Stents in 
Patients with Renal Dysfunction are Independent of 
Target Lesion Revascularization
Saurabh Gupta, Jeffrey L. Anderson, Bejamin D. Horne, Tami L. Bair, Heidi T. May, 
Joseph B. Muhlestein, Intermountain Medical Center, Murray, UT
Background: In most patient subpopulations, drug-eluting stents (DES) provide signiﬁcant 
beneﬁts over bare metal stents (BMS) for coronary artery restenosis and other major 
adverse cardiovascular events (MACE). However, the effect of DES in patients with renal 
dysfunction is not known.
Methods: Baseline clinical information was obtained from 2695 consecutive patients 
undergoing coronary artery stent deployment at LDS hospital after the availability of 
DES. Patients with unavailable serum creatinine values (n=48) or those receiving both 
DES and BMS (n=272) were excluded. In the remaining 2375, clinical characteristics and 
glomerular ﬁltration rate (GFR, MDRD formula) were recorded. Patients were followed 
for 6 months for death, MI, and target lesion revascularization (TLR) or the composite 
(MACE). A GFR < 60 ml/min was designated as impaired renal function. Outcomes were 
stratiﬁed by GFR [a60 ml/min (n= 632) vs. >60 ml/min (n= 1742)].
Results: Age averaged 64±12 years and 75% were male. Among those with GFR>60 
ml/min, DES were superior to BMS for MACE (9.8% vs. 17.3%, p<0.001), TLR (4.8% 
vs. 7.0%, p=0.077), MI (4.9% vs. 7.8%, p=0.019) and death (1.6% vs. 4.4%, p=0.001). 
Among patients with GFR a60 ml/min, DES were superior to BMS for MACE (13.5% vs. 
21.4%, p=0.011), TLR (4.2% vs. 8.0%, p=0.049), and MI (4.9% vs. 11.4%, p=0.003); 
however, no signiﬁcant differences were observed for death (6.3% vs. 8.6%, p=0.29). 
Moreover, the rates of TLR were independent of baseline GFR for both BMS (7.0% vs. 
8.0%) and DES (4.8% vs. 4.2%).
Conclusion: The beneﬁts of DES were conﬁrmed in a large population of patients with 
normal and also with impaired renal function (6-month MACE was decreased in both renal 
function categories). The study was not powered to speciﬁcally show improved death rates 
with DES among those with impaired renal function although the trend was favorable. Rates 
of TLR did not vary by renal insufﬁciency in the two stent types. These ﬁndings suggest 
mechanisms other than TLR may be responsible for increased adverse outcomes with BMS 
in impaired renal function patients. If conﬁrmed, these results may have important clinical 
implications in the choice of stent type for this high-risk patient group.
3:00 p.m.
1010-87 Long-term compliance with guideline-based medical 
therapies is the strongest predictor of event-free 
survival following acute coronary syndromes (ACS) 
and myocardial infarction (MI)
Amit P. Amin, Ekanka Mukhopadhyay, Sandeep Nathan, Sirikarn Napan, Russell F. Kelly, 
Rush University Medical Center, Chicago, IL, Cook County Hospital, Chicago, IL
Background: While acute medical therapies signiﬁcantly improve in-hospital outcomes 
in patients (pts) with ACS/MI, the impact of sustained compliance with evidence-based 
medical therapies remains less clear.
Methods: 878 consecutive pts admitted from 2003-04 to a large academic center with 
high-risk ACS/MI, were followed for compliance with 5 key classes of medical therapy 
(aspirin, clopidogrel, statins, beta blockers and ACEI/ARB). The effect of medical 
compliance on the primary composite outcome, mortality and MI, was explored using 
Kaplan-Meier and Cox regression analyses.
Results: Of 878 pts (66% male, 54% DM), 134 (15.3%) presented with STEMI, 390 (44.4 
%) with NSTEMI and 354 (40.3%) with unstable angina. 566 pts (64.5%) underwent 
revascularization (PCI 406 (46.3%), CABG 160 (18.2%)) and 312 (35.6%) were medically 
managed. Outpt follow-up was available in 92% of pts. 100 (11.4%) pts died, and 25 
(2.9%) had recurrent outpt MI at median follow-up of 2.2 years. In a stepwise Cox model 
adjusting for risk covariates, medical compliance (per incremental therapy) was the 




strongest factor associated with event-free survival (HR 0.57, P<0.0001, 95%CI 0.51-
0.63). The beneﬁt was ampliﬁed with sustained compliance with >/= 4 medical therapies 
(Figure 1).
Conclusions: Long-term compliance with 5 key medical therapies post-ACS is strongly 
and independently associated with event-free survival. The time-dependent relative 
contributions of each individual class are currently being investigated.
3:00 p.m.
1010-88 Polymorphism of endothelial NOS gene promoter is 
associated with endothelial dysfunction, increased 
arterial stiffness and has negative prognostic impact 
after ACS
Yaroslav M. Lutay, Sr., Viktor Dosenko, Sr., Alexander Parkhomenko, Sr., Institute of 
Cardiology, Kiev, Ukraine, Institute of Physiology, Kiev, Ukraine
Background: an endothelial nitric oxide synthase (eNOS) gene polymorphism (-786T>C) 
in promoter region has been associated with cardiovascular disease. We investigated 
whether carriage of the polymorphism was associated with functional changes in the 
endothelium, arterial stiffness and how it affected prognosis in patients with ACS.
Methods: 332 patients with ACS (142 patients without ST elevation and 190 patients with 
ST elevation ACS) and 83 controls were investigated. The eNOS gene polymorphism 
has been analyzed by PCR-RFLP (restriction fragment length polymorphism) analysis. 
Endothelium-dependent, ﬂow-mediated brachial artery dilatation (FMD) was measured 
using high-resolution ultrasound. Carotid-femoral and carotid-radial pulse wave velocity 
(PWV) were measured as an index of aortic stiffness using an automated non-invasive 
device (Complior®)
Results: A signiﬁcant difference in genotype distribution was observed between patients 
and controls. Pathological CC genotype was more often determined in ACS patients 
(16,6% vs. 6,0%, p<0,01). The multivariate analysis showed that C/C genotype in the 
eNOS gene promoter was associated with increased risk of recurrent ischemic events 
(death/ myocardial infarction) during one-year follow-up. Homozygosity for the CC variant 
of the eNOS gene promoter in ACS patients was associated with lower ﬂow-mediated 
brachial artery dilatation (6.4±1.4% vs 9.0±0.7%, p<0.05) CC genotype carriers had 
signiﬁcantly higher carotid-radial PWV than patients with TT genotype (9.4±0.16 vs 
8.9±0.13 m/sec, p<0.05). Carotid-femoral PWV did not differ between groups.
Conclusions: CC genotype of eNOS gene promoter may predispose to the development 
of ACS and among ACS patients this genotype is associated with poor prognosis that 
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1017-41 ST Segment Deviation Resolution is an Indicator for 
Coronary Artery Patency Prior to Primary Percutaneous 
Coronary Intervention in Patients With Acute 
Myocardial Infarction
Niels J. Verouden, Karel T. Koch, José P. Henriques, Jan Baan, René J. van der Schaaf, 
Marije M. Vis, Jan G. Tijssen, Martin G. Meesterman, Jan J. Piek, Robbert J. de Winter, 
Academic Medical Center, Amsterdam, The Netherlands
Background: Pre-procedural Thrombolysis in Myocardial Infarction (TIMI) ﬂow is known to 
be an independent predictor of long-term mortality in high-risk patients with ST Elevation 
Myocardial Infarction (STEMI) undergoing primary Percutaneous Coronary Intervention 
(PCI). We evaluated whether pre-procedural ST segment deviation Resolution (STR) 
adequately correlates with TIMI ﬂow at ﬁrst dye injection.
Methods: In this single center cohort study, 1206 STEMI patients underwent primary PCI 
between 2000 and 2005. STR was deﬁned as the relative difference (in %) of the summed 
ST deviation between the 12-lead electrocardiogram (ECG) recorded on admission and 
the12-lead ECG recorded immediately prior to PCI. TIMI ﬂow through the culprit vessel 
was determined at ﬁrst angiographic ﬂim of the infarct related coronary artery. Coronary 
artery occlusion was deﬁned as TIMI ﬂow 0 or 1.
Results: Coronary artery occlusion was observed in 911 patients (75.5 %) at coronary 
angiography preceding primary PCI. The ROC-curve revealed that STR was predictive for 
TIMI ﬂow prior primary PCI (area under the curve = 0.72; p < 0.0001). Figure 1 shows the 
percentage of patients with pre-procedural occlusion as a function of the degree of STR 
(p for trend < 0.0001).
Conclusions: It is apparent that although STR is associated with TIMI ﬂow prior primary 
PCI, it is an imperfect, non-invasive measure of spontaneous reperfusion. Therefore, 
adequate STR should not restrain from performing coronary angiography in STEMI. 
11:00 a.m.
1017-42 A Propensity Score Analysis of the Beneﬁt of Upstream 
Platelet Glycoprotein IIb/IIIa Receptor Antagonists in 
Acute Coronary Syndromes - Insights From the TRACS 
Registry
Amit P. Amin, Sandeep Nathan, Yasmeen Golzar, James E. Calvin, Jr., Rush University 
Medical Center, Chicago, IL, Cook County Hospital, Chicago, IL
Background: In patients (pts) with high-risk acute coronary syndromes (ACS) who 
undergo an early, invasive strategy, current guidelines recommend glycoprotein IIb/IIIa 
inhibitors (GPI), administered either “upstream” prior to angiography or “downstream” 
in the catheterization laboratory during PCI however the optimal approach remains 
unknown. We examined the effect of upstream GPI use via propensity score analysis in 
a large ACS registry.
Methods: The Registry of Acute Coronary Syndromes (TRACS) is a prospective registry 
of 3,468 ACS pts from 9 institutions, established to track quality of care. Pts receiving 
upstream GPI (in the emergency room, CCU or chest pain unit) constituted “early GPI use” 
group vs. cath lab use comprising the “deferred/selective” group. In-hospital death was the 
primary outcome variable. A propensity score predicting use of early GPI was developed 
from a logistic model with early GPI as the dependent variable and male gender, age q 
65, ST depression, TIMI score, diabetes and troponin release as independent variables.
Results: Overall, 1,376 (40%) pts received GPI of which, 294 (8.5%) received GPI in 
the ER, 249 (7.2%) received GPI prior to cardiac catheterization (in the CCU or chest 
pain unit) comprising the “early GPI use” group (n= 543, 15.7%). A propensity score 
predicting the use of early GPI had an ROC AUC of 0.63 and was divided into quintiles for 
further covariate adjustment. A simple multivariate logistic model controlling only for the 
propensity score quintiles showed that early GPI use was strongly associated with survival 
beneﬁt (OR 0.4, p=0.013, 95% CI 0.19-0.82). A more comprehensive multivariable logistic 
model controlling for additional covariates like gender, diabetes, dyslipidemia, prior MI, 
ST depression, TIMI score, revascularization, aspirin, beta-blocker and heparin use in 
addition to propensity score quintiles, showed that early GPI use was independently 
associated with survival (OR 0.47, p=0.04, 95% CI 0.22-0.99).
Conclusions: This propensity score analysis in a large ACS registry reveals independent 
in-hospital mortality beneﬁt with upstream GPI use even after adjusting for important 
covariates.
11:00 a.m.
1017-43 The TRACS Score Predicts Beneﬁt of Upstream 
Glycoprotein IIb/IIIa Use in Acute Coronary Syndromes
Sandeep Nathan, Amit P. Amin, James E. Calvin, Jr., Rush University Medical Center, 
Chicago, IL, Cook County Hospital, Chicago, IL
Background: The TRACS score is a simple scoring system for predicting mortality in 
acute coronary syndromes (1). We attempt to evaluate the relative beneﬁt of upstream 
glycoprotein IIb/IIIa (GPI) use across categories of the TRACS score.
1. J Am Coll Card 2006;47; Issue 4 Suppl A:1018-227·224A.
Methods: The Registry of Acute Coronary Syndromes (TRACS) is a registry of 3,468 
ACS patients (pts) from 9 institutions. Pts receiving GPI in the ER, CCU or chest pain unit 
constituted the “upstream” group. In-hospital death was the primary outcome variable. 
The TRACS score is a validated scoring system based on multiple clinical variables and 



















cardiac biomarker postivity calculated as previously published (1). Mortality rates across 
TRACS score categories by upstream vs. downstream (cath lab) use of Gp2b3a agents 
were ascertained
Results: Overall GPI were used in 1,376 (40%) pts of which “upstream” use was in 543 
(15.7%) pts (294 (8.5%) in ER, 249 (7.2%) in CCU or chest pain unit). Upstream GPI 
use was strongly associated with survival beneﬁt (OR 0.47, p=0.04, 95% CI 0.22-0.99). 
This survival beneﬁt was seen to be greater in the patients with higher categories of the 
TRACS score (Figure 1).
Conclusions: There was a strong survival beneﬁt seen with upstream GPI use in this 
prospective registry. This survival beneﬁt was greater across higher categories of the 
previously published TRACS score. The TRACS score may be used to guide early, 
upstream initiation of GPI agents.
11:00 a.m.
1017-44 The Relationship between ECG Computer Interpretation 
and Catheterization Laboratory Activation Time in 
Patients with Suspected ST Elevation Myocardial 
Infarction
Muhammad Arida, James K. McCord, Akshay Khandelwal, Steven Mast, Karthik Iyer, 
Glenn Tokarski, Nabil Khoury, Aaron Kugelmass, Henry Ford Heart and Vascular 
Institute, Detroit, MI
Background: The beneﬁt of primary angioplasty for treatment of ST Elevation Myocardial 
Infraction (STEMI) is highly time dependent.Many primary angioplasty centers rely on 
computer-generated ECG interpretation for initial patient triage. We sought to determine 
the relationship of different computer ECG Interpretations on emergency department 
arrival time to CLA in patients presenting with suspected STEMI.
Methods: We included consecutive patients with suspected STEMI from 9/2003-6/2006 
who had ECG changes that met criteria for reperfusion therapy and had subsequent CLA 
at our institution. ECG computer interpretation results were categorized into 5 groups: 
acute MI, Left Bundle Branch Block (LBBB), MI of unknown onset, normal and other.
Results: 392 patients were analyzed in the study. Overall, the computer interpretation 
was acute MI in 277 (71%) of cases. The different door to activation time among different 
ECG groups is listed in the table below. Overall, there was a signiﬁcant time difference 
between the acute MI group vs. all other patients (12 ± 13 vs. 46 ± 74 minutes; 95% CI: 
10-14 vs. 33-60, p < 0.0001).
Conclusions: Physician based ECG interpretation lead to CLA in 29% of patients in whom 
the computer based interpretation did not identify as acute MI. This resulted in signiﬁcant 
delays in door to activation time in this group of patients with suspected STEMI. A new 
protocol to overcome the limitation of this approach is currently being implemented and 
studied.
ECG Group Number of patients Door to activation time (minutes)
Acute MI 277 12 ± 13
MI unknown onset 69 43 ± 51
LBBB 9 14 ± 10
No change 6 17 ± 20
Other 31 68 ± 115
11:00 a.m.
1017-45 Implications of History of Clinical Coronary Heart 
Disease on Incident Heart Failure in the Elderly
Andreas Kalogeropoulos, Vasiliki Georgiopoulou, Syed A. Agha, Nicolas Rodondi, 
Melissa Garcia, Douglas Bauer, Suzanne Satterﬁeld, Anne Newman, Andrew Smith, 
Tamara Harris, Stephen Kritchevsky, Javed Butler, for the Health ABC Study, Emory 
University, Atlanta, GA
Background: Although clinically manifest coronary heart disease (CHD) is a major risk factor 
for heart failure (HF), many elderly subjects may develop HF in the absence of a coronary 
event, often ascribed to age-related ventricular changes. The epidemiologic and clinical 
signiﬁcance of incident HF in the elderly with and without CHD is not well described.
Methods: We compared clinical characteristic and outcomes between 477 participants 
with CHD at baseline (age 74.0±2.8 years, 38% females, 40% blacks) and 2320 
participants without CHD (age 73.5±2.9 years, 55% females, 41% blacks) in the Health 
ABC study. CHD was deﬁned as history of myocardial infarction (MI) or angina or coronary 
revascularization whereas new coronary event was deﬁned as hospitalization for MI or 
angina. Incident HF was deﬁned as hospitalization for new onset HF.
Results: Overall 91/477 (19.1%) participants with and 153/2320 (6.6) without CHD 
developed HF during the 6.5±1.8 yr follow-up (HR 3.25, p<0.001). In both groups systolic 
blood pressure, serum creatinine and fasting glucose levels, and continued smoking were 
independent predictors of new HF. In patients without CHD, age, increased heart rate, left 
ventricular hypertrophy, and low albumin levels were additional independent predictors. 
Among the 153/2320 participants with new HF without baseline CHD, 35 (22.8%) were 
hospitalized for MI and 39 (25.5%) for angina prior to new HF development; overall 
66/153 (43%) developed a coronary event prior to HF whereas 87/153 (57%) developed 
HF without any preceding coronary event. In the 2.4±2.1 yr follow-up period post-HF 
development, participants without prior coronary event had higher mortality as compared 
to those who did (26% vs. 13% per year, p=0.013 unadjusted, p=0.070 after adjustment 
for gender, race, and age), and similar re-hospitalization rate (68% vs. 59%, p=0.309). 
In comparison, participants with baseline CHD who developed HF had 18% per year 
mortality and 79% re-hospitalization rate.
Conclusions: Although prevalent CHD is a major risk factor for incident HF, subjects 
who develop HF without an intervening coronary event maybe at a higher mortality risk, 
underscoring the need to study this group further.
11:00 a.m.
1017-46 Evaluation of Coronary Artery Disease in Women Using 
Magnetocardiography
Amelia Young, Indraneil Ray, David Gallegos, Melissa Slivka, Jana Williams, Margo 
Minissian, Donna Polk, C. Noel Bairey Merz, Robert Siegel, Kirsten Tolstrup, Cedars-
Sinai Medical Center, Los Angeles, CA
Background: Women have an increased death rate from coronary heart disease (CHD) 
compared to men, partly due to delays in diagnosis. Magnetocardiography (MCG) is a 
rapid, noninvasive scan that has the ability to detect ischemia without exposure to radiation 
using an automated analysis that collects, processes, and analyzes the magnetic ﬁeld 
generated by the heart’s electrical conductivity.
Methods: A 6 minute resting MCG scan (9-channel CMI 2406) was performed in 35 
women presenting with chest pain (study group), and 19 normal controls (control group). 
Automated MCG analysis of cardiac repolarization was performed and results were 
available immediately. All individuals were angina free at the time of scanning. Sensitivity, 
speciﬁcity, and predictive values were calculated for typical or atypical angina secondary 
to CHD as determined after noninvasive and invasive work up.
Results: The mean age for women in the study group was 61 ± 13 years. The prevalence 
of cardiovascular risk factors was high: hypertension 60%, diabetes 32%, hyperlipidemia 
71%, smoking 32%, family history 37%, prior infarct 23%, and prior CABG 6%. The control 
group women included in this study had no cardiac risk factors, and had normal ECG. In 
the study group, 12-lead ECG was normal in 80%, and 88% had normal troponin I. An 
abnormal MCG was signiﬁcantly associated with the presence of myocardial ischemia 
(p<0.0001). The sensitivity, speciﬁcity, positive and negative predictive values for the ECG 
for ischemia were 40%, 88%, 57%, and 79%, respectively, compared to 100%, 80%, 67% 
and 100%, respectively for MCG. In comparison, the sensitivity, speciﬁcity, positive and 
negative predictive values for single photon emission computed tomography scan were 
83%, 83%, 71% and 91%, respectively.
Conclusion: Magnetocardiographic scanning detects CHD in women with high diagnostic 
accuracy. These results suggest that MCG scanning may be useful for the early diagnosis 
of myocardial ischemia and thus may facilitate timely intervention and treatment in 
women.
11:00 a.m.
1017-47 Carotid Plaque Inﬂammation in Patients with 
Acute Coronary Syndrome Assessed by 18F-
ﬂuorodeoxyglucose Positron Emission Tomography
Jin Won Kim, Sung Eun Kim, Soon Yong Suh, Cheol Ung Choi, Jin Oh Na, Eung 
Joo Kim, Seung-Woon Rha, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, 
Cardiovascular Center Korea University, Guro Hospital, Seoul, South Korea, Nuclear 
Medicine, Korea University Guro Hospital, Seoul, South Korea
Background: A systematic plaque instability is suggested in patients with acute 
coronary syndrome. Plaque inﬂammation could be assessed by 18F-ﬂuorodeoxyglucose 
Positron Emission Tomography (18F-FDG PET). We investigated whether carotid 
plaque inﬂammation could be related to coronary plaque instability using 18F-FDG PET. 
Methods: In 50 (male 14, 48.1±7.7 yrs) patients who were newly diagnosed as acute 
coronary syndrome (28 patients, male 6, 46.8±7.9 yrs) or stable angina (22 patients, male 
13, 49.5±9.8), the co-registration of PET and contrast enhanced computed tomography 
(CT) images was performed within 1 week after percutaneous coronary intervention. 
Regional (neck) PET/CT imaging at 1 hour (early scan) and additional scan at 2 hours 
(delayed scan) after 555 MBq of 18F-FDG injection and the multislice CT angiogram were 
acquired at 180 min on the Philips GEMINI TF scanner with 16 slice CT. The maximum 
standardized uptake values (SUVs) were measured in individual plaques. Results: In 
all patients, carotid plaque with increased 18F-FDG uptake was observed in the fused 
PET/CT images. Age and gender-adjusted SUV of FDG on delayed scan was signiﬁcantly 
higher in the carotid plaques of patients with acute coronary syndrome than those of 
patients with stable angina (mean 4.13±1.24 (3.19 to 5.27) vs. 2.87±0.98 (2.47 to 3.62), 
p=0.003). There were no differences of risk factors between two groups. Conclusions: 
The patients presenting with acute coronary syndrome demonstrate simultaneous 
increase of inﬂammatory activity of the carotid plaque, supporting a potential causal 
role of inﬂammation regarding widespread plaque destabilization associated with acute 
coronary syndrome.





1017-48 Nationwide trends in the incidence of acute ST
elevation myocardial infarction (STEMI) in the United
States 
Mohammad Reza Movahed, Mehrtash Hashemzadeh, Mazen Jamal, University of 
Arizona Sarver Heart Center and Southern Arizona VA Health Care System, Tucson, AZ
Background: Advances in the prevention and treatment of atherosclerosis risk factors 
have been dramatic in the last ten years. The goal of this study was to evaluate any 
decline in the age adjusted incidence of acute ST elevation myocardial infarction (STEMI) 
in a very large data base from 1988 to 2004.
Method: The Nationwide Inpatient Sample (NIS) database was utilized to calculate the 
age-adjusted rate for STEMI from 1988 to 2004 retrospectively. Speciﬁc ICD-9-CM codes 
for STEMI were used to compile the data. Patient demographic data was also analyzed 
and adjusted for age from the database.
Results: The NIS database contained a total of 1,352,574 patients who had a diagnosis 
of STEMI from 1988 to 2004. The mean age for these patients was 66.06 ±13.69 years 
old. Male has almost twice age adjusted STEMI rate than female (male: 62.4%, female 
37.6%). From 1988 the age-adjusted rate for all acute STEMI remained steady for 8 
years (108.32 per 100.000 (95%CI=99.06-117.58) in 1988 and 102.56 per 100.000 
(95%CI=94.70-110.42) in 1996). However, from 1997, the age-adjusted incidence of 
STEMI steadily declined to half of the incidence of previous 8 years (50.06 per 100.000 
(95%CI=46.59-53.53) by the year 2004 (P<0.01))(See ﬁgure).
Conclusion: The incidence of STEMI was stable from 1988 to 1996 with steady linear 
decline to half by the year 2004. The cause of steady decline in STEMI rate is not 
known. It is most likely reﬂecting the advancement in the prevention and treatment of 
atherosclerosis risk factors. 
11:00 a.m.
1017-49 Lack of Beneﬁt with PCI for Total Occlusions in Stable 
Patients Following Myocardial Infarction is Time 
Independent: Results from the Occluded Artery Trial (OAT)
Venu Menon, Camille A. Pearte, Christopher E. Buller, Ph. Gabriel Steg, Sandra A. 
Forman, Harvey D. White, Paolo N. Marino, Demosthenes G. Katritsis, Paulo Caramori, 
Ricardo Lasevitch, Krystyna Loboz-Grudzien, Aleksander Zurakowski, Gervasio A. 
Lamas, Judith S. Hochman, Cleveland Clinic, Cleveland, OH, New York University 
School of Medicine, New York, NY
Background: The Occluded Artery Trial (OAT) (n=2201) showed no beneﬁt for routine PCI 
(n=1101) over medical therapy (MED) (n=1100) alone in stable post-MI patients with late 
occluded infarct-related arteries up to 28 days post MI. MI onset was protocol deﬁned as 
Day 1 and the earliest time to study entry was 3 calendar days after MI onset, which could 
be as early as 24 hours (23.59 pm Day 1 - 00.01 hours Day 3) post MI. The potential for 
selective early beneﬁt led us to explore outcomes with PCI over MED in the < 3 days; < 
7days, and > 7days time windows.
Results: Earlier time to randomization was associated with higher 48-month life table 
event rates of death, MI, and class IV CHF; (adj HR 1.04/day: 95% CI 1.02-1.06; p<0.001). 
The 48-month event rates for < 3 days, < 7days and > 7days post MI enrolled patients 
were similar for PCI vs. MED. 
48-Month Life Table Event Rates (%)













Death/MI/CHF 18.3 17.6 0.71 18.8 17.4 0.31 15.0 13.4 0.74
Death 7.9 7.9 0.88 9.4 10.7 0.91 9.4 8.5 0.90
MI 6.6 7.2 0.90 7.5 5.9 0.20 5.7 3.7 0.27
CHF 6.9 6.2 0.76 5.5 5.1 0.77 3.6 3.7 0.64
There was no interaction between time to randomization deﬁned as a continuous (p=0.55) 
or categorical variable with a cut-point of 3 days (p=0.98) or 7 days (p=0.64) post MI and 
treatment effect.
Conclusions: Consistent with overall OAT trial ﬁndings, patients enrolled in the < 3 
days and < 7day time windows derived no beneﬁt with PCI over MED. Although earlier 
enrolled patients were at higher risk of events, there was no interaction between time to 
randomization and treatment effect. Thus, the results of OAT are broadly applicable over 
the entire enrollment window.
11:00 a.m.
1017-50 Survival And Cardiac Remodeling Beneﬁts In Patients
Undergoing Late Percutaneous Coronary Intervention
Of The Infarct-Related Artery: Evidence From A Meta-
Analysis Of Randomized Controlled Trials
Antonio Abbate, Giuseppe GL Biondi-Zoccai, Darryn L. Appleton, Paul Erne, Andreas W. 
Schoenenberger, Michael J. Lipinski, Pierfranseco Agostoni, Imad Sheiban, George W. 
Vetrovec, Virginia Commonwealth University Pauley Heart Center, Richmond, VA
Background. There is uncertainty about the role of late PCI in stable patients with AMI. The 
aim of this study was to perform a systematic review and meta-analysis of randomized 
trials comparing percutaneous coronary intervention (PCI) with medical therapy in 
patients randomized >12 hours after acute myocardial infarction (AMI).
Methods. PubMed, CENTRAL, and other databases were searched (July 2007). Studies 
were included if comparing PCI with medical management, randomizing hemodynamically 
stable patients >12 hours and up to 60 days after AMI. Odds ratios (OR) were pooled for 
dichotomous outcomes, with all-cause mortality as the primary end-point. Left cardiac 
remodeling parameters were pooled with generic-inverse-variance weighting.
Results. We retrieved 10 studies enrolling 3560 patients, with median time from AMI to 
randomization of 12 days (range 1-26), and follow-up of 2.8 years (42 days-10 years). 
Randomization allocated 1779 subjects to PCI and 1781 to medical treatment. There 
were 112 (6.3%) and 149 (8.4%) deaths in the 2 groups, respectively, yielding signiﬁcantly 
improved survival in the PCI group (OR=0.49 [0.26-0.94], P=0.030). These beneﬁts were 
associated with similarly beneﬁcial effects on cardiac remodeling, such as improved left 
ventricular ejection fraction in the PCI group (+4.4% change [1.1 to 7.6], P=0.009).
Conclusions. PCI of the IRA performed late (12 hours to 60 days) after AMI is associated 
with signiﬁcant improvements in cardiac function and survival. 
11:00 a.m.
1017-51 Procedural Delay does not Explain the Circadian
Variation Observed in Outcomes of Primary PCI for
STEMI: Insights from the APEX-AMI Trial
Kiranbir Josan, Cynthia M. Westerhout, Arnoud WJ van ‘t Hof, William W. O’Neill, 
David R. Holmes, Jr., Petr Widimsky, Witold Ruzyllo, Christopher B. Granger, Paul W. 
Armstrong, APEX AMI Investigators, University of Alberta, Edmonton, AB, Canada
Background: Evening and early morning onset of ST-elevation myocardial infarction 
(STEMI) has been linked with worse outcomes in patients undergoing reperfusion. The 
extent to which biologic versus process of care factors modulate this phenomenon is 
unknown. We hypothesized that process of care issues in patients undergoing primary 
PCI i.e. longer door to balloon times at night would result in worse procedural and clinical 
outcomes.
Methods: Risk-adjusted post-PCI TIMI 3 ﬂow and 90-day mortality (overall 3.6%) were 
examined by hour of symptom onset (Sx onset) in 4835 STEMI patients enrolled in APEX-
AMI (testing pexelizumab, a complement inhibitor). Hour of sx onset was classiﬁed as 
“daytime ” (08.00-20.00h) or “nighttime ” (20.00-08.00h).
Results: Of 4835 patients, 64.0% had Sx onset during daytime hours. Nighttime Sx onset 
was associated with lower rates of successful reperfusion (i.e., post-PCI TIMI Flow 3) 
and higher 90-day mortality rates (ﬁgure). Interestingly whereas nighttime Sx onset was 
associated with longer delays from Sx onset to hospital arrival, door to balloon times were 
consistent regardless of time of day.
Conclusion: In this large, contemporary well treated STEMI cohort undergoing primary 
PCI, Sx onset and outcomes exhibited a clear circadian rhythm. Patient care-seeking 
behaviors, rather than procedural delays, appear to be the primary modulator of longer 
times to reperfusion. 




















1017-52 Low Molecular Weight Dalteparin As An Adjunct In 
Treatment Of Acute Myocardial Infarction: A Meta-
Analysis
Amol A. Bahekar, Rohit Arora, Sarabjeet Singh, Ahmad Khraisat, Janos Molnar, Param 
Puneet Singh, Sandeep Khosla, Rosalind Franklin University/Chicago Medical School, 
North Chicago, IL
Background: Aim of the current study is to evaluate the effectiveness of short-term and 
long-term dalteparin in preventing new cardiovascular (CV) events after an episode of 
acute myocardial infarction (AMI).
Methods: A systematic review of the literature revealed 3 randomized controlled trials 
comparing short-term dalteparin with unfractionated heparin (UFH) and 4 randomized 
controlled trials comparing long-term dalteparin with placebo in AMI. Heterogeneity of the 
studies was assessed by Cochran’s Q test. The Mantel-Haenszel ﬁxed-effect model was 
used to calculate combined relative risks (RR) for those outcomes where the studies were 
homogenous and the random effect model was used when the studies were heterogenic. 
A two-sided alpha error of < 0.05 was considered to be statistically signiﬁcant.
Results: No signiﬁcant difference was seen in the 7 day mortality, revascularization and 
risk of bleeding when dalteparin was compared to UFH. The risk of death or infarction was 
signiﬁcantly reduced with long-term (up to 45 days) dalteparin as compared to placebo 
group (RR: 0.760; CI: 0.627-0.920). There was an increased risk of minor hemorrhage 
(RR: 1.912; CI: 1.308-2.796) but not major hemorrhage (RR: 1.411; CI: 0.417-4.776) with 
dalteparin. The rate of revascularization was decreased with dalteparin use as compared 
to placebo (RR: 0.819; CI: 0.713-0.941).
Conclusions: Long-term dalteparin lowers CV endpoints in AMI when compared to 
placebo, but it is not superior to UFH in short-term treatment of AMI. 
11:00 a.m.
1017-53 Randomized trial of early vs. late abciximab 
administration in patients undergoing primary 
angioplasty: infarct size assessment with magnetic 
resonance imaging (the Myocardial Perfusion Study)
Anna S. Petronio, Marco De Carlo, Alessandra Mazzoni, Elisabetta Strata, Federica 
Castellano, Roberto Gistri, Nicola Ciabatti, Giovanni D. Aquaro, Umberto Paradossi, 
Gabriele Borelli, Maria Grazia Delle Donne, Massimo Lombardi, Sergio Berti, University 
of Pisa, Pisa, Italy, Institute of Clinical Physiology, Massa, Italy
Background: Abciximab improves outcome in patients undergoing primary percutaneous 
coronary intervention (PPCI). Our aim was to demonstrate that early abciximab (before 
transfer from remote hospital to cath lab) compared to late abciximab (during PPCI) 
enhances myocardial salvage, as assessed by magnetic resonance imaging (MRI).
Methods: At present, a total of 107 patients (out of 120 intended) admitted <6 hours 
to remote hospitals with anticipated delay to PPCI >45 minutes, were prospectively 
randomized to either Early (57 pts) or Late (50 pts) abciximab administration. Four days 
after PPCI, contrast-enhanced MRI was performed (99 patients) to assess perfusion 
defects (identiﬁed by delayed enhancement, DE). Cardiac MRI was repeated after 6 
months to assess myocardial salvage (48 patients). Complete data will be presented.
Results: The 2 groups had similar baseline clinical characteristics. Baseline TIMI 2-3 ﬂow 
(38.5% vs. 31.6%, P>0.2), ﬁnal TIMI 3 ﬂow (90.4% vs. 94.7%, P>0.2), and ST elevation 
resolution >70% 60 minutes after PPCI (71.2% vs. 68.4%, P>0.2) were not signiﬁcantly 
better in the Early group. Preliminary MRI data (Table) show no signiﬁcant difference in 
initial and 6-month perfusion defects, although a trend to a greater reduction in ﬁnal infarct 
size is observed in the Early group (P=0.09).
Conclusions: Preliminary MRI data show that early abciximab administration is not 


















(n=30) 53±11 22±11 27±14 53±9 14±9 17±13 -8±5
Late 
(n=18) 54±11 17±12 21±15 56±13 12±10 15±13 -5±7
P >0.20 0.18 >0.20 >0.20 >0.20 >0.20 0.09
11:00 a.m.
1017-54 Primary Percutaneous Coronary Intervention Performed 
During Nightshift Hours Was Associated With Increased 
In-Hospital Mortality in Patients With ST Elevation 
Myocardial Infarction. Results From EUROTRANSFER 
Registry
Zbigniew Siudak, Tomasz Rakowski, Artur Dziewierz, Wojciech Zasada, Michal 
Brzezinski, Magnus Janzon, Ralf Birkemeyer, Dariusz Dudek, Department of 
Interventional Cardiology, Krakow, Poland
Background: Scattered evidence suggest that there might be a trend towards poorer 
outcome of ST-Elevation Myocardial Infarction (STEMI) patients treated by Primary 
Percutaneous Coronary Intervention (PPCI) during night hours.
Methods: Consecutive 1,650 STEMI patients treated with PPCI were enrolled in 7 
european countries in the setting of hospital networks from November 2005 to January 
2007. Two patients who died during transport to cathlab were excluded from the analysis. 
Patients were divided into two groups according to their time of admission to cathlab, from 
8 am - 5.59 pm (Dayshift) and from 6 pm - 7.59 am (Nightshift). Shift cut-off points were 
chosen based on daily schedules of the participating centers.
Results: There were 985 patients admitted during Dayshift and 663 during Nightshift. 
Patients in both groups did not differ in baseline demographics and clinical status. Overall 
time from chest pain onset to balloon inﬂation was similar in Dayshift and Nightshift 
respectively (301+/-223 vs 295+/-225 minutes). Infarct related artery patency (TIMI 2+3) 
in baseline angiography was similar (27% in both groups). Nightshift admission was an 
independent predictor of in-hospital death in multivariate regression analysis model (OR 
1.47, 95%CI 1.11-1.94, p=0.007 ).
Conclusions: Performing PPCI for STEMI patients in the setting of hospital networks 
during nightshift hours is an independent predictor of poorer immediate clinical outcome 
of these patients, namely higher in-hospital mortality.
Medications and Clinical Outcome
Medications pre-cathlab Dayshift(n=985) Nightshift(n=663) p value
Aspirin 94.7% 93.7% 0.365
Clopidogrel loading dose > 300 mg 30.1% 34.1% 0.169
Thrombolysis 3.1% 7.8% <0.0001
Early abciximab 43.7% 44.7% 0.719
Outcome Parameters
Death in-hospital 3.1% 5.3% 0.022
Death+reMI in-hospital 3.8% 5.9% 0.044
Death at 30 days 4.6% 6.5% 0.089
Major bleeding requiring transfusion 1.5% 1.8% 0.653
11:00 a.m.
1017-55 Bypassing the Emergency Room After Pre-Hospital 
ECG Transmission as a Major Contributor to Reduced 
Door-to-Balloon Times in Patients With Acute ST-
Elevation Myocardial Infarctions
Dorothe Ahlersmann, Karl-Heinrich Scholz, Holger Duwald, Rolf Nitsche, Georg von 
Knobelsdorff, Reinhard Hilgers, Friederike Keating, St. Bernward Hospital, Hildesheim, 
Germany, University of Vermont, Burlington, VT
Background: Streamlining diagnosis and treatment of patients with ST-elevation 
myocardial infarction (STEMI) reduces time to revascularization. We prospectively 
examined the effects of a strategy to bypass the emergency room in those patients in 
whom the diagnosis was established pre-hospital with a transmitted 12-lead ECG.
Methods: All patients with STEMI transported by ambulance to a center with 24-hour 
primary PCI capability in semirural Germany over an 18-month period (1/2006 to 6/2007) 
were included. Patients transferred from other hospitals were excluded. All ambulances 
serving the hospital were equipped with portable 12-lead ECG machines capable of 
wireless transmission. The previously established protocol for diagnosing, transporting 
and treating patients with STEMI included the goal of transmitting a 12-lead ECG 
(tele-ECG) for every patient suspected of having an acute MI. Time sheets were used 
to prospectively assess time points from ﬁrst patient contact to balloon inﬂation and to 
record whether a tele-ECG was performed.
Results: During the study period, 130 patients presented to the PCI center with STEMI. 
A tele-ECG was obtained and transmitted in 107 patients (82%). The mean contact-to-
balloon time was 101 min (median 96 min) in patients without tele-ECG as compared 
to 76 min (median 75 min) in those with tele-ECG (p<0.0001). A signiﬁcant reduction in 
mean door-to-balloon time from 66 min (median 54 min) to 34 min (median 29 min) was 
observed in patients with tele-ECG transmission (p=0.0005). Of those patients receiving 
a tele-ECG, 82 (77%) bypassed the emergency room with a direct handoff from the 
emergency response team to the catheterization lab staff. In this group of patients, mean 
door-to-balloon time was 28 min (median 26 min) as compared to 53 min (median 50 min) 
in patients with tele-ECG not bypassing the ER (p<0.0001).Thus, most of the time savings 
seen in the group of patients who received a tele-ECG were attributable to the subgroup 
who bypassed the emergency room.
Conclusion: Bypassing the emergency room on the way to the catheterization laboratory 
is associated with a marked reduction in time to revascularization in those patients with 
STEMI who receive a pre-hospital ECG.





1017-56 Percutaneous Coronary Intervention with Off-site 
Cardiac Surgery Backup for Acute Myocardial Infarction 
as a Strategy to Reduce Door-to-Balloon Time
Victor A. Umans, Hans O. Peels, Hans de Swart, Raymond Hautvast, Medical Center 
Alkmaar, Alkmaar, The Netherlands
Background: we sought to determine whether primary percutaneous coronary intervention 
(PCI) for patients admitted with an acute ST-segment elevation myocardial infarction 
(STEMI) can be performed more rapidly and with comparable outcomes in a community 
hospital vs. a tertiary center with cardiac surgery.
Method: we started the ﬁrst PCI with off-site surgery program in the Netherlands in 2002 
and report the results of 739 consecutive pts.
Results: in the safety phase, 199 pts presenting with STEMI were randomly assigned to 
treatment at our off-site center vs a more distant cardiac surgery center. In the conﬁrmation 
phase, 540consecutive patients were treated in the off-site hospital. Safety and efﬁcacy 
endpoints were the rate of angiographically successful PCI procedure (diameter stenosis 
<50% and TIMI 3 ﬂow) in the absence of major adverse cardiac and cerebrovascular 
events (MACCE) at 30 days. The randomization phase showed a signiﬁcant decrease 
of 37 minutes in door-to-balloon time (p<0.001) with comparable procedural and clinical 
success (91% TIMI-3 ﬂow in both groups). In the conﬁrmation phase, the 30-day MACCE-
free rate was 95%. None of the 739 patients in the study required emergency surgery for 
failed primary PCI.
Conclusion: PCI at hospitals with off-site cardiac surgery backup can be considered as 
one of the needed strategies to improve access to primary PCI for a larger segment of the 
population basis, and can be delivered with a very favorable safety proﬁle. 
11:00 a.m.
1017-57 Impact of Spontaneous Reperfusion in Diabetics with 
Acute Myocardial Infarction
Kevin R. Bainey, Yuling Fu, Christopher B. Granger, Christian W. Hamm, David R. 
Holmes, Jr., William W. O’Neill, Ricardo Seabra-Gomes, Matthias E. Pﬁsterer, Frans Van 
de Werf, Paul W. Armstrong, APEX AMI Investigators, University of Alberta, Edmonton, 
AB, Canada
Background: Spontaneous reperfusion (SR) in STEMI is known to improve clinical 
outcome, yet its incidence and impact amongst diabetics is unclear. Accordingly, in the 
APEX AMI study we undertook a systematic analysis of SR in the 15.5% of diabetics 
versus non-diabetic patients.
Methods: A total of 4,944 patients undergoing primary PCI in APEX AMI whom both core 
lab ECG and investigator determined TIMI ﬂow grade data were studied.
Results: Overall, SR deﬁned as pre-PCI TIMI 3 ﬂow occurred in 11.5% of patients. SR 
was less common in diabetics (9.2%, 70/764) as compared to non-diabetics (11.9%, 
498/4180, p= 0.031). The table shows angiographic, ECG, baseline glucose and 90 
day primary clinical outcomes according to the presence or absence of SR in the total 
population, diabetics, and non-diabetics. 
All patients Diabetics Non- Diabetics
SR No SR SR No SR SR No SR
N= 568 4376 70 694 498 3682
























Baseline blood glucose 
q 7.8 mmol/l % 40.7
 a 53.5 83.6 89.5 34.2 a 46.6 b
Post PCI TIMI 3 ﬂow % 99.6 a 89.4 98.6 a 84.9 b 99.8 a 90.3
q 70% ST Resolution 30 
min post PCI % 54
 a 49.5 45.7 37.9 b 55.2 51.7
90-day death % 2.5 4.0 4.3 6.1 b 2.2 3.6
90-day death/shock/CHF % 5.1 a 9.8 10.0 14.9 b 4.4 a 8.9
a
 denotes p<0.05 for comparison of SR versus No SR within each category, b denotes 
p<0.05 for comparison of diabetics without SR versus their counterpart with non-
diabetics
Patients without SR had worse epicardial ﬂow, higher baseline blood glucose and 
tended towards less ST resolution post PCI than those with SR, especially in diabetics. 
Multivariable analysis identiﬁed SR, complete ST resolution post PCI and baseline 
glucose <7.8mmol/l as independent predictors of the 90 day composite clinical outcome.
Conclusion: These data indicate that while SR is less common in diabetics, it is associated 
with comparable subsequent epicardial ﬂow post PCI to non-diabetics and improved clinical 
outcomes. By contrast, diabetics without SR have achieve diminshed epicardial patency with 
impaired microvascular perfusion post PCI likely contributing to their worse clinical outcomes.
11:00 a.m.
1017-58 Incidence and Bleeding Outcomes of Excess 
Unfractionated Heparin Dosing Among Patients 
with ST-Segment Elevation Myocardial Infarction 
Undergoing Fibrinolysis
Tracy Y. Wang, Anita Y. Chen, Eric D. Peterson, Karen P. Alexander, E. Magnus Ohman, 
W. Brian Gibler, Matthew T. Roe, Duke Clinical Research Institute, Duke University 
Medical Center, Durham, NC
Background: Practice guidelines recommend heparin therapy for patients (pts) with 
ST-segment-elevation myocardial infarction (STEMI) undergoing ﬁbrinolysis, yet an 
associated increased bleeding risk is well known.
Methods: We examined the incidence of excess unfractionated heparin dosing and 
subsequent bleeding complications among 964 STEMI pts treated with ﬁbrinolytics in the 
CRUSADE initiative (2004-2006). Excess dosing was deﬁned as a bolus dose >60 U/kg 
or an infusion dose >12 U/kg/hr, and was stratiﬁed into mild and major (bolus >70 U/kg 
or infusion >15 U/kg/hr) excess. Generalized estimating equations method was used to 
compare bleeding risk among groups.
Results: A total of 758 ﬁbrinolytic-treated STEMI pts (79%) received adjunctive 
unfractionated heparin therapy. Among these, 49% received an excess dose while 
18% received a major excess dose. Female sex and low body mass were signiﬁcantly 
associated with excess dosing (ORs 2.17 [1.32, 3.56] and 2.65 [2.03, 3.47], respectively). 
Pts who received major excess dosing had higher unadjusted rates of bleeding and 
transfusion compared with pts without excess dosing (Table). After adjustment, a trend 
persisted for the association with higher transfusion risk.
Conclusions: Almost half of STEMI pts treated with ﬁbrinolytics received excess heparin 
dosing that was associated with increased bleeding. Careful attention to dosing may limit 
the compounded bleeding risk when heparin is used in conjunction with ﬁbrinolytic agents.












Unadjusted rates 12.4% 18.7% 19.2% 0.004
Adjusted OR (95% CI)* -- 0.96 (0.41, 2.27) 0.87 (0.38, 2.15) 0.86
Transfusion
Unadjusted rates 4.7% 8.6% 13.5% 0.0002
Adjusted OR (95% CI)* -- 0.89 (0.41, 1.92) 1.39 (0.61, 3.14) 0.90
11:00 a.m.
1017-59 The Smoker’s Paradox with a Clopidogrel Twist: 
Insights from CLARITY-TIMI 28
Nihar R. Desai, Jessica L. Mega, Wei Guo, Christopher P. Cannon, Marc S. Sabatine, 
TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA
Background: Clopidogrel is a prodrug that needs to be converted into its active metabolite 
by cytochrome P450 enzymes. One of these enzymes, CYP1A2, is potently induced by 
cigarette smoking and has a half-life of 1.5d. We hypothesized that acute therapy with 
clopidogrel would be especially effective in smokers.
Methods: We examined the effect of clopidogrel on outcomes in CLARITY-TIMI 28, a 
randomized trial of clopidogrel v. placebo in STEMI patients undergoing ﬁbrinolysis. 
Patients were stratiﬁed by smoking intensity. Formal interaction terms in logistic regression 
models were used to test for effect modiﬁcation by smoking on clopidogrel.
Results: 1732 patients were not current smokers and 1697 were, the latter consisting of 
206 light (1-9 cigs/d, median=5), 354 moderate (10-19 cigs/d, median=10), 715 heavy (20-
29 cigs/d, median =20), and 422 very heavy smokers (30+ cigs/d, median=40). Current 
smokers were younger and less likely to have hypertension or diabetes, present with an 
anterior MI, and get a ﬁbrin-speciﬁc lytic. The beneﬁt of clopidogrel on angiographic and 
clinical events was greater in higher intensity current smokers, even after adjusting for 
differences in baseline characteristics (Fig).
Conclusion: A greater beneﬁt of clopidogrel was observed in q10 cigs/d current smokers. 
A potential explanation is increased CYP1A2 activity and hence greater ADP-receptor 
antagonism. The differential effects of clopidogrel based on current smoking status merits 
further exploration.




















1017-60 Constrasting ex Vivo and in Vitro Effects of Pexelizumab 
on Complement Activation and Cell Apoptosis in 
Patients With ST-Segment Elevation Myocardial 
Infarction Undergoing Primary PCI: A Substudy of The 
APEX-AMI Trial
Catherine Martel, Benoit Labarthe, Jacinthe Rivard, Marta Ghitescu, Arnaud Bonnefoy, 
Pierre Théroux, Montreal Heart Institute, Montreal, QC, Canada, University of Montreal, 
Montreal, QC, Canada
Background: Complement (C) activation and apoptosis are involved in the pathophysiology 
of STEMI. Yet, Pexelizumab (PEX), a MAb to C5 designed to prevent activation of terminal 
complement (Term C), failed to beneﬁt STEMI patients enrolled in the APEX-AMI trial. We 
therefore explored why and examined C activation and cell apoptosis in patients treated 
with PEX or placebo.
Methods: Blood was obtained from 45 patients enrolled at MHI before the initiation of 
PEX and PCI, and 24 hours later before drug discontinuation. C activity was measured 
ex vivo in serum and in vitro in the supernatant formed after incubation of the serum for 
72 hours on HUVEC monolayers. C4a, C3a, Bb, and MBL (proximal C), and C5a, sC5b-9 
and HUVEC-bound C5b-9 (Term C), were assessed by CBA, ELISA and ﬂow cytometry. 
Apoptosis was quantiﬁed as % of HUVEC with DNA fragmentation after membrane 
permeabilization, and by cells positive to propidium iodide and/or annexinV. Analyses 
were performed blinded to treatment allocation.
Results: Baseline levels of all parameters were similar in PEX and placebo groups. At 24 
hours, proximal C remained unchanged in the 2 study groups in both the ex vivo and in 
vitro studies. An increase at 24 hours in C5a levels in serum from 6.24 to 8.85 ng/ml in 
placebo patients (p=0.031) was abrogated with PEX (5.6 to 6.2 ng/ml, NS). sC5b-9 values, 
however, increased more with PEX (743 to 1892 ng/ml, p=0.003) than with placebo (858 
to 1473 ng/ml, NS). In cell cultures, PEX strikingly inhibited C5a (26.3 to 2.0 ng/ml vs. 32.5 
to 38.7 ng/ml with placebo; p=0.002), sC5b-9 (3235 to 743 ng/ml vs. 3505 to 4259 ng/ml, 
p=0.033), and HUVEC-bound C5b-9 (3.27 to 0.6 % vs. 3 to 3.2%, p=0.002). Despite a 
positive correlation at baseline between HUVEC-bound C5b-9 and HUVEC apoptosis 
(r=0.628, pa0.0001), PEX had no detectable direct effects on apoptosis.
Conclusions: PEX in the early hours of STEMI blunts C5a activation in serum but tends 
to promote formation of sC5b-9. In cell culture, it blocked C5a and sC5b-9 formation in 
supernatant and C5b-9 assembly on cells, with no impact on apoptosis. The reasons for 
these paradoxical effects ex vivo and in vitro remain to be investigated; they could help 
understand why PEX failed to prevent ischemic events.
11:00 a.m.
1017-61 Predictors of Excessive Anticoagulation with 
Unfractionated Heparin in STEMI
Susan Cheng, David A. Morrow, Sarah Sloan, Elliott M. Antman, Marc S. Sabatine, TIMI 
Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 
Boston, MA
Background: Although weight-based nomograms are used to guide unfractionated 
heparin (UFH) dosing, additional patient characteristics may affect the ability to achieve a 
therapeutic activated partial thromboplastin time (aPTT).
Methods: ExTRACT-TIMI 25 enrolled 20,506 STEMI patients; half were randomized to 
UFH, dosed per the ACC/AHA wt-based nomogram w/ centrally monitored aPTTs. We 
used multinomial logistic regression to determine the independent association between 
patient characteristics and achieving target aPTT.
Results: 7634 patients received UFH and had an aPTT w/in 4-8 h of starting therapy. 
Despite 99% compliance with recommended dosing, only 29.5% of initial aPTTs were 
therapeutic (1.5-2x control); 11.1% were excessively low (<1.25x), requiring re-bolusing; 
and 24.2% were excessively high (>=2.75x), requiring temporary UFH cessation. 
Excessively high initial aPTTs were signiﬁcantly more likely to occur in patients who were 
age >=75, female, with BSA <=1.75 m2, or with creatinine >=1.2 mg/dL (Fig) and were 
associated with a signiﬁcantly increased risk of TIMI major or minor bleeding by 48 h (adj 
OR 1.83; P=0.011).
Conclusion: The standard weight-based UFH nomogram in STEMI often fails to achieve 
initial therapeutic anticoagulation. Excess anticoagulation is more likely among patients 
who are older, female, of smaller body size, or with renal impairment, and is associated 
with increased bleed risk. These ﬁndings should be considered when dosing UFH in 
support of lytic therapy.
11:00 a.m.
1017-62 Does Statin Pre-treatment Promote Thrombolysis in 
Patients With Acute Myocardial Infarction Treated With 
Thrombolytic Therapy?
Masayoshi Kiyokuni, Masami Kosuge, Toshiaki Ebina, Kiyoshi Hibi, Kengo Tsukahara, 
Jyunn Okuda, Noriaki Iwahashi, Toshiyuki Ishikawa, Kazuaki Utino, Satoshi Umemura, 
Kazuo Kimura, Yokohama City University Medical Center, Yokohama, Japan
Background: Statins promote vascular thrombolysis. We hypothesize that statin pre-
treatment provides a more efﬁcient response of the infarct-related artery to thrombolytic 
therapy, resulting in smaller infarct size in patients with acute myocardial infarction (AMI).
Methods: We studied 319 patients with ﬁrst AMI within 12 h after symptom onset. All 
patients underwent thrombolysis, and rescue or immediate percutaneous coronary 
intervention (PCI) was performed on the basis of angiographic ﬁndings. Patients were 
classiﬁed into 2 groups: 39 who had received statin before AMI onset (statin group) and 
280 who had not (non-statin group). QRS score, a marker of transmural damage, was 
measured by ECGs at admission and 1 h after recanalization.
Results: Age, time from onset to admission (110 vs 108 min), preinfarction angina, door 
to needle time, and the rate of PCI (79 vs 68%) did not differ between statin and non-
statin groups. Statin group had higher rates of women (36 vs 10%), hypertension (74 
vs 55%), hyperlipidemia (100 vs 54%), diabetes mellitus (47 vs 26%), non-anterior AMI 
(63 vs 47%), and a smaller QRS score on admission (1.9+3.4 vs 3.1+3.3) and 1 h later 
(3.1+4.2 vs 5.0+3.9) (all p<0.05). Initial TIMI grade 3 rate did not differ between the groups 
(31 vs 31%). Among 123 patients with initial TIMI grade 0/1, TIMI grade >2 (70 vs 35%, 
p=0.03) was more frequently observed in statin group until the ﬁrst balloon inﬂation. Final 
TIMI grade 3 rate was higher in statin group (95 vs 85%, p=0.09). Peak creatine kinase 
was lower in statin group (2187+1967 vs 3383+3401 IU/L, p=0.03). When restricted to 
patients with anterior AMI, QRS scores on admission (2.2+2.2 vs 4.4+3.4, p=0.03) and 1 
h later (3.4+3.5 vs 6.3+3.7, p=0.02) and peak creatine kinase (2758+2910 vs 4170+3995, 
p=0.21) were lower in statin group. Multivariate analysis showed that statin pre-treatment 
was an independent predictor of a smaller infarct size, deﬁned as a peak creatine kinase 
level of <3000 IU/L(OR 2.87, 95%CI 1.06-6.10, p=0.039).
Conclusions: Smaller infarct size in patients with statin pre-treatment may result from 
partly promoting thrombolysis and directly protecting myocardium by statin in AMI treated 
with thrombolytic therapy.
11:00 a.m.
1017-63 Platelet Responsiveness to Aspirin Loading in 
Patients with ST Elevation Myocardial Undergoing 
Primary Percutaneous Intervention is Associated with 
Myocardial Reperfusion and Clinical Outcome
Shlomi Matetzky, Paul Fefer, Boris Shenkman, Michael Shechter, Levi Nitza, David 
Varon, Naphthali Savion, Hanoch Hod, Sheba Medical Center, Tel Hashomer, Israel, 
Hadassah University Hospital, Jerusalem, Israel
Background: In patients treated with aspirin in the setting of primary prevention, as well 
as in patients with stable coronary artery disease, and patients undergoing elective 
percutaneous coronary intervention (PCI), laboratory resistance to aspirin is associated 
with a higher incidence of adverse events. Nevertheless, the responsiveness to aspirin in 
acute myocardial infarction (AMI) and its implications have not yet been investigated.
Methods: The study comprised 76 aspirin naïve patients who underwent primary PCI 
(PPCI) for ST-elevation MI (STEMI). Platelet reactivity was assessed 30-60 mins after a 
loading dose of 300mg chewable aspirin, by conventional aggregometry and Impact R, 
where platelet reactivity to arachidonic acid (AA) was expressed by platelet deposition 
under ﬂow conditions.
Results: Patients were stratiﬁed using the median value of AA-induced platelet aggregation 
(PA) (49%) to good responders to aspirin (n=38), who had a median AA-induced PA of 
33% (25-41), and poor responders to aspirin (n=38), who had a median AA-induced 
PA of 77% (70-84). Similarly, good compared with poor responders had higher surface 
coverage by Impact R (3.9±2.6 vs. 2.2±1.3, p=0.003). Good versus poor responders 
were similar regarding baseline demographic, clinical and angiographic characteristics. 
However, good responders were more likely to demonstrate early ST-segment resolution 
q70% after PPCI (84% vs 54%, p <0.01), suggestive of better myocardial reperfusion. 
Good compared to poor responders had a lower incidence of adverse cardiovascular 
events (re-infarction, need for re-intervention, congestive heart failure and/or death) 
throughout a 6-month follow-up (11% vs 24%, respectively; p<0.11).
Conclusions: Ex vivo poor platelet responsiveness to aspirin loading in STEMI patients is 
associated with a worse prognosis in patients undergoing PPCI.
11:00 a.m.
1017-64 Early Abciximab Administration Before Primary 
Percutaneous Coronary Interventions Reduces 
Mortality but Not in Low-Risk Patients: Results From 
EUROTRANSFER Registry on ST-Elevation Myocardial 
Infarction Patients
Tomasz Rakowski, Artur Dziewierz, Zbigniew Siudak, Waldemar Mielecki, Jacek 
Legutko, Magnus Janzon, Ralf Birkemeyer, Rafal Depukat, Dariusz Dudek, Jagiellonian 
Unversity Medical College, Krakow, Poland
Background: Early abciximab administration before primary percutaneous coronary 
intervention (PPCI) for ST-elevation myocardial infarction (STEMI) is recommended in 
guidelines. However, the randomized trials provide conﬂicting results. Target population 
which beneﬁts from this strategy has to be deﬁned.




Methods: Consecutive 1,650 STEMI patients treated with PPCI were enrolled in 7 
European countries from Nov 2005 to Jan 2007 and were stratiﬁed into “not low-risk” 
(NLR n=1107; 67%) and “low-risk” (LR n=543; 33%) groups according to the Thrombolysis 
In Myocardial Infarction criteria. Abciximab was administered early (before admission to 
cath lab) in 44% of not low-risk and 44% of low-risk patients.
Results: Higher rate of infarct-related artery patency in baseline angiography (TIMI 
2+3- NLR: 30.2 vs 21.3% p<0.001; LR: 35.8% vs 26.1% p=0.01), as well as better ST-
segment resolution >50% after PPCI (NLR: 74.1 vs 63.2% p<0.001; LR: 88.8 vs 75.6% 
p=0.01) were found after early abciximab in both risk groups. Mortality reduction after 
early abciximab was found only in NLR group. In multivariate Cox regression NLR proﬁle 
and lack of early abciximab administration were independent predictors of 30-day death 
(Figure).
Conclusions: Early abciximab administration before transfer for PPCI in STEMI results 
in more frequent infarct-related artery patency before PPCI, better myocardial perfusion 
after PPCI regardless of patients’ risk proﬁle but mortality reduction is present only in not 
low-risk group. 
11:00 a.m.
1017-65 Remote Ischemic Preconditioning in Humans 
Attenuates Procedure-Related Cardiac Troponin-
I Release After Elective Percutaneous Coronary 
Intervention: A Single-Center Randomized Controlled 
Trial
Stephen Hoole, Patrick Heck, Sadia Khan, Linda Sharples, Cameron Densem, Sarah 
Clarke, Leonard Shapiro, Peter Schoﬁeld, Michael O’Sullivan, David Dutka, Papworth 
Hospital, Cambridge, United Kingdom, Addenbrooke’s Hospital, Cambridge, United 
Kingdom
Background: Endogenous “early” protection by remote ischemic preconditioning (remote 
IPC) attenuates myocardial ischemia-reperfusion injury in animals, but translation into 
clinical beneﬁt has been slow. We hypothesized that remote IPC may prevent procedure-
related cardiac troponin (cTnI) release during elective percutaneous coronary intervention 
(PCI).
Methods: We randomized 180 patients undergoing elective PCI to either remote IPC (n = 
92): three 5-minute blood pressure cuff inﬂations to 200mmHg around the upper arm with 
5-minutes of cuff deﬂation between, or control (n = 88): a deﬂated cuff throughout, before 
PCI. Patients taking nicorandil or glibenclamide were excluded. Baseline and 24-hour 
post-PCI serum cTnI levels, creatinine and CRP were measured and compared.
Results: Patient demographics were matched between groups (mean age: control: 62.5 
yrs, remote IPC: 63.8 yrs; diabetes: control: 15/88, remote IPC: 21/92). Interval between 
remote IPC and coronary balloon inﬂation was 68 ± 29 minutes. Baseline mean cTnI was 
below the lower limit of detection in both groups, but 24-hour mean cTnI was lower in the 
remote IPC group. This difference was signiﬁcant for the incidence of myocardial infarction 
and normal cTnI after PCI (Figure). There was no difference in 24-hour creatinine or CRP 
levels between the two groups.
Conclusion: Remote IPC attenuates procedure-related cTnI release after elective PCI, 
which may have prognostic signiﬁcance. It is feasible in normal clinical practice. 
11:00 a.m.
1017-66 Effect of Chronic Statin Therapy on Hospital Course in 
Patients With Acute Myocardial Infarction
Timm Bauer, Oliver Koeth, Claus Juenger, Tobias Heer, Anselm Gitt, Ralf Zahn, 
Jochen Senges, Michael Boehm, Uwe Zeymer, ACOS-registry group, Herzzentrum 
Ludwigshafen, Ludwigshafen, Germany, Uniklinikum Saarland, Homburg/Saar, Germany
Background: Chronic treatment with statins reduces the risk of adverse clinical outcomes 
in patients with coronary artery disease. It is less clear whether prior statin therapy 
beneﬁts patients who develop an acute myocardial infarction.
Methods: We analyzed data of consecutive patients with ST-elevation myocardial 
infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) who were 
prospectively enrolled in the German Acute Coronary Syndromes registry between July 
2000 and November 2002. Aim of the study was to investigate the impact of a prior statin 
therapy on hospital course in patients presenting with acute myocardial infarction (AMI) 
in clinical practice.
Results: Overall 14661 patients were included and we compared those who were on 
chronic statin treatment (n=2322, 15.8%) to those who were not (n=12339, 84.2%). 
Pretreated patients were older (68.2 versus 66.9 years, p<0.01), had a higher incidence 
of prior myocardial infarction (46.2 versus 15.2%, p<0.0001), percutaneous coronary 
intervention or coronary artery bypass grafting (41.5 versus 8.3%, p<0.0001) as well as 
diabetes mellitus (36.6 versus 26.7%, p<0.0001). Patients with prior statin use were less 
likely to suffer from prehospital resuscitation (2.2 versus 5.0%, p<0.05) and STEMI (46.3 
versus 58.6%, p<0.0001) and had more often NSTEMI (53.7 versus 41.4%, p<0.0001) 
and lower peak CK levels (364 versus 566U/l, p<0.0001). In the propensity score analysis 
a strong tendency towards a reduction of in-hospital death could be observed in statin 
users (OR 0.83, 95% CI 0.69-1.00). The beneﬁt was higher in elderly (NNT to prevent 
one death 44), diabetics (NNT 44) and in patients with known coronary artery disease 
(NNT 29).
Conclusions: In clinical practice chronic use of statins is associated with smaller 
myocardial infarction size and borderline signiﬁcant reduction of hospital mortality.
11:00 a.m.
1017-67 Transfer for Primary Percutaneous Coronary 
Intervention in Patients With ST Elevation Myocardial 
Infarction: Not All Delays Are Created Equal
Michael D. Miedema, Marc C. Newell, Scott W. Sharkey, Wes R. Pedersen, Katie M. 
Menssen, Sue Duval, David M. Larson, Timothy D. Henry, Minneapolis Heart Institute 
Foundation at Abbott Northwestern Hospital, Minneapolis, MN
Background: Primary percutaneous coronary intervention (PCI) is the preferred treatment 
for ST-elevation myocardial infarction (STEMI), if it can be performed in a timely manner. 
Prolonged treatment times are associated with increased mortality.
Methods: The Level 1 STEMI program is a standardized protocol designed for PCI in 
STEMI patients including transfer from 31 rural and community hospitals. We divided 
treatment times into 3 segments: in door-out door >45 min at community hospital (CH), 
transfer (Tr) >30 min, and door-to-balloon > 30 min at PCI center (PC) were considered 
delays and the speciﬁc reason for delay was documented prospectively.
Results: From 03/2003 to 11/2006, 1,014 patients were transferred for PCI. In-hospital 
(4.9% vs 2.8%, p-value 0.13) and 1 year mortality (8.2% vs 4.5%, p-value 0.04) was greater 
in patients with total door-to-balloon >90 minutes. The associations between in-hospital 
mortality and the speciﬁc reason for delay for each segment are shown in Table 1.
Conclusions: Mortality is higher in STEMI patients with prolonged treatment time but 
varies signiﬁcantly according to the reason for delay. Delays were most frequent at the 
CH where awaiting transfer, ED delay and non-diagnostic EKG were frequent but did 
not increase mortality. In contrast, delays due to cardiac arrest or cardiogenic shock 
signiﬁcantly increased mortality at both CH and PC. Delays during Tr did not increase 
mortality while PC delays had the highest mortality. All delays are not created equal. 
Community hospital Mortality Transfer Mortality PCI center Mortality
Total # of delays 
(n=663) 35 (5.3%)





























cardiac arrest (n=47) 12 (25.5%)
Unknown (n=31) 2 (6.5%)




















1017-68 Are Staged Interventions Really Necessary in Patients 
Presenting With Acute Myocardial Infarction and Multi-
Vessel Disease and Treated With Primary Percutaneous 
Coronary Intervention?
Tami L. Bair, Jeffrey L. Anderson, Heidi T. May, Benjamin D. Horne, Donald L. Lappé, 
Joseph B. Muhlestein, Intermountain Medical Center, Murray, UT
Background: The most recent (2005) ACC/AHA/SCAI guidelines for percutaneous 
coronary intervention (PCI) state that, when performing primary PCI for acute myocardial 
infarction (AMI) with multi-vessel disease, “Elective PCI should not be performed in a 
non-infarct-related artery at the time of primary PCI of the infarct-related artery in patients 
without hemodynamic compromise.” However, this guideline is based only on expert 
opinion and not on scientiﬁc evidence. With the advancement of PCI technology, multi-
vessel PCI might safely be performed during primary PCI, thus eliminating the need for 
staged interventions. However, evidence for this approach is also lacking.
Methods: We evaluated 227 consecutive AMI patients admitted to a single institution 
who were diagnosed with multi-vessel CAD at the time of primary PCI. Of these, 190 
underwent guidelines-directed staged PCI within 3 months and 37 underwent multi-
vessel PCI at the same time as primary PCI. Logistic regression was used to determine 
odds ratios (OR) corrected for baseline characteristics to determine differences in death 
and MI at 6-months and 1-year.
Results: Patients averaged 63.6±12.2 years, 73% were males, left ventricular ejection 
fraction was 52.3±12.2% and 41.5% of staged PCIs were performed during the same 
hospitalization. Both groups were similar in baseline characteristics. By 6-months, 5.3% of 
patients undergoing staged PCI and 17.9% undergoing non-staged PCI were deceased 
(multivariable OR=0.22, p=0.005) and 13.3% and 5.1% respectively had experienced non-
fatal AMI (multivariable OR=2.97, p=0.15). By 1-year, 6.6% of patients undergoing staged 
PCI and 17.9% undergoing non-staged PCI were deceased (multivariable OR=0.28, 
p=0.02) and 16.0% and 5.1% respectively had experienced a non-fatal AMI (multivariable 
OR=4.50, p=0.05). Conclusions: In this series of AMI patients with multi-vessel disease 
undergoing primary PCI, those receiving guidelines-directed staged PCI fared signiﬁcantly 
better at both 6-months and 1-year follow-up than those undergoing multi-vessel PCI 
at the same time as primary PCI. This study provides evidence supporting the existing 
guidelines regarding this issue.
11:00 a.m.
1017-69 Sequence Variations in CYP Metabolism Genes and 
Cardiovascular Outcomes following Treatment With 
Clopidogrel: Insights From the CLARITY-TIMI 28 
Genomic Study
Jessica L. Mega, Joseph V. Thakuria, Christopher P. Cannon, Marc S. Sabatine, Brigham 
& Women’s Hospital, Boston, MA
Background: Clopidogrel is a pro-drug that requires oxidation by cytochrome P450 (CYP) 
enzymes to generate an active metabolite. Gene sequence variations in the CYP pathway 
have been associated with variability in clopidogrel responsiveness, as measured by 
platelet aggregation. The clinical signiﬁcance of these observations is unknown.
Methods: CLARITY-TIMI 28 randomized STEMI patients undergoing ﬁbrinolysis to 
clopidogrel (300 mg loading dose, then 75 mg daily) or placebo. Patients were to undergo 
angiography at 48-192 h and were followed for 30 d for clinical events. Genotyping was 
performed using an Illumina GoldenGate Assay.
Results: 465 patients were genotyped for 5 commonly studied SNPs: CYP1A2*1F 
(rs762551), CYP2C9*3 (rs1057910), CYP3A4*1B (rs2740574), CYP3A5*3 (rs776746), 
and rs1277806, which tags CYP2C19*2 (r2=1.0). There were no signiﬁcant interactions 
between the evaluated genotypes and the effect of clopidogrel on either the primary 
efﬁcacy endpoint (occluded infarct-related artery, death, or recurrent MI) or the composite 
of cardiovascular death, MI, or urgent revascularization by 30 d (Fig). Likewise, there 
was no observed heterogeneity for the relationship between genotype, treatment, and 
bleeding (Pinteraction >0.50 for each).
Conclusions: Whereas genetic sequence variations have been associated with clopidogrel 
responsiveness in ex vivo platelet studies, in this cohort, we did not observe an impact of 
these SNPs in CYP genes on the clinical efﬁcacy of clopidogrel. 
11:00 a.m.
1017-70 Relation of Body Mass Index and Waist Circumference 
to Mortality After Acute Myocardial Infarction
Marianne Zeller, Philippe G. Steg, Laurent Mock, Jean-Claude Beer, Yves Laurent, 
Pierre Sicard, Luc Janin-Maniﬁcat, Anne-Cecile Lagrost, Hamid Makki, Luc Rochette, 
Yves Cottin, Cardiology department, CHU, Dijon, France
Background: From a large contemporary population-based cohort of patients with acute 
MI, we analysed the respective impact of waist circumference (WC) and body mass index 
(BMI) on mortality.
Methods: One-year mortality was evaluated in 2229 consecutive acute MI patients. Patients 
were classiﬁed into normal, overweight, obese and very obese (BMI<25, 25 to 29.9, 30 to 
34.5 and >35) and to Abdominal Obesity (AO), (WC >88 cm (women)/>102 cm (men)).
Results: Only 660 patients had a normal BMI, half were overweight (n=1044), and ¼ were 
obese or very obese (n=397 and n=128, respectively). Patients with overweight or obesity 
were younger than patients with a normal BMI (p<0.001). AO was present in half of the 
patients (n=1110) and associated with older age (71(58-79) vs 65(53-75) y). An increased 
BMI was associated with reduced mortality, with a 5% risk reduction for each increase in 
BMI unit (HR(95%CI): 0.95(0.93-0.98), p<0.001). Conversely, AO was associated with a 
30% increase in mortality. Diagonal stratiﬁcation of mortality identiﬁed patients with AO but 
normal BMI as high risk patients (Figure). When adjusted for baseline predictors of mortality 
(age, Nt-proBNP), neither BMI nor AO were independent predictors of mortality.
Conclusion: WC and BMI have opposite relations with mortality after acute MI, the 
former being associated with increased and the latter with reduced mortality. Moreover, 
our ﬁndings show that these relations are largely explained by differences in baseline 
predictors of mortality. 
11:00 a.m.
1017-71 Impact of the Absence of Signiﬁcant Changes on the 
Electrocardiogram Throughout the Hospital Phase in 
Patients With Non ST Segment Elevation Myocardial 
Infarction: Data From the RICO Survey
Jean-Claude Beer, Laurent Mock, Pierre Sicard, Michel Vincent-Martin, Isabelle 
L’huillier, Yves Laurent, Anne-Cecile Lagrost, Marianne Zeller, Yves Cottin, Cardiology 
department, CHU, Dijon, France
Background: The impact of ECG modiﬁcations during non ST segment elevation 
myocardial infarction (NSTEMI) deserves to be better speciﬁed. The goal of our study was 
to evaluate characteristics and outcomes of NSTEMI patients in the absence of signiﬁcant 
ECG changes during the course of MI.
Methods: Between the 1st of January 2001 and the 1st of September 2005, from the 
French regional RICO survey, all the consecutive NSTEMI patients who beneﬁted from 
coronary angiography <48h were included. Patients were categorized into 2 groups 
based on either the presence (ECG+) or absence (ECG-) of signiﬁcant changes on ECG 
recordings. ECGs were continuously monitored during the ﬁrst 48h after admission and 
then once a day until discharge. Signiﬁcant ECG changes were deﬁned by the presence 
of either ST depression >= 1 mm, or T wave inversion in 2 or more consecutive leads.
Results: Among the 829 patients included, 85 (10%) were ECG -. Patients from the ECG- 
group were younger (61(51-72) vs 69(56-76) y; p=0.002), more frequently men (85 vs 
70%, p=0.006), with a better LVEF (p=0.002), a lower troponin Ic peak, and lower levels 
of CRP and Nt-ProBNP on admission (p<0.001) than the ECG+ group. Angiographic data 
showed an increased proportion of patient with normal coronary arteries in the ECG - 
group (21 vs 9%; p=0.002) and more patients with single vessel disease than in the ECG 
+ group. Acute treatments were similar for the 2 groups, except for diuretics (p=0.004), 
which were more frequently used in the ECG+ group. Also, reperfusion therapy (PCI or 
CABG) was more frequently used in the ECG+ group. Mortality at one year was markedly 
reduced in the ECG- when compared to the ECG+ group (2 vs 11%, p=0.023). Multivariate 
analysis showed that the absence of signiﬁcant ECG changes remained associated with 
improved long-term survival, even after adjustment for potential co-variates.
Conclusions: Our observational study on a population with NSTEMI shows that the 
absence of modiﬁcations in ECG printouts throughout the hospital phase identiﬁes a 
subgroup of low risk patients at one year follow-up.





1017-72 Improving Door-to-Balloon Time in ST-Elevation 
Myocardial Infarction
Sun K. Scolieri, Joon S. Lee, Suresh Mulukutla, Vincent N. Mosesso, Donald M. Yealy, 
Charissa B. Pacella, Kathleen Zell, UPMC Presbyterian Hospital, Pittsburgh, PA
Background: Prompt percutaneous coronary intervention (PCI) guided reperfusion therapy 
in the management of ST-elevation myocardial infarction (STEMI) improves patient 
outcomes. Despite consensus guidelines recommending a door-to-balloon time (D2B) 
of a90 minutes, this is achieved less than 50% of the time. We sought to determine the 
effect of, a multidisciplinary collaborative effort involving emergency medicine, cardiology, 
pre-hospital, and nursing departments to improve D2B performance.
Methods: We analyzed non-transfer patients with STEMI presenting between July 2005 
and May 2007 at UPMC Presbyterian Hospital. Beginning in September 2006, a multi-
departmental effort including the following elements was implemented: 1) Commitment 
from leadership of involved departments to make improvement of D2B highest priority. 2) 
Empowerment of emergency physician to directly activate cardiac cath team 3) Single call 
activation system for in-house cardiology, cath lab staff, interventional fellow and attending. 
4) Deﬁned time expectations for triage to ECG time, decision to activate cath lab, transfer 
time. 5) Detailed real time feedback of each component of D2B to all caregivers involved 
within 1 day of patient encounter. The baseline group consisted of 63 consecutive STEMI 
patients between July 2005 and August 2006, and we compared these to 31 consecutive 
STEMI patients enrolled after protocol implementation. Performance data are described 
in mean +/- SD or frequencies, and analyzed using paired t tests and Fischer’s Exact 
test, alpha set at 0.05.
Results: Mean D2B decreased from 108.3±34.7 to 72.2± 23.6 minutes (p<0.00001) 
after the new protocol was implemented. D2B goal of a90 minutes improved from 28.6% 
of patients in the baseline group to 87.1% in the group after protocol implementation 
(p<0.00001).
Conclusions: Our protocol mirrors the AHA/ACC Guidelines Applied in Practice-Door 
to Balloon (GAP-D2B) launched in November 2006. At our institution, a constant feed 
back system and commitment from multiple disciplines must be established in order to 
maintain a well-orchestrated chain of activation in the face of STEMI.
11:00 a.m.
1017-73 Left Ventricular Remodeling and Heart Failure in Elderly 
Patients With Acute Myocardial Infarction Treated With 
Primary Angiopalsty
Nazario Carrabba, Guido Parodi, Renato Valenti, Gentian Memisha, Umberto Signorini, 
Angela Migliorini, David Antoniucci, Division of Cardiology, Florence, Italy
Background: The ability of primary percutaneous coronary intervention (PCI) to salvage 
ischemic myocardium and to prevent left ventricular (LV) remodeling in elderly patients 
(pts) with acute myocardial infarction (AMI) is questioned.
Aim: To assess the impact of aging on LV remodeling and subsequent heart failure (HF) 
after primary PCI.
Methods: For this purpose, 512 consecutive pts with AMI successfully treated with 
primary PCI underwent serial 2D echo at admission, at 1 and 6 months. LV volumes, 
ejection fraction (EF) and wall motion score index (WMSI) were measured. Pts were 
divided in two groups: younger pts (<70 years, n= 361), and elderly pts (q70 years, n= 
151). LV remodeling was deﬁned as an increase >20% in end-diastolic volume (EDV) from 
baseline to 6-months. HF was deﬁned as the presence of Killip class >I.
Results: Elderly pts showed a higher prevalence of female gender (36% vs 15%, p<.0001), 
multivessel disease (66% vs 52%, p=.003), and a longer time to reperfusion (247 ± 126 
min vs 202 ± 93 min, p<.0001) as compared to the younger pts, and they showed a lower 
peak creatine kinase (2475±1938 vs 2915±2303, p=.040). The 6-month prevalence of LV 
remodeling was higher in elderly pts as compared to younger pts (34% vs 25%, p=.041), 
and a lower recovery of EF and WMSI were found in elderly (from baseline to 6-month, 
p=.00002 for both by ANOVA analysis). The incidence of 6-month HF was 2-fold higher in 
elderly (17% vs 8%, p=.002) as compared to younger pts. By stepwise multivariate logistic 
regression analyses, the independent predictors of LV remodeling were: infarct size (OR 
1.43, 95% CI 1.31 to 1.54), baseline LV EDV (OR 0.79, 95% CI 0.72 to 0.85) and WMSI 
(OR 1.23, 95% CI 1.11 to 1.34). Whereas, the independent predictors of 6-month HF 
were: infarct size (OR 1.29 95% CI 1.18 to 1.41), age (OR 1.18, 95% CI 1.08 to 1.28), 
WMSI (OR 1.13, 95% CI 1.02 to 1.24), anterior location of MI (OR 1.11, 95% CI 1.01 to 
1.21), and diabetes (OR 1.09, 95% CI 1.00 to 1.18).
Conclusions: Our results suggest that after primary PCI aging is associated with an 
increased risk of HF, but not of LV remodeling. Factors other than LV remodeling may play 
a signiﬁcant role in the development of HF in elderly pts.
11:00 a.m.
1017-74 Modiﬁcation of Traditional ECG Evolution of Myocardial 
Infarction by Early Intervention: Analysis of the CZECH 
Registry of Acute Coronary Syndromes
Milka Klinceva, Petr Widimsky, Michal Zelizko, Petr Jansky, Frantisek Tousek, Michal 
Aschermann, Cardiocentrum Vinohrady, Prague, Czech Republic
Background: Early reperfusion therapy and especially primary percutaneous coronary 
intervention (PCI) changed the classical electrocardiographic scheme of the myocardial 
infarction (MI) evolution: ST elevation myocardial infarction (STEMI) can be turned into 
a nonQ wave MI (nonQMI) and conversely a non-ST elevation MI (nonSTEMI) may 
occasionally develop into Q wave MI (QMI) when reperfusion is not performed in time or 
is not successful. The aim of this study was to analyze these ECG changes in the real life 
setting in a country with very high use of very early PCI.
Methods: The data from the CZECH Registry of Acute Coronary Syndromes (ACS) 
were analyzed. A total of 722 patients were admitted for ACS that developed Q or 
nonQMI at discharge ECG. Patients were divided into 4 groups (STEMI - QMI, STEMI 
- nonQMI, nonSTEMI - QMI and nonSTEMI - nonQMI). The clinical and angiographic 
differences between Q and nonQMI admitted to the hospital for STEMI or NonSTEMI 
were examined.
Results: ST elevation developed into a nonQMI in 20% of the patients (93/456) and 
into a QMI in 80% of patients (363/456). Patients that developed a nonQMI comprised 
mostly females (p=0.02), patients who suffered from heart failure (p=0.01), and half of 
the patients had an ejection fraction more than 50% (p<0.001) and an uncomplicated 
outcome (p=0.01).
NonSTEMI developed into a QMI in 11% of the patients (29/266) and into a nonQMI in 
89% of patients (237/266).
The patients with QMI were mostly men (p=0.03), more persistent smokers (p<0.001), 
had less diabetes mellitus (p=0.02), received less aspirin before hospital admission 
(p=0.05), suffered more heart failure (p=0.03), had more complicated outcome (p=0.01) 
and underwent more often primary PCI (p=0.04).
There were no differences in the time from the onset of the symptoms to the coronary 
angiography and in-hospital mortality between the QMI patients and the nonQMI patients 
admitted as either STEMI or nonSTEMI.
Conclusions: Nationwide implementation of early interventional treatment of acute 
coronary syndromes leads to the abolishment of ECG ,,transmurality“ in 20% of STEMI. 
On the other hand, no use or late use of the intervention causes 11% of the nonSTEMI 
to evolve into STEMI patients.
11:00 a.m.
1017-75 Coordinated Inter-Hospital Transfer Program Improves 
Quality of Care Delivered to ST Elevation Myocardial 
Infarction Patients Presenting in Rural Communities
Frank V. Aguirre, Joji J. Varghese, Anushree Agarwal, Leah Turner, Lisa Page, Sheryl 
Friedrich, Jayne Thompson, Diane Tebrugge, Wilfred Lam, Michael Kelley, Frank Mikell, 
Prairie Cardiovascular Consultants. Ltd, Springﬁeld, IL, Southern Illinois University 
School of Medicine, Springﬁeld, IL
Background: Inter-hospital transfer of ST elevation myocardial infarction (STEMI) patients 
(pts) for primary percutaneous revascularization (PPCI) are increasingly being established 
in United States. The clinical utility and ﬁnancial impact of these programs have been 
questioned because of inherent delays leading to prolonged door-balloon times and 
increased resource utilization. In this study, we examined the impact of a coordinated 
inter-hospital transfer program on overall process of STEMI care and ﬁnancial outcomes.
Methods: In 2005, we established a STEMI inter-hospital PPCI program between 6 
STEMI-Referral hospitals and 2 STEMI-Accepting hospitals in Central Illinois. Between 
2005 and 2007, 188 STEMI-conﬁrmed pts have been treated (STAT Heart). Before 
initiation of this program (2003-2004), 389 STEMI-conﬁrmed pts were transferred for care 
(Pre STAT Heart).
Results:
Comparison of Variables before and after initiation of STAT Heart Program
STAT Heart 
(n= 188)
Pre STAT Heart 
(n=389) p-value
Primary PCI (%) 87 10 <0.0001
Thrombolytics (%) 8.5 62.7 0.001
No initial reperfusion strategy (%) 0 19.3 <0.0001
Door - Needle(median minutes) 28 (23, 35) 35 (22, 57) ns
Door - Balloon (median minutes) 117 (99, 137) 235 (199, 313) <0.0001
Bleeding Complications (%) 3.7 13.1 <0.0001
Death+ReMI+Stroke (%) 4.8 8.7 <0.0001
Length of Stay (mean±SD) 3.8±4 5.4±9 <0.0001
Total cost in $ (mean±SD) 19708.3±15108.4 26839.3±3638.3 <0.0001
Helicopter was used for inter-hospital transport in 68.1% STAT Heart patients vs 44.2% 
patients in pre STAT Heart (p=<0.0001).
Conclusions: As compared to Pre-STAT Heart, the establishment of this coordinated rural 
inter-hospital STEMI transfer program signiﬁcantly reduced door-balloon times, length of 
hospitalization and contributed to achievement of greater number of patients recieving 
reperfusion therapy with resultant improvement in in-hospital clinical outcomes . Despite, 
increased resource utilization (i.e. PPCI and helicopter transport), total hospital cost were 
signiﬁcantly reduced.
11:00 a.m.
1017-76 Bleeding and Ischemic Events Run Parallel in NSTEMI 
Patients
Karen P. Alexander, Richard G. Bach, Anita Y. Chen, Sumeet Subherwal, Brian F. Gage, 
Sunil V. Rao, W. Brian Gibler, Charles V. Pollack, Jr., E. Magnus Ohman, Matthew T. Roe, 
Eric D. Peterson, Duke Clinical Research Institute, Durham, NC, Washington University 
in St. Louis School of Medicine, St. Louis, MO
Background: Bleeding and ischemia are both important considerations when selecting 
among treatment options for NSTEMI patients (pts). The ability to distinguish between 
these risks at the pt level has not been explored.
Methods: The CRUSADE Bleeding Score combines 9 patient characteristics, lab values, 
and vital signs (HCT, CrCl, heart rate, systolic BP, weight, diabetes, peripheral vascular 
disease, signs of HF, female sex) by assigning a weighted value for each variable in a 



















nomogram predicting risk for in-hospital bleeding (score range 1-100). With the score, 
71,277 CRUSADE pts were stratiﬁed into tertiles of bleeding risk (low risk 1-16, moderate 
risk 17-32, high risk 33-88 points). Patient characteristics and in-hospital outcomes were 
assessed across tertiles.
Results: Major bleeding occurred in 3.3% of low-risk (n=23,693), 8.1% of moderate-
risk (n=22,780), and 16.9% of high-risk (n=23,259) groups. Mean age (57.4, 67.5, 76.1 
y), female sex (10.6, 44.0, 64.7%), comorbidity (diabetes: 13.6, 33.2, 51.8%; renal 
insufﬁciency: 1.3, 6.8, 32.5%), and disease acuity (heart rate: 75.8, 86.4, 97.2 bpm; 
signs of CHF: 2.1, 15.9, 51.1%) all increase respectively from low- to high-risk groups. 
In-hospital death or MI and CHF are shown (Figure, p<.0001).
Conclusions: Patients at high-risk for bleeding are also at high risk for ischemic events 
and CHF, largely due to their shared predictors. These outcomes, therefore, should not be 
viewed in isolation when selecting treatments for this population. 
11:00 a.m.
1017-77 Clinical Characteristics and In-Hospital Outcomes of 
Patients Undergoing Rescue Percutaneous Coronary 
Intervention Compared to Primary Percutaneous 
Intervention
Sukesh C. Burjonroppa, Paul D. Varosy, Matthew Roe, Eric Peterson, Fang-Shu Ou, 
Sunil V. Rao, Mandeep Singh, Kendrick A. Shunk, For the National Cardiovascular 
Data Registry, University of California San Francisco, San Francisco, CA, Duke Clinical 
Research Institute, Durham, NC
Background: Fibrinolytic therapy is the most widely used reperfusion strategy in patients 
with STEMI. The clinical characteristics and in-hospital outcomes of patients that require 
percutaneous coronary intervention (PCI) for ongoing or recurrent myocardial ischemia 
(rescue angioplasty) are largely limited to small studies. In-hospital outcomes data for 
these “real life” rescue PCI patients are clinically useful.
Methods: The study population consisted of all patients undergoing primary or rescue PCI 
in 484 hospitals contributing to NCDR from 1/1/04-3/31/06. Clinical characteristics and in-
hospital outcomes of patients undergoing rescue PCI were assessed and compared with 
patients undergoing primary PCI.
Results:  Of a total 309,351 PCI procedures, 2829 STEMI patients underwent rescue PCI 
and 30,690 patients underwent primary PCI. Of the rescue PCI cohort 89.8% of patients 
received aspirin, 57.4% received a Gp IIb/IIIa inhibitor and 64.7% received a thienopyridine. 
Clinical characteristics and in-hospital outcomes are shown in Tables 1 and 2.
Conclusion: When compared to the primary PCI cohort, rescue PCI patients were at 
higher risk of heart failure, stroke and death. The risk of bleeding did not differ despite 
more than half the rescue patients receiving potent anti-platelet regimens in the setting 
of ﬁbrinolytic therapy. 
Table1. Clinical characteristics
Primary PCI (n=30690) Rescue PCI (n=2829) p Value
Age 61±13 59±12 <0.0001
Male 21620(70) 2102(74) <0.0001
Caucasian 26469(86) 2496(88) <0.0001
BMI 28.7±6 29.1±6 0.03
Diabetes 6452(21) 568(20) 0.03
Cerebrovascular disease 2096(6.8) 146(5.2) 0.005
Peripheral Vascular disease 2011(6.6) 144(5.1) 0.02
Smoking 20423(66.5) 1982(70) <0.0001
Prior PCI 5254(17) 425(15) 0.005
IABP 3331(11) 372(13) <0.0001
LVEF 46.1±12.7 45.2±12.4 0.04
Table 2. In-hospital outcomes
Mortality 1570(5.35) 170(6.2) 0.006
Cardiogenic shock 993(3.3) 124(4.5) 0.14
Congestive heart failure 941(3.1) 138(5.0) 0.0001
Stroke 167(0.6) 54(2.0) 0.0001
Tamponade 108(0.4) 35(1.3) 0.47
Post procedure TIMI 3 ﬂow 28450(92.7) 2583(91.3) 0.004
No reﬂow phenomenon 943(3.1) 156(5.5) <0.0001
Acute closure 317(1) 47(1.7) 0.008
Bleeding 1586(5.2) 158(5.7) 0.97
Age, BMI, and LVEF are presented as mean ± STD. 
The remainder are presented as frequency (percentage)
11:00 a.m.
1017-78 Modulating Effects of Intravenous Recombinant 
Human Brain Natriuretic Peptide on Activation 
of Neuroendocrine Systems in Acute Myocardial 
Infarction Patients With Cardiac Dysfunction
Xianghua Fu, Shiqiang Li, Weize Fan, Xinna Fan, Xinshun Gu, Yunfa Jiang, Ling Xue, 
Ling Xue, Guozhen Hao, 2nd Hospital of Hebei Medical University, Shijiazhuang, 
People’s Republic of China
Background: To compare the modulating effects of intravenous injection of recombinant 
human brain natriuretic peptide (rhBNP) versus nitroglycerin (NIT) on neurohormonal 
activation in the early stage of patients of acute myocardial infarction with cardiac 
dysfunction (AMI-CDF) through a prospective study.
Methods: Forty-two anterior wall AMI-CDF patients within 12 to 24 hours from the onset 
were randomized into rhBNP group(n=21, 1.5µg ·kg-1 bolus, 0.0075µg·kg-1·min-1 for the 
ﬁrst 3 hrs and 0.015-0.03µg·kg-1·min-1 infusion for following 21 hrs)and NIT group(n=21, 
10 to 100µg ·min-1 infusion for 24 hours, Blood samples were taken at baseline, 6h, 24h 
after administration and 6h postinfusion to measure epinephrine(E), norepinephrine (NE), 
rennin(R), angiotensin II (AII) and aldosterone(Ald)
Results: The plasma concentration levels of E, NE, R, AII, and Ald, which were no 
signiﬁcant differences at baseline between the two groups, were signiﬁcant reduced 
6h after the administration of rhBNP (240.28±77.05 vs 1191.46±360.07 pg·ml-1, 
8.82±4.78vs14.20±6.42ng ·ml-1, 4.82±1.88 vs 7.69±2.75 ng·ml-1·h-1, 39.82±23.75 vs. 
84.60±32.72pg·ml-1, 128.84±71.25 vs. 189.21±120.80pg·ml-1, all P<0.01), and these 
changes continued during the whole 24 hours of infusion, while in NIT group, they were 
only slightly decreased at 6h of NIT infusion, then became signiﬁcant reduction at 24h 
of NIT infusion, but still obviously higher than those in rhBNP group (E: 685.08±176.29 
vs. 216.85 ±62.47pg ·ml-1, NE: 10.64±4.70 vs. 9.28±4.35ng·ml-1, R: 5.26±2.19 vs. 
4.08±1.26ng·ml-1·h-1, AII: 62.82±27.45 vs. 36.47±15.62pg·ml-1, Ald: 120.35±84.29 vs. 
88.76±56.70pg·ml-1, P<0.05). 6h postinfusion, levels of above neurohormone were still 
lower than those at baseline in rhBNP group, which except that of NE were still lower 
than those in NIT group (E: 286.01±67.72 vs. 643.51±162.44pg ·ml-1, R: 4.20±2.01 vs. 
5.87±2.40ng ·ml-1·h-1, AII: 56.13±21.82 vs. 78.30 ±29.75pg ·ml-1, Ald: 107.28±49.48 vs. 
145.50 ± 77.01 pg ·ml-1, P<0.05).
Conclusion: Intravenous injection of rhBNP results in more rapid, stronger and longer 
antagonistic action against plasma levels of E, NE, R, AII and Ald than NIT does in AMI-
CDF patients.
11:00 a.m.
1017-79 Role of Embolic Protection Devices in Acute Myocardial 
Infarction. Is Their Routine Use of Clinical Beneﬁt at Six 
Months?
Hector Salazar, Xavier Freixa, Neus Bellera, Ricardo Kiamco, Carlos Fernández, 
Amadeo Betriu, Mònica Masotti, Thorax Institute - Hospital Clinic, Barcelona, Spain
Background: Thromboembolic debris liberated during primary angioplasty (PCI) might 
worsen clinical outcomes. Individual randomized control trials (RCT’s) on the use of 
thrombectomy or distal protection and aspiration devices in STEMI have documented 
improvement in ST-segment resolution or myocardial perfusion. Although no clinical beneﬁt 
has consistently been demonstrated at 1 month, longer follow-up data are lacking.
Objective: To combine data from all RTC’s using these devices in the setting of STEMI. 
The primary end-point of this investigation was to asses the potential impact on death, 
reinfarction (reMI), or both at 6 months.
Methods: Data from seven RCT’s (X AMINE ST, De Luca, DEAR-MI, ASPARAGUS, 
DIPLOMAT, EMERALD, PREMIAR) were analyzed. The study population included 1456 
patients; of them, 733 were randomized to active treatment whilst the remaining 723 
were controls.
Results: Clinical outcomes were as follows:
Conclusion: Embolic protection devices in STEMI patients undergoing PCI does not 
decrease the risk of death or reinfarction at 6 months. Therefore, routine use of this 
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1017-80 Arterial Access and Door-to-Balloon Times for Primary 
Percutaneous Coronary Intervention in Patients 
Presenting with Acute ST-Elevation Myocardial 
Infarction
Rick A. Henderson, Ian Gilchrist, Steven M. Ettinger, Penn State College of Medicine, 
Hershey, PA
Background: The radial approach for cardiac catheterization and PCI (r-PCI) is an 
alternative to the femoral artery approach (f-PCI). Survival following STEMI is directly 
related to reperfusion times (door-to-balloon; D2B). For patients undergoing primary PCI 
for acute STEMI, potential beneﬁts of r-PCI as compared to f-PCI in reducing D2B times 
have not been fully studied.
Methods: Consecutive patients presenting with an STEMI at the M.S. Hershey Medical Center 
were enrolled in the Penn State Heart & Vascular Institute - Heart Alert program (HA) and 
were included in this analysis. Speciﬁc time parameters measured included: door-to-ECG, 
ECG-to-HA activation, HA activation-to-cath lab team arrival, patient arrival to cath lab-to- 
arterial access, and arterial access-to-balloon inﬂation. Groups were stratiﬁed according to 
the arterial access approach (r-PCI vs. f-PCI). Times are reported as medians.
Results: Of 131 total patients, 107 underwent successful PCI (n=47 r-PCI; n=60 f-PCI). 4 
patients underwent emergent surgery, 16 patients had non-obstructive disease, 3 patients 
were medically managed, and 1 patient could not be treated (failure to cross lesion with 
guidewire). No signiﬁcant difference was observed in the pre-cath lab times (door-to-
ECG, ECG-to-HA activation, HA activation-to-cath lab team arrival). Case start times for 
r-PCI took signiﬁcantly longer (11min vs. 10min; p=0.005) due to patient preparation. 
Once arterial access was obtained, balloon inﬂation occurred faster in the r-PCI group 
(17min vs. 24min; p=0.004). Total time from patient arrival to the cardiac cath lab to PCI 
was reduced in the r-PCI group (31min) as compared to the f-PCI group (34min) but did 
not reach statistical signiﬁcance (p=0.10). There was no difference in D2B time (r-PCI 
83min vs. f-PCI 84min). Less diagnostic catheters were required in the r-PCI group (1.8) 
compared to the f-PCI group (2.2); (p=<0.001). Fluoroscopy times were similar (r-PCI 
12.3min vs. 14.3min) as was contrast used (r-PCI 168cc vs. f-PCI 189cc).
Conclusion: Patients presenting with STEMI can undergo successful PCI via a radial artery 
approach without compromise in D2B times as compared to a femoral artery approach.
11:00 a.m.
1017-83 Long-term Outcome of Primary Angioplasty Compared 
with Fibrinolysis across Age groups: A DANAMI-2 
substudy
Emil L. Fosbol, Jens J. Thune, Henning Kelbaek, Henning R. Andersen, Kari Saunamäki, 
Torsten T. Nielsen, Leif S. Mortensen, Lars Kober, The Heart Centre, University Hospital 
of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Background: Primary angioplasty in patients with acute ST-elevation myocardial infarction 
has been shown to be superior to ﬁbrinolysis. Whether elderly patients have the same 
long-term beneﬁt from angioplasty compared to ﬁbrinolysis as younger patients is 
unknown.
Methods: The effect of angioplasty versus ﬁbrinolysis was investigated in 1572 patients 
from the Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute 
Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) study across age-
groups. Endpoints were total mortality and a composite endpoint of death, reinfarction, or 
disabling stroke. Follow-up was three years.
Results: Increasing age was associated with mortality (adjusted hazard ratio [HR]= 2.51 
per 10 year increment, 95% conﬁdence interval [CI] 1.83-3.45, p<0.0001) and composite 
event rate (adjusted HR=1.47, CI:1.23-1.75, p<0.0001). The long-term superiority of 
angioplasty over ﬁbrinolysis on the combined outcome was independent of age: HR=0.73 
(CI:0.41-1.31), HR=0.83 (CI:0.52-1.33), HR=0.71 (CI:0.48-1.04) and HR=0.83 (CI:0.59-
1.17) for patients <56, 56-65, 66-75 and >75 years, respectively (p=0.006 for overall 
treatment effect and p=0.5 for interaction between age and treatment). There was no 
long-term effect of angioplasty versus ﬁbrinolysis on mortality and no interaction with age 
(p=0.5 and p for interaction=0.6).
Conclusions: The effect of primary angioplasty compared to ﬁbrinolysis in patients with 
ST-elevation myocardial infarction is not affected by age.
11:00 a.m.
1017-84 The Relative Contribution of Clinical Factors, Treatments, 
Bleeding, and CV Complications to Mortality in 20,323 
Patients Receiving Fibrinolysis for STEMI
Robert P. Giugliano, Roberto R. Giraldez, David A. Morrow, Elliott M. Antman, C. Michael 
Gibson, Satishkumar Mohanavelu, Sabina A. Murphy, Carolyn H. McCabe, Eugene 
Braunwald, Brigham and Women’s Hospital, Boston, MA
Background: In ExTRACT-TIMI 25, enoxaparin death/MI (9.9 vs 12.0%, P<0.001), k
major bleeds (2.1 vs 1.4%, P<0.001) but not ICH (0.83 vs 0.65%, P=0.14), improving net 
clinical beneﬁt (death/MI/ICH: 10.1 vs 12.2%, P<0.001) c/w UFH in STEMI pts receiving 
lytic. We explored how pt and clinical factors contributed to mortality.
Methods: We used Cox models to predict death (30d, 1yr) in 20,323 ExTRACT-TIMI 
25 pts who rec’d lytic and antithrombin, using 5 covariate groups: pt characteristics, 
antithrombotic Rx, revasc, major bleed (ICH, non-ICH bleed with hgb >5 g/dL), CV events. 
We used the Likelihood Ratios (LR) of covariates to estimate their model contribution.
Results: ICH (HR 12.4, LR=295) and non-ICH major bleeds (HR 2.2, LR=14) were 
associated with 30d death in the unadjusted model (both P<0.001). In the adjusted 
model, ICH (HR 9.2, P<0.0001) but not non-ICH major bleeds (HR 1.03, P=0.91) were 
associated with 30d death (Table). Cardiogenic shock (c-shock) strongly inﬂuenced the 
relationship between non-ICH bleeds and death (adj HRs: c-shock/no bleed 19.2, c-
shock then bleed 14.6, bleed then c-shock 4.7 [all P<0.001]). 1-year mortality models 
were qualitatively similar.
Conclusion: Cardiogenic shock, age, ICH, heart rate, and no revascularization 
predischarge are the strongest independent correlates of death in STEMI pts receiving 
lytic. Non-ICH major bleeding is not associated with death after controlling for pt and 
clinical factors, particularly antecedent c-shock, in lytic-treated STEMI pts.
Key Variables from the Cox Model Predicting Death Through 30 Days
Covariate HR (95% CI) LR Mortality Contribution
Cardiogenic Shock 14.6 (12.6, 17.0) 1691 68%
Age (per decadek) 1.5 (1.4, 1.6) 362 15%
ICH 9.2 (7.0, 12.1) 135 5.4%
HR (per 10BPMk) 1.13 (1.09, 1.17) 81 3.3%
No Revasc predischarge 2.1 (1.7, 2.7) 61 2.5%
Severe CHF 2.0 (1.5, 2.6) 29 1.2%
Enoxaparin 0.88 (0.77, 0.99) 3.8 0.2%
Non-ICH major bleed 1.03 (0.65, 1.62) 1.3 0.05%
P<0.0001 for each except enox (P=0.039), non-ICH major bleed (P=0.91). 7 other 
independent covariates had small (<1%) contributions.
11:00 a.m.
1017-85 The Impact of Gender on the Outcomes of Invasive 
versus Conservative Treatment of Patients with Acute 
Coronary Syndrome
Li Ching LEE, Poh Leng, Tiffany Tang, Yee Leng Tan, Han Wen Tee, Luming Shi, Kian 
Keong Poh, Huay Cheem Tan, Cardiac Department, National University Hospital, 
Singapore, Singapore
Background: Recent data has suggested that women who presented with non ST-
elevation myocardial infarction (NSTEMI) did not beneﬁt from early invasive strategy. 
We examined the impact of gender difference in patients with NSTEMI with respect to 
outcomes following invasive versus conservative treatment.
Methods: Patients enrolled in our national MI registry between January 2000 and September 
2005 with diagnosis of NSTEMI was retrospectively analyzed. The study end points were 
mortality rates during hospitalization and at 1 year; and reinfarction at 1 year.
Results: A total of 1472 patients (63.5% female) with NSTEMI were studied. The mean 
age of men was 62.2±13.6 years old versus 71.5±11.8 years in women. The prevalence of 
hypertension, hyperlipidaemia, and diabetes mellitus were signiﬁcantly higher in women. 
Men were more likely to undergo percutaneous coronary intervention (PCI) than women 
(OR 2.65, 95% CI 1.99-3.54, p <0.001). Among those who underwent PCI, there was 
no gender difference in survival and reinfarction rates during hospitalisation and at 1 
year. However, there were more in-hospital cardiovascular complications of heart failure, 
arrhythmias, periprocedural MI in women who underwent PCI (OR =1.82, 95% CI 1.01-
3.13, p=0.03). In the medically treated group, the difference was even greater (OR =1.86, 
95% CI 1.38-2.45, p<0.001). Compared with medical therapy, PCI was associated with 
a signiﬁcant reduction in 1-year mortality or reinfarction in women (HR 15.7, 95% CI 3.8 
to 65.1) and men (HR 8.6, 95% CI 4.7 to 15.9). The most important predictor of adverse 
events for females was diabetes (HR = 0.41; 95% CI= 0.25-0.66).
Conclusions: There is a gender-based difference in the rate of PCI among patients with 
NSTEMI. Women beneﬁt from an invasive approach but have higher rate of attendant 
cardiovascular complications. Mortality associated with reperfusion treatment is 
independent of gender.
11:00 a.m.
1017-86 Pre-hospital Electrocardiograms: Potential Answer to 
the Time to Reperfusion Challenge
Deborah B. Diercks, Joseph Lynch, Michael C. Kontos, John S. Rumsfeld, Anita Y. 
Chen, W. Brian Gibler, Christopher P. Cannon, Steven D. Wiviott, Charles V. Pollack, 
Jr., David J. Magid, Matthew T. Roe, University of California Davis School of Medicine, 
Sacramento, CA, Duke Clinical Research Institute, Durham, NC
Background: Current ACC/AHA guidelines and the nationwide Door to Balloon (D2B) 
Initiative advocate pre-hospital electrocardiograms (ECGs) to accelerate the identiﬁcation 
of patients with ST-segment elevation myocardial infarction (STEMI) by Emergency 
Medical Services (EMS). However, the current use of pre-hospital ECGs for the triage of 
STEMI patients has not been evaluated.
Methods: We evaluated nontransfer-in patients with STEMI who received reperfusion 
therapy (n = 4138) included in the NCDR ACTION registry from 202 U.S. hospitals 
between January 1, 2007, and June 30, 2007, to determine the use of pre-hospital ECGs 
(any ECG done prior to arrival in the emergency department [ED]) and the association 
of pre-hospital ECGs with reperfusion times. Continuous data are presented as median 
(25th, 75th percentile) times.
Results: Among the analysis population, 2417 patients (58.4%) were transported to 
the ED by EMS, of whom 728 patients (17.6%) received a pre-hospital ECG. Primary 
percutaneous coronary intervention (PCI) was performed in 3906 patients (94.4%) while 
the remainder received ﬁbrinolytic therapy. Median door-to-needle time was signiﬁcantly 
shorter among patients with a pre-hospital ECG (18 min [10, 30] vs. 28 min [20, 47], 
p=0.03). In patients receiving primary PCI, use of a pre-hospital ECG resulted in 
signiﬁcantly shorter median D2B times (63 min [49, 83] vs. 81 min [64, 106], p<0.0001). 



















Among subjects presenting by EMS, median ﬁrst medical contact to balloon time was 
shorter, with a pre-hospital ECG (89 min [70, 112] vs. 102 min [79, 128], p <0.0001). 
There was no difference in in-hospital death among groups.
Conclusion: Fewer than one ﬁfth of STEMI patients are being evaluated with a pre-hospital 
ECG in contemporary U.S. practice even though more than half of STEMI patients receiving 
reperfusion therapy are transported to the ED via EMS. Moreover, when a pre-hospital ECG 
is used, time to reperfusion is more rapid. Equipping all EMS ambulances with pre-hospital 
ECG capabilities should markedly shorten the average times to reperfusion.
11:00 a.m.
1017-87 A novel cardioprotective medication after an acute 
ST-elevated myocardial infarction decreases 
proinﬂammatory response and stimulates vascular 
endothelial growth factor release
Sergey Kozhukhov, Alexander Parkhomenko, National Scientiﬁc Center “Institute of 
Cardiology”, Kiev, Ukraine
Background: Myocardial damage is associated with an inﬂammatory response and leads 
to complement activation and free radical generation, triggering a cytokine cascade and 
chemokine upregulation. Prognosis after AMI has been linked to the infarct size and 
detection of left ventricular enlargement. In order to evaluate efﬁcacy of the i.v. form of 
bioﬂavonoid Quercetin 91pts with successful reperfusion (PCI or TLT) within the ﬁrst 6 h of 
AMI were randomized into two groups identical as regard baseline clinical, hemodynamic 
characteristics and concomitant medication.
Methods: Dynamic 2-D echocardiography, infarct size measurement by serial serum CK-
MB assessment were used during the ﬁrst 10 days of AMI. Leukotrien C4 was measured 
at the admission and on day 3, CRP, von Willebrand factor and VEGF were measured at 
the admission and on day 10 and differences (in %) were calculated.
Results are presented in the table (M±m). [* - <0,05 compared with the 1st day value; 
ESVI, EF - changes in end-systolic, end-diastolic volume indexes and ejection fraction; 
CK-MB time of peak - time from AMI onset to peak value of CK-MB isoenzyme; N time 
- normalization time of CK-MB; ISI - infarct size index].
Conclusions: These ﬁndings suggest that intravenous form of lipoxygenase inhibitor Q in 
AMI pts with successful reperfusion reduces ﬁnal infarct size and improves heart function. 
Obtained cardioprotective effect of Q was accompanied by decreases proinﬂammatory 
activation and induces VEGF expression.
Quercetin gr. (n=54) Control gr. (n=37) P
$ESVI (%) - 10.1* - 4.5
$EF (%) + 13,3* + 8.4
CK-MB time of peak (h) 8.9±0.3 9.0±0.3
N time (h) 32.2±1.3 37.1±1.4 P<0.05
ISI (g/equivalent) 45.3±2.1 52.2±2.1 P<0.05
CRP (%) - 67.4* - 42.1
LTC4 (%) - 30.2* - 3.9
vWF (%) - 38.8* - 16.0
VEGF (%) + 266.9* + 83.3
11:00 a.m.
1017-88 Dose-effect of clopidogrel reloading in patients on 
75mg maintenance dose (The RELOAD study)
Antoine Landivier, jean-philippe collet, Johanne Silvain, Guillaume Cayla, Marie-Laure 
Tanguy, Farzin Beygui, Olivier Barthelemy, Raphaelle Dumaine, Nicolas Vignolles, 
Delphine Brugier, Sophie Gallier, Gilles Montalescot, IHopital Pitie-Salpetriere Institut de 
Cardiologie, Paris, France
Background The most appropriate loading strategy with clopidogrel in patients on 
a maintenance dose of 75mg of clopidogrel scheduled for coronary angiography and 
eventually ad-hoc percutaneous coronary intervention remains unknown.
Aim: To evaluate 3 different strategies of administration of a loading dose of 900 mg of 
clopidogrel in patients already on chronic clopidogrel therapy.
Methods: Patients on chronic maintenance dose of 75 mg/day and aspirin 75 mg/day were 
assigned to receive either 300 mg, 600mg or 900mg of clopidogrel as initial reloading dose. 
Four hours later, a second loading dose was administered (600, 300 or nothing respectively) 
to achieve a ﬁnal loading dose of 900mg in all patients. Platelet aggregation(PA) was 
evaluated at baseline, 4 hours after the initial load (and before second load) and at 24 hours 
using light transmission aggregometry with 20µMol ADP. The primary objective of the study 
was to evaluate the % of inhibition of late PA (ILPA) in the three groups at H4. ILPA was 
calculated as LPA at H0-LPA at H4/LPA at H0. ILPA at 24 hours was also evaluated as well 
as the rate of suboptimal response at 4 hours deﬁned as ILPA<10%.
Results: We included 166 consecutive patients with either ACS (45%), stable angina (42%) 
or scheduled catheterization/PCI (11%). Baseline characteristics were similar in the three 
dose groups. There was a signiﬁcant stepwise increase in ILPA assessed at 4 hours in 
patients assigned to an initial load of 300mg vs 600 mg vs 900mg (30.7% vs 40.3% vs 
64.0%, respectively, p=0.0024). Differences in ILPA at 4 hours were signiﬁcant between 
600mg and 900mg, and between 300mg and 900mg. ILPA at 24 hours after all patients 
received 900mg did not differ between the three loading regimens. The rates of suboptimal 
response (ILPA<10% at H4) were 23.6% vs 20.4% vs 5.3%, in patients who received 300, 
600 and 900 mg, respectively (p=0.01 for all). The rate of slow responders (variation of 
maximum aggregation<10%) was 63.6% vs 53.7% vs 38.6%, respectively (p<0.028).
Conclusion: Reloading with 900mg of clopidogrel patients on a maintenance dose of 
75mg of clopidogrel is more effective than 600mg or 300mg to inhibit ADP induced PA, 
prevent slow response and/or poor response to clopidogrel.
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806-4 One Year Follow Up Results of the FINESSE Trial of 
Facilitated PCI
Stephen G. Ellis, Michael Tendera, Mark A. De Belder, Ad J. van Boven, Petr Widimsky, 
Luc Janssens, H.R. Andersen, Amadeo Betriu, Stefano Savonitto, Jerzy Adamus, Jan 
Z. Peruga, Maciej Kosmider, Olivier Katz, Thomas Neunteuﬂ, Julia Jorgova, Maria 
Dorobantu, Liliana Grinfeld, Paul Armstrong, Bruce Brodie, Howard C. Herrmann, Gillies 
Montalescot, Franz-Josef Neumann, Mark B. Effron, Elliot S. Barnathan, Eric J. Topol, 
Cleveland Clinic Foundation, Cleveland, OH
Background: The hypothesis that early facilitation with a combination of half dose 
reteplase + abciximab prior to primary PCI (combination-facilitated PCI) would be superior 
to PCI with abciximab in the cath lab (primary PCI) for patients with ST elevation MI <6 
hours duration, with expected delays to the cath lab of 1-4 hours was evaluated in the 
FINESSE trial. A second active treatment group received abciximab alone immediately 
after randomization (abciximab-facilitated PCI).
Methods: 2452 patients from 20 countries (age = 62+/-11 years, 26% female, 48% 
anterior MI, median door to balloon time = 2.2 [interquartile range, 1.8-2.8]) hours were 
randomized in a 1:1:1 fashion. The primary endpoint was evaluated at 90 days with 
mortality follow up through 1 year. All cause mortality at one year was a pre-speciﬁed 
secondary endpoint.
Results: The composite primary outcome of all cause mortality, cardiogenic shock, heart 
failure, or ventricular ﬁbrillation > 48 hours after MI was seen in 9.8% of the combination-
facilitated, 10.5% of the abciximab-facilitated and 10.7% of the primary PCI groups, 
respectively (p=NS). ST segment resolution at 60-90 minutes, pre-PCI TIMI ﬂow and 
infarct size by CK curve analysis, however, were improved with combination therapy 
compared with primary PCI (all p<0.01), whereas indices of bleeding worsened. After 
discharge, 88%, 85% and 77% of patients were treated with statins, beta-blockers and 
ace inhibitors/angiotensin receptor blocker agents, respectively.
Conclusion: Whether or not measures of improved early ﬂow and reduction of infarct size 
might favorably impact long-term survival will be ascertained with this analysis. All one-
year follow-up visits are expected to be complete by the end of 2007. Final data will be 
available for presentation at the ACC meeting.
1:15 p.m.
806-5 A Randomized, Double-Blind, Placebo-Controlled, Multi-
Center Investigation of MC-1 to Eliminate Necrosis 
and Damage in Coronary Artery Bypass Graft Surgery: 
Primary Endpoint Results of The MEND-CABG 2 Trial
John H. Alexander, Michel Carrier, Robert W. Emery, Jr., Stephen J. Ellis, Ahmad Khalil, 
Robert A. Harrington, Jean-Claude Tardif, for the MEND-CABG 2 Investigators, Duke 
University Medical Center, Durham, NC, Montreal Heart Institute, Montreal, QC, Canada
Background: Coronary artery bypass graft (CABG) surgery is effective in relieving 
angina and improving survival in patients with obstructive coronary disease. However, 
myocardial infarction, stroke, and death can occur postoperatively. MC-1 (Cardoxal; 
Medicure, Inc.) is a novel agent that has shown promise in reducing myocardial injury 
following percutaneous coronary intervention and in a post-hoc study of high-risk patients 
undergoing CABG.
Methods: MEND-CABG 2 is a phase 3, multi-center clinical trial evaluating the efﬁcacy 
and safety of MC-1 in high-risk patients undergoing CABG on cardiopulmonary bypass. 
Patients were randomized to receive either MC-1 (250 mg/day) or matching placebo 
immediately before and for 30 days following surgery. The primary endpoint is the 
occurrence of cardiovascular death or nonfatal myocardial infarction (CK-MB q 100 ng/
ml) through postoperative day 30.
Results: A total of 3023 patients were enrolled from 130 Canadian, United States, and 
German sites between October 29, 2006 and September 19, 2007. Interim aggregate 
baseline characteristics of enrolled patients (n=1840) (Table) reﬂect the enrollment of a 
high-risk CABG population. Complete 30-day efﬁcacy and safety results will be available 
for the ACC Meetings.
Conclusions: The results of the MEND-CABG 2 trial will establish whether perioperative 
treatment with MC-1 can reduce myocardial necrosis and improve clinical outcomes in 
high-risk patients undergoing CABG. 
Baseline Characteristics
Age (yrs), median (IQR) 66 (58,73)















Prior Heart Failure 20%
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806-6 SR123781A, a Synthetic Antithrombin-Dependent 
Thrombin and Factor Xa Inhibitor, in Patients with 
Non-ST-segment Elevation Acute Coronary Syndromes 
(NSTEACS): Results of an Active-Controlled, Dose-
Ranging Study
A. Michael Lincoff, Paulo Caramori, Paul W. Armstrong, Fernando A. Cura, Judith S. 
Hochman, Neal S. Kleiman, Frans Van de Werf, Luis O. Carreras, Dianna L. Bash, John 
M. Galla, Eric J. Topol, Cleveland Clinic, Cleveland, OH
Background: SR123781A, a synthetic hexadecasaccharide, is a potent antithrombin-
dependent inhibitor of factors IIa and Xa with strong antithrombotic activity in animal 
models.
Methods: A randomized double-blind, dose-ranging trial was conducted in patients 
presenting with NSTEACS for whom catheterization and percutaneous coronary 
intervention (PCI) within 48 hrs was planned. Patients were randomized to receive a 
ﬁxed daily dose of subcutaneous SR123781A (0.25, 0.5, 1, 2 or 4 mg) for 5 days or to 
hospital discharge or intravenous (IV) UFH. An additional IV dose of SR123781A was 
administered immediately before PCI. Abciximab was used during PCI in the UFH arm. 
The primary outcome was a composite of all-cause mortality, myocardial infarction or 
urgent repeat target vessel revascularization within 7 days. Bleeding and procedural 
outcomes were analyzed.
Results: A total of 1,243 patients were treated (ITT population). Due to excess catheter-
related thrombotic events, the three lowest dose arms were stopped and a 5000 U bolus 
of UFH was used in the SR123781A arms immediately prior to PCI. Similar rates of the 
primary outcome and bleeding were observed for all doses when compared to control 
(Table). PCI thrombotic complications were not increased in the high-dose groups.
Conclusions: SR123781A in doses of 2 to 4 mg/day may provide similar protection 
against ischemic events as UFH and abciximab, without an apparent increased bleeding 
risk. Lack of dose response suggests further dose optimization is necessary. 



































3.4% 5.7% 6.0% 5.8% 5.9% 4.9%
PCI thrombotic 
complications 
(p = 0.0003 for 
dose effect)
11.9% 11.3% 6.8% 3.6% 2.4% 2.7%
 Three Year Follow-Up of the TYPHOON Trial, a 
Randomized Trial Comparing the Use of Sirolimus-
Eluting Stents and Bare Metal Stents During Primary 
Angioplasty for Acute Myocardial Infarction
Christian Spaulding, Patrick Henry, Emmanuel Teiger, Kevin Beatt, Ezio Bramucci, 
Didier Carrie, Michel Slama, Olivier Varenne, Philippe Commeau, Bernard Glatt, Pieter 
R. Stella, Ana Cabrian, Kristel Wittebols, Hans Peter Stoll, Christoph Bode, Cochin 
Hospital, Rene Descartes University, Paris, France, Inserm U 780, Paris, France
Background:Several large registries have provided conﬂicting data on the long term 
safety of drug eluting stents implanted during primary angioplasty for acute myocardial 
infarction (AMI). Long term follow-up of dedicated randomized trials in this setting is 
therefore necessary
Methods:The TYPHOON trial is a single-blind, multicenter, prospectively randomized 
trial. 712 patients with an acute myocardial infarction with ST segment elevation were 
randomized between October 2003 and October 2005 to receive either Sirolimus Eluting 
Stents (SES) (355 patients) or Bare Metal Stents (BMS) (357 patients) The primary end-
point, target vessel failure at one year was signiﬁcantly lower in the SES group than in 
the BMS group (7.3% vs. 14.3%, P = 0.004). This reduction was driven by a decrease 
in the rate of target-vessel revascularization (5.6% and 13.4%; P<0.001). There was no 
signiﬁcant difference between the two groups in the rate of death (2.3% and 2.2%; P = 
1.00), reinfarction (1.1% and 1.4%; P = 1.00), or stent thrombosis (3.4% and 3.6%; P = 
1.00). Follow-up was planned at one year. In July 2007, a follow-up extension of ﬁve years 
was initiated. Between September 2007 and February 2008, patients will be contacted by 
telephone. Angina status, medical treatment, repeat revascularization and all cause death 
will be assessed. Data from this three year follow-up will be available for presentation in 
March 2008.
1:30 p.m.
806-7 Intracoronary Compared with Intravenous Bolus 
Abciximab Application in Patients with ST-Elevation 
Myocardial Infarction Undergoing Primary Coronary 
Intervention
Holger Thiele, Kathrin Schindler, Josef Friedenberger, Ingo Eitel, Georg Fürnau, Eigk 
Grebe, Dietmar Kivelitz, Gerhard Schuler, University of Leipzig - Heart Center, Leipzig, 
Germany
Background: Abciximab reduces major adverse cardiac events in patients with ST-elevation 
myocardial infarction undergoing primary percutaneous coronary intervention (PCI). 
Intracoronary bolus application of abciximab results in high local drug concentrations and 
may be more effective than standard intravenous bolus application for reduction of infarct 
size, no-reﬂow and improvement in perfusion
Methods: Patients undergoing primary PCI were randomized to either intracoronary 
(n=77) or intravenous (n=77) bolus administration of abciximab with subsequent 12 
hour intravenous infusion. Primary endpoint was infarct size and extent of microvascular 
obstruction assessed by delayed enhancement magnetic resonance. Secondary 
endpoints were ST-resolution at 90 minutes, Thrombolysis in Myocardial Infarction (TIMI)-
ﬂow and perfusion grade post PCI, and the occurrence of major adverse cardiac events 
within 30 days.
Results: The primary endpoint infarct size could be reduced by absolute 7% (17.7% 
i.c. versus 24.7% i.v., p=0.005). Similarly, the extent of microvascular obstruction was 
signiﬁcantly smaller in i.c. patients in comparison to i.v. patients (p=0.02). Myocardial 
perfusion measured as early ST-segment resolution was signiﬁcantly improved in i.c. 
patients with an absolute ST-resolution of 76±23% versus 64±31% (p=0.009). The TIMI 
ﬂow after PCI was not different between treatment groups (p=0.51), but there was a trend 
towards an improved perfusion grade (p=0.12). There was a trend towards a higher major 
adverse cardiac event rate after intravenous versus intracoronary abciximab application 
(15.6% versus 5.2%, p=0.06; relative risk 3.00; 95% conﬁdence intervals 0.94-10.80).
Conclusions: Intracoronary bolus administration of abciximab is superior to standard 
intravenous treatment with respect to infarct size, extent of microvascular obstruction, 
and perfusion in primary PCI. An adequately powered trial for major adverse cardiac 
event reduction is warranted.
1:45 p.m.
806-8 Decline in the Use of Drug-Eluting Stents for Patients 
With Non-ST-Segment Elevation Myocardial Infarction 
Undergoing Percutaneous Coronary Intervention: 
Results From the CRUSADE and ACTION Registries
Matthew T. Roe, Christopher P. Cannon, Anita Y. Chen, Sunil V. Rao, John S. Rumsfeld, 
Lloyd W. Klein, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson, Duke Clinical 
Research Institute, Duke University Medical Center, Durham, NC
Background: Relative risks and beneﬁts of drug-eluting stents (DES) vs. bare-metal 
stents (BMS) have been scrutinized recently given concerns regarding the risk of stent 
thrombois in patients receiving DES. How the controversy surrounding DES use has 
impacted patterns of stent use in patients with acute myocardial infarction (MI), an off 
label indication for DES, is unclear.
Methods: We examined temporal patterns of DES vs. BMS use in patients with non-ST-
elevation MI (NSTEMI) by quarter (1/06-6/07) in the CRUSADE and ACTION national 
registries. CRUSADE ended in December 2006 and transitioned to ACTION, which 
began data collection in January 2007. NSTEMI patients who underwent PCI during 
the initial hospitalization were analyzed by quarter among hospitals that submitted data 
during all 4 quarters of 2006 (CRUSADE) and during both the ﬁrst and second quarters 
of 2007(ACTION).
Results: Data were collected from 153 CRUSADE hospitals and 185 ACTION hospitals. 
There was a slight increase in the percentage of patients undergoing PCI over the 1.5-
year period. Among PCI patients, there was a progressive decline in the use of DES vs. 
BMS (Table).
Conclusions: Over a 1.5-year period, the proportion of NSTEMI patients undergoing 
PCI who received a DES declined from 92% to 63%, despite a slight increase in the 
proportion of patients who underwent PCI. These ﬁndings suggest that off-label DES use 
patterns have been rapidly affected by the recent controversy regarding the risk of stent 
thrombosis associated with DES. 
CRUSADE ACTION
Quarter and Year Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07
Number of patients 5505 5602 5333 4654 6563 6353
Patients undergoing PCI 43.4% 44.5% 45.4% 45.6% 45.7% 46.6%
Drug-eluting stent * 91.9% 90.4% 89.5% 81.6% 66.7% 63.3%
Bare-metal stent* 8.1% 9.6% 10.5% 18.4% 33.3% 36.7%
*Percentages calculated among those patients undergoing PCI
 “Abstract withdrawn by author”




















806-09 The CRUSADE Bleeding Score to Assess Baseline 
Risk of Major Bleeding in Non-ST-Segment Elevation 
Myocardial Infarction
Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, Tracy 
Y. Wang, W. Brian Gibler, E. Magnus Ohman, Eric D. Peterson, Matthew T. Roe, Karen P. 
Alexander, Washington University in St. Louis School of Medicine, St. Louis, MO, Duke 
Clinical Research Institute, Durham, NC
Background: Major bleeding adversely affects outcomes in non-ST-segment elevation 
myocardial infarction (NSTEMI). Early identiﬁcation of those at high risk of bleeding 
could improve outcomes by guiding treatment, but estimation of baseline risk is limited by 
including treatment variables in existing models.
Methods: Using the NSTEMI population in CRUSADE, we performed logistic regression 
to identify baseline predictors of bleeding in a derivation cohort (n=71,277); the model 
was tested in a validation cohort (n=17,857). A major bleed was deﬁned as hematocrit 
(HCT) drop q12%, intracranial hemorrhage, witnessed retroperitoneal bleed, any RBC 
transfusion when baseline HCT q28%, or baseline HCT <28% with witnessed bleed; 
post-CABG bleeding was censored. A scoring system (range 1-100) was developed by 
assigning a weighted integer based on the coefﬁcient of each predictor.
Results: Independent predictors of bleeding included glomerular ﬁltration rate, SBP 
(mm Hg), heart rate, weight, baseline HCT, peripheral vascular disease, signs of CHF, 
diabetes, and female sex. The regression model (derivation C=.72 and validation C=.71), 
and scoring system (derivation C=0.70 and validation C=.69) had good discriminative 
power overall and across treatment subgroups. The patient’s risk of bleeding is predicted 
by the score (Figure).
Conclusions The CRUSADE bleeding score identiﬁes a patient’s baseline risk for major 
bleeding. Its potential to guide management may improve safety and outcomes in NSTEMI.
2:15 p.m. 
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1024-41 What is the Effect of Late Revascularization of a Totally 
Occluded Infarct-Related Artery?
Andrew N. Rassi, Anthony A. Bavry, Michael L. Sarkees, Arman T. Askari, Deepak L. 
Bhatt, Duke University Medical Center, Durham, NC, Cleveland Clinic, Cleveland, OH
Background: Although there is beneﬁt to early revascularization of the infarct-related 
artery in ST-elevation myocardial infarction, there is conﬂicting data on how best to treat 
patients who present late for revascularization.
Methods: We conducted a Medline search for clinical trials that randomized patients who 
presented greater than 12 hours after the onset of symptoms with ST-elevation myocardial 
infarction to percutaneous revascularization versus medical therapy. We included trials 
where there was angiographic evidence of total occlusion of the infarct-related artery at 
randomization. We excluded trials that performed surgical revascularization, studies that 
included stenosed arteries, and those without available clinical outcomes.
Results: In all, there were 7 trials with 2,678 patients available for analysis. On average, 
patients were randomized 8.5 days after symptom onset with 99.9% demonstrating TIMI 
0-1 ﬂow. At a weighted mean follow-up of 44 months, the incidence of all-cause mortality 
was 7.6% in the revascularization group, compared with 8.0% in the medical group 
(risk ratio [RR] = 0.98, 95% conﬁdence interval [CI] 0.75 to 1.27, p = 0.86). Similarly, 
cardiovascular mortality was 5.1% and 5.2% (RR = 1.00, 95% CI 0.72 to 1.41, p = 0.98), 
heart failure was 4.0% and 5.2% (RR = 0.59, 95% CI 0.29 to 1.22, p = 0.18), non-fatal 
myocardial infarction was 5.1% and 3.8% (RR = 1.36, 95% CI 0.95 to 1.97, p = 0.097) 
and subsequent revascularization was 16.4% and 19.2%, respectively (RR = 0.85, 95% 
CI 0.72 to 1.00, p = 0.051). At the extent of follow-up, ejection fraction was noted to be 
53.5% in the revascularization group compared to 50% in the medical group (p = 0.26) 
while the incidence of persistent occlusion was 19.4% versus 74.0, respectively (RR = 
0.30, 95% CI 0.17 to 0.54, p < 0.0001).
Conclusions: Late revascularization of an occluded infarct related artery after an 
acute coronary syndrome reduces persistent occlusion and the need for subsequent 
revascularization procedures. Despite these beneﬁts, available data does not indicate 
that this therapy reduces death or myocardial infarction.
3:00 p.m.
1024-42 Improvements in Time to Reperfusion: Women Have an 
Advantage
Veena S. Rao, Basmah Safdar, Veronica Lee, Janet Parkosewich, Gail D’Onofrio, 
JoAnne M. Foody, Yale University, New Haven, CT
Background: Several studies demonstrate that women have greater delays in primary 
percutaneous coronary intervention (PCI). To improve cardiovascular care for women, 
the Women’s Heart Advantage (WHA) at Yale-New Haven Hospital (YNHH) developed 
patient and physician level interventions to improve early diagnosis and management of 
acute coronary syndrome (ACS) in women presenting to the emergency department.
Methods: We analyzed chart-abstracted data from all patients undergoing PCI for ST-
elevation myocardial infarction (STEMI) at YNHH from January 2004-July 2007 and 
assessed quality of care for ACS in addition to trends in time to reperfusion. WHA and 
YNHH orchestrated several clinical initiatives as well as instituted hospital-wide systems 
to improve ACS care over these 31 months.
Results: Both men and women had declines in time to reperfusion (91 to 73 minutes and 
120 to 74 minutes for men and women, respectively). Notably, improvements in time to 
reperfusion were more substantial in women; the greatest improvement was a reduction 
in the door-to-table time (50% decrease in women compared with 19% decrease in men 
[p<0.05]).
Conclusion: In this single-site study of men and women undergoing primary PCI at a 
large, urban teaching hospital, where ongoing interventions to increase both patient and 
physician awareness regarding heart disease in women were initiated, time to reperfusion 
for women improved to a greater degree than in men. These results are encouraging, 
showing that signiﬁcant improvements in time to reperfusion can be made over a relatively 
short time frame. It is hoped that these reductions in time to reperfusion, particularly in 
women, are associated with improved outcomes; however, further studies are needed to 
verify this potential beneﬁt.
3:00 p.m.
1024-43 Efﬁcacy and Safety of Early Clopidogrel Administration 
with or without Abciximab in Patients with ST-Segment 
Elevation Myocardial Infarction Transferred for Primary 
PCI. Results from the EUROTRANSFER Registry
Jacek Legutko, Tomasz Rakowski, Zbigniew Siudak, Lukasz Rzeszutko, Magnus 
Janzon, Ralf Birkemeyer, Pawel Kleczynski, Dariusz Dudek, Jagiellonian University 
Medical College, Krakow, Poland
Background: Pre-treatment for primary PCI (pPCI) with 600 mg loading dose (LD) of 
clopidogrel is indicated by ESC guidelines. However, the efﬁcacy and safety of early 
clopidogrel LD administration (before admission to cath lab) in patients with ST-segment 
elevation myocardial infarction (STEMI) remains unclear. 
Methods: Consecutive data on 1,650 STEMI patients transferred for pPCI were gathered 
from 7 countries in Europe. We compared the rates of 30-day major adverse cardiac 
events (MACE) and bleedings in four groups of patients, according to early antiplatelet 
treatment: aspirin (Group 1, n=553), aspirin + clopidogrel LD (Group 2, n=370), aspirin + 
abciximab (Group 3, n=580), aspirin + clopidogrel LD + abciximab (Group 4, n=147).
Results: There was no difference between study groups according to baseline clinical 
characteristics. Rates of MACE are shown in table. Early administration of 600 mg LD of 
clopidogrel with aspirin and abciximab was an independent predictor of bleedings (Odds 
Ratio [OR], 4.62; 95% CI, 1.67-12.82; P=.003), including puncture site hematoma (OR, 
3.57; 95% CI, 1.25-10.20; p=.017), and major bleedings requiring transfusion (OR, 11.34; 
95% CI, 1.55-82.79; P=.017).
Conclusions: Early administration of clopidogrel LD in addition to aspirin and to aspirin + 
abciximab decreases the risk of 30-day MACE in STEMI patients transferred for primary 
PCI. However, early administration of 600 mg LD of clopidogrel with aspirin and abciximab 
signiﬁcantly increases the risk of bleedings.
MACE from diagnosis to 30 days
Group 1 Group 2 Group 3 Group 4 P-value
Death, % 7.1 5.7 4.3 2.0 0.053
Death + ReMI, % 9.6 6.5 5.7 2.0 0.004
Death + ReMI + Revascularization, % 10.1 7.3 6.2 2.7 0.002
3:00 p.m.
1024-44 Attenuated Soluble P-selectin Levels by Treatment 
with an Oral Direct Thrombin Inhibitor in Patients with 
Recent Myocardial Infarction
Christina Christersson, Jonas Oldgren, Lars Wallentin, Agneta Siegbahn, Department of 
Medical Sciences, Uppsala, Sweden
Background: Acute myocardial infarction (MI) is a thrombotic complication with platelet 
and coagulation activity. Thrombin is a powerful platelet activator and we aimed to 
investigate whether treatment with an oral direct thrombin inhibitor will affect platelet 




activity measured by soluble P-selectin (sP-selectin).
Methods: In a biomarker substudy to ESTEEM, a phase II study for safety and efﬁcacy 
of the oral direct thrombin inhibitor ximelagatran, 518 patients with acute MI were within 
14 days randomized to treatment with one of four doses (24-60 mg twice daily) of 
ximelagatran or placebo for 6 months. All patients received aspirin 160 mg once daily. SP-
selectin was analyzed at randomization, after 1 week and 6 months on study treatment.
Results: Results describe change of sP-selectin from the levels at randomization 
Treatment Increase (%) in sP-selectin 1 week 
Increase (%)in sP-selectin 
6 months 
Placebo 








7 (9-22)† 7 (9-26)
p* 0.002 0.02
* Mann Whitney U-test comparing the 40-60mg ximelagatran group and the placebo 
group. †p=0.01 comparing the two ximelagatran groups.
Conclusions: There is an increase in soluble P-selectin levels up to six months after an 
acute MI despite treatment with aspirin. This might indicate increased platelet activity after 
cessation of the acute antithrombotic treatment for the index MI. Long-term treatment 
with an oral direct thrombin inhibitor signiﬁcantly attenuates platelet activity in a dose 
dependent manner.
3:00 p.m.
1024-45 The role of pre-procedural N-terminal pro B-type 
natriuretic peptide level in patients with acute 
ST-segment elevation myocardial infarction who 
underwent primary percutaneous coronary intervention
Youngkeun Ahn, Seo Na Hong, Nam Sik Yoon, Hyun Ju Yoon, Jae Yeon Moon, Kye Hun 
Kim, Young Joon Hong, Ju Han Kim, Hyung Wook Park, Myung Ho Jeong, Jeong Gwan 
Cho, Jong Chun Park, Chonnam National University Hospital, Gwangju, South Korea
Background: The aim of this study was to assess the relation between pre-procedural 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) and angiographic no-reﬂow 
phenomenon and improvement of left ventricular (LV) systolic function in patients who 
underwent primary PCI.
Methods: We enrolled 163 patients (60.4±11.4 years, male 79.7 %) with LV systolic 
dysfunction [deﬁned as an echocardiographic LV ejection fraction (EF) <45 %] who 
underwent primary PCI for acute STEMI. The level of NT-proBNP was measured on 
admission and before PCI. Angiographic no-reﬂow after PCI was deﬁned as TIMI ﬂow grade 
<3. All patients with no-reﬂow received intracoronary injection of nicorandil and adenosine 
after no-reﬂow. The follow-up LVEF was measured at 9.1±4.2 months after PCI.
Results: The baseline characteristics between the groups with no-reﬂow group (n=55) and 
normal reﬂow group (n=92) are similar. The level of NT-proBNP was signiﬁcantly higher 
in the no-reﬂow group than that in the normal reﬂow group (2879.9±2198.2 vs. 1270.5± 
1627.8 pg/mL, p=0.022). The LVEF was improved more signiﬁcantly in normal reﬂow 
group (42.5 to 52.9 % vs. 43.8 to 47.9 %, p=0.017). In no-reﬂow group, the group was 
divided according to LVEF recovery at follow up: LVEF recovery group (n=30) and LVEF 
no-recovery group (n=25). The baseline LVEF was similar between the groups (42.6±2.2 
vs. 40.1±3.1 %, p=0.558), but at follow-up LVEF was signiﬁcantly higher in LVEF recovery 
group compared with that in LVEF no-recovery group (51.5±1.5 vs. 41.2±5.6 %, p=0.007). 
The baseline NT-proBNP level was signiﬁcantly higher in LVEF no-recovery group 
than that in LVEF recovery group (3209.3±1946.6 vs. 1990.7±862.3 pg/mL, p=0.048). 
In multivariate analyses, baseline NT-proBNP level was the independent predictor for 
angiographic no-reﬂow phenomenone (odds ratio, 4.04; 95% CI 1.33 to 12.28, p=0.014) 
and no-recovery of LVEF in patients with no-reﬂow (odds ratio, 3.24; 95% CI 1.01 to 
10.43, p=0.013).
Conclusions: Baseline NT-proBNP level is a strong predictor for development of no-
reﬂow phenomenon and no-recovery of LVEF in acute STEMI patients who underwent 
primary PCI.
3:00 p.m.
1024-46 One Year Mortality of Patients with ST-Elevation 
Myocardial Infarction: Primary PCI versus Thrombolytic 
Therapy in the VIENNA-STEMI Registry
Karim Kalla, Guenter Christ, Ronald Karnik, Reinhard Malzer, Georg Norman, Herbert 
Prachar, Wolfgang Schreiber, Gerhard Unger, Helmut Glogar, Alfred Kaff, Anton 
Laggner, Gerald Maurer, Johannes Mlczoch, Joerg Slany, Heinrich Weber, Kurt Huber, 
3.Dept. Med. Wilhelminenhospital, Vienna, Austria
Background and Aim: In several trials and large registries the impact of reperfusion 
strategy, either primary PCI (PPCI) or Thrombolytic Therapy (TT), and time to treatment 
in patients (pts) with acute STEMI on late clinical outcome have been discussed 
controversely. The aim of this study was to compare one-year mortality rates of pts treated 
either with PPCI or TT and the inﬂuence of time from onset of symptoms to treatment on 
late mortality.
Patients and Methods: All consecutive pts with an acute STEMI of < 12 hours (h) duration 
presenting at the participating PCI centers between March 2003 and December 2004 
were included (n=1053). Impact of time to treatment (onset of pain to 1st balloon inﬂation 
or injection of the thrombolytic agent) on one-year mortality was investigated according to 
different time delays: < 2 h from onset of pain or > 2 h, respectively.
Results: Of the 1053 consecutive pts 18 were lost to long term follow up. Of the remaining 
1035 pts (61,9±13,5 yrs; m/f=71,3/28,7 %) presenting with acute STEMI, 59,6% (n=617) 
underwent PPCI. If PPCI could not be offered within 90 min of 1st medical contact TT 
was performed (n=277, 26,8%). The median time from onset of symptoms to treatment 
was 205 min in the PPCI group and 120 min in the TT group. One-year mortality in the 
PPCI group was 11,8% and in the TT group 11,9%. In 141 pts (13,6%) no reperfusion 
therapy was offered due to long presentation delays or contraindication against both 
reperfusion strategies. One-Year Mortality was 24,8% in this group. One-year mortality 
of patients treated within 2 hours after symptom onset was lower compared to mortality 
rates of patients treated later in both reperfusion groups. (PPCI a 2 hours: 10% vs. > 
2 hours 12.1%; TT a 2 hours: 5.7% vs. > 2 hours: 18.2%;) with a trend in favour of TT 
over PPCI in the very early treatment period (p=0.236). Conclusion: One-year mortality 
in both treatment groups, was time-dependent and lowest when treatment was offered 
within 2 hrs of onset of symptoms without signiﬁcant differences between PPCI and TT. 
Accordingly, pts presenting with acute STEMI of < 2 hrs duration should be treated with 
the earliest available reperfusion method while PPCI should be the preferred method in 
all other pts.
3:00 p.m.
1024-47 The Gender Gap in Door-to-Treatment Time and 
Outcomes in Acute ST Segment Myocardial Infarction
Elizabeth Z. Grey, Norma L. Thiessen, Timothy D. Henry, Denise Widenburg, Catherine 
A. Pastorius, Sue Duval, Joseph Decker, Robert G. Hauser, Minneapolis Heart Institute 
Foundation, Minneapolis, MN
Background: Gender differences exist in the treatment and outcomes of acute ST 
segment elevation myocardial infarction (STEMI). The aim of this study was to asssess 
clinical variables in women and men who underwent emergency percutaneous coronary 
intervention (PCI) or surgical revascularization (CAB) for STEMI at our institution.
Methods: The records of consecutive STEMI patients treated by us with emergency 
PCI or CAB as part of our Level 1 acute STEMI program were reviewed. These patients 
presented to our hospital or to 30 non-PCI capable community hospitals within 210 miles 
between March 2003 and July 2007. Patients received half-dose thrombolytic therapy if 
their transfer for PCI was delayed or if the community hospital was more than 60 miles 
from our center.
Results: Of the 1,665 patients, 28% (n=463) were women whose average age was 
68.6+/-14.6 years vs 59.7+/-13.8 years for men ( p<0.001); 27% of women and 10% 
of men were >80 years. In addition to being older, women were more likely to have 
hypertension (women-65%; men-52%, p<0.0001), fewer were current smokers (women-
33%, men-42%, p=0.0006), and more men had a family history of premature coronary 
artery disease (women-40%, men-47%, p=0.010). The median door-to-needle time 
was 96 minutes for men and 103 minutes for women (p=0.002), and more women had 
cardiogenic shock (women-16%, men-11%, p=0.005). The 30-day mortality for was 7.6% 
for women vs 4.6% for men (p=0.02 ) and the 1-year mortality was 11.0% for women and 
6.4% for men (p=0.002). The stroke rate at 30 days was 1.9% for women and 0.7% for 
men (p=0.02).
Conclusions: Women who suffer STEMI are at greater risk for death and stroke at 30 days 
and death at 1 year than men. These outcomes appear to be related to older age and 
delays in treatment despite a standardized Level 1 STEMI protocol. The higher incidence 
of cardiogenic shock in women implies that a signiﬁcant delay exists between symptom 
onset and arrival at a health care facility. Thus women are disadvantaged by age and lags 
in presentation and treatment.
3:00 p.m.
1024-48 Predictors of Prehospital Delay Time in Acute ST-
Elevation Myocardial Infarction
Carlos T. Aguiar, Jorge S. Ferreira, Investigators of the Portuguese Registry of 
AcuteCoronary Syndromes, Centro Nacional de Colheita de Dados de Cardiologia, 
Coimbra, Portugal
Background: In patients (Pts) suspected of acute myocardial infarction (MI), an excessive 
delay between symptom onset and initial clinical evaluation - prehospital delay - may 
impede the administration and compromise the efﬁcacy of life-saving therapies. The 
relation between time to reperfusion and survival beneﬁt of reperfusion is particularly 
strong in the ﬁrst 2 hrs after symptom onset. The aim of this study is to identify predictors 
of prehospital delay time.
Methods: We studied 2,827 Pts with ST-elevation MI included in a nationwide registry and 
explored the relation between prehospital delay and age, gender, body mass index, hour 
(0-8h vs 8-24h) and day (working vs holiday/week-end) of symptom onset, risk factors, 
and prior history of angina, MI, revascularization, peripheral arterial or cerebrovascular 
disease. The effects of prehospital delay on frequency of administration of reperfusion 
therapy and all-cause hospital mortality were also evaluated.
Results: Median prehospital delay was 184 min. Prehospital delay was >2 hrs for 1925 
Pts (68.1%) and >12 hrs for 466 (16.5%). Independent predictors of prehospital delay >2 
hrs were age (OR 1.02; 95% CI, 1.02-1.03), symptom onset at night (OR 1.32; 95% CI, 
1.08-1.61), diabetes (OR 1.44; 95% CI, 1.14-1.81), and prior history of angina (OR 1.35; 
95% CI, 1.06-1.71). Age >60 years more accurately discriminated Pts presenting >2 hrs 
after symptom onset. Reperfusion therapy was delivered to 64% of all Pts and 74.1% of 
those presenting in ﬁrst 12 hrs. Among Pts eligible for reperfusion, prehospital delay a2 
hrs was associated with a higher likelihood of receiving this treatment: 81.3% vs 69.6% 
when prehospital delay was >2 hrs (OR 1.90; 95% CI, 1.55-2.33). Hospital mortality was 
8.7% overall (245 deaths), and higher among Pts with a prehospital delay >2 hrs: 9.6% vs 
6.7% when prehospital delay was a2 hrs (OR 1.49; 95% CI, 1.10-2.02).
Conclusions: Prehospital delay for ST-elevation MI is far from being optimal and 
is particularly long in the elderly, diabetics, and Pts with prior history of angina or for 
whom symptoms began during the night. Strategies aimed at improving prognosis of ST-



















elevation MI should target these Pt subgroups in a more aggressive manner.
3:00 p.m.
1024-49 Systematic Bayesian Meta-Analysis Evaluating Cardiac 
Outcomes of Low Molecular Weight Heparin Versus 
Unfractionated Heparin Therapy in Patients With ST 
Elevation Acute Myocardial Infarction
Christopher Lang, Zafeer Baber, Mujtaba Ali, Phillip Tseng, Rohit R. Arora, Chicago 
Medical School, North Chicago, IL
Background: Several recent trials have compared the low molecular weight heparins 
(LMWHs) to unfractionated heparin (UFH) in patients with acute myocardial infarction 
(AMI). The results of these trials suggest a beneﬁt conferred to LMWH versus UFH, yet 
the extent of this beneﬁt is unclear. In order to elucidate the degree of this advantage, we 
conducted a systematic Bayesian meta-analysis with evaluation of the cardiovascular 
outcomes in post-AMI patients using LMWHs and UFHs.
Methods: A Bayesian meta-analysis of seven randomized trials totaling 27,604 patients 
was performed. The trials evaluated the efﬁcacy of LMWHs or weight-based UFH in 
patients with ST-AMI who were treated with ﬁbrinolytic therapy. The endpoints evaluated 
included mortality and reinfarction at both 7 and 30 days. Bayesian probabilities of beneﬁt, 
and a sensitivity analysis of LMWH compared to UFH in ST-AMI were computed.
Results: The results of the Bayesian meta-analysis indicate that use of LMWH is 
associated with a greater than 90% likelihood of beneﬁt compared to UFH for each of 
the endpoints. LMWH has a probability of beneﬁt (Pb) of 0.944 for 7 day incidence of 
mortality, sensitivity analysis indicates a modest probability of a greater than 10% beneﬁt 
(Pb (>10%) = 0.445). Similarly, the Pb for 30 day incidence of mortality is 0.945, while 
the Pb (>10%) is 0.39. Reinfarction at 7 days is associated with a Pb of 0.997 and a 
Pb (>50%) beneﬁt equal to 0.954. At 30 days, incidence of reinfarction using LMWH is 
associated with a Pb of 0.997, and a Pb (>50%) beneﬁt of 0.905.
Conclusions: The Bayesian meta-analysis we report conﬁrms that patients with ST-AMI 
undergoing ﬁbrinolytic therapy are more likely to beneﬁt from using LMWH than UFH in 
terms of reduced incidence of mortality and reinfarction. However, the Bayesian meta-
analysis indicates LMWH is unlikely to provide a clinically signiﬁcant reduction in mortality. 
The analysis indicates the superiority of LWMH in the reduction of reinfarction compared 
to UFH. Thus, the Bayesian statistics generated suggest that LMWH can achieve a 
clinically important reduction in reinfarction in patients with acute ST-AMI, while providing 
a marginal beneﬁt in reducing mortality.
3:00 p.m.
1024-50 Treatment of Spontaneous Coronary Dissection 
Presenting as Acute Myocardial Infarction
Charles X. Kim, Patricia J.M. Best, Mayo Clinic, Rochester, MN
Background: Spontaneous coronary artery dissection is a poorly understood 
phenomenon that often occurs outside the context of atherosclerotic coronary disease. 
The acute presentation can mimic signs and symptoms of traditional acute coronary 
syndrome, including biomarker elevation and electrocardiographic changes. It is unclear 
what the optimal therapeutic strategy entails. We sought to further characterize the initial 
presentation, comorbid conditions, angiographic anatomy, initial treatment strategy, and 
outcomes on follow-up.
Methods: The Mayo Clinic electronic medical record (1996-2007) was queried for the 
intersecting terms “spontaneous” and “coronary artery dissection.” All patients with 
detailed description of spontaneous coronary dissection were included. Follow-up data 
were obtained from the subsequent electronic medical record.
Results: 21 unique patients were identiﬁed. The median age was 44 years at presentation. 
90% were female and 95% had chest pain / pressure as a presenting symptom with 
clinical evidence of myocardial infarction (ST-elevation or cardiac biomarker elevation). 
Patients received standard therapies for ACS, including aspirin and heparin. 33% of 
patients received thrombolytics and 11% received gpIIb/IIIa antagonists. On angiography, 
81% involved a single vessel, with the LAD being involved 62% of the time. Nondissected 
arteries were largely free of coronary disease, with predominantly “normal” appearance. 
No female patients had stenosis >20% by diameter in uninvolved arteries. Treatment 
entailed coronary stent (38%), emergency CABG (14%), or medical therapy alone 
(52%). Subsequent dissection and myocardial infarction were uncommon after the index 
hospitalization. Only one patient died (non-coronary cause) in > 1000 months of follow-up 
(49 month average).
Conclusions: Spontaneous coronary dissection presenting as acute coronary syndrome 
with myocardial infarction is not associated with traditional coronary artery disease. 
However, treatment of the thrombotic complications with early revascularization and 
standard therapies for ACS can lead to durable outcomes and sustained survival free of 
repeat cardiovascular events.
3:00 p.m.
1024-51 Door-to-Balloon Times - Are We Meeting the AHA/ACC 
Guidelines? Results from an Australian Multicenter 
Registry
Christopher C. S. Lim, Andrew Teh, Louise Roberts, Nicholas Andrianopoulos, 
Christopher Reid, David Clark, Greg Szto, Andrew Ajani, Stephen Duffy, Box Hill 
Hospital, Box Hill, Australia, Melbourne Interventional Group, Melbourne, Australia
Background: Recent AHA/ACC guidelines recommend a door-to-balloon time (DTB) of 
90 minutes or less. Previous studies have shown an association between longer DTB 
and mortality. The recent (National Registry of Myocardial Infarcts) NRMI-3 and NRMI-
4 registries in the US showed that the majority of STEMI patients did not meet the 
guidelines target of DTB within 90 minutes. There has been no similar large registry data 
in an Australian setting.
Methods: Melbourne Interventional Group (MIG) is a voluntary collaborative of major 
hospitals with a primary PCI service in Melbourne, Australia. From April 2005 to January 
2007, data was collected on primary PCI cases for the MIG registry. Door-to-balloon times 
and 30-day outcomes were analysed. Cardiogenic shock and rescue PCI cases were 
excluded.
Results: Median DTB was 105 minutes. Median DTB was longer in cases transferred from 
a non-PCI facility (146 minutes, n = 45) compared to cases presenting to a PCI facility (98 
minutes, n = 252). Less than half (42%) of all cases met the guidelines target of DTB<90 
minutes. Only 24% of transferred cases met the target of DTB<90 minutes, compared to 
45% of non-transferred cases. 




TVR 1.6% (2) 4.7% (8) 0.20
MI (CK > 3x ULN) 0.8% (1) 1.2% (2) 1.00
Mortality 1.6% (2) 4.7% (8) 0.20
MACE 3.9% (5) 10.5% (18) 0.047
Conclusions: This Australian registry shows the AHA/ACC guidelines are difﬁcult to 
achieve. These real-world results are similar to that of the US NRMI-3 and NRMI-4 
registries. Door-to-balloon times greater than 90 minutes resulted in increased MACE, 
conﬁrming previous studies. Further ways to reduce DTB need to be examined.
3:00 p.m.
1024-52 Trends in Reperfusion Strategies, Door-to-Needle 
and Door-to-Balloon Times and In-Hospital Mortality 
among Patients with ST-Segment Elevation Myocardial 
Infarction Enrolled in the National Registry of 
Myocardial Infarction Database from 1990 to 2006
C. Michael Gibson, Yuri B. Pride, Paul D. Frederick, Charles V. Pollack, Jr., John G. 
Canto, Alan J. Tiefenbrunn, W. Douglas Weaver, Costas T. Lambrew, Eric D. Peterson, 
William J. Rogers, Beth Israel Deaconess Medical Center, Boston, MA, University of 
Alabama Medical Center, Birmingham, AL
Background: Among patients with ST-segment elevation myocardial infarction (STEMI), 
rapid reperfusion of the infarct-related artery has been associated with improved mortality. 
As such, door-to-needle (DN) and door-to-balloon (DB) times have become two metrics of 
quality care and targets for intense quality improvement efforts.
Methods: The National Registry of Myocardial Infarction (NRMI) collected data regarding 
reperfusion therapy, its timing and in-hospital mortality among STEMI patients from 1990 
through 2006.
Results: Since 1990, NRMI has enrolled 1,374,232 STEMI patients at 2,157 hospitals. 
Among those, 774,279 (56.3%) were eligible for reperfusion upon arrival to the ﬁrst 
hospital. Since 1990, NRMI has enrolled 1,374,232 STEMI patients at 2,157 hospitals. 
Among those, 774,279 (56.3%) were eligible for reperfusion upon arrival to the ﬁrst 
hospital. The proportion receiving ﬁbrinolytic therapy fell from 52.5% in 1990 to 27.6% 
in 2006 (p<0.001), while the proportion undergoing primary percutaneous coronary 
intervention (pPCI) increased from 2.6% to 43.2%. Among those who received ﬁbrinolytic 
therapy, there was a nearly linear decline in median DN time from 59 minutes in 1990 to 
29 minutes in 2006 (p<0.001 for trend). This was accompanied by a signiﬁcant decrease 
in hospital mortality from 7.0% in 1994 to 6.0% in 2006 among the ﬁbrinolytic group 
(p<0.001). Among those undergoing pPCI, DB time among non-transfer patients also 
declined linearly from 111 minutes in 1994 to 79 minutes in 2006 (p<0.001) with a 
decline in mortality from 8.6% to 3.1% (p<0.001). The relative improvement in mortality 
attributable to improvements in DN and DB times were 16.5% and 7.7%, respectively.
Conclusions: Since 1990, there has been a progressive decline in both DN and DB time 
among reperfusion-eligible patients treated with ﬁbrinolytic therapy and pPCI. These 
improvements have contributed, at least in part, to a progressive decline in mortality.
3:00 p.m.
1024-53 Myocardial Viability assesed by FDG-PET as a predictor 
of cardiac events in patients with Acute Myocardial 
Infarction
Masanori Tsurugida, Shuichi Hamasaki, Koichi Kihara, Ryo Arikawa, Shin Kawasoe, 
Chuwa Tei, Fujimoto Hayasuzu Hospital, Miyakonojyo, Japan, Kagoshima University, 
Kagoshima, Japan
Background: To predict cardiac events by myocardial viability has not been reported in 
patients with acute myocardial infarction (AMI).
Object: The purpose of this study was to examine whether myocardial viability assessed by 
FDG-PET in acute phase of AMI can be a predictor of cardiac events in patients with AMI.
Methods: A total of 37 patients with reperfused ﬁrst anteroseptal AMI were studied. FDG-
PET was perfomed 2 weeks after PCI. Myocardial viability was assessed by viability score 
(VS). VS is derived from the mean value of score of FDG-PET uptake for infarcted areas 
with 5-point score system (no uptake=0, best uptake=4). We divided the patients into 2 
groups; good viability group: VS> 2 (n=23), and good viability group: VS<2 (n=14). We 
examined whether there was a difference in the appearance of subsequent cardiac events 
(death, heart failure, CABG, re-PCI and serious arrhythmia) by Kaplan Meier method as 
an end point of the duration from the onset of AMI to the day of cardiac events.
Results: The average observation period was 692 days. The event free survivial rate assessed 
by Kaplan-Meier method was signiﬁcantly (P=0.02) reduced in good viability group.
Conclusion: The present study demonstrated that the preservation of good myocardial viability 
can predict subsequent cardiac events. Therefore, it is clariﬁed that myocardial viability 
assessed by FDG-PET is useful for assessing clinical outcome in patients with AMI. 





1024-54 Effects of Ranolazine on Disease-Speciﬁc Health Status 
and Quality of Life: Results From the MERLIN-TIMI 36 
Randomized Trial
Suzanne V. Arnold, David A. Morrow, Kaijun Wang, Yang Lei, Elizabeth M. Mahoney, 
Judith A. Kempf, Benjamin M. Scirica, David J. Cohen, Mid America Heart Institute, 
Kansas City, MO, TIMI Study Group, Brigham and Women’s Hospital, Boston, MA
Background: Ranolazine (RAN) has been shown to reduce ischemia and symptom 
severity among selected pts with chronic angina. However, the effect of RAN on quality of 
life (QOL) and health status (HS) in a broad population of pts with CAD is unknown.
Methods: MERLIN-TIMI 36 was a randomized, double blind trial of RAN vs placebo in 
6560 pts with non-ST elevation ACS. HS/QOL was evaluated at baseline and 4, 8 and 12 
months after index hospitalization using the Seattle Angina Questionnaire (SAQ), London 
Dyspnea Questionnaire, SF-12 and EuroQol. Random effect growth curve models were 
used to examine changes in HS/QOL over time.
Results: All HS/QOL scores were similar at baseline and improved signiﬁcantly at all follow-
up time points for both treatment groups. RAN was associated with greater 12 month 
improvements in angina frequency, treatment satisfaction, and CAD-speciﬁc QOL (all 
p<0.05). Among pts with prior angina (n=3565), treatment with RAN was associated with 
substantial beneﬁts across the full range of HS/QOL domains while there were no signiﬁcant 
beneﬁts among pts without prior angina (see Table). These beneﬁts were independent of 
revascularization status and were observed despite the fact that RAN-treated pts received 
fewer other anti-anginal medications than those treated with placebo.
Conclusion: Among pts with a history of angina, treatment with RAN resulted in a 
signiﬁcant and sustained improvement in HS and QOL over 12 months. 
Mean Effect of Ranolazine vs. Placebo on CAD-Speciﬁc HS and QOL Over 12 
Months









SAQ Angina Frequency† 3.62 (1.99, 5.26) <0.001 0.34 (-1.51, 2.18) NS
SAQ Physical Limitations 1.85 (-0.01, 3.71) NS -1.16 (-3.22, 0.90) NS
SAQ Quality of Life† 2.73 (1.25, 4.20) 0.003 0.72 (-0.85, 2.29) NS
SAQ Treatment 
Satisfaction† 1.50 (0.50, 2.49) 0.003 -0.04 (-1.12, 1.04) NS
Dyspnea Score -0.13 (-0.22, -0.03) 0.012 0.03 (-0.08, 0.14) NS
EuroQol Utility 0.016 (0.004, 0.028) 0.007 0.004 (-0.008, 0.017) NS
SF-12 Physical 
Component 0.85 (0.08, 1.62) 0.030 0.35 (-0.46, 1.16) NS
SF-12 Mental 
Component† 0.93 (0.19, 1.67) 0.014 -0.25 (-1.03, 0.53) NS
* Higher scores indicate improved HS/QOL, except Dyspnea where lower scores 
indicate less severe symptoms
† Signiﬁcant interaction between treatment effect and prior angina (p<0.05)
3:00 p.m.
1024-55 Collateral Flow to the Occluded Infarct-related Artery 
is Associated with a Lower Rate of Heart Failure in the 
Occluded Artery Trial (OAT)
Ph. Gabriel Steg, Arthur Kerner, Christopher E. Buller, Sandra A. Forman, Harvey D. 
White, Antonio C. Carvalho, Harmony R. Reynolds, Viliam Fridrich, Eric A. Cohen, G. B. 
John Mancini, Gervasio A. Lamas, Judith S. Hochman, Hôpital Bichat-Claude Bernard, 
Assistance Publique - Hôpitaux de Paris, Paris, France, New York University School of 
Medicine, New York, NY
Background: The OAT randomized trial (n=2201) found that percutaneous coronary 
intervention (PCI) of an occluded infarct related artery after recent infarction was not 
associated with superior clinical outcomes compared to medical therapy alone (MED).
Aims: To assess the impact of collaterals on clinical outcomes and potential interaction 
with assignment to PCI or MED.
Methods: Core laboratory TIMI collateral scores were available for 1087 and 1086 pts in 
the PCI and MED groups respectively. 12.3 and 10.8% (NS) of the patients in the PCI 
and MED groups respectively had no angiographic collaterals to the infarct related artery. 
These patients were compared to those with grade I (71.6 and 70.9% respectively) or II 
(16.1 and 18.3% respectively) collaterals.

























(Death, MI, class 
IV CHF)




All patients 15.4% 11.3% 0.16
PCI (17)16.1% (74)11.1% 0.44MED (11)14.8% (81)11.5%
Fatal and non fatal 
recurrent MI
All patients 6.5% 6.1% 0.6
PCI (8)6.9% (52)7.1% 0.73MED (6)6.0% (39)5.1%
Class III or IV CHF
All patients 11.6% 5.2% <0.001
PCI (9)7.5% (48)5.6% 0.02MED (18)16.3% (42)4.8%
Death or Class III or 
IV CHF
All patients 20.5% 14.1% 0.005
PCI (23)20.8% (108)14.2% 0.60MED (22)19.4% (111)14.1%
Presence of collaterals to the infarct related artery was associated with reduced risk of 
heart failure at 60 months in both treatment groups. There was a strong trend towards 
interaction between treatment assignment and collateral ﬂow for heart failure, but not for 
the primary, or other secondary endpoints.
Conclusion: In the OAT trial, angiographically-visible collaterals subtending the infarct 
territory were associated with a lower rate of heart failure, regardless of treatment 
assignment. In patients without collaterals, the trend towards beneﬁt of PCI was not 
detectable when fatal events were factored in.
3:00 p.m.
1024-56 Increased Mortality in Patients with Acute Coronary 
Syndromes and Delay to Angioplasty of Greater than 24 
Hours after Hospital Admission: An ACUITY Substudy
Paul Sorajja, Bernard J. Gersh, Brent T. McLaurin, David C. Cox, Michael E. Bertrand, 
A. Michael Lincoff, Jeffrey W. Moses, Harvey D. White, Stuart J. Pocock, James H. Ware, 
Roxana Mehran, E. Magnus Ohman, Gregg W. Stone, Mayo Clinic College of Medicine, 
Rochester, MN, Columbia University Medical Center, New York, NY
Background: Although late reperfusion worsens survival in patients with ST-segment 
elevation myocardial infarction, there is a paucity of data on the potential harm from delay 
in early revascularization in patients with acute coronary syndromes due to unstable 
angina or non-ST segment elevation myocardial infarction (UA/NSTEMI).
Methods: 7,749 pts (median age, 63 yrs; 73% men) with UA/NSTEMI who underwent 
PCI as part of the ACUITY trial were examined. Patients were stratiﬁed according to 
revascularization by PCI at <8 hrs (n=2,197), 8-24 hrs (n=2,740), and >24 hrs (n=2,812) 
after hospital admission for analysis of outcomes.
Results: Delay in PCI >24 hrs after hospital admission was associated with increased 30-
day mortality, death or myocardial infarction, and composite myocardial ischemia (Figure). 
The increase in mortality persisted at 1 yr (<8 hrs vs. 8-24 hrs vs. >24 hrs, 5.2% vs. 4.2%. 
vs. 7.5%; p=0.02). By multivariate analysis, delay to PCI >24 hrs was an independent 
predictor of mortality at 30 days (HR [95%CI] = 2.03 [1.29-3.19]; p=0.002) and 1 year (HR 
[95%CI] = 1.55 [1.19 - 2.02]; p=0.001). The differences in death attributable to PCI delay 
>24 hrs were greatest in high-risk patients.
Conclusions: In this large-scale study, delaying revascularization with PCI >24 hrs in 
patients with UA/NSTEMI was an independent predictor of one-year mortality. These 
ﬁndings suggest that urgent angiography and triage to revascularization should be a 
priority in acute coronary syndromes. 




















1024-57 The Beneﬁt of an Invasive Strategy in Diabetic Versus 
Non-Diabetic Subjects With Non-ST-Elevation Acute 
Coronary Syndromes: A Collaborative Meta-Analysis of 
Randomized Trials
Michelle O’Donoghue, William E. Boden, Christopher P. Cannon, Tim C. Clayton, 
Robbert J. de Winter, Keith AA Fox, Bo Lagerqvist, Peter A. McCullough, Sabina 
A. Murphy, Rudolf Spacek, Eva Swahn, Lars Wallentin, Fons Windhausen, Marc 
S. Sabatine, Massachusetts General Hospital, Boston, MA, Brigham and Women’s 
Hospital, Boston, MA
Background: Patients with diabetes mellitus (DM) have a worse prognosis after ACS than 
do non-diabetic patients. Whether DM patients derive particular beneﬁt from an invasive 
(INV) vs. conservative (CONS) strategy in non-ST-elevation (NSTE) ACS remains unclear.
Methods: We conducted a collaborative meta-analysis of randomized trials of INV vs. 
CONS in NSTE ACS stratiﬁed by DM. Odds ratios (OR) from each trial were combined 
using a random-effects model.
Results: Across 8 trials, 1722 subjects had DM and 7736 did not. The OR for death, MI 
or ACS for INV vs. CONS was similar in DM (OR 0.75, 95% CI 0.61-0.93) and non-DM 
(OR 0.82, 95% CI 0.64-1.05, P int=0.59). INV reduced recurrent ACS to a similar extent 
in DM (OR 0.67, 0.52-0.87) and non-DM (OR 0.71, 0.56-0.89). INV reduced recurrent MI 
in DM (OR 0.71, 95% CI 0.53-0.95), but had no signiﬁcant effect in non-DM (OR 0.93, 
95% CI 0.72-1.32, P int=0.22). INV did not reduce mortality in DM (OR 0.97, 0.73-1.28) 
or non-DM (OR 0.94, 0.74-1.19). In non-DM, the beneﬁt of INV tended to be greater in 
those with elevated biomarkers (OR 0.72, 0.53-0.97) vs. those w/o (OR 0.92, 0.66-1.29, 
P int=0.29). DM patients beneﬁted from INV irrespective of biomarker status (OR 0.75, 
0.56-1.01; OR 0.76, 0.53-1.08).
Conclusion: An INV strategy reduces death, MI or ACS to a similar extent in DM and non-
DM patients, but the former tend to have a greater reduction in recurrent MI. Regardless of 
biomarker status, DM patients have a comparable beneﬁt from INV as high-risk biomarker 
positive non-DM patients.
3:00 p.m.
1024-58 Decreasing Coronary Heart Disease Mortality Over Two 
Decades: Prevention or Postponement? (A New Jersey 
Statewide Study)
William J. Kostis, Yu-Hsuan Shao, Abel E. Moreyra, Alan C. Wilson, John B. Kostis, For 
the Myocardial Infarction Data Acquisition System (MIDAS) Study Group, UMDNJ-
Robert Wood Johnson Medical School, New Brunswick, NJ
Background: Over the last two decades, there has been a marked decrease in age-
adjusted coronary heart disease (CHD) mortality. However, it is unclear whether this 
decrease is due to prevention or postponement of CHD deaths.
Methods: We studied admissions for acute myocardial infarction (N=344,659) and 
total CHD deaths (N=355,572) in New Jersey over the 19-year period 1986-2004 and 
examined differences in trends of crude and age-adjusted rates.
Results: In the years under consideration, there was a decrease in age-adjusted CHD 
mortality per 100,000 (640 to 339 [47%] in men and 537 to 309 [42%] in women, in the 
time intervals 1986-89 and 2001-04, respectively). The decrease in the crude CHD death 
rate was less pronounced (640 to 360 [44%] in men and 537 to 349 [35%] in women). The 
difference between the crude and age-adjusted CHD death rates increased progressively 
during the years studied. Of the 301 per 100,000 decrease in age-adjusted mortality in 
men, 280 deaths per 100,000 annually appear to have been truly prevented and 21 (7%) 
postponed to an older age during the 19-year period studied. In women, of the 228 per 
100,000 decrease in age-adjusted mortality, 280 deaths per 100,000 annually appear 
to have been truly prevented and 40 (17%) postponed to an older age. Contrary to fatal 
CHD, both the age-adjusted and the crude rates of hospital admission for nonfatal acute 
myocardial infarction did not decline appreciably in the 19-year period studied. The age-
adjusted rate declined slightly from 853 to 844 per 100,000 (1% decrease) among men 
but increased from 488 to 559 (14% increase) among women. Median age, and the rate of 
comorbidities such as diabetes, hypertension, and renal disease also increased.
Conclusions: 1. The marked decrease in age-adjusted CHD mortality observed in 
the last 20 years is primarily due to true prevention while a signiﬁcant minority is due 
postponement to an older age, especially among women (17%). 2. The increase in 
admissions for nonfatal acute myocardial infarction may be due to changes in case 
deﬁnition, increased co-morbidity, and decreasing in-hospital mortality.
3:00 p.m.
1024-59 Temporal Changes In The Use Of Early Invasive 
Management For Non-ST Elevation Acute Coronary 
Syndromes: Inﬂuence Of Age On Treatment Selection 
And Outcome
Alan J. Bagnall, Shaun G. Goodman, Thao Huynh, Asim N. Cheema, David H. Fitchett, 
Raymond T. Yan, Anatoly Langer, Andrew T. Yan, for the Canadian ACS Registry I and 
II Investigators, Canadian Heart Research Centre, Toronto, ON, Canada, Terrence 
Donnelly Heart Centre, St. Michael’s Hospital, Toronto, ON, Canada
Background: Randomized clinical trials support early invasive management of high-risk 
non-ST elevation (NSTE) acute coronary syndromes (ACS). However, only limited data 
support this strategy in the elderly (65-74) and very elderly (q75). We examined temporal 
changes in the relationship between age, in-hospital use of coronary angiography/
revascularization and outcome.
Methods: The Canadian ACS registries were prospective observational studies of less selected 
(than clinical trial) patients with ACS. ACS I recruited 3279 NSTE ACS patients from 51 centres 
from Sept 99 to Jun 01; ACS II recruited 1956 patients from 36 centres from Oct 02 to Jan 04.
Results: Elderly and very elderly patients comprised 29.6% and 28.2% (in ACS I) 
and 27.8% and 27.5% (in ACS II), respectively. Rates of angiography, PCI and CABG 
increased signiﬁcantly over time (all p<0.001). 



































45.8 41.1 27.6 <0.001 75.6* 64.7* 45.3* <0.001
% PCI 18.5 12.9 10.8 <0.001 40.2* 28.9* 17.9* <0.001
% CABG 5.6 4.4 3.3 <0.01 11.5* 11.7* 8.6* 0.11
% any 
revascularization
23.9 17.2 14.0 <0.001 51.0* 40.4* 26.5* <0.001
% In hospital 
death/re-MI
4.2 4.3 8.0 <0.001 6.6† 6.1 8.0 0.39
% 1 yr mortality 3.1 9.1 20.1 <0.001 2.9 5.1† 14.9† <0.001
*p<0.001 †p<0.05 comparing within age groups between ACS I and II.
After adjusting for gender and other GRACE risk score prognosticators, older age 
remained independently associated with lower use of angiography (OR elderly=0.81, 
95%CI 0.70-0.94 p=0.006; very elderly=0.45, 95%CI 0.39-0.53 p<0.001).
Conclusions: Despite increased use of an invasive strategy, compared to younger patients, 
the elderly and very elderly remain signiﬁcantly less likely to undergo coronary angiography/
revascularization, with an associated worse outcome. Future studies should determine 
whether more aggressive treatment of these high-risk patients improves outcome.
3:00 p.m.
1024-60 The Divergent Effect of Age on Functional and Mortality 
Outcomes Post-Myocardial Infarction
Suzanne V. Arnold, Karen P. Alexander, Frederick A. Masoudi, P. Michael Ho, Alpesh A. 
Amin, John A. Spertus, Mid America Heart Institute, Kansas City, MO
Background: Age is a well-established and powerful risk factor for death after AMI, even 
after adjusting for comorbidities and disease severity. Among patients who survive, it 
is not known whether increasing age is associated with functional decline, a similarly 
important, patient-centered outcome.
Methods: PREMIER, a 19-site US registry of post-MI pts, was analyzed to identify patients 
who had a decline in function at 1 year, as deﬁned by either a >5 point decrease in SF-
12 Physical Components score from baseline or if the patient reported being “too ill” to 
provide a follow-up interview at 1 year. The proportion of those with functional decline was 
compared across age in 10-year increments using the Cochran-Armitage Trend Test. One 
year mortality was also compared across age groups.
Results: Of 1789 patients who survived to 1 year and were able to be assessed for 
functional decline, 524 (29%) experienced decline. While age was strongly associated 
with 1-year mortality (p for trend<0.001), there was no association between age and 1-
year functional decline among survivors (p for trend=0.39; Figure).
Conclusion: While age remains strongly associated with post-MI death, there does not 
appear to be a signiﬁcant relationship between age and functional decline among AMI 
survivors. More investigation is needed to understand the mechanisms behind this 
observed disassociation between functional and survival outcomes by age.





1024-61 High Density Lipoprotein Cholesterol Is a Strong 
Independent Predictor of All-Cause Mortality in the 
Non-ST Segment Elevation Acute Coronary Syndrome
Alon Yarkoni, Nicholas Kalayeh, Yosef Kahn, Francisco J. Gonzalez, Akil Loli, Frank 
Cardello, Robert E. Halligan, Jr., Richard Gerkin, Kenneth B. Desser, Nathan Laufer, 
Banner Good Samaritan/Veterans Affairs Medical Center Cardiology Fellowship 
Program, Phoenix, AZ
Background: High density lipoprotein cholesterol (HDL) has been shown to have speciﬁc anti-
inﬂammatory activity. Although HDL is used in combination with other markers such as low 
density lipoprotein cholesterol (LDL) and total cholesterol, the signiﬁcance of HDL alone is 
unclear. We assessed the hypothesis that HDL alone is an independent predictor of all-cause 
mortality in patients with the non-ST segment elevation acute coronary syndrome (ACS).
Methods: A Total of 6881 patients who presented during 2000-2003 with non-ST segment 
elevation ACS had fasting lipid panels collected within the ﬁrst 24 hours of admission. 
Patients were divided into quintiles based on values of each of the following lipid proﬁles: 
HDL level alone, triglyceride (TG)/HDL ratio, and low density lipoprotein cholesterol 
(LDL)/HDL ratio. The patient population with the lowest expected risk was selected as 
reference group for comparison. Isolated HDL as well as the ratios of TG/HDL and LDL/
HDL were analyzed as predictors of all-cause mortality. Follow-up occurred up to 5 years 
after initial presentation, with a mean of 1269 days.
Results: After adjustment for coronary risk factors, isolated HDL and both TG/HDL and 
LDL/HDL ratios were statistically signiﬁcant predictors of all-cause mortality, with HDL 
being the strongest. The hazard ratio among all patients with HDL levels < 31 mg/dl was 
2.11 (95% CI 1.79-2.4, p<0.005). Patients with low HDL levels had increased all-cause 
mortality in the ﬁrst 120 days following discharge. Kaplan-Meier Survival curves showed 
wide and signiﬁcant separation between the ﬁrst and fourth quintiles of HDL levels (log 
rank test p < 0.01).
Conclusions: HDL, TG/HDL and LDL/HDL were all found to be independent predictors of 
all-cause mortality in the non-ST segment elevation ACS, with HDL alone as the strongest 
predictor. Strategies to increase HDL levels may play a pivotal role for overall cardiac 
protection in this population. These ﬁndings contradict conventional opinion regarding the 
inﬂuence of isolated HDL levels as an independent predictor of survival in patients with 
ischemic heart disease.
3:00 p.m.
1024-62 Sex and Race Are Associated with the Finding of Non-
Obstructive Coronary Artery Disease in Patients with 
Acute Coronary Syndromes
Neel P. Chokshi, Rachel L. Berger, Judith S. Hochman, Norma M. Keller, Frederick 
Feit, Michael J. Attubato, James N. Slater, Ivan Pena-Sing, Anvar Babaev, Harmony R. 
Reynolds, NYU School of Medicine, New York, NY
Background: A substantial minority of patients with acute coronary syndromes (ACS) 
are found to have no obstructive CAD (NOb-CAD) at angiography. The prevalence of 
this ﬁnding is variable in the literature. We examined the frequency of NOb-CAD in ACS 
in a diverse patient population to better understand factors predisposing patients to this 
disease entity.
Methods: We reviewed the results of all angiograms from 5/19/06 - 9/29/06 at one 
private (NYU Medical Center, N=613) and one public (Bellevue, N=522) urban academic 
medical center. Charts were reviewed for indication for and results of angiography and 
demographic data. ACS was deﬁned as cardiac marker elevation and/or ST segment 
deviation with ischemic symptoms. Non-obstructive CAD (NOb-CAD) was deﬁned as the 
absence of q50% stenosis in any major epicardial vessel.
Results: Overall, 32% of angiograms performed for varied indications showed NOb-CAD. 
The cohort included 547 pts with ACS, 52% of whom had conﬁrmed MI by cardiac marker 
elevation. NOb-CAD was found at angiography in 20% of ACS pts overall and in 18% 
of pts with MI. Women were more likely to have NOb-CAD than men in the overall ACS 
group (31% vs. 14%, p<0.001) and in the subset with MI (30% vs. 11%, p<0.001). See 
Table for distribution of NOb-CAD by race/ethnicity among 528 ACS pts for whom race/
ethnicity was recorded.
Conclusion: The rate of NOb-CAD at angiography was high in this multi-ethnic sample 
of patients with ACS. NOb-CAD was particularly common among women and African-
Americans. 
All Caucasian Hispanic African-American Asian p (by ANOVA)
N=547 N=241 N=158 N=70 N=59
NOb-CAD
All pts % (N) 20% (108) 18% (44) 20% (31) 36% (25) 8% (5) 0.0002
Women 31% (55) 27% (17) 27% (17) 57% (16) 18% (3) 0.03
Men 14% (53) 15% (27) 15% (14) 21% (9) 5% (2) 0.29
3:00 p.m.
1024-63 Incidence and Impact of Acquired Thrombocytopenia 
Among Patients With Acute Coronary Syndromes
Tracy Y. Wang, Fang-Shu Ou, Matthew T. Roe, E. Magnus Ohman, W. Brian Gibler, 
Charles V. Pollack, Jr., Eric D. Peterson, Duke Clinical Research Institute, Durham, NC, 
University of Cincinnati College of Medicine, Cincinnati, OH
Background: Therapies used to manage acute coronary syndromes (ACS) can contribute 
to the risk of developing thrombocytopenia. However, the incidence and impact of varying 
severities of thrombocytopenia in contemporary practice are not well known.
Methods: We stratiﬁed 42,580 ACS patients (pts) with normal admission platelet counts 
(>150x109/L) in the CRUSADE initiative (2004-2006) into 3 groups based on nadir platelet 
counts: normal >150, mild 100-150, and moderate/severe thrombocytopenia <100 x109/
L. A generalized estimating equations method was used to compare outcomes among 
these groups after adjusting for baseline characteristics.
Results: A total of 6168 (15%) pts developed mild thrombocytopenia and 1542 (4%) 
had moderate/severe thrombocytopenia. Thrombocytopenic pts were older and more 
likely to have lower body mass, diabetes, and renal insufﬁciency than pts without 
thrombocytopenia. Unfractionated heparin therapy was more commonly used in the 
thrombocytopenic groups (normal 56% v mild 60% v mod/severe 62%, p<0.0001). Higher 
risks of bleeding, transfusion, and mortality were observed with increasing severity 
of thrombocytopenia (Figure). Notably, even thrombocytopenia was associated with 
increased adverse outcomes.
Conclusions: Approximately 1 in 5 pts treated with contemporary ACS therapies developed 
new thrombocytopenia that was associated with increased bleeding and mortality. Even 
mild thrombocytopenia is of clinical signiﬁcance and warrants further evaluation. 
3:00 p.m.
1024-64 Trends in Presenting Characteristics and Hospital 
Mortality in Patients With ST-Elevation and Non-ST-
Elevation Myocardial Infarction in the National Registry 
of Myocardial Infarction from 1990-2006
William J. Rogers, Paul D. Frederick, Edna Stoehr, John G. Canto, Joseph P. Ornato, C. 
Michael Gibson, Charles V. Pollack, Jr., Joel M. Gore, Nisha Chandra-Strobos, Eric D. 
Peterson, William J. French, University of Alabama Medical Center, Birmingham, AL
Background: Although ST-elevation (STEMI) and non-ST elevation (NSTEMI) myocardial 
infarction (AMI) have been the focus of intense, recent clinical investigation, limited 
information exists on characteristics and hospital mortality of patients not enrolled in 
clinical trials. Although previous large databases have reported declining mortality of 
patients with STEMI, substantial mortality change among those with NSTEMI has not 
previously been reported.
Methods: The National Registry of Myocardial Infarction enrolled 2,515,106 patients at 
2,157 U.S. hospitals from 1990-2006. Of these, we evaluated 1,950,561patients with 
diagnoses reﬂecting acute myocardial ischemia on hospital admission.
Results: From 1990-2006, the proportion of NSTEMI increased from 14.2% to 59.1% 
(p<.0001), while the proportion of STEMI decreased. The mean age increased (from 64.1 
to 66.4 years, p<.0001) as did the proportion of females (from 32.4% to 37.0%, p<.0001). 
On admission, patients were less likely to report prior angina, prior AMI or family history of 
coronary artery disease but were more likely to report history of diabetes, hypertension, 
current smoking, heart failure, prior revascularization, stroke and hyperlipidemia. From 
1994-2006, hospital mortality fell among all non-transferred-out patients (10.4% to 6.3%), 
STEMI (11.5% to 8.0%), and NSTEMI (7.1% to 5.2%), (all p<.0001). After adjustment for 
baseline covariates, hospital mortality fell among all patients by 23.6% (odds ratio (OR) 
0.764, 95% CI 0.744-0.785), STEMI by 24.2% (OR 0.758, 0.732-0.784), and NSTEMI by 
22.6% (OR 0.774, 0.741-0.809), all p < 0.001.
Conclusions: This large, observational database from 1990-2006 shows a rising 
prevalence of NSTEMI, and, despite a higher risk proﬁle on presentation, a falling risk-
adjusted hospital mortality in patients with STEMI and, for the ﬁrst time, in patients with 
NSTEMI as well.
3:00 p.m.
1024-65 Lack of Association Between Bleeding and Inﬂammation 
Among Patients With Acute Coronary Syndrome: 
Insights From the Aggrastat to Zocor (A to Z) Trial
Tracy Y. Wang, Fang-Shu Ou, Michael A. Blazing, James A. De Lemos, Robert M. Califf, 
Eric D. Peterson, Duke Clinical Research Institute, Durham, NC, University of Texas 
Southwestern Medical Center, Dallas, TX
Background: In-hospital bleeding among patients with acute coronary syndromes (ACS) 
has been associated with worse long-term outcomes. One hypothesis is that inﬂammation, 
as a result of bleeding and transfusion, may contribute to long-term risk.
Methods: We studied C-reactive protein (CRP) levels as a marker of inﬂammation, 
collected at baseline, 1, 4 and 8 months after discharge among ACS patients enrolled in 
the A to Z trial. CRP trends over time were compared among patients with and without 
in-hospital bleeding or transfusion and by severity.
Results: Among 2322 ACS patients, 281 (12%) had an in-hospital bleeding event. 
Patients with bleeding tended to have higher baseline CRP levels (median CRP 20.1 
mg/L among patients with severe bleeding v. 16.8 mg/L mild bleeding vs. 15.0 mg/L no 



















bleeding, p=0.10). CRP levels were similar between patients with and without transfusion 
(median CRP 15.3 v. 16.9 mg/dL respectively, p=0.79). CRP levels fell rapidly in time in 
all groups (Figure) and there was no difference in CRP levels among patients with and 
without bleeding/transfusion or by bleeding severity at 1, 4, or 8 months.
Conclusion: Although CRP levels may be acutely elevated among patients with a bleeding 
event, this elevation in inﬂammatory markers resolved rapidly. There does not appear to 
be a persistent pro-inﬂammatory state as assessed by CRP among patients with a bleed, 
suggesting that inﬂammation per se does not contribute to the excess long-term mortality 
associated with bleeding. 
3:00 p.m.
1024-66 Myeloperoxidase Levels Associated With Risk of 
Cardiovascular Death and Heart Failure After Non-ST 
Elevation Acute Coronary Syndrome
Benjamin M. Scirica, Marc S. Sabatine, Petr Jarolim, Sarah Sloan, Sabina A. Murphy, 
James L. de Lemos, David A. Morrow, TIMI Study Group, Boston, MA, Brigham and 
Women’s Hospital, Boston, MA
Background: Myeloperoxidase (MPO) is released from leukocytes and implicated in the 
pathophysiology of ACS. Initial studies demonstrated an association of higher MPO with 
poor cardiovascular (CV) outcomes but prospective evaluation together with contemporary 
biomarkers is still needed.
Methods: 4516 pts randomized in MERLIN-TIMI 36 with NSTEACS had baseline samples 
obtained within 48hrs of last symptoms. MPO, cTnI (99%ile =0.07), and NT-proBNP were 
measured (Dade Behring Dimension) and MPO was categorized by quartiles and a 
cutpoint of 670 pM (based on prior work). Median followup was ~1-year.
Results: MPO was >670 pM in 1938 pts(43%). Increasing quartiles of MPO were 
associated with greater risk of CV death/heart failure (HF) (Figure). Elevated MPO 
(>670pM) was associated with increased risk of CV death (adjHR 1.8, p<0.001) and CV 
death/HF after adjusting for baseline risk factors and biomarkers (adjHR 1.7, p<0.001). 
(Figure) This relationship was consistent in pts with normal cTnI (adjHR 1.9, p=0.001) or 
elevated cTnI (Adj HR 1.7, p=002). Elevated MPO was associated with CVD/MI at 30d 
(adjHR 1.6, p=0.016) with an attenuated relationship by 1-year (adjHR 1.3, p=0.06).
Conclusions: Elevated levels of MPO, a marker of leukocyte activation, are associated 
with a substantially higher risk of cardiac events in pts with ACS. This relationship is 
independent of other biomarkers and suggests that MPO offers additive information 
regarding cardiovascular outcomes. 
3:00 p.m.
1024-67 The Effect of Intended Duration of Clopidogrel Use on 
Early and Late Mortality and Major Adverse Cardiac 
Events in Patients With Drug-Eluting Stents
Michelle J. Butler, David Eccleston, David J. Clark, Andrew E. Ajani, Nick 
Andrianopoulos, Angela Brennan, Alexander Black, Chris Reid, Anthony Dart, Stephen 
J. Duffy, Melbourne Interventional Group, Alfred Hospital, Melbourne, Australia, Monash 
University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia
Background: The optimal duration of clopidogrel use for prevention of stent thrombosis 
with drug-eluting stent (DES) use is uncertain.
Methods: We analysed data from 2980 patients who underwent percutaneous coronary 
intervention (PCI) in a large registry who had 12-month follow-up; 1669 (56.0%) with DES 
implantation and 1311 (44.0%) with bare-metal stents (BMS). We compared outcomes at 
30 days and 12 months in 3 patient groups according to planned duration of clopidogrel 
use: a3months, 6 months and q12 months.
Results: Procedural success was similar among the 3 patient groups, irrespective of 
stent type used. Among patients receiving a DES, 30-day follow up demonstrated no 
difference in mortality (p=0.32) or overall MACE (p=0.55) between the groups. In patients 
who received a DES, 12-month mortality was signiﬁcantly lower in the group of patients 
with a longer (q12 months) planned duration of clopidogrel when compared with a shorter 
(a6 months) planned duration (2.8% vs. 5.3%, p=0.012). However, 12-month myocardial 
infarction (6.4% vs. 6.6%, p=0.82), target-vessel revascularization (7.1% vs. 6.5%, 
p=0.61), and overall MACE (14.3% vs. 14.8%, p=0.76) were similar in the longer- and 
shorter-duration clopidogrel strategies. In contrast, mortality at 12 months was similar 
among the 3 clopidogrel-duration strategies in patients receiving a BMS, as was 12-month 
myocardial infarction, target-vessel revascularization and overall MACE. Kaplan-Meier 
analysis demonstrated improved cumulative survival with planned clopidogrel use of q12 
months (log rank p=0.017). Premature cessation of clopidogrel in patients receiving a 
DES was documented in 5.2% of patients alive at 30-day follow up and these patients 
had increased 12-month mortality (10.6% vs. 1.4%, p<0.0001) and MACE (22.4% vs. 
12.0%, p=0.005).
Conclusions: These data suggest that in patients treated with DES, longer (q12 months) 
planned duration of clopidogrel results in reduced 12-month mortality, and that premature 
cessation of clopidogrel results in signiﬁcantly higher event rates. Randomized studies 
are urgently needed to address this issue.
3:00 p.m.
1024-68 Impact of Anemia on Long-term Mortality in Patients 
with Acute Coronary Syndrome
Umesh U. Tamhane, Irfan Hameed, Daniel Montgomery, Krishna Aragam, Garry Ng, 
Saagar Sanghvi, Eva Kline-Rogers, Kim A. Eagle, Hitinder S. Gurm, University of 
Michigan Medical Center, Ann Arbor, MI
Background: Anemia is an independent marker of short term mortality in patients with 
acute coronary syndromes (ACS). We investigated the role of anemia as a prognostic 
marker of long-term mortality in unselected patients with ACS. Further, we assessed 
the incremental value of adding hemoglobin (Hb) to Global Registry of Acute Coronary 
Events (GRACE) risk model.
Methods: We analyzed 3078 consecutive patients with ACS admitted to the University 
of Michigan between December 1998 and October 2004 with complete follow-up data. 
Admission Hb was available for 3052. Patients were divided into two groups based on 
whether they had anemia according to WHO criteria (Hb <13.0g/dL [male] / <12.0g/dL 
[female]). Primary endpoint of our analysis was all cause six-month mortality. Kaplan-
Meier curve was used to plot the survival of anemic and non-anemic patients. A 
Multivariate model was used to assess the additive value of anemia beyond that provided 
by the GRACE risk score.
Results: There were 171 deaths on follow-up. Anemic patients had a signiﬁcantly higher 
risk of death (p< 0.001).After adjusting for GRACE risk score, anemia remained an 
independent predictor of mortality (OR= 2.42; 95% CI 1.74-3.35, p< 0.001;Unadjusted 
OR= 3.40). Adding Hb into the GRACE model modestly improved the prediction of six-
month mortality (C statistic 0.78 versus 0.77).
Conclusion: Lower Hb level is a signiﬁcant predictor of long-term mortality. This readily 
available marker added value to established independent risk predictor models. 
3:00 p.m.
1024-69 Low REsponsiveness to CLOpidogrel and Sirolimus- or 
Paclitaxel-Eluting StEnt Thrombosis (RECLOSE) Trial: 
the Long-Term Mortality
Piergiovanni Buonamici, Angela Migliorini, Guia Moschi, Ruben Vergara, Rossella 
Marcucci, Gian Franco Gensini, Rosanna Abbate, David Antoniucci, Careggi Hospital, 
Florence, Italy
Background The RECLOSE trial showed that non-responsiveness to clopidogrel is 
predictive of DES thrombosis and cardiac mortality at 6 months. No data exist about the 
predictive value of long-term adverse events in patients with DES and clopidogrel loading 
non-responsiveness.Our objective was to determine whether non-responsiveness to 




clopidogrel, as revealed by high in vitro residual platelet reactivity after a 600 mg loading 
of the drug, is predictive of drug-eluting stent (DES) thrombosis and cardiac mortality at 
long-term follow-up. 
Methods Prospective observational cohort study conducted from July 2005 to August 2007 
in an academic hospital. A total of 804 patients who had successful sirolimus or paclitaxel-
eluting stent implantation and who were compliant to clopidogrel treatment for at least 1 
year, had the assessment of residual platelet reactivity after a loading dose of 600 mg of 
clopidogrel by light transmittance aggregometry (LTA). Long-term cardiac mortality was 
deﬁned as death of cardiac or unexplained cause that occurred after 6 months from DES 
implantation. Very late deﬁnite/probable/possible DES thrombosis was deﬁned according 
to the ARC deﬁnitions. Survival curves were generated using the Kaplan-Meier method, 
and the difference between curves was assessed by log-rank test.
Results The median follow-up time was 639 (IQ 555-756) days; follow-up was completed 
in 803 (99.9%) patients. After 6 months there were 11 late cardiac deaths, 4 in the 
nonresponder group (3.8%) and 7 in the responder group (1%). The overall long-term 
cardiac survival rates in non responder and responder patients were 89 ± 3%, and 97 ± 1%, 
respectively; p < 0.001. Very late deﬁnite/probable/possible DES thrombosis was higher in 
non responders than in responders patients, 2.8% and 0.3%, respectively; p=0.002
Conclusions High residual platelet reactivity after 600 mg loading dose of clopidogrel, 
as revealed by a single assessment with LTA, is a strong predictor of cardiac death and 
DES thrombosis.
3:00 p.m.
1024-70 Does the Pattern of Serial Values of C-Reactive Protein 
Predict Outcome in Patients With Acute Coronary 
Disease? The RISCA Study
Peter Bogaty, Luce Boyer, Serge Simard, Franz Dauwe, Robert Dupuis, BenoÃ®t Verret, 
Thao Huynh, Fernand Bertrand, Gilles R. Dagenais, James M. Brophy, Quebec Heart 
Institute/Laval Hospital/Laval University, Quebec, QC, Canada
Background: The predictive value of serial measurements of the inﬂammatory marker, 
C-Reactive Protein (CRP), in the follow-up of patients with acute coronary syndromes 
is undeﬁned.
Methods: We prospectively measured CRP at admission, hospital discharge, and 1 month 
later in 1210 patients with acute myocardial infarction (MI; 64%) or unstable angina (UA; 
36%). Patients were followed for 1 year and were classiﬁed into 5 patterns of serial CRP 
values: low plateau; high plateau; rising values; falling values; and no pattern. High values 
and low values were those in the top and bottom tertiles, respectively, at that sampling 
time point. We evaluated the odds ratios (OR) and 95% conﬁdence intervals (CI) of each 
pattern for occurrence at 1 year of the primary composite endpoint of death, MI, and UA 
with ECG changes.
Results: Mean age was 62 ± 12 years, 75% were men, 20% had diabetes, 28% previous 
MI, 30% vascular disease, and 6% previous heart failure. From hospital discharge to 1 
year, there were 37 deaths (3.1%), 59 nonfatal MI (5.0%) and 26 UA with ECG changes 
(2.2%). The primary endpoint occurred in 109 patients (9.2%) at 1 year. ORs with 95% CI 
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(193) 1.25 (0.64, 2.43) High Plateau (97) 1.59 (0.52, 4.91)
Rising Values 
(425) 0.96 (0.53, 1.73)
Rising Values 
(110) 1.83 (0.63, 5.30)
Falling Values 
(141) 1.16 (0.55, 2.43)
Falling Values 
(105) 0.60 (0.15, 2.47)
No Pattern 
(193) 1.70 (0.91, 3.19) No Pattern (733) 1.63 (0.69, 3.87)
Conclusion: Neither low or high plateaus nor rising or falling values predicted occurrence 
or non-occurrence of the primary endpoint at 1 year. This large prospective study does not 
support the clinical utility of measuring serial CRP values to predict outcome in patients 
with acute coronary disease.
3:00 p.m.
1024-71 Economic Evaluation of Bivalirudin With or Without 
Glycoprotein IIB/IIIA Inhibition Versus Heparin With 
Routine Glycoprotein IIB/IIIA Inhibition for Early 
Invasive Management of Acute Coronary Syndromes
Duane S. Pinto, Gregg W. Stone, Meghan York, Matthew R. Reynolds, Brent T. McLaurin, 
David A. Cox, Elizabeth A. Schneider, Chunxue Shi, Joshua Walczak, David A. Machon, 
Ronna H. Berezin, Roxana Mehran, E. Magnus Ohman, A. Michael Lincoff, David J. 
Cohen, Beth Israel Deaconess Medical Center, Boston, MA, Cardiovascular Research 
Foundation, Columbia University, New York, NY
Background: The ACUITY trial demonstrated that in ACS pts undergoing early invasive 
management, bivalirudin (BIV) monotherapy yields similar ischemic complication rates 
and less bleeding than regimens that include glycoprotein IIb/IIIa receptor inhibitors (GPI). 
The economic impact of this strategy is unknown.
Methods: We performed a prospective economic analysis of US pts enrolled in ACUITY 
(n=7851) who were randomized to receive heparin (UFH or LWMH) + GPI, BIV + GPI 
or BIV alone. Resource utilization data were collected through 30 days and costs were 
estimated using resource-based accounting, hospital (HOSP) billing data and the 
Medicare fee schedule.
Results: At 30 days, ischemic event rates were similar for all groups, but major bleeding 
was signiﬁcantly lower with BIV alone (see Table). Although anticoagulant costs were 
lowest for heparin + cath lab GPI, initial HOSP costs were lowest with BIV alone compared 
to either heparin + upstream GPI or heparin + cath lab GPI (p<0.001) with similar ﬁndings 
at 30 days. Regression modeling demonstrated that savings with BIV were primarily due 
to less major and minor bleeding (incremental cost = $8658 and $2282/event).
Conclusions: Among US ACUITY patients, BIV monotherapy compared to heparin + GPI, 
resulted in similar rates of ischemic events, reduced bleeding and shorter LOS. Despite higher 
drug costs, aggregate HOSP and 30 day costs were lowest with BIV alone. BIV is thus an 
economically attractive alternative to heparin + GPI in pts with moderate-high risk ACS. 












Revascularization 7.3% 8.1% 8.3% 0.60
Major Bleeding 5.5% 5.0% 3.2% <0.001
Other Bleeding 29.1% 22.0% 14.2% <0.001
Length of Stay (Days) 3.47 3.83 3.74 0.02
Costs
Antithrombotic therapy $896 $515 $976 <0.001
Index hospitalization $14,440 $14,028 $13,844 <0.001
Follow-up $767 $856 $917 0.66
Total 30 day costs $15,207 $14,884 $14,761 0.005
GPI=Glycoprotein IIb/IIIa Receptor Inhibitor; Values in brackets represent medians
3:00 p.m.
1024-72 Coronary ﬂow reserve is related to extension and 
trasmural entity of myocardial necrosis and predicts 
functional recovery after acute myocardial infarction.
A study performed with contrast-enhanced magnetic 
resonance
Roberta Montisci, Massimo Ruscazio, Francesco Tona, Francesco Corbetti, Cristiano 
Sarais, Sara Pontarollo, Luisa Cacciavillani, Ramondo Angelo, Luigi Meloni, Sabino 
Iliceto, Clinical Cardiology, Cagliari, Italy, Clinical Cardiology, Padova, Italy
Background: In humans, few studies have examined the effect of the transmural entity 
of myocardial necrosis on coronary microcirculation and its related role in predicting 
functional recovery. The aim of this study was to examine the inﬂuence of clinical and 
gadolinium contrast-enhanced cardiac magnetic resonance (GE-MRI) derived structural 
determinants of coronary ﬂow reserve (CFR) after anterior myocardial infarction (AMI), 
and their predictive value on regional functional recovery.
Methods : CFR by transthoracic echocardiography and GE-MRI were studied in 37 
patients with AMI, who underwent coronary revascularization with coronary angioplasty. 
The wall motion score index in left descending anterior coronary artery territory (A-
WMSI) was calculated at admission and follow-up (FU). Recovery of regional left 
ventricular(LV)function was deﬁned as the difference in A-WMSI at admission and FU 
. The necrosis score index (NSI) and transmurality score index (TSI) by GE-MRI were 
calculated in the risk area.
Results: Bivariate analysis indicated that the CPK peak (P<0.001), Troponin I peak 
(P=003), heart rate (P=0.03), NSI (P< 0.0001) and TSI ( P=0.01) were related to CFR and 
that CFR (P< 0.0001), NSI (P= 0.01), TSI (P< 0.0001), microvascular obstruction at GE-
MRI (P=0.01) and heart rate (P=0.03) are all related to functional recovery. Multivariable 
analysis revealed that TSI (P< 0.0001) was the only independent determinant of CFR and 
that CFR (P< 0.0001) was the only independent predictor of LV functional recovery.
Conclusions: Preservation of microvascular function after AMI is related to the transmural 
entity of myocardial necrosis, and is an important factor inﬂuencing regional LV recovery.
3:00 p.m.
1024-73 Major Bleeding Is Associated With Increased One-Year 
Mortality and Ischemic Events in Patients With Acute 
Coronary Syndromes: Results From the ACUITY Trial
Steven V. Manoukian, Frederick Feit, Steven R. Steinhubl, Michele D. Voeltz, George D. 
Dangas, Ramin Ebrahimi, Roxana Mehran, Gregg W. Stone, Emory University School of 
Medicine, Atlanta, GA
Background: Major bleeding (MB) is associated with increased short-term mortality and 
ischemic events in acute coronary syndromes, although its long-term impact is less clear. 
We evaluated the relationship between MB and rates of one-year mortality and ischemic 
events in patients with acute coronary syndromes.
Methods: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial is 
a randomized comparison of unfractionated heparin or enoxaparin (H) + glycoprotein IIb/IIIa 
inhibition (GPI), bivalirudin (BIV) + GPI and BIV alone in 13,819 patients with moderate and 
high-risk acute coronary syndromes undergoing an early invasive strategy. MB (non-coronary 
artery bypass surgery-related) was deﬁned as: intracranial, intraocular, or retroperitoneal, 
access site with intervention, hematoma q5 cm, hemoglobin drop q3g/dL with source or q4g/
dL without source or transfusion within 30 days. The impact of MB on one-year mortality and 
composite ischemic events (death, myocardial infarction and unplanned revascularization) 
was assessed using a time-updated covariate-adjusted Cox model.
Results: Of 13,819 patients, 645 (4.7%) had MB. Patients with MB were more likely to be 
older, female and have lower body weight, diabetes, hypertension, reduced creatinine 
clearance and elevated biomarkers. They were more likely to receive GPI and less likely 
to have had prior percutaneous coronary intervention, smoke and have hyperlipidemia 
(all p<0.05). MB was less frequent for BIV vs. H+GPI (3.0% vs. 5.7%, p<0.0001), and 
similar for BIV+GPI vs. H+GPI (p=ns). Mortality at one year was higher in patients with 
vs. without MB (14.4% vs. 3.3%, p<0.0001). Composite ischemic event rates at one year 



















were also higher in patients with vs. without MB (32.7% vs. 14.9%, p<0.0001). MB was 
an independent predictor of one-year mortality (hazard ratio [95% conﬁdence interval] = 
2.89 [2.24-3.72], p<0.0001).
Conclusion: MB is an independent predictor of one-year mortality and is associated with 
increased rates of ischemic events at one year in patients with acute coronary syndromes. 
MB rates are lower in patients treated with BIV (vs. H+GPI) and similar in regimens 
containing GPI.
3:00 p.m.
1024-74 Transfusion Is Associated With Increased One-Year 
Mortality and Ischemic Events in Patients With Acute 
Coronary Syndromes: Results From the ACUITY Trial
Steven V. Manoukian, Michele D. Voeltz, Frederick Feit, Sunil V. Rao, Steven R. 
Steinhubl, George D. Dangas, Roxana Mehran, Gregg W. Stone, Emory University 
School of Medicine, Atlanta, GA
Background: Blood product transfusion is associated with increased rates of short-term 
mortality and ischemic events in patients with acute coronary syndromes. Whether 
transfusion adversely affects long-term outcomes is not well-studied. We assessed the 
relationship between transfusion and rates of one-year mortality and ischemic events in 
patients with acute coronary syndromes.
Methods: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial 
is a randomized comparison of bivalirudin (BIV), heparin or enoxaparin (H) + glycoprotein 
IIb/IIIa inhibition (GPI) and BIV+GPI in 13,819 patients with moderate and high-risk acute 
coronary syndromes undergoing an early invasive strategy. Transfusion was deﬁned as the 
administration of any blood product, including whole blood, packed red blood cells, platelets 
or fresh frozen plasma within 30 days. The association between transfusion and rates of one-
year mortality and composite ischemic events (death, myocardial infarction and unplanned 
revascularization) was assessed using a time-updated covariate-adjusted Cox model.
Results: Of 13,819 patients, 319 (2.3%) received a transfusion. Transfusion rates were 
signiﬁcantly lower in patients treated with BIV vs. H+GPI (1.6% vs. 2.7%, p=0.0003) but 
similar in patients treated with BIV+GPI vs. H+GPI (2.6% vs. 2.7%, p=ns). Composite 
ischemic event rates at one year were higher in transfused vs. nontransfused patients (40.1% 
vs. 15.1%, p<0.0001). Mortality at one year was also higher in transfused vs. nontransfused 
patients (21.9% vs. 3.4%, p<0.0001). Transfusion was an independent predictor of one-year 
mortality (hazard ratio [95% conﬁdence interval] = 3.89 [2.88-5.25], p<0.0001).
Conclusion: Blood product transfusion is an independent predictor of one-year mortality 
and is associated with increased one-year ischemic event rates in patients with acute 
coronary syndromes. Transfusion rates are lower in patients treated with BIV compared 
to those treated with H+GPI. These data suggest that BIV may have a beneﬁcial effect 
on mortality in part due to a reduction in the risk of transfusion in patients with acute 
coronary syndromes.
3:00 p.m.
1024-75 Anemia Is Associated With Increased One-Year 
Mortality and Ischemic Events in Patients With Acute 
Coronary Syndromes: Results From the ACUITY Trial
Steven V. Manoukian, George D. Dangas, Michele D. Voeltz, Frederick Feit, Roxana 
Mehran, Gregg W. Stone, Emory University School of Medicine, Atlanta, GA
Background: Anemia is associated with increased rates of short-term mortality and 
ischemic events in patients with acute coronary syndromes. Whether anemia adversely 
impacts long-term outcomes is less clear. We assessed the relationship between anemia 
and rates of one-year mortality and ischemic events in patients with acute coronary 
syndromes.
Methods: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) 
trial is a randomized comparison of unfractionated heparin or enoxaparin (H) + 
glycoprotein IIb/IIIa inhibition (GPI), bivalirudin (BIV) + GPI and BIV alone in 13,819 
patients with moderate and high-risk acute coronary syndromes undergoing an early 
invasive strategy. Anemia was deﬁned using baseline hemoglobin values and the World 
Health Organization deﬁnition of hemoglobin <13.0 g/L in men and <12.0 g/dL in women. 
The association between anemia and rates of one-year mortality and composite ischemic 
events (death, myocardial infarction and unplanned revascularization) was assessed 
using a time-updated covariate-adjusted Cox model.
Results: Of 13,039 patients with baseline hemoglobin data, 2,200 (16.9%) were anemic. 
Mean hemoglobin values were signiﬁcantly lower in anemic vs. nonanemic patients (11.64 
± 0.99 mg/dl vs. 14.48 ± 1.22 mg/dl, p<0.0001). Anemic patients had higher composite 
ischemic event rates at one year vs. nonanemic patients (20.8% vs. 14.6%, p<0.0001). 
Similarly, unadjusted mortality rates at one year were higher in anemic vs. nonanemic 
patients (7.0% vs. 3.1%, p<0.0001). Anemia was an independent predictor of one-year 
mortality (hazard ratio [95% conﬁdence interval] = 1.61 [1.32-1.98], p<0.0001).
Conclusion: Anemia is a common ﬁnding in patients with acute coronary syndromes and 
is associated with a signiﬁcant increase in one-year mortality and ischemic event rates. 
Furthermore, anemia is an independent predictor of one-year mortality. Anemia should be 
recognized as a high-risk marker in patients with acute coronary syndromes.
3:00 p.m.
1024-76 ST Segment Deviation Resolution Predicts Long-
term Mortality in Patients With Acute Myocardial 
Infarction Undergoing Primary Percutaneous Coronary 
Intervention
Niels J. Verouden, Karel T. Koch, José P. Henriques, Jan Baan, René J. van der Schaaf, 
Marije M. Vis, Jan G. Tijssen, Martin G. Meesterman, Jan J. Piek, Robbert J. de Winter, 
Academic Medical Center, Amsterdam, The Netherlands
Background: Because the predictive value of ST segment deviation Resolution (STR) 
originates from the ﬁbrinolysis era, we evaluated whether STR is predictive for long-term 
mortality in patients with ST Elevation Myocardial Infarction (STEMI) patients undergoing 
primary Percutaneous Coronary Intervention (PCI).
Methods: In this single center cohort study, 1572 STEMI patients underwent primary PCI 
between 2000 and 2005. Mean clinical follow-up was 2.5 years (SD ± 1.3 years). STR was 
deﬁned as the relative difference (in %) of the summed ST deviation between the pre-PCI 
and the immediately post-PCI 12-lead electrocardiogram. We discriminated between 687 
anterior MI and 885 non-anterior MI patients.
Results: During follow-up, 83 patients with anterior MI and 82 with non-anterior MI died.
Among patients with non-anterior MI, there was an inverse relationship between STR and 
mortality. Compared to patients with STR q 70% (reference), patients with STR between 
70 and 30% showed a hazard ratio (HR) of 3.0 (95% conﬁdence interval (CI), 1.5 - 6.1; p = 
0.002), and patients with STR < 30% showed a HR of 4.9 (95% CI, 2.4 - 9.8; p < 0.0001).
Among anterior-MI patients, mortality was solely higher in patients with STR < 30% 
compared to patients with STR q 30% (HR 2.0; 95% CI, 1.2 to 3.3; p = 0.005) (see table).
Conclusions: STR immediately post procedure is a strong predictor of long-term mortality 
in STEMI patients undergoing primary PCI. Different cut-off points should be used for 
anterior versus non-anterior MI. 
3:00 p.m.
1024-77  Chronic Kidney Disease, Cardiovascular Outcomes, 
and Treatment Disparities following Non-ST Elevation 
Myocardial Infarction
Jessica L. Mega, Benjamin M. Scirica, Jie Qin, C. Michael Gibson, David A. Morrow, 
Brigham & Women’s Hospital, Boston, MA
Background: Chronic kidney disease (CKD) is associated with an increased risk of death 
and CV events following an MI. There is concern regarding underutilization of medical and 
interventional therapies in this population.
Methods: MERLIN-TIMI 36 randomized NSTE ACS patients to ranolazine or placebo, and 
the study did not exclude subjects based on renal dysfunction (except dialysis). Glomerular 
ﬁltration rate (GFR, ml/min/1.73 m2) was estimated using MDRD in 6,557 patients.
Results: Patients with worse renal function were older and more likely to have a history of DM, 
htn, prior revasc, and heart failure (P<0.0001 for each). Lower GFR was associated with a 
striking increase in risk of CV death and MI through 1 y (Fig), despite adjustment for baseline 
variables (GFR <30 vs >90: HR 2.10, 95% CI 1.32-3.35). During the hospitalization, patients 
with lower GFR were found to have a greater extent of coronary disease on angiography and 
worse LV function (P<0.0001 for each); however, they were less likely be treated with evidence-
based medicines (including aspirin, clopidogrel, heparin, GPIIb/IIIa receptor inhibitors, P<0.04 
for each) and undergo an early invasive management strategy (Fig).
Conclusions: There was a strong graded relationship between worse renal function and 
cardiovascular events, and patients with lower GFR were less likely to be treated with 
evidence-based medications and an early invasive treatment strategy. Continued efforts 
to modify the high risk of this CKD population are warranted.





1024-78 Prognosis of Elderly Patients after Acute Myocardial 
Infarction and Coronary Revascularization Procedure
NIcolas Mansencal, Rémy Pillière, Alain Beauchet, Thierry Joseph, Franck Digne, 
Pascal Lacombe, Olivier Dubourg, AP-HP, Hôpital universitaire Ambroise Paré, 
Boulogne, France
The aim of this study was to assess the prognosis of pts > 80 years referred to a cath-lab 
for acute myocardial infarction (MI).
Methods: Over an 10-year study period, we analyzed the data of 1687 pts referred to our 
cath-lab for acute MI. We compared data between group 1 (pts > 80 years of age (n=152; 
83.9 ± 3.3 yo)) and group 2 (pts < 80 years (n=1535; 59.5 ± 11.6 yo)). Follow-up was 
established by phone contact with the pts, their families or their physicians.
Results: Global in-hospital mortality was 7%: 18% in pts q 80 years versus 5.5% in pts of 
group 2 (p < 0.0001). Among pts presenting with cardiogenic shock (18 pts in group 1 and 
60 pts in group 2), the in-hospital mortality was 83% versus 62% (p = 0.07). In pts without 
initial cardiogenic shock, in-hospital mortality was 10% in group 1 versus 2% in group 2 
(p < 0.0001). Follow-up was obtained in 97.4% in group 1 (30 ± 28 months) and 96.5% 
in group 2 (63 ± 49 months). Kaplan-Meier analysis showed an early increased mortality 
of pts q 80 years at one month (p < 0.0001, Fig), whereas the rate of mortality among 
pts q 80 years at one year but after the initial hospitalization following acute MI was low 
(4% versus 3% in group 2, p = 0.58). Long-term follow-up (> 10 years) reveals that elderly 
patients died, as expected.
Conclusions: This study demonstrates that elderly patients presenting with acute MI had 
an early increased risk of mortality. Interestingly, once the acute phase passed, prognosis 
at one year is excellent and is comparable with younger patients. 
3:00 p.m.
1024-79 Aspirin Resistance As A Predictor Of Adverse 1-Year 
Outcome In Patients With Non-ST Elevation Acute 
Coronary Syndromes
Michael Zairis, Georgios Z. Tsiaousis, Stamatis Makrygiannis, Dionisios Xenos, 
Anastasios Theodosis-Georgilas, Konstantinos Kontos, Stilianos Karvounaris, ZInon 
Katidis, Stella Nini, Evdokia Adamopoulou, Ioannis Hatzissavas, Stephanos Foussas, 
Tzanio Hospital, Piraeus, Greece
Background: There is scant data concerning the impact of aspirin resistance on long 
term outcome in patients (pts) with unstable coronary artery disease. We evaluated 
the predictive value of aspirin resistance for the incidence of 1-year composite of 
cardiovascular death and rehospitalization for non-fatal myocardial infarction in pts with 
non-ST elevation acute coronary syndromes (NSTE-ACS).
Methods: A total of 496 consecutive pts (age=69±9 yrs, 69% males) who hospitalized in 
the ﬁrst 24 hrs following index pain, were included. Platelets response to aspirin therapy 
was measured by the platelet function analyzer (PFA-100) closure time (CT). CT was 
measured upon presentation or 6 hours after aspirin loading in pts with or without prior 
aspirin therapy respectively. Aspirin resistance was deﬁned as a CT<193 sec based on 
the 90% central interval of normal.
Results: A total of 121 (24.4%) pts had a CT<193 sec (aspirin resistants). By 1-year 
64 (10.7%) pts died and 42 (8.5%) were rehospitalized due to a non fatal myocardial 
infarction. Although there were not signiﬁcantly differences between pts with or without 
aspirin resistance, the former were at signiﬁcantly higher risk for the composite end 
point (37.2% vs. 16.3%; hazard ratio [HR]= 2.7; 95% CI=1.8-3.9; p<0.001). In particular 
aspirin resistants were at signiﬁcantly higher risk for both cardiovascular death (23.1% vs. 
9.6%; HR=2.6; 95% CI=1.6-4.3; p<0.001) and rehospitalization for non-fatal myocardial 
infarction than non aspirin resistants (14% vs. 6.7%; HR=2.2; 95% CI=1.2-4.1; p=0.01).
Conclusion: The present results show that aspirin resistance portends an increased risk 
for long term thrombosis related adverse outcome in pts with NSTE-ACS.
3:00 p.m.
1024-80 Is Right Ventricular Involvement A Predictor Of Long-
Term Mortality In Patients With Acute Inferior ST 
Elevation Myocardial Infarction?
Stamatis Makrygiannis, Michael Zairis, Georgios Z. Tsiaousis, Dionisios Xenos, 
Anastasios Theodosis-Georgilas, Evridiki Gougourela, Petros Smilakos, Joseph 
Papadopoulos, Konstantinos Garefallakis, Nikolaos Tellis, Konstantinos Katsaros, 
Stephanos Foussas, Tzanio Hospital, Piraeus, Greece
Background: It is well known that right ventricular (RV) myocardial involvement carries 
an increased risk of early fatal and non-fatal complications in patients (pts) who are 
hospitalized due to an acute inferior ST elevation myocardial infarction. However, there is 
scant data concerning the long term impact of RV myocardial involvement in this setting.
Methods: The study cohort comprised 1208 consecutive pts (mean age=64.5±10.3 yrs, 
79.2% males) who survived to hospital discharge after hospitalization for acute inferior ST 
elevation myocardial infarction. The cohort was divided into two groups according to the 
presence (459 pts) or no (749 pts) of RV involvement, deﬁned as ST-segment elevation q 
1mm in V4R, in admission ECG. Cardiac death by 3 years was the prespeciﬁed primary 
study endpoint.
Results: There were no signiﬁcant differences in baseline characteristics, medical history 
and medical therapy during the study period between the 2 groups. By 3 years, the 
incidence of the primary endpoint was similar in both groups (17.6% and 16.8% for pts 
with or without RV involvement, respectively; RR=1.1, 95%CI=0.8-1.4; p=0.73).
Conclusion: In patients who survived to hospital discharge following hospitalization for 
acute inferior ST elevation myocardial infarction, right ventricular involvement does not 
portend any increased risk for long term mortality. 
3:00 p.m.
1024-83 Extent of ST Segment Resolution After Fibrinolysis 
Adds Dynamic Risk Stratiﬁcation to the TIMI Risk Score 
for STEMI
James R. Harkness, Benjamin M. Scirica, Marc S. Sabatine, David A. Morrow, Sarah 
Sloan, Stephen D. Wiviott, Robert P. Giugliano, Christopher P. Cannon, Eugene 
Braunwald, TIMI Study Group, Boston, MA, Brigham and Women’s Hospital, Boston, MA
Background: The TIMI risk score (TRS) for STEMI is a validated risk score for predicting 
mortality. Though not part of the TRS, ST segment resolution (STRes) may provide a 
dynamic method of risk stratiﬁcation based on response to reperfusion and therefore 
improve on the risk stratiﬁcation of the TRS alone. Methods: CLARITY-TIMI 28 
randomized 3491 pts with STEMI receiving ﬁbrinolysis to clopidogrel v. placebo. 2347 
pts had ECGs valid to calculate STRes at 90min, which was deﬁned as complete(>70%), 
partial(30-70%), or no resolution(30%). TRS was deﬁned as low(0-2), medium(3-4) and 
high(q5). Pts were followed for 30 days. Results: In a multivariable analysis, both TRS 
and STRes were strongly associated with death (high TRS [adjOR 10.2, p<0.01], mod 
TRS [adjOR 3.1, p<0.01], no STRes [adjOR 5.2, p<0.01] and partial STRes [adjOR 3.1, 
p<0.01]) and death/HF (high TRS [adjOR 6.2, p<0.01], mod TRS [adjOR 2.2, p<0.01], 
no STRes [adjOR 3.7, p<0.001], and partial STRes [adjOR 1.8, p=0.01]). Furthermore, 
STRes status provided a consistent gradient of risk across all TRS categories (Figure). 
The area under the receiver-operating characteristic curves for death/HF increased from 
0.72 with TRS alone to 0.76 when STRes was added (p<0.01), with a similar relationship 
with mortality alone. Conclusion: The extent of STRes is an independent and additive 
predictor of death and HF when used with the TRS. STRes may be used together with the 
TIMI risk score to better risk stratify pts following ﬁbrinolysis. 




















1024-84 Does Continuous ST-Segment Monitoring Add 
Prognostic Information to the TIMI, PURSUIT, and 
GRACE Risk Scores?
Pedro L. Carmo, Jorge S. Ferreira, Carlos T. Aguiar, Pedro A. Goncalves, Luis F. Raposo, 
Antonio M. Ferreira, Jose M. Aniceto Silva, Hospital Santa Cruz, Carnaxide, Portugal
Background: Recurrent ischemia is frequent in patients (pts) with non-ST-elevation 
acute coronary syndromes (NSTE-ACS), and portends a worse prognosis. Continuous 
ST-segment monitoring (CSTM) adequately reﬂects the dynamic nature of myocardial 
ischemia and allows the detection of silent ischemic episodes. The aim of this study is to 
investigate whether CSTM adds prognostic information to the risk scores currently used 
in clinical practice.
Methods: We studied 234 pts with NSTE-ACS in whom CSTM was performed in the ﬁrst 
24 hours after admission. An ST episode was deﬁned as a transient ST-segment deviation 
in q1 lead of q0.1 mV, and persisting q1 min. Three risk scores were calculated for each 
pt: TIMI (for NSTE-ACS), PURSUIT (death/MI model), and GRACE. The endpoint was 
deﬁned as death or nonfatal myocardial infarction (MI), whichever occurred ﬁrst by 1 
year follow-up.
Results: ST episodes were detected in 54 pts (23.1%) and associated with worse 1-year 
outcome: 25.9% endpoint rate vs 12.2% for pts without ST episodes (OR = 2.51; 95% CI, 
1.18-5,35; P = 0.026). All 3 risk scores predicted 1-year outcome, but the GRACE risk 
score (c-statistic = 0.755; 95% CI, 0.695-0.809) was superior to both TIMI risk score (c-
statistic = 0.632; 95% CI, 0.567-0.694) and PURSUIT risk score (c-statistic = 0.644; 95% 
CI, 0.579-0.706). A GRACE risk score >124 showed the highest accuracy for predicting 
the study endpoint. The presence of ST episodes added independent prognostic 
information to the TIMI risk score (HR = 2.23; 95% CI, 1.13-4.38) and to the PURSUIT 
risk score (HR = 2.03; 95% CI, 1.03-3.98), but not to the GRACE risk score.
Conclusions: CSTM provides incremental prognostic information beyond the TIMI and 
PURSUIT risk scores, but not the GRACE risk score. Hence, the GRACE risk score 
should be the preferred stratiﬁcation model in daily clinical practice.
3:00 p.m.
1024-85 Chromogranin A Levels in the Acute Phase 
Independently Predicts Mortality and Heart Failure 
Hospitalizations During Follow-up in Patients With Non-
ST Elevation Acute Coronary Syndromes
Helge Rosjo, Anna M. Jansson, Alan Flyvbjerg, Anita Persson, Thomas Karlsson, 
Marianne Hartford, Torbjorn Omland, Kenneth Caidahl, Akershus University Hospital, 
Lorenskog, Norway, Karolinska University Hospital, Stockholm/ Solna, Sweden
Introduction: The neurohumoral marker chromogranin A (CgA) has in small studies 
been shown to predict mortality and heart failure hospitalizations after ST-elevation 
myocardial infarction. We hypothesized that CgA also would predict mortality and 
heart failure hospitalizations during follow-up in patients with non-ST elevation acute 
coronary syndromes (NST-ACS), and that CgA would provide additional information to 
echocardiographic ﬁndings and contemporary cardiovascular biomarkers.
Methods: CgA, cardiac troponin I, C-reactive protein (CRP) and B-type natriuretic peptide 
(BNP) were measured within 24 hrs of admission in 477 patients with NST-ACS (mean 
age 65 years, 32 % female). Echocardiographically determined left ventricular ejection 
fraction (LVEF) was obtained within day 5 of admission (n=357).
Results: During a median follow-up of 44 months, 85 patients (18%) died and 50 (10%) 
were hospitalized for heart failure. By Cox proportional hazards regression model (hazard 
ratio per 1 SD increase in log transformed CgA), baseline CgA concentration was strongly 
associated with the primary outcome mortality or heart failure hospitalizations (HR 1.61 
[1.39-1.86], p<0.0001). After adjusting for contemporary cardiovascular biomarkers and 
conventional risk markers (age, gender, smoking status, prior myocardial infarction, 
diabetes, hypertension, congestive heart failure, heart rate, Killip class (>I) on admission, 
creatinine clearance, and peak CKMB), CgA still predicted outcome (HR 1.33 [1.07-
1.66]; p=0.01). Further adjustment for LVEF attenuated the association, but baseline CgA 
concentrations were still predictive of mortality or heart failure hospitalizations (HR 1.33 
[1.03-1.73], p=0.03).
Conclusions: CgA is a powerful predictor of mortality and heart failure in NST-ACS and 
provides incremental prognostic information to cardiac Troponin I, CRP, BNP, and LVEF.
3:00 p.m.
1024-86 Effect of Enhanced External Counterpulsation on 
Symptoms, Quality of Life, 6-Minute Walking Distance, 
and Left Ventricular Systolic and Diastolic Function 
After 35 Days of Treatment and at 1-Year Follow-Up in 
47 Patients With Chronic Refractory Angina
Anil Kumar, Wilbert S. Aronow, Aniket Vadnerkar, Puneet Sidhu, Sanjay Mittal, Ravi R. 
Kasliwal, Naresh Trehan, Soundshore Medical Center/New York Medical College, New 
Rochelle, NY, ESCORTS Heart Institute and Research Center, New Delhi, India
Background: Enhanced external counterpulsation (EECP) improves symptoms and 
exercise duration in patients with refractory angina pectoris. The effect of EECP on left 
ventricular (LV) systolic and diastolic function needs to be investigated.
Methods: In a prospective study, EECP was performed for 1 hour each day for 35 days in 
47 patients, mean age 61 ± 8 years, with prior coronary revascularization who had chronic 
refractory angina despite antianginal drugs and who were not candidates for further 
coronary revascularization. The effect of EECP on symptoms, quality of life, 6-minute walking 
distance, and LV systolic and diastolic function measured by 2-dimensional and Doppler 
echocardiography was investigated after 35 days of EECP and at 1 year after EECP.
Results: Compared to baseline values, EECP signiﬁcantly improved anginal symptoms, 
dyspnea on exertion, and quality of life after 35 days of treatment (p<0.001) and at 1-year 
follow-up (p<0.001). Compared to the baseline value of 653 ± 249 feet, EECP signiﬁcantly 
improved the 6-minute walking distance to 1,025 ± 234 feet after 35 days of treatment 
(p<0.001) and to 1,040 ± 221 feet at 1-year follow-up (p <0.001). However, EECP did 
not signiﬁcantly affect LV ejection fraction, LV end-diastolic and end-systolic dimensions, 
LV end-diastolic and end-systolic volumes, E/A ratio, isovolumic relaxation time, and 
deceleration time measured by 2-dimensional and Doppler echocardiography.
Conclusions: EECP caused a signiﬁcant improvement in symptoms and in exercise 
tolerance after 35 days of therapy and at 1-year follow-up in patients with refractory 
angina pectoris who were not candidates for further coronary revascularization. However, 
EECP did not improve any measurements of LV systolic function or LV diastolic function.
3:00 p.m.
1024-87 Do Different Healthcare Systems Impact Major 
Outcomes In Stable Coronary Disease Patients 
Enrolled In COURAGE?
Bernard R. Chaitman, Pamela M. Hartigan, David C. Booth, Koon K. Teo, John Mancini, 
William J. Kostuk, John A. Spertus, David J. Maron, Marcin Dada, Robert A. O’Rourke, 
William S. Weintraub, William E. Boden; for the COURAGE Investigators, Daniel S. 
Berman, Leslee J. Shaw, Saint Louis University School of Medicine, St. Louis, MO
Background: The COURAGE trial reported no signiﬁcant differences in major 
cardiovascular outcomes when coronary angioplasty (PCI) was added to optimal medical 
therapy (OMT) after a median 4.6 yr follow-up. Patients were enrolled from US Veteran 
Affairs (VA) (n=968), US non-VA (US) (n=385) and Canadian (CDN) (n=931) healthcare 
systems; randomization was blocked by hospital and prior bypass surgery. We examined 
cardiovascular outcomes by individual healthcare system (HCS) to determine whether 
HCS (and their associated practice cultures) was associated with the study.
Methods: Cox regression analyses after adjustment for baseline patient characteristics 
was used to assess the association of HCS with death and for the composite endpoint of 
death/myocardial infarction (MI).
Results: Baseline demographics were not signiﬁcantly different among treatment groups 
within each HCS. Five yrs after randomization, the percent of pts that exercised 30-45 min 
at least 5 times/week was 33%, 35% and 46% (p<0.001) and LDL cholesterol was <70 
mg/dL in 39%, 42% and 50% of pts (p<0.001) in the VA, US, and CDN HCS, respectively. 
In spite of these differences, the interaction between HCS was not signiﬁcant for the 
endpoint of death (p=0.25) or the composite endpoint of death/MI (p=0.24). Similar results 
were obtained after analyses for cardiovascular death and cardiovascular death/MI.
Conclusions: In COURAGE, PCI was not shown to improve survival or reduce death/MI 
compared to OMT across all 3 healthcare systems studied. 
OMT PCI P OMT PCI P
Death Death Death/MI Death/MI
VA 58 (12.1) 42 (8.6) 0.07 104 (21.7) 107 (21.9) 0.94
US 15 (7.9) 15 (7.7) 0.94 38 (19.9) 30 (15.3) 0.24
CDN 22 (4.7) 28 (6) 0.37 60 (12.8) 74 (16) 0.17
Total 95 (8.3) 85 (7.4) 0.38 202 (17.8) 211 (18.4) 0.62
3:00 p.m.
1024-88 Routine PCI Improves Short but not Long term Angina 
Status in Patients with an Occluded Infarct Artery: 
Results from the Occluded Artery Trial (OAT)
Gerard P. Devlin, Daniel B. Mark, Gervasio A. Lamas, Antonio C. Carvalho, Vladimir 
Dzavik, Sandra A. Forman, Carlos R. Vozzi, Michael Ragosta, Jamie M. Rankin, Paulo 
Caramori, George Sopko, Eduardo Balcells, Jonathan Leor, Bruce A. Barton, Judith S. 
Hochman, Waikato Hospital, Hamilton, New Zealand, New York University School of 
Medicine, New York, NY
Background: OAT (n= 2201) reported no reduction in the primary endpoint of death, re-
MI or heart failure with routine (3-28 days post-MI) percutaneous coronary intervention 
(PCI) (n=1101) of an occluded infarct-related artery (IRA) relative to medical treatment 
(MED) (n=1100). Anginal symptoms and non-protocol revascularization (revasc) were 
major secondary endpoints.
Methods: Angina status and revasc were collected at 4 months and then annually. Rx 
comparisons are by intention-to-treat.
Results: During follow-up, 764 pts developed angina. Compared with MED, 6 per 100 
more pts assigned to PCI were angina free at 1 year (p=.002) (ﬁgure) narrowing to 3 
per 100 at 3 yrs (p=.08). Use of anti-anginal therapy was similar in the 2 groups. At 5 
yrs, revasc was more frequent in MED (22% vs. 19% for PCI, p=.03). However, in pts 
with follow-up angina (n=764), revasc rates were not different between groups (17% PCI 
vs. 19% MED, p=.56). Most pts with angina in follow-up either had no revasc or had it 
performed prior to symptom onset (PCI 83% vs. MED 81%, p=.56). Reasons for revasc 
were similar in the 2 groups including ACS in 37%, stable angina in 33%, physician 
preference in 18%, other in 12%.
Conclusions: In a large randomized clinical trial of stable post MI pts, PCI of an occluded 
IRA produced a modest early beneﬁt on angina status that was lost by 3 years. Follow-up 
revasc was slightly more common in the MED group and was not driven by more frequent 
ischemia, with almost one in ﬁve procedures related to physician preference alone.
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813-4 COX-2 Inhibition with Parecoxib Abrogates Acute and 
Delayed Cardioprotective Effects of Sildenaﬁl against 
Ischemia/reperfusion Injury
Fadi N. Salloum, Evan D. Ownby, Rakesh C. Kukreja, Virginia Commonwealth University 
Medical Center, Richmond, VA
Background: Phosphodiesterase-5 (PDE-5) inhibitor sildenaﬁl (Viagra) induces protective 
effect against ischemia/reperfusion injury (I/R) in the intact heart and cardiomyocytes 
through generation of nitric oxide (NO). Since cyclooxygenase-2 (COX-2) is activated 
by NO, we tested the hypothesis if sildenaﬁl-induced acute and delayed cardioprotective 
effect is also dependent on COX-2.
Methods: Adult male ICR mice were anesthetized and subjected to ischemia by coronary 
artery occlusion for 30 min followed by 24 hr reperfusion. Six groups were studied. 1- 
Controls; 2- Sildenaﬁl (0.71 mg/kg; ip) given 1 hr before I/R; 3- Sildenaﬁl (as in group 
2) + Parecoxib (COX-2 inhibitor; 0.75 mg/kg; ip) given 30 min before I/R; 4- Parecoxib 
given as in group 3; 5- Sildenaﬁl given 24 hr before I/R and 6- Sildenaﬁl given as in group 
5 + Parecoxib as in group 3. At the end of reperfusion, IS was measured by computer 
morphometry of triphenyl tetrazolium chloride stained heart sections.
Results: IS (mean ± SEM) was signiﬁcantly reduced with acute and delayed sildenaﬁl 
treatment compared to saline controls (Fig. 1). The risk area was not different between 
the groups. Interestingly, administration of parecoxib following either acute (30 min) or 
delayed (24.5 hrs) after sildenaﬁl treatment completely abolished the protective effects of 
sildenaﬁl. Parecoxib alone had no effect on IS.
Conclusions: For the ﬁrst time, this study identiﬁes COX-2 as a novel mediator of 
cardioprotection induced by a PDE-5 inhibitor. 
8:15 a.m.
813-5 Aspirin is Insufﬁcient in Inhibition of Platelet 
Aggregation and Thromboxane Formation Early after 
Coronary Artery Bypass Surgery
Frantisek Bednar, Pavel Osmancik, Vera Jedlickova, Jan Hlavicka, Zoltan Paluch, Tomas 
Vanek, Cardiocenter, Kralovske Vinohrady University Hospital, Clinic of Cardiac Surgery, 
Prague, Czech Republic
Background: Aspirin administered early after coronary artery bypass grafting surgery 
(CABG) improves graft patency and patients survival. However, the antiplatelet effect of 
aspirin seems to be variable and aspirin resistance is currently still being discussed. The 
aim of the study was to asses aspirin efﬁcacy in the early postoperative period.
Methods: Thirty patients undergoing elective CABG surgery (15 in on-pump and 15 in off-
pump) were enrolled in the study. Functional and biochemical responses to aspirin were 
evaluated by arachidonic acid (ARA) -induced platelet aggregation and urine 11-dehydro 
thromboxane B2 metabolite excretion. Samples were collected before surgery (baseline; 
> 7 days after aspirin withdraval) and on days 1,2 and 5 after surgery.
Results: Baseline ARA aggregability was 55%; 95% CI [52%,58%]. On day 1, platelet 
aggregability decreased (22%; 95% CI [16%,26%],p<0.05). On day 2, despite the aspirin 
administration, platelet aggregability increase above the values from day 1 (32%; 95% 
CI [27%,38%],p<0.05). Only on day 5, sufﬁcient inhibition of platelet aggregation was 
achieved (15%; 95% CI [10%,20%],p<0.05).
Preoperative urine concentration of 11-dehydro TX B2 was 95ng/mL;95% CI [67,122]. On 
day 1, there was increase in concentration (181ng/mL;95% CI [104,258], p<0.05) and on 
day2, the concentration remained almost similar in comparing with the preoperative values 
(85ng/mL; 95% CI[49,120], p=N.S.). Only on day 5, signiﬁcant decrease in concentration 
of thromboxane metabolite was achieved (63ng/mL; 95% CI [38,88], p<0.05).
Conclusion: Aspirin did not sufﬁciently inhibit platelet aggregation and thromboxane 
formation in the early postoperative period. Thus, antiplatelet treatment strategy should 
be intensiﬁed or modiﬁed in patients early after bypass surgery.
8:30 a.m.
813-6 Relative Contribution of Patient Characteristics and 
Clinical Site Characteristics to Saphenous Vein Graft 
Stenosis and Adverse Cardiac Events Following 
Coronary Artery Bypass Graft Surgery: A PREVENT-IV 
Analysis
Jacqueline L. Buros, Yuri B. Pride, John H. Alexander, Nicholas T. Kouchoukos, Eric D. 
Peterson, T. Bruce Ferguson, C. Michael Gibson, Beth Israel Deaconess Medical Center, 
Harvard Medical School, Boston, MA, Duke University Medical Center, Durham, NC
Background: The goal of this analysis was to evaluate the relative contribution of patient 
characteristics and surgical clinical site characteristics on saphenous vein graft (SVG) 
stenoses at routine follow-up angiography as well as major adverse clinical events 
(MACE) during clinical follow-up in the PREVENT-IV study.
Methods: PREVENT-IV randomized 3,014 patients undergoing CABG at 105 sites to either 
edifoligide or placebo. Of those, 1,293 patients underwent routine follow-up angiography 
to evaluate the patency of saphenous vein grafts from 12-18 months following surgery. 
Percent diameter stenosis was measured by quantitative coronary analysis (QCA) at an 
angiographic core laboratory. MACE were deﬁned as the composite of all-cause mortality, 
myocardial infarction, or repeat revascularization procedure with graft failure.
Results: Twenty percent of the variance in SVG percent diameter stenosis by QCA at 
follow-up was attributable to patient characteristics (i.e. the intra-class correlation (ICC) 
was 0.20, p<0.001). Independent of the contribution of patient characteristics, 3% of the 
variance in SVG stenoses was explained by characteristics of the clinical center enrolling 
the patient (ICC=0.03, p=0.02). 15% of the variance in MACE was attributable to the 
clinical center (theta=0.15, p<0.001).
Conclusions: While 20% of the variance in SVG stenoses is explained by patient 
characteristics, up to 15% of the variance in MACE outcomes are attributable to the 
clinical site characteristics. Future CABG trials should consider adjusting for clustering of 
events within enrolling centers. Further research in cardiovascular trials is warranted to 
understand the processes of care, techniques or decisions that contribute to the role of 
clinical sites in adverse outcomes.
8:45 a.m.
813-7 Clopidogrel and CABG-related Bleeding: Not as 
Important as Currently Believed?
John H-J Kim, L. Kristin Newby, Robert Clare, Linda K. Shaw, Andrew Lodge, Peter 
Smith, Marc E. Jolicoeur, Daniel B. Mark, Christopher B. Granger, Duke University 
Medical Center, Durham, NC, Stanford University, Palo Alto, CA
Background: Acute clopidogrel in ACS patients reduces ischemic events, but concerns 
of coronary artery bypass surgery (CABG)-related bleeding and delays to CABG limit 
early use.
Methods: Using 4794 consecutive CABGs in the Duke Databank for Cardiovascular 
Disease (Dec 1999 to Jun 2003), we created multivariable logistic regression models of 
CABG-related bleeding (reoperation for bleeding [re-op], red cell transfusion [transfusion], 
and a composite of re-op/transfusion/hematocrit drop >15%) relative to clopidogrel 
use <5 d pre-CABG. Models were adjusted for baseline covariates and propensity for 
clopidogrel <5 d.
Results: Of 4794 patients, 332 (6.9%) had clopidogrel <5 d pre-CABG; 65, >5 d prior 
and 4397, never. Bleeding rates for clopidogrel <5 d vs no clopidogrel <5 d were: re-op, 
3.3 vs 2.6%; transfusion, 70.2 vs 68.2%; and composite, 94.3 vs 91.3%. Of those with 
clopidogrel <5 d, re-op was higher with clopidogrel stopped nearer CABG: 1 d (5.6%) or 2 
d (7.5%) vs 3 d (1.9%) or 4 d (2.6%). There was no temporal pattern by day for transfusion 
or composite. After adjustment, neither re-op (OR 1.24 [0.64-2.41]) nor composite (OR 
1.23 [0.72-2.10]) were signiﬁcantly different between groups. Clopidogrel <5 d pre-CABG 
was modestly associated with transfusion, OR 1.40 (1.04-1.89) and number of PRBC 
units, but much more weakly than other factors (Table).
Conclusion: While bleeding risks were modestly higher with clopidogrel use <5 days pre-
CABG, surgeon-based variations and GP 2b/3a use appear much more important.



















Independent Variables Predicting Transfusion





Creatinine Clearance 54.0 <0.0001
Cardiopulmonary Bypass 26.1 <0.0001
Number of Diseased Vessels 25.4 <0.0001
Age 20.6 <0.0001
Use of GP 2b/3a During Hospitalization 17.0 <0.0001
Urgent Surgery 12.8 0.0003
Clopidogrel <5 days 4.9 0.03
9:00 a.m.
813-8 Frequency And Clinical Outcome of Patients 
Undergoing Non-Cardiac Surgery in the Year After 
Drug Eluting Stent Placement: Results from the EVENT 
Registry
Peter B. Berger, Neal S. Kleiman, Wen-hua Hsieh, Michael Pencina, Steven R. 
Steinhubl, Allan Jeremias, Ali Sonel, Kevin F. Browne, Greg Barseness, David J. Cohen, 
Geisinger Clinic, Danville, PA
Background: Little is known about the risk associated with non-cardiac surgery after drug-
eluting stent (DES) implantation.
Methods: In the EVENT Registry, consecutive patients (pts) who underwent attempted 
stent placement at 42 hospitals in the USA between 7/04 and 9/05 were enrolled and 
followed for 1 year. We analyzed all pts who received >1 DES to determine the frequency 
of non-cardiac surgery and subsequent adverse events. The main outcome measure was 
a composite of death, MI or stent thrombosis in the week after non-cardiac surgery.
Results: Among 4,637 DES recipients in the ﬁrst 2 waves of recruitment, 206 pts (4.4%) 
underwent major non-cardiac surgery in the year after their index PCI (median time to 
surgery 179 days). Overall, stent use averaged 1.5/pt; 53% of pts received a Taxus, 51% 
a Cypher, and 7% a BMS. The operations were orthopedic (36%), abdominal (31%), 
vascular (20%), ENT (4%), thoracic (3%), urologic (1%), intracranial (1%), and other 
(4%). Compared with pts who did not undergo surgery, those who did were older (67 
vs 64 yrs, p<0.001), more likely to be female (39 vs 31%, p=0.016) and have had a 
prior stroke (13 vs 8%, p=0.021); the frequency of prior MI (39 vs 37%), prior CABG (25 
vs 20%), and diabetes (36 vs 34%) were similar, as were LVEF and the indication for 
PCI. In the ﬁrst 7 days after surgery, 4 pts died, had an MI, or suffered stent thrombosis 
(1.9%). Moreover, pts who underwent non-cardiac surgery were less likely to remain on 
dual antiplatelet therapy at 1 year (54 vs 64%, p=0.001). By time-dependent proportional 
hazards analysis, the risk of the composite ischemic outcome was increased 27-fold in 
the week following non-cardiac surgery (hazard ratio (HR) 27.3 [95 % CI, 10.1, 74.2], 
p<0.001) and remained similar in risk-adjusted analyses (HR 27.1 [95% CI, 9.9, 74.1], 
p<0.001).
Conclusions: The frequency of major non-cardiac surgery in the year after DES placement 
is >4%. Although the overall risk of adverse outcomes appears to be less than previously 
reported, it is signiﬁcantly increased in the week after major non-cardiac surgery.
9:15 a.m.
813-9 Validation of a Risk Score for a New Target Vessel 
Revascularization After Coronary Stent Implantation
Alexandre S. Quadros, Fabiane Diemer, Carlos AM Gottschall, Institute of Cardiology of 
Rio Grande do Sul / FUC, Porto Alegre, Brazil
Background: Coronary drug-eluting stent implantation is associated with low rates of 
target vessel revascularization (TVR), but recent evidence has questioned its long-term 
safety. A selective approach of bare-metal stent (BMS) implantation in patiens at low risk 
for restenosis could be a reasonable alternative to this problem. The objective of this 
research was to validate a risk score for a new TVR after BMS implantation.
Methods: The risk score was developed in a consecutive cohort of patients treated with 
BMS implantation at our institution, as previously reported (J Invasive Cardiol. 2006; 
18:22). This risk score ranges from 0 to 5 points, according to the presence of diabetes 
mellitus (1 point), the reference vessel diameter (>3.5 mm=0 points; 3-3.5mm=1; <3 
mm=2) and the lesion length (10mm or less=0 points; 10-20mm=1; greater than 20 
mm=2).Patients included in the validation cohort were treated between January and 
December 2005, and those with cardiogenic shock, intrastent restenosis or unsuccessful 
procedures were excluded. Patient characteristics and one-year clinical follow-up were 
prospectively recorded into a dedicated database. A new angiographic study in the follow-
up period was done only when recurrent ischemia was suspected.
Results: In the study period, 491 patients were included, with a mean age of 61 ± 10.5 
years, and 35% of women. Diabetes mellitus was present in 22%, a previous percutaneous 
coronary intervention in 12% and previous myocardial infarction in 35%. The mean 
reference vessel diameter was 2.80±0.56 mm and the mean lesion length was 12.45±6.3 
mm. Clinical follow-up was complete in 88% of the patients, and the overall TVR rate was 
13.9%. One-year TVR rates increased with each score level: Score=0, TVR=0%; Score 
1=5.3%; Score 2=12%; Score 3=14%; and Score 4/5=25%; (p=0,008; chi-square test for 
trend). The c-statistic of the risk score was 0.60 (Conﬁdence interval=0.51-0.67); p=0.02.
Conclusions: The risk score was signiﬁcantly associated with a new TVR after BMS 
implantation. This score can be used as a tool to aid in the clinical decision making 
process of the type of stent to be implanted, since it is simple and based on variables 
obtained before stent implantation.
ACC.POSTER CONTRIBUTIONS
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1031-41 Prognostic Value and Therapeutic Implications of the 
Ischemic Cascade Using Dipyridamole Stress CMR in 
Patients With Known or Suspected Coronary Disease
Vicente Bodi, Juan Sanchis, Julio Nunez, Luis Mainar, Oliver Husser, Maria P. Lopez-
Lereu, Vicente Ruiz, Eva Rumiz, Francisco J. Chorro, Angel Llacer, Hospital Clinico 
Universitario, Valencia, Spain, University of Valencia, Valencia, Spain
Background: Data on the prognostic value and the therapeutic implications of the ischemic 
cascade on the basis of stress perfusion cardiovascular magnetic resonance) CMR is 
largely preliminary to date.
Methods: Dipyridamole stress CMR was performed in 601 patients with ischemic chest 
pain and known or suspected coronary artery disease. Myocardial infarction and coronary 
revascularization within the previous 3 months were exclusion criteria. The presence (>1 
segment) of perfusion deﬁcit (at stress ﬁrst-pass perfusion imaging) and inducible wall 
motion abnormalities (WMA) with dipyridamole were analyzed. According to the ischemic 
cascade patients were categorized in C1 (no evidence of ischemia, n=354, 59%), C2 
(isolated perfusion deﬁcit, n=181, 30%) and C3 (simultaneous perfusion deﬁcit and 
inducible WMA, n=66, 11%).
Results: During a median follow-up of 80 weeks, 69 major adverse cardiac events 
(MACE), including 21 cardiac deaths, 14 nonfatal myocardial infarctions and 34 re-
admissions for unstable angina with documented abnormal angiography were detected. 
In non-revascularized patients, MACE were 4% in C1, 20% in C2 and 39% in C3 (p 
<0.001). Once adjusted for baseline characteristics, C2 (3 [1.5-5.9], p=0.001 vs. C1) and 
C3 (7.7 [3.4-17.3], p <0.001 vs. C1) independently increased the risk of MACE. Once 
adjusted for a fair propensity score (C-statistic=0.83) to undergo revascularization, CMR-
related revascularization (n=102, 17%) increased the risk of MACE in C1 (4% vs. 21%, 
3.4 [0.9-12.5], p=0.06) and had neutral effects in C2 (20% vs. 19%, 1.1 [0.5-2.4], p=0.7). 
Only in patients with severe ischemia, C3, CMR-related revascularization independently 
reduced the risk of MACE (39% vs. 11%, 0.2 [0.1-0.7], p=0.01).
Conclusions: Assessment of the ischemic cascade using dipyridamole stress CMR is 
useful for predicting the outcome and for making decisions in patients with ischemic chest 
pain. The presence of ischemia in stress perfusion CMR associates to a higher risk but 
only patients with severe ischemia, namely simultaneous perfusion deﬁcit and inducible 
WMA, beneﬁt from revascularization in terms of event rate reduction.
11:00 a.m.
1031-42 Effect of Amlodipine, Atorvastatin and the Combination 
on Transient Myocardial Ischemia in Coronary Artery 
Disease from the DUAAL Study
John Deanﬁeld, Jan Bultas, Philippe Sellier, Erik Thaulow, University College of London, 
London, United Kingdom
Background: Transient myocardial ischemia (TMI) in patients with coronary disease 
(CAD) is associated with poor outcome and may reﬂect disturbed arterial biology. We 
hypothesized that the pleiotropic effects of statins would decrease ischemia.
Methods: Randomized double blind parallel group multi country trial (2 weeks run-in and 
24 weeks active therapy, titrated at Week 6) comparing 3 treatments: 1) Amlodipine (AM) 
5->10 mg, 2) Atorvastatin (AT) 10->80 mg, 3) Combination (AM/AT) 5/10mg->10/80 mg; 
in 311 patients (78% men, mean age 62 yrs) with stable angina (q2 attacks /week), CAD 
history, q3 TMI episodes and/or q 15 min ischemia on 48 hr Holter monitoring. Efﬁcacy 
variables were change in TMI by Holter monitoring, exercise ischemia and inﬂammatory 
biomarkers at Week 26.
Results: Background therapy included beta blockers (81%), nitroglycerin (62%) and 
aspirin (79%). TMI episodes decreased by >66% with >50% of patients becoming TMI 
free in all 3 groups. This was accompanied by comparable marked reduction in angina 
and nitroglycerin consumption. AT was as effective as AM in relief of TMI. CRP fell by 
40% in patients receiving AT with no change for AM. Adverse events were comparable 
in all groups.
Conclusions: AT was as potent an anti ischemic agent as AM. The mechanism for beneﬁt 
is likely to be different. TMI decrease was so great with monotherapy that no additional 
beneﬁt was shown for the combination. The complementary mechanisms of AT and AM 
may be advantageous in the management of patients with CAD and TMI.
Key Efﬁcacy Results at Week 26















































1031-43 Carotid Intima-Media Thickness Measurement Is an 
Excellent Screening Tool for the Detection of Severe 
Coronary Artery Disease Associated with Left 
Ventricular Systolic Dysfunction
Harmony R. Reynolds, David A. Steckman, Peter J. Hynes, Nitasha Sarswat, Paul A. 
Tunick, Bernardo D. Vargas, Raj M. Khandwalla, Itzhak Kronzon, Barry P. Rosenzweig, 
NYU School of Medicine, New York, NY
Background: CAD is the most common cause of LV systolic dysfunction (LVSD). Pts with 
ischemia as the cause of LVSD may warrant revascularization. Angiography is the most 
accurate method of CAD diagnosis but is invasive and expensive and has some risk. 
Noninvasive imaging for CAD involves radiation exposure, medication and/or contrast. 
Carotid ultrasound for measurement of intima-media thickness (CIMT) is safe, inexpensive 
and well correlated with CAD.
Aim: To assess the accuracy of CIMT measurement for diagnosis of ischemic 
cardiomyopathy.
Methods: Pts with LVSD (EFa40%) of uncertain etiology referred for coronary 
angiography underwent carotid ultrasound. Pts with known CAD were excluded. Two 
echocardiographers blinded to CAD status determined CIMT and plaque (deﬁned as 
q50% increase over background IMT). Signiﬁcant CAD was deﬁned as q50% stenosis 
of any major vessel. Ischemic cardiomyopathy was deﬁned as: (a) left main q50%, (b) 
proximal LAD q75% or (c) q2 major arteries with q75% stenosis.
Results: Mean EF was 26±10% in 96 pts aged 60±12 yrs; 69% were male. Signiﬁcant 
CAD was found in 50.0% and ischemic cardiomyopathy in 32.3%. Carotid plaque was 
seen in 66.7%. Mean CCA IMT was q0.9 mm in 44.2%. See Table for diagnostic accuracy. 
The combination of mean CCA IMT a0.9 mm and no plaque had negative predictive value 
96% for ischemic cardiomyopathy.
Conclusion: CIMT is an excellent screening tool for excluding ischemic cardiomyopathy 
and should be considered as the ﬁrst test to determine etiology of LVSD. 
Mean CCA IMT 
q 0.9 mm Plaque
Plaque or mean CCA IMT q 
0.9 mm
 
Ischemic Cardiomyopathy p*=0.011 p=0.0002 p<0.0001
Sensitivity (%) 62.5 90.9 97.0
Speciﬁcity (%) 64.5 45.1 40.3
Negative Predictive Value 
(%) 76.9 90.3 96.2
Positive Predictive Value (%) 47.6 46.9 46.4
 
“Signiﬁcant” CAD p=0.018 p=0.0008 p=0.0002
Sensitivity (%) 61.7 83.3 89.6
Speciﬁcity (%) 70.2 48.9 44.9
Negative Predictive Value 
(%) 64.7 74.2 80.8
Positive Predictive Value (%) 67.4 62.5 44.7
*all p by Fisher’s exact test
11:00 a.m.
1031-44 Risk of Contrast-Induced Nephropathy in Diabetic 
Patients With and Without Dipstick Proteinuria Referred 
for Cardiac Catheterization
Reyan A. Ghany, Erik Bernstein, Julio Chirinos, Cesar Mendoza, Eduardo de Marchena, 
University of Miami Miller School of Medicine, Miami, FL, Jackson Memorial Hospital, 
Miami, FL
Background: Contrast-Induced Nephropathy (CIN) is a signiﬁcant concern in diabetic 
patients referred for cardiac catheterization. Decreased glomerular ﬁltration rate increases 
the risk of CIN. However, the risk of CIN in the presence of normal creatinine levels and 
proteinuria is unknown.
Methods: We prospectively studied 93 diabetic patients undergoing non-emergent 
cardiac catheterization who had normal serum creatinine values (a1.4 mg/dL). Patients 
were stratiﬁed into those with proteinuria (n=56) and without proteinuria (n=37). Repeat 
serum creatinine values were obtained on day 2-5 and day 7-10. CIN was deﬁned as an 
increase in serum creatinine of at least 0.5 mg/dL within 48 hrs.
Results: At baseline, patients with proteinuria were slightly leaner, more likely to receive 
ACE inhibitors, and tended to have lower diastolic and higher pulse pressures than those 
without proteinuria. Patients with proteinuria received signiﬁcantly greater intravenous 
ﬂuid voulme prior to cardiac catheterization.
None of the 37 patients without proteinuria developed CIN (95% CI for proportion = 0-
9.5%), whereas 4 out of 56 with proteinuria developed CIN (7.1%; 95%CI=1.9-17.3%). 
Table 1 shows trends in serum creatinine between the two groups before and after 
catheterization.
Conclusion: With current patient preparation protocols, the risk of CIN in diabetic patients 
with normal serum creatinine referred for non-emergent cardiac catheterization is low 





Mean SD Mean SD
Age in Years 58.1 10.0 60.3 8.6 0.25
Brachial Systolic Blood Pressure, 
mmHg 144.6 15.5 145.8 15.7 0.69
Brachial Diastolic Blood Pressure, 
mmHg 86.6 10.2 82.7 11.1 0.09
Brachial Pulse Pressure, mmHg 58.0 14.5 63.1 12.3 0.05
Hemoglobin at baseline, g/dL 13.8 1.2 13.6 1.3 0.46
Body Mass Index, kg/m2 26.5 1.8 25.6 1.5 0.03
Left ventricular Ejection Fraction, % 51.4 7.0 51.0 7.2 0.9
Pre-Catheterization IV Fluids, mL 335.9 234.1 463.8 284.7 0.03
Contrast Volume, mL 121.0 43.6 118.8 51.9 0.28
N % N %
Male Gender 25 67.6 44 78.6 0.23
LDL Cholesterol > 130 mg/dL 19 51.4 26 46.4 0.64
Smoking 11 29.7 14 25 0.61
ACE Inhibitor Use 23 62.2 21 37.5 0.02
ARB Use 4 10.8 6 10.8 1
Mean SD Mean SD P value
Baseline Serum Creatinine, mg/dL 1.0 0.2 1.1 0.2 0.59
Serum Creatinine at 48 hours, mg/dL 1.1 0.2 1.2 0.2 0.35
Serum Creatinine at 7 Days, mg/dL 1.1 0.1 1.1 0.1 0.75
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1031-45 Efﬁcacy and Safety of Ranolazine in Chronic Angina: 
Observations from the Randomized, Double-blind, 
Placebo-controlled MERLIN-TIMI 36 Trial
Sean R. Wilson, David A. Morrow, Benjamin M. Scirica, Sabina A. Murphy, Jacqueline 
L. Buros, Carolyn H. McCabe, Eugene Braunwald, Brigham and Women’s Hospital, 
Boston, MA
Background: Ranolazine (RAN) is a novel anti-anginal that has been shown to reduce 
angina frequency and improve exercise performance in selected patients (pts) with early 
positive exercise testing and those with frequent angina. RAN has previously not been 
studied in as large and diverse group of pts with angina.
Methods: We investigated the efﬁcacy and safety of RAN compared with placebo in pts 
with any history of prior angina (N = 3565) followed long-term (~ 1 yr) in the MERLIN-TIMI 
36 trial of pts with NSTE ACS.
Results: Pts with prior angina received evidence-based therapy (95% ASA, 77% statins, 
89% B-blockers, avg 2.7 anti-anginals) balanced between the two groups. The 1° endpoint 
(CV death, MI, recurrent ischemia (RI)) occurred in 29.4% vs. 25.2% (placebo vs RAN); 
HR 0.86; 95% CI 0.75-0.97; p=0.017). CV death or MI did not differ between treatment 
groups (HR 0.97; p=0.71). However, RAN signiﬁcantly reduced the risk of RI (HR 0.78; 
p=0.0021), worsening angina (HR 0.76; p=0.0482) and intensiﬁcation of anti-anginal 
therapy (HR 0.78; p=0.0093) (Figure). All cause mortality and symptomatic arrhythmias 
did not differ between RAN vs placebo (both p>0.9).
Conclusions: In this largest study of RAN in pts with established CAD, RAN was effective 
in reducing angina and RI in a substantially broader group of pts with angina than studied 
previously. RAN is a valuable option as part of optimal medical therapy for pts with angina.
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1031-46 Sustained Increase Of Platelet Activation Indices 
Following Sirolimus-Eluting Stent Implantation
Maria Marketou, George Kochiadakis, Katerina Sﬁridaki, Aikaterini Giaouzaki, Dimitris 
Arfanakis, Emmanouel Skalidis, Ermioni Kantidaki, Panos Vardas, Heraklion University 
Hospital, Heraklion, Greece, Venizelio Hospital, Heraklion, Greece
Background: Despite the proven superiority of sirolimus-eluting stents (SES) compared to 
bare metal stents (BMS), recent data demonstrates that stent thrombosis after successful 
SES implantation is substantially higher. In patients treated with SES or BMS we 
measured serial changes in sP-selectin and soluble CD40 ligand (sCD40L) - as indices 
of platelet activation, von Willebrand factor (vWf) - as an index of endothelial damage and 
levels of factor VIII, ﬁbrinogen and d-dimer - as indices of ﬁbrinolytic response.
Methods: We evaluated 50 patients (35 male, 62Â±28 years) with stable angina 
> 6 months and single vessel coronary artery disease, who underwent elective 
percutaneous coronary intervention (PCI). SES were implanted in 29 patients and BMS 
in the remainder. Blood samples were taken before PCI, 48 hours and 1 month later 



















to evaluate plasma concentrations of sP-selectin, sCD40L, vWf, factor VIII, ﬁbrinogen 
and d-dimer each time.
Results: Circulating levels of vWf, factor VIII, ﬁbrinogen and d-dimer did not differ 
signiﬁcantly between the two groups (p=NS). However, a signiﬁcant increase of cCD40L 
and sP-selectin levels was detected in the SES group that was maintained until the end 
of the 1 month (Table 1. *: p < 0.05 compared to baseline).
Conclusions: Patients treated with SES showed a sustained increase in platelet activation 
indices compared to those treated with BMS. This ﬁnding may emphasize the need for 
more aggressive antiplatelet therapy in patients with SES. 
Table 1
SES BMS
before 48 hours 1 month before 48 hours 1 month
sCD40L 
(pg/ml) 140 ± 85 195 ± 78* 192 ± 75* 152 ± 72 142 ± 64 164 ± 88
sP-selectin 
(ng/ml) 45 ± 16 47 ± 22 60 ± 35* 55 ± 37 59 ± 27 58 ± 39
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1031-47 Vascular endothelial growth factor protein levels 
and gene expression in peripheral monocytes after 
stenting: A randomized comparative study of sirolimus-
eluting and bare metal stents
Maria Marketou, George Kochiadakis, Dimitrios Panutsopulos, Dimitrios Arfanakis, 
Emmanuel Skalidis, Nikolaos Igoumenidis, Michael Hamilos, George Sourvinos, 
Demetrios Spandidos, Panos Vardas, Heraklion University Hospital, Heraklion, Greece, 
Heraklion University, Heraklion, Greece
Background: Although previous studies have indicated that vascular endothelial growth 
factor (VEGF) plays an important role in the vascular healing process after stent 
implantation, its effect on in-stent restenosis has not been fully investigated. We assessed 
VEGF serum protein levels and gene expression in peripheral monocytes in relation to 
in-stent restenosis after implantation of sirolimus-eluting stents (SES) and bare metal 
stents (BMS).
Methods: Forty-two patients (28 men, age 62 ± 11 years) with stable angina, who 
underwent elective single-vessel percutaneous coronary intervention, were randomly 
assigned to SES (n=21) or BMS (n=21) implantation. Follow-up coronary angiography 
was performed 6-8 months later. Blood samples were taken before and 1 month after 
stent implantation. Mononuclear cells were isolated using anti-CD14+ antibodies and 
mRNAs were estimated by real-time quantitative reverse transcriptase-PCR (TaqMan). 
VEGF serum levels were determined each time by ELISA.
Results: VEGF protein levels in the BMS group showed an increasing trend (from 386 pg/
ml to 458 pg/ml, p=0.083) while in the SES group they decreased signiﬁcantly (from 403 
pg/ml to 296 pg/ml, p=0.002). Similarly, BMS implantation induced an upregulation of VEGF 
mRNA levels, compared to SES where a downregulation was observed (fold induction: 1.44 
± 0.84 in BMS group versus 0.72 ± 0.35 in SES group, p=0.001). A signiﬁcant correlation 
was found between VEGF gene expression, as measured by fold induction, and late luminal 
loss in both groups (BMS: r=0.98, p<0.001; SES: r=0.65, p=0.002).
Conclusion: SES implantation, in comparison with BMS, results in signiﬁcantly lower 
VEGF protein levels and gene expression in peripheral monocytes. The latter shows a 
strong positive relationship with in-stent late-luminal loss, suggesting that its role in the 
reduced in-stent restenosis seen in SES may be essential.
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1031-48 Prognostic Impact of Various Platelet Function Assays 
and Deﬁnitions of Non-responsiveness to Clopidogrel 
600 mg on Early Outcome After Elective PCI
Dietmar Trenk, Willibald Hochholzer, Christian Stratz, Christian M. Valina, Hans-Peter 
Bestehorn, Heinz Joachim Buettner, Franz-Josef Neumann, Herz-Zentrum Bad 
Krozingen, Bad Krozingen, Germany
Background The EXCELSIOR-study showed that patients with a residual platelet 
aggregation (RPA) above the median of the cohort (14% ADP 5µM) after loading with 
clopidogrel 600 mg carried a 6.7-fold increased risk for major adverse cardiac events 
within 30 days following elective coronary stent implantation (PCI). We assessed the 
prognostic impact of alternate platelet function assays and currently used non-responder 
deﬁnitions as alternate approach.
Methods The prognostic impact of the expression of the platelet surface proteins activated 
GP IIb/IIIa (PAC-1) and P-selectin was determined in the EXCELSIOR cohort (802 
patients). In addition, we tested the impact of RPA after stimulation with ADP 20µM and 
two currently used deﬁnitions of non-responsiveness to clopidogrel. Non-responsiveness 
was deﬁned either as a10% change in RPA or as <20% inhibition of RPA using ADP 
20µM as stimulant. Parameters were obtained from blood samples drawn immediately 
before PCI
Results Odds ratios with 95% conﬁdence intervals for the different parameters 
characterizing antiplatelet response to the 600-mg bolus dose of clopidogrel are provided 
in the table. 
Parameter Odds ratio 95% CI p-value
RPA ADP 5µM above median 6.71 1.52 - 29.41 0.003
Activated GPIIb/IIIa above median 1.42 0.38 - 5.71 0.76
P-Selectin above median 1.04 0.28 - 3.94 0.85
Non-responsiveness [a10% change] 1.51 0.34 - 13.88 0.89
Non-responsiveness [<20% inhibition] 1.58 0.42 - 5.15 0.57
In contrast to RPA after stimulation with ADP 5µM neither the expression of PAC-1 or P-
selectin nor currently used non-responder deﬁnitions to clopidogrel showed a signiﬁcant 
prognostic impact on MACE within 30 days after PCI.
Conclusion RPA after stimulation with ADP 5 µM provides superior prognostic impact 
regarding 30-days clinical outcome after elective PCI.
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1031-49 Demographic and Clinical Factors Predicting the 
Antiplatelet Effect of a Loading Dose of Clopidogrel 
600 mg in Patients Undergoing Cardiac Catheterization 
With and Without PCI
Dietmar Trenk, Willibald Hochholzer, Christian Stratz, Christian M. Valina, Hans-Peter 
Bestehorn, Heinz Joachim Buettner, Franz-Josef Neumann, Herz-Zentrum Bad 
Krozingen, Bad Krozingen, Germany
Background The EXCELSIOR-study showed the impact of variability in antiplatelet 
response to a 600-mg clopidogrel bolus on major adverse cardiac events within 30 
days following elective coronary stent implantation (PCI). Predictors for an insufﬁcient 
antiplatelet effect of clopidogrel have not been deﬁned so far.
Methods We analyzed prospectively in 1,987 patients receiving clopidogrel 600 mg the 
impact of demographics, clinical parameters and concomitant medication on residual 
platelet aggregation (RPA) determined by optical aggregometry (ADP 5µM) at baseline 
and before coronary angiography without (n=1,185) or with PCI (n=802).
Results Differences in baseline RPA accounted for 27% of variability in RPA at angiography. 
Female patients (+3.0%, 95% conﬁdence interval [CI]: 1.1-5.0%; p=0.003), elderly 
patients (per 10 years of age: +2.0%; 1.1-2.9%; P<0.001) and patients with a blunted 
response to aspirin (+20.7%; 16.0-25.3%; P<0.001) had an exaggerated RPA at baseline. 
Demographic and clinical parameters predicting an increased RPA at angiography are 
summarized in the Table. Patients treated with verapamil/diltiazem (+5.7%; 95% CI:1.6-
9.8%; P=0.007; n=71) and diabetics with sulfonyl urea drugs (+6.6%; 95% CI:3.1-10.2%; 
P<0.001; n=94) had an increased RPA at angiography. 
$ RPA (%) [95% CI] P-Value
Age per 10 years 2.2 [1.2-3.1] p<0.001
Body weight per 10 kg 1.1 [0.5-1.7] p=0.001
Diabetes mellitus 3.5 [1.3-5.7] p=0.002
Coronary heart disease 2.2 [0.3-4.1] p=0.023
Angiography <2h after clopidogrel 600 mg 10.5 [8.8-12.2] p<0.001
Conclusion Antiplatelet effect of clopidogrel 600 mg in patients undergoing elective 
coronary angiography without/with PCI is affected by demographic and clinical parameters 
as well as by concomitant medication.
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1031-50 What Drove the Marked Improvement in Angina During 
the Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation (COURAGE) Trial?
John H. Lee, James H. O’Keefe, John A. Spertus, Robert A. O’Rourke, Wei Zhang, 
David J. Maron, Paul Kolm, William S. Weintraub, William E. Boden, Mid America Heart 
Institute, Kansas City, MO, University of Missouri-Kansas City, Kansas City, MO
Background: Although initial percutaneous coronary intervention (PCI) + optimal medical 
therapy (OMT) produced greater anginal relief than OMT, ultimately, OMT was equally 
effective at 36 months of treatment. The purpose of this study is to identify correlates of 
angina-free status in both PCI+OMT and OMT patients (pts).
Methods: Analysis was conducted on 2,287 pts enrolled in the COURAGE trial correlating 
angina-free status by the Seattle Angina Questionnaire (SAQ) with age > 65, gender, 
race, previous myocardial infarction (MI), diabetes, baseline Canadian Cardiovascular 
Society (CCS) class, previous coronary artery bypass graft (CABG), previous PCI (>6 
months prior to enrollment), history of congestive heart failure and hypertension (HTN), 
basal metabolic index, baseline A1c, systolic blood pressure (BP) and diastolic BP, use 
of angiotensin converting enzyme (ACE) inhibitors, lipid-lowering therapies, beta-blockers 
and angiotensin II receptors antagonists.
Results: At baseline, a similar proportion of pts in the PCI+OMT and OMT groups were 
angina-free by SAQ adjusted for covariates (31% vs 29%, p=0.545). At 1 month follow-
up, PCI+OMT pts were more likely to be angina-free than the OMT pts (36% vs 32%, 
p<0.001). A signiﬁcant difference persisted for up to 12 months (63% vs 54%, p=0.006), 
but by 24 months no signiﬁcant difference in angina-free status existed between 
PCI+OMT and OMT (54% vs 51%, p=0.091). Signiﬁcant correlates of angina-free status 
included use of lipid lowering therapy (OR 1.068 95% CI 1.033-1.105; p<0.001), use of 
ACE inhibitors (OR 1.04 95% CI 1.004-1.077; p=0.029), and age > 65 (OR 1.315 95% CI 
1.128-1.533; p<0.001). Signiﬁcant correlates of less angina improvement included higher 
baseline CCS class (p<0.001), previous CABG (p=0.004) or previous PCI (p=0.015) and 
history of hypertension (p=0.011).
Conclusion: Although PCI + OMT was superior to OMT for attaining angina-free status 
during the ﬁrst year, the two strategies were equally effective at 2 yrs and thereafter. Lipid 
lowering therapy and ACE inhibitors increased likelihood of freedom from angina, while 
HTN, prior PCI, CABG and higher baseline CCS class predicted lower prevalence of 
angina-free status at 3 years.





1031-51 Healthcare Resource Utilization in Patients With 
Refractory Angina
Alex R. Campbell, Daniel Satran, Richard Birkett, Ross Garberich, Daniel Hayward, 
Rachel E. Olson, Charlene R. Boisjolie, Timothy D. Henry, Minneapolis Heart Institute 
Foundation at Abbott Northwestern Hospital, Minneapolis, MN
Background: An increasing number of patients with chronic, extensive CAD are poor 
candidates for traditional revascularization and have refractory angina. The extent of 
healthcare resource utilization for this group of “no option” patients is unknown.
Methods: The OPTions In Myocardial Ischemic Syndrome Therapy (OPTIMIST) clinic 
at Abbott Northwestern Hospital (Minneapolis, MN) offers traditional and investigational 
therapies for patients with refractory angina. A prospective clinical database with 1135 
patients includes detailed baseline and yearly follow up information. Over a one year 
period, resource utilization information for 200 consecutive living patients was analyzed 
as well as data for major cardiovascular interventions over a lifetime.
Results: For 200 patients (mean age 69, 82% male), lifetime cardiovascular interventions 
and one year follow up resource utilization are summarized (Table). Over one year, MI 
occurred in only 8 patients (4%). Hospitalization for a cardiac cause occurred in 71 
(36%) patients (114 admissions); mean length of hospital stay was 1.9 days. Scheduled 
cardiology clinic visits (mean 2.4 visits per patient) as well as ER visits (70 total visits for 
45 patients (23%)) were frequent.
Conclusions: Healthcare resource utilization for patients with refractory angina--including 
diagnostic imaging studies and hospitalization rates--is extensive. Invasive procedures 
are also common in this population in spite of poor candidacy for revascularization.
Healthcare Resource Utilization in Patients with Refractory Angina
Lifetime (n=200) Percentage of Population Mean per Patient Range
Coronary Angiograms 100 6.2 0-38
PCI 81 2.6 0-30
CABG 74 1 0-4
One Year Period (n=200)
Coronary Angiograms 32 0.4 0-4
Revascularization 17 0.19 0-5
Echocardiograms 46 0.64 0-6
SPECT Imaging 30 0.33 0-2
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1031-52 Long-Term Mortality in Patients With Refractory Angina
Timothy D. Henry, Daniel Satran, Alex R. Campbell, Randall J. Johnson, Anil K. Poulose, 
James Hodges, Bradley A. Bart, Rachel E. Olson, Karen L. Harvey, Patricia A. Mitchell, 
Theresa L. Arndt, Jay H. Traverse, Minneapolis Heart Institute Foundation at Abbott 
Northwestern Hospital, Minneapolis, MN
Background: The population of “no option” patients with refractory angina is increasing. 
Controversy exists regarding long-term mortality in this group of patients.
Methods: The OPtions In Myocardial Ischemic Syndrome Therapy (OPTIMIST) clinic at 
Abbott Northwestern Hospital (Minneapolis, MN) offers traditional and investigational 
therapies for patients with refractory angina. A prospective clinical database includes 
detailed baseline and yearly follow up information. Death status and cause of death were 
determined using the Social Security Death Index, clinical data and death certiﬁcates. 
Time to event analysis was performed using time from determination of no traditional 
revascularization options.
Results: For 1135 patients average age was 63 yrs (77% male) with 72% prior CABG, 
74% prior PCI, 32% CHF, and 36% DM. Median follow up was 4.7 yrs (range 0-16 yrs, 
10% over 9 yrs). 197 patients died (17.4%). From Kaplan Meier analysis, mortality was 
3.3% (95% CI 2.3-4.3) at 1 yr and 25.8% (95% CI 22-29) at 9 yrs. There were 126 (64%) 
cardiovascular deaths (37 CHF, 29 sudden death, 26 MI, 34 unclear). 18 pts (9%) suffered 
periprocedural death. Predictors of all cause mortality were: age, DM, CHF, moderate/
severe valve disease, kidney disease (all p<0.0001), cerebrovascular disease (p=0.001), 
prior MI (p=0.0006).
Conclusions: Patients with refractory angina actually have low long-term mortality. 
Therapeutic options for this growing population should focus on chest pain relief and 
improved quality of life. 
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1031-53 Refractory Angina Is Associated With Increased Arterial 
Stiffness and Elevated Wave Reﬂection Amplitude
Matheen A. Khuddus, Wilmer W. Nichols, Scott J. Denardo, C. Richard Conti, University 
of Florida, Gainesville, FL
Background: Early return of reﬂected pressure waves from the lower body augments 
central systolic blood pressure and increases left ventricular (LV) afterload and myocardial 
oxygen demand. Such changes are due to increased arterial stiffness and pulse wave 
velocity and are associated with increased wasted LV energy expenditure and reduced 
stroke volume. The aim of this study was to determine if arterial properties and wave 
reﬂection characteristics are altered in patients with chronic stable angina resistant to 
anti-anginal therapy.
Methods: High-ﬁdelity radial artery pressure waveforms were recorded non-invasively 
by applanation tonometry and ascending aortic pressure waveforms generated using 
a mathematical transfer function in 32 patients (age 65±9,0 yrs) with refractory angina 
taking two or more anti-anginal drugs and 32 treated hypertensive patients matched for 
age, sex, height, weight, mean arterial pressure and heart rate. Pulse wave analysis was 
used to determine arterial properties and wave reﬂection characteristics.
Results: Sphygmomanometric determined brachial systolic (134±19 vs 128±11 mm Hg, 
P=NS) and diastolic (71±9.1 vs 74±7.2 mm Hg, P=NS) pressures were similar in the two 
groups and within the normal range but augmentation index (Ala)(26±7.7 vs 19±7.0%, 
P<0.001) and reﬂected wave amplitude (14±7.2 vs 8.2±4.2 mm Hg, P<0.001) were higher 
in the refractory angina group compared to the treated hypertensive group resulting in 
an increased aortic systolic (122±18 vs 114±10.0 mm Hg, P<0.05) and pulse (50±15 vs 
40±10 mm Hg, P<0.001) pressures and elevated wasted LV pressure energy (6263±4086 
vs 2901±1784 dyne-sec-cm-2, P<0.001) .
Conclusion: Patients with refractory angina have increased arterial stiffness and elevated 
wave reﬂection amplitude compared to treated hypertensive patients which cause the LV 
to expend wasted energy in late systole resulting in an imbalance between myocardial 
oxygen supply and demand despite adequate drug therapy as assessed by standard cuff 
blood pressure measurements.
11:00 a.m.
1031-54 Accuracy of 64-Slice Computed Tomography for the 
Deﬁnition of the Atherosclerotic Coronary Plaque: 
Comparison With Coronary Artery Angiography and 
Intravascular Ultrasound
Ilaria D’Angeli, Giovanni Pedrazzini, Francesco Faletra, Elena Pasotti, Carlo Gaudio, 
Tiziano Moccetti, Stefano De Castro, Angelo Auricchio, Cardiocentro Ticino, Lugano, 
Switzerland
Background: 64-slice computed tomography (MSCT) seems to have the ability to quantify 
the degree of coronary artery stenosis and to assess dimensions and characteristics of 
coronary plaques. The aim of the present study was to assess the diagnostic accuracy 
of MSCT to identify and quantify atherosclerotic coronary plaques in comparison with 
catheter-based angiography (QCA) and intravascular ultrasound (IVUS). Methods: After 
MSCT scan demonstrated signiﬁcant CAD, 28 patients with stable angina, underwent 
QCA and IVUS at the time of cardiac catheterization. 44 plaques in the major coronary 
vessels, with stenosis degree >50%, were obtained. Coronary artery angiography 
and intravascular ultrasound with motorized pullback at the velocity of 0.5 mm/s were 
performed. Correlations of lumen cross-sectional area, external elastic membrane 
cross-sectional area, plaque cross-sectional area, as well as percent vessel obstruction 
(lumen area stenosis) for MSCT and IVUS and percent vessel obstruction and lumen 
cross-sectional area for MSCT, QCA and IVUS were determined by calculating the Lin 
coefﬁcient. For all measurements Pearson’s r was evaluated. Bland-Altman correlation 
analysis was determined too.
Results: The following measurements were performed. MSCT and IVUS measurements 
yield equal results. QCA understimate MSCT and IVUS plaques.
Conclusions: IVUS readings may be replaced by MSCT whereas QCA, as previously 








































External Elastic Membrane Cross-Sectional 
Area (mm2)
18,0 ± 5,0 
vs 
17,1 ± 4,4 
r =0,847 
P=0,031


























1031-55 Postconditioning Protects the Human Heart After Flow 
Restoration in Patients With Subtotal or Signiﬁcant 
Coronary Lesions
Efstathios K. Iliodromitis, Ioannis A. Paraskevaidis, Dimitrios Farmakis, Ioanna 
Andreadou, Aikaterini Fountoulaki, Ignatios Ikonomidis, Aias Antoniadis, Dimitrios T. 
Kremastinos, Attikon University Hospital, Athens, Greece
Background: Postconditioning (postC) is protective after ﬂow restoration in ST elevation 
myocardial infarction but it is not known whether it is also effective in subtotal or signiﬁcant 
coronary lesions. We sought to determine whether postC is protective, in terms of 
oxidative and nitrosative stress, wall motion score (WMS) and ejection fraction (EF), in 
patients with acute coronary syndromes or stable angina and indication for percutaneous 
coronary intervention (PCI).
Methods: Fifty ﬁve patients with coronary artery disease and target lesions causing 
stenoses of 80-100% were enrolled. All patients underwent PCI and, immediately after 
successful stent implantation, the balloon was inﬂated 6 times of 10sec each with 10sec 
deﬂation period in-between in order to mimic postC with 6 cycles of 10sec ischemia/
10sec reperfusion (postC group, N=29) or it was withdrawn with no additional intervention 
(control group, N=26). Blood samples were taken at baseline, immediately after the 
end of the last deﬂation and 15min later. Malondialdehyde (MDA) and nitrotyrosine 
(NT) were assessed as indexes of oxidative stress and nitrosative stress, respectively. 
Echocardiographic assessment of EF and WMS was performed at 24 hours and 10 days 
after the intervention.
Results: Baseline MDA, NT and conventional echocardiographic measurements including 
EF and WMS did not differ between postC and control group. MDA remained stable in 
the postC group (1.54±0.12 vs 1.55±0.13 µM), but increased gradually from the baseline 
(1.31±0.06 µM) to the ﬁnal measurement in controls (2.26±0.21 µM, p<0.05 vs all he 
other values). NT decreased signiﬁcantly in the postC group (3.4 ± 1.2 vs 0.72 ± 0.2 
nmol/l) and increased in controls (3.24 ± 1 vs 6.44 ± 1.1 nmol/l). Both wall motion score 
and EF improved signiﬁcantly in the postC group, from 1.17±0.18 to 1.08±0.11 (p=0.009) 
and from 64±8 to 69±10% (p=0.01), respectively, but remained unaffected in controls.
Conclusion: PostC is effective not only in total but also in subtotal or signiﬁcant coronary 
artery lesions in coronary artery disease patients. This intervention diminishes the 
oxidative and nitrosative stress and improves EF and WMS early after PCI.
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1031-56 Key Role of Postchallenge Hyperglycemia for the 
Presence and Extent of Coronary Atherosclerosis: An 
Angiographic Study
Christoph H. Saely, Heinz Drexel, Harald Sourij, Stefan Aczel, Heidrun Jahnel, Robert 
Zweiker, Peter Langer, Thomas Marte, Guenter Hoeﬂe, Werner Benzer, Thomas C. 
Wascher, VIVIT Institute, Feldkirch, Austria, Medical University Graz, Graz, Austria
Background: The associations between impaired glucose tolerance (IGT) and 
postchallenge diabetes with the presence and extent of angiographically characterized 
coronary artery disease (CAD) are unclear.
Methods: We enrolled 1040 consecutive Caucasian patients undergoing coronary 
angiography for the evaluation of CAD. An oral 75g glucose tolerance test was performed 
in patients without previously diagnosed diabetes.
Results: From our patients, 394 had normal glucose tolerance (NGT), 190 impaired 
glucose tolerance (IGT), 90 isolated postchallenge diabetes (postchallenge glucose q200 
mg/dl), and 366 type 2 diabetes previously established or newly diagnosed on the basis 
of fasting glucose (conventional diabetes). Angiographically detectable CAD was more 
frequent in patients with IGT, isolated postchallenge diabetes, or conventional diabetes 
when compared to NGT subjects (87.9%, 95.6%, 89.1% vs. 80.7%; p = 0.030, 0.001, 
0.043, respectively). The prevalence of signiﬁcant coronary stenoses q50%, compared 
to NGT subjects (57.4%), was similar in IGT patients (59.5%; p = 0.628), but signiﬁcantly 
higher in patients with isolated postchallenge diabetes (77.8%; p = 0.001) or conventional 
diabetes (68.0%; p = 0.002). Also the number of signiﬁcant stenoses compared to 
NGT subjects was similar in IGT patients, but signiﬁcantly higher in those with isolated 
postchallenge or conventional diabetes. These results were conﬁrmed after multivariate 
adjustment in logistic regression analyses.
Conclusions: Abnormal glucose tolerance is strongly and independently associated with 
angiographically characterized CAD. In IGT, non-signiﬁcant CAD is more frequent than in 
NGT; the prevalence and number of signiﬁcant stenoses increases when postchallenge 
diabetes evolves.
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1031-57 Long-Term Clinical Prognosis of Patients With Cardiac 
Syndrome X
Gregory A. Sgueglia, Antonella Spinelli, Pasquale Santangeli, Priscilla Lamendola, 
Antonio Di Monaco, Giancarla Scalone, Fabio Infusino, Leonardo Marinaccio, Alfonso 
Sestito, Gaetano A. Lanza, Filippo Crea, Catholic University of Sacred Heart, Rome, Italy
Background: Classical follow-up studies of patients with angina and normal coronary arteries 
at angiography consistently reported an excellent prognosis of these patients. However, 
some recent series questioned the excellent prognosis of CSX patients, suggesting an 
increased risk of cardiac events in those with evidence of endothelial dysfunction.
Methods: We performed clinical follow-up of 154 patients (mean age 58.9±10 years, 39 
men) diagnosed to have CSX at our Institute between 1991 and 2004, according to the 
following criteria: 1) typical effort angina; 2) evidence of myocardial ischemia based on 
ECG exercise stress test and/or ECG Holter monitoring and/or myocardial scinrigriphic 
stress tests; 3) totally normal epicardial arteries at coronary angiography. All patients were 
administered a detailed questionnaire about their angina history and clinical outcome 
during the years of follow-up.
Results: At a mean follow-up of 137±78 months (range 24-372) from the onset of 
symptoms, no patient died from cardiovascular causes, whereas 4 deaths (2.6%) 
occurred for non cardiac causes (3 cancers, 1 acute pancreatitis). Furthermore, no 
patient developed an acute myocardial infarction during follow-up. Despite the lack of 
major cardiac events, at least 1 hospital readmission because of acute chest pain at rest 
or worsening effort angina occurred in 89 patients (57.8%), 33 of whom (21% of total) 
underwent at least one further coronary angiographic study, with two of them showing 
ﬂow-limiting coronary stenoses in at least one epicardial vessel (6% of patients who 
repeated angiography; 1.3% of all patients). Compared to the basal evaluation, angina 
symptoms were improved in 82 patients (53%), unchanged in 51 (33%) and worsened 
signiﬁcantly, despite treatment, in 21 (14%) patients.
Conclusions: Our study, which involves the largest cohort of CSX pts until now followed-up, 
show the substantial absence of major cardiac events at long term follow-up (average >10 
years) in CSX patients. Our data, however, show the persistence or worsening of symptoms, 
which may signiﬁcantly impair quality of life, in a signiﬁcant proportion of these patients.
11:00 a.m.
1031-58 Effects of Rosuvastatin And Ezetimibe on Flow 
Mediated Dilation in Patients With Congestive Heart 
Failure: A Double-Blind, Cross-Over Trial
Penny Gounari, Dimitris Tousoulis, Charalambos Antoniades, Nikos Papageorgiou, 
Georgia Roulia, George Latsios, Alexios Antonopoulos, Gerasimos Siasos, George 
Hatzis, Anna-Maria Kampoli, Christodoulos Stefanadis, 1st Cardiology Department, 
Hippokration Hospital, Athens Medical School, Athens, Greece
Background: Congestive heart failure is characterised by increased proinﬂammatory 
stimulation and impaired endothelial function. Although statin treatment exerts a beneﬁcial 
effect on endothelial function, reﬂected in an improvement of clinical outcome in patients 
with heart failure, it is still unclear whether this effect is due to lipid-lowering or their 
pleiotropic effects. We compared the effect of short-term treatment with rosuvastatin or 
ezetimibe on endothelial function in patients with congestive heart failure.
Methods: In this double-blind, placebo controlled, cross-over trial, 13 patients with 
congestive heart failure (ejection fraction 31.9±1.5%, age 59.7±3.3 years old) were 
randomised to receive ezetimibe 10mg/d or rosuvastatin 10mg/d for 4 weeks, with 4 
weeks wash-out period between the two interventions. Endothelial function was evaluated 
by ﬂow mediated dilation (FMD) in the brachial artery at the beginning and at the end of 
each treatment period.
Results: There was no change in the baseline brachial diameter after treatment with 
either ezetimibe (from 47±1.8mm to 48±2.3 mm, p=NS) or rosuvastatin (from 48±2mm 
to 48±1.3mm, p=NS). However, there was a signiﬁcant improvement of FMD in the 
rosuvastatin group (from 4.23±1.7% to 9.88±2.29%, p<0.05) but not in the ezetimibe 
group (from 3.1±2.1% to 5.3±2.2%, p=NS). The change in lipid levels were similar 
between groups (p=NS). The change in FMD was not signiﬁcantly correlated with the 
decrease of serum LDL in either the ezetimibe (r=-0.104, p=0.747) or rosuvastatin (r=-
0.364, p=0.271) treated groups.
Conclusions: Rosuvastatin improves endothelial function in patients with congestive heart 
failure, by mechanisms independent of lipid-lowering. On the contrary, lipid-lowering 
treatment achieved by ezetimibe is unable to affect endothelial function in these patients. 
These ﬁndings indicate a direct beneﬁcial effect of statins in patients with congestive 
heart failure, further to lipid-lowering.
11:00 a.m.
1031-59 The Ala379Val Polymorphism of Lipoprotein-Associated 
Phospholipase A2 Affects the Risk for Arterial 
Hypertension and Modiﬁes Platelets Activation
Despina Kardara, Dimitris Tousoulis, Charalambos Antoniades, Nikolas Koumallos, 
Alexios Antonopoulos, Nikos Papageorgiou, Costas Tsiouﬁs, Charalambos 
Vlachopoulos, Elli Stefanadi, Carmen Vasiliadou, Christodoulos Stefanadis, 1st 
Cardiology Department, Hippokration Hospital, Athens Medical School, Athens, Greece
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity has been 
identiﬁed as a risk factor for atherosclerosis. Lp-PLA2 has proinﬂammatory properties 
and it hydrolyses platelet activating factor. Genetic polymorphism Ala379Val has been 
associated with Lp-PLA2 activity, but its effect on platelets activation and redox state 
is obscure. We examined the impact of Ala379Val polymorphism on the risk for arterial 
hypertension, platelets activation and systemic redox state.
Methods: In this case-control study, 488 subjects were recruited: 235 with arterial 
hypertension and 253 age and gender matched controls. Ala379Val polymorphism was 
detected by PCR, while plasma levels of sCD40L, P-selectin oxidized LDL (ox-LDL) were 
measured by ELISA.
Results: The genotype distribution was: Val/Val: 9 (3.8%), Ala/Val:69(29.4%) and Ala/
Ala: 157(66.8%) in hypertensives, and Val/Val: 9 (3.6%), Ala/Val:98(38.7%) and Ala/Ala: 
146(57.7%) in controls. The carriers of the Val allele had signiﬁcantly lower risk for arterial 
hypertension (OR[95%CI]:0.678[0.469-0.980], p=0.04) compared to Ala homozygotes. 
In the overall population, ox-LDL was signiﬁcantly lower in the presence of the Val allele 
(62.8±2.7U/L) compared to Ala homozygotes (71.3±2.4U/L, p<0.05). Val homozygotes 
also had lower levels of P-selectin (20.0±6.4 ng/ml) and sCD40L (3.5±0.8ng/ml) compared 
to Ala homozygotes (38.0±1.8 ng/ml and 5.7±0.3ng/ml respectively, p<0.05 for both).
Conclusions: The presence of the 379Val variant of Lp-PLA2 is associated with lower 
risk for arterial hypertension and decreased oxidative stress status. Furthermore, 
homozygosity for this allele is associated with lower levels of sCD40L and P-selectin, 
suggesting lower platelets activation. These ﬁndings suggest that this polymorphism may 
be implicated in the pathogenesis of hypertension and platelets activation.





1031-60 Long-Term Outcome of Korean Patients With 
Vasospastic Angina
Sang-Yong Yoo, Sang-Sig Jeong, Hyuk Ko, Gangneung Asan Hospital, Gangneung, 
South Korea
Background: The overall prognosis of patients with vasospastic angina (VA) is relatively 
good. However, it is not well known about the long-term prognosis and inﬂuential 
factors for Korean patients with VA. Methods: From August 1996 to January 2007, 256 
consecutive patients with VA were enrolled (215 men, 53±9 years). Coronary spasm 
was conﬁrmed during the coronary angiography in all study patients by intravenous 
ergonovine provocation. Major adverse cardiac events (MACEs) were deﬁned as 
myocardial infarction (MI), resuscitation from cardiac arrest, or repeated hospitalization 
due to recurrent angina. Results: 256 patients were followed for an average of 59 months 
(range, 5 months to 11 years). 31 patients (12.1%) were lost to follow-up. Cardiac death, 
a nonfatal MI, and MACEs occurred in 6 (2.3%), 3 (1.2%), and 52 (20.3%) patients, 
respectively. Survival, and survival without MI at 1, 3, and 5 years was 99%, 97%, and 
97%, 99%, 96%, and 95%, respectively. MACEs-free survival at 1, 3, and 5 years was 
91%, 81%, and 62%, respectively. MI at the initial presentation and current smoking were 
signiﬁcantly associated with MACEs. Multivariate analysis showed current smoking to 
be the only independent predictor of MACEs-free survival (odd ratio 2.16; 95% CI 1.12 
- 4.23; p = 0.022). Conclusion: Despite treatment with calcium channel blockers, recurrent 
episodes of angina were frequently observed whereas sudden cardiac death or non-fatal 
MI was rare. Cessation of smoking may reduce the incidence of recurrence.
11:00 a.m.
1031-61 Comparison Between Three-Dimensional Angiographic 
Reconstruction and Intravascular Ultrasound Imaging 
for the Measurement of Intracoronary Cross-Sectional 
Luminal Dimensions
Tim A. Fischell, Edmund Bermudez, Borgess Heart Institute, Kalamazoo, MI
Background: Given its greater spatial resolution over traditional two-dimensional 
angiography, intravascular ultrasound has enabled the measurement of minimal luminal 
area of coronary stenoses, of which, an area of less than 4.0 mm2 has been shown 
to correlate with hemodynamically signiﬁcant stenoses. Angiographic three-dimensional 
reconstruction of luminal dimensions can provide similar measurements without further 
invasive study. Methods: We prospectively enrolled consecutive patients undergoing 
invasive coronary angiography and intravascular ultrasound for the assessment of 
angiographically intermediate coronary lesions (50-70%) at a high volume tertiary care 
hospital between July 1, 2006 and June 1, 2007. Intravascular Ultrasound using motorized 
pullback was performed on all lesions with ofﬂine measurements of minimal luminal 
dimension and area. Using a commercially available three-dimensional angiographic 
reconstruction software package (CardiOP-B, Paieon Inc., Israel), two orthogonal 
angiographic views were obtained to reconstruct and calculate lesion dimensions. 
Results: A total of 31 patients were enrolled with 32 lesions assessed in 31 vessels. 
Lesions were assessed in the left anterior descending artery, left circumﬂex artery, and 
right coronary artery in 42% (n=13), 26% (n=8), and 32% (n=10), respectively. Overall 
mean minimal luminal area was 3.5 mm2 ± 1.6mm and minimal luminal dimension 1.87 
mm ± 0.58 mm. Three-dimension reconstruction measurements of cross-sectional minimal 
luminal area highly correlated in a linear fashion with measurements by intravascular 
ultrasound (r=0.88, p<0.0001). Similarly, minimal luminal dimensions correlated in a 
statistically signiﬁcant fashion between both methods (r=0.78, p<0.0001). The sensitivity 
of angiographic reconstruction to detect a hemodynamically signiﬁcant lesion (minimal 
luminal area <4.0 mm2) was 89%, with a speciﬁcity of 46% and overall accuracy of 72%. 
Conclusions: Three-dimensional angiographic measurements of intracoronary stenoses 
highly correlate with measurements by intravascular ultrasound and provide a sensitive 
method of detecting cross-sectional areas of less than 4.0 mm2 .
11:00 a.m.
1031-62 Gender Differences in Risk Factors Including C-
Reactive Protein in a Large Consecutive Patient Cohort 
Undergoing Elective Coronary Angiography
Alois Suessenbacher, Maria Wanitschek, Suzanne De Waha, Jakob Doerler, Matthias 
Frick, Otmar Pachinger, Hannes F. Alber, Division of Cardiology, Innsbruck, Austria
Background: Little information is available about gender differences concerning the 
presence and inﬂuence of cardiovascular risk factors including C-reactive protein (CRP) 
in consecutive patients undergoing coronary angiography (CA) for the evaluation of 
coronary artery disease (CAD).
Methods: 5641 consecutive patients (33.1% women) undergoing elective CA were 
analysed. Cardiovascular risk factors were assessed by standardised questionnaire 
and routine blood chemistry. CAD was graded by visual estimation of lumen diameter 
stenosis. Signiﬁcant stenoses were deﬁned as lumen diameter reduction q70% in at least 
one major coronary artery. Coronary angiograms were graded as non-signiﬁcant CAD, as 
1-, 2- or 3-vessel disease or as non-CAD.
Results: Women were older than men (65.2±11.0 vs. 63.1±11.0 years, p<0.001)and had 
more often a positive family history for premature CAD (30.2 vs. 24.5%, p<0.001). The 
number of risk factors was higher in men (2.4±1 vs. 2.3±1, p=0.01) and smoking was more 
common in men (55.9 vs. 35.0%, p<0.001). In addition, CRP levels were higher in men 
(0.82 vs. 0.97mg/dl, p=0.02). The prevalence of hypertension (76.1 vs. 77.5%, p=0.25), 
hypercholesterolemia (68.5 vs. 69.4%, p=0.47) and diabetes (17.6 vs. 17.4%, p=0.86) 
was not different between gender. CAD was more often found in men (80.0 vs. 59.1%, 
p<0.001). In multinomial logistic regression analyses including age, total cholesterol, 
HDL-cholesterol, CRP, diabetes, hypertension and prior statin use in men all variables 
except hypertension were independent predictors of CAD. In women total cholesterol and 
hypertension were not independently associated with CAD. According to Wald statistics, 
CRP was a much stronger independent predictor of CAD in men than in women.
Conclusion: In this large consecutive patient cohort women and men have almost similar 
risk factor proﬁles when referred for CA. The inﬂuence of traditional risk factors on 
the prevalence of CAD is similar between gender, but CRP is a stronger independent 
predictor of CAD in men.
11:00 a.m.
1031-63 Prevalence and Predictors of Suboptimal Response to 
Aspirin in Patients with Coronary Artery Disease
Roland Youssef Kassab, Mirna Germanos, Georges Badaoui, Miche Fahed, Youssef 
Massaad, Zeina Kadri-Maalouf, Elie Salame, Rabih R. Azar, Hotel Dieu de France 
Hospital, Beirut, Lebanon
Background: Patients with coronary artery disease (CAD) who are resistant to aspirin 
(ASA) are at increased risk for recurrent cardiac events. However, the prevalence and 
predictors of a suboptimal response to ASA remain insufﬁciently deﬁned. Methods: 
We measured platelet aggregation in response to 125 µg of arachidonic acid using the 
Plateletworks test (Helena Laboratories). With this test, patients who are not exposed 
to ASA have an inhibtion of platelet aggregation < 40%. Based on this, we deﬁned a 
suboptimal response in patients taking ASA by an inhibition < 40%. We enrolled patients 
with stable CAD who have been on ASA for > 1 month. Patients with acute coronary 
syndrome and those on other anti-platelet drugs were excluded. Results: 352 patients 
were enrolled: 37% with prior MI, 32% with prior PCI and 45% with prior CABG. Mean 
inhibition of platelet aggregation was 48 + 17% in the whole group. One hundred thirteen 
patients (32%) were poor responder to ASA and had a mean platelet inhibition of 29 + 
8% compared to 57 + 12% in patients with good response (p < 0.001). ASA dose was 
similar between the 2 groups (104 + 40 vs. 100 + 29 mg/day). Increased age, lower body 
mass index, male gender and a history of prior MI were associated with a suboptimal ASA 
response (table) while traditional risk factors and medications other than aspirin were not. 
Conclusion: The prevalence of a suboptimal response to ASA is as high as 32% and 
should be especially considered in elderly male patients with low body mass index and 
a history of prior MI.
Predictors of Suboptimal Response to ASA
Relative Risk (95% CI) P Value
Male gender 2.2 (1.3-3.6) < 0.001
Age 1.03 (1.01-1.05) 0.007
Body Mass Index 0.9 (0.84-0.97) 0.008
Prior MI 1.3 (1.01-1.85) 0.04
11:00 a.m.
1031-64 Comparison of Stress CMR with Stress SPECT for the 
Diagnosis of Coronary Artery Disease
Ijaz Ahmad, John Heitner, Igor Klem, Frederick Meine, Michele Parker, Robert Judd, 
Michael W. Hanson, Salvatore Borges-Neto, Raymond J. Kim, New York Methodist 
Hospital, Brooklyn, NY, Duke University Medical Center, Durham, NC
Background: Single positron emission scintigraphy (SPECT) imaging is one of the most 
utilized outpatient procedures. The diagnostic accuracy of SPECT can be limited by 
soft tissue attenuation and low resolution. Cardiac magnetic resonance imaging (CMR) 
assesses myocardial perfusion with higher spatial resolution and without susceptibility to 
soft tissue attenuation.
Objectives: To compare stress CMR to stress SPECT in the diagnosis of coronary artery 
disease (CAD) in patients who present with chest pain.
Methods: We prospectively enrolled 65 patients with chest pain who were at intermediate 



















risk for CAD. All patients underwent both a CMR and SPECT. CMR included cine, 
adenosine- stress and rest perfusion, and delayed enhancement. SPECT included stress 
and rest perfusion, assessment of wall motion and ejection fraction. If either of the two 
stress tests were positive, patients were referred for coronary angiography. Patients were 
followed for myocardial infarction, revascularization, or cardiac death.
Results: Thirty-seven patients were referred for coronary angiography, 13 of whom had 
signiﬁcant CAD (>70%). The sensitivity, speciﬁcity, positive predictive value and negative 
predictive value for CMR are 71%, 83%, 56%, and 91% and for SPECT are 64%, 87%, 
60%, and 89%, respectively. In patients who had a negative CMR and SPECT, there were 
no clinical events on follow up (mean 2 ½ years).
Conclusion: In patients being evaluated for the presence of CAD, CMR has similar 
diagnostic accuracy as SPECT.
Baseline Characteristics





Age(years) 58.1 58.5 58
Males 41(65%) 11 (85%) 30(60%)
Diabetes 12 (19%) 5(38%) 7(14%)
Hypertension 38(60%) 10 (77%) 28(56%)
Hypercholesterolemia 32(51%) 8(61%) 24(48%)
Statins 28 (44%) 8 (61%) 20(40%)
Beta Blocker 18 (29%) 6 (46%) 12(24%)
Aspirin 30 (48%) 9 (69%) 21(42%)
C-reactive Protein 0.4 0.58 0.36
11:00 a.m.
1031-65 Clinical Outcomes in Older Patients Treated with 
Optimal Medical Therapy with or without Percutaneous 
Coronary Intervention for Stable Coronary Disease: A 
Pre-Speciﬁed Subset Analysis of the COURAGE Trial
William E. Boden, Steven P. Sedlis, Teo Koon, Robert O’Rourke, David Maron, Pamela 
Hartigan, Marcin Dada, William Weintraub, Western New York VA Healthcare Network 
and Buffalo General Hospital/SUNY, Buffalo, NY
Background: Individuals q age 65 years comprise the fastest growing segment of the U.S. 
population. The impact of percutaneous coronary intervention (PCI) on clinical outcomes 
in older patients with stable coronary artery disease (CAD) treated with optimal medical 
therapy (OMT) remains ill-deﬁned. While age dichotomized at 65 years was one of 8 
prespeciﬁed covariates that did not show a difference between PCI and OMT for the 
primary endpoint of death or MI during a median 4.6 year follow-up, other important 
cardiovascular (CV) outcomes that could vary by treatment in older vs. younger patients 
have not been previously reported.
Methods: We compared baseline characteristics and long-term CV outcomes of patients 
whose age was < 65 years vs. q 65 years enrolled in the COURAGE trial.
Results: Of the 2,287 patients randomized to OMT or OMT + PCI, 1,381 patients (60%) 
were < age 65 years (mean age: 56 ± 6 years) and 904 patients (40%) were q age 
65 years (mean age: 72 ± 5 years). Rates of death, MI, stroke, and ACS stratiﬁed by 
treatment arm and age dichotomized at 65 years are shown (Table). 
CV Outcomes Age PCI + OMT OMT P value
Death < 65 28 (4 %) 41 (6 %) 0.12
q 65 57 (12 %) 54 (12 %) 0.92
MI < 65 83 (12 %) 76 (11 %) 0.52
q 65 60 (13 %) 52 (12 %) 0.54
Death or MI < 65 107 (16 %) 109 (16 %) 0.93
q 65 104 (23 %) 93 (21 %) 0.54
Death, MI, stroke < 65 113 (16 %) 114 (16 %) 0.99
q 65 109 (24 %) 99 (22 %) 0.62
ACS < 65 87 (13%) 85 (12%) 0.83
q 65 60 (13%) 52 (12%) 0.47
Death, MI, stroke, ACS < 65 172(25%) 175 (25%) 0.91
q 65 141 (31%) 130 (29%) 0.65
Conclusions: Patients q age 65 years had more deaths than younger patients, but not 
more nonfatal MIs. The addition of PCI to OMT did not reduce CV events; thus, it appears 
difﬁcult to justify PCI as an initial strategy in older stable CAD patients, and it is unlikely to 
be cost-effective as well. These data support adherence to published ACC/AHA treatment 
guidelines advocating OMT as the preferred initial strategy, regardless of age.
11:00 a.m.
1031-66 Serial Analysis of Neointimal Coverage Following 
Sirolimus-eluting Stent Implantation Using Optical 
Coherence Tomography: Comparison with Bare-metal 
Stent
Tatsuya Ito, Mitsuyasu Terashima, Yoshihiro Takeda, Jean-François Surmely, Osamu 
Katoh, Tetsuo Matsubara, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: Late stent thrombosis (LST) in sirolimus-eluting stents (SES) after 
discontinuation of antiplatelet therapy develops a serious complication. Previous 
pathologic studies have shown the relationship between LST and delayed arterial healing 
following SES implantation. However, the time course of arterial healing is unknown in 
the clinical setting. Optical coherence tomography (OCT) is a novel imaging technique 
with high resolution and is expected to visualize microscopic vascular response to 
coronary intervention. The aim of this study was to investigate healing process following 
SES implantation in comparison with bare metal stent (BMS) using OCT. Methods: We 
evaluated 8 SES in 6 patients and 5 BMS in 5 patients. Serial OCT images of inplanted stent 
segment were analyzed at intervals of 1mm. Eight SES including 1270 struts and 5 BMS 
including 787 struts were evaluated in each stent at 2-month and 8-month chronologically. 
Every observed strut was classiﬁed into either covered or uncovered by OCT ﬁndings. 
The frequency of uncovered struts in each stent were calculated. Results: At 2-month, 
frequency of uncovered struts was signiﬁcantly higher in SES than in BMS (18.0 ± 13.6% 
vs 1.2 ± 1.7%, p=0.02). Although uncovered struts gradually decreased with time, even 
8 months after implantation of SES, these sites were not completely covered, whereas 
BMS were almost completely covered (6.4 ± 5.1 vs 0.6 ± 0.9%, p=0.03). Conclusions: 
The window of thrombotic risk for SES extends far beyond that for BMS. 
11:00 a.m.
1031-67 Circulating Progenitor Cells and Erythropoietin 
Levels in Patients Undergoing Enhanced External 
Counterpulsation
BARRY A. BOILSON, Thomas J. Kiernan, Linda J. Tesmer, Adriana Harbuzariu, Laurel 
S. Kleppe, Robert D. Simari, Gregory W. Barsness, Mayo Clinic, Rochester, MN
Background: The mechanism underlying the beneﬁts of Enhanced External 
Counterpulsation (EECP) is not clear. We hypothesized that this could be associated with 
an increase in circulating bone-marrow derived progenitor cells (CPCs) and increased 
erythropoietin (Epo) levels, as studies have demonstrated that Epo is a potent mobilizer 
of bone marrow cells to the peripheral circulation, partly accounting for its pro-angiogenic 
properties.
Methods: Nine patients scheduled to receive EECP treatment were enrolled. Blood (5ml) 
was drawn on day 1, day 17, day 35 (ﬁnal session) and one month post completion 
of therapy. Buffy coat was extracted and FACS enumeration of CD34+ and/or CD133+ 
CPCs was performed using ISHAGE criteria. Epo levels were measured at baseline and 
at day 35.
Results: Flow cytometric analysis revealed an increase in CPC counts over the course 
of treatment, which was statistically signiﬁcant for CD133+ and CD34+,CD133+ CPCs 
(p<0.05) (see ﬁgure). Epo levels also increased signiﬁcantly with EECP therapy (12±2 
MU/ml at baseline to 22±3 MU/ml at day 35, p<0.05).
Conclusions: This study shows that CD133+ and CD34, CD133+ CPCs are signiﬁcantly 
increased in response to EECP therapy, and this is matched by a signiﬁcant increase 
in circulating Epo. This may reﬂect increased release of progenitor cells from the bone 
marrow, likely through hormonal activation. Homing of these cells to the coronary 
vasculature may effect improvements in vascular function and clinical symptomatic 
improvement. 





1031-68 Enhanced External Counterpulsation Improves One 
Year Mortality in Angina Patients With End Stage 
Coronary Disease
William E. Lawson, John CK Hui, Elizabeth D. Kennard, Marc A. Silver, Oslem Soran, 
Sheryl F. Kelsey, Gregory Barsness, Andrew Michaels, SUNY Stony Brook, Stony Brook, 
NY, University of Pittsburgh, Pittsburgh, PA
Background: Enhanced External Counterpulsation (EECP) improves angina class and 
ischemia, exercise tolerance and function, QOL in refractory angina patients (pts) with 
end stage coronary disease, but its effect on mortality and what factors predict survival in 
this group of pts is unknown.
Methods: The IEPR is a prospective registry of 8,000 EECP treated pts. About 14% of 
pts do not complete (q30 hours) EECP therapy (1.7% for medical reasons), providing a 
comparator group for Landmark analysis when early events (within 60 days of starting 
therapy) are censored. Demographics, comorbidities, baseline characteristics were 
recorded and (1 year) outcomes, including mortality, were compared using Kaplan-Meir 
survival analysis and a Cox proportional hazards regression model from centers providing 
1 year follow-up. Multivariable analysis of pts alive at 60 days after EECP was begun was 
used to determine independent predictors of one year mortality.
Results: Records of 4,597 pts were analyzed; 3,962 pts (86%) completed (C) the usual 
course of therapy, 14% did not (IC). Cardiac events (death, MI, CABG, PCI) accounted for 
12% of the IC. Baseline demographics and history of IC and C cohorts were comparable: 
89% prior CABG or PCI, 70% prior MI, 91.5% Class III or IV angina, and only 15% 
considered candidates for CABG or PCI. Post EECP angina class improved signiﬁcantly, 
85% versus 25% improving q1 CCS, in the C(mean 36±4 hours) versus the IC cohort 
(mean 13±8 hours). At 1 year there was a signiﬁcant difference in mortality rates favoring 
the C group (4.1% versus14.1%; p<0.001), and decreased rates of myocardial infarction 
(4.1% versus 7.7%), CABG (2.5% versus 6%), and PCI (6.3% versus 11.3%)(all p<0.001). 
Predictors of 1 year mortality in pts alive at 60 days included: LVEF a 35%, HR=2.70 
(p<0.001); completion of EECP, HR=2.00 (p<0.001); CHF, HR=1.65 (p<0.001); Diabetes, 
HR=1.47 (p=0.012); Age (per year), HR=1.05 (p<0.001).
Conclusions: EECP therapy completion improves CCS angina class and 1 year survival 
in end stage CAD pts. Predictors of mortality are similar to those having prognostic value 
in coronary disease pts, including: heart failure and left ventricular dysfunction, diabetes, 
male gender, age.
11:00 a.m.
1031-69 Is Cardiac Magnetic Resonance Imaging a Useful Test 
in the Diagnosis of Women with Microvascular Angina?
Melissa H. Slivka, Chrisandra Shufelt, Yuching C. Yang, Louise E. Thomson, Saibal Kar, 
Leslee Shaw, Daniel S. Berman, Bina Ahmed, Kirsten Tolstrup, C. Noel Bairey Merz, 
Cedars Sinai Medical Center, Los Angeles, CA
Background: Women with microvascular angina (open coronary arteries but myocardial 
ischemia) have an adverse prognosis comparable to that of obstructive coronary disease 
as shown in prior research. Coronary reactivity testing (CRT) is useful in this diagnosis as 
traditional imaging tests are unable to detect subendocardial ischemia. Cardiac magnetic 
resonance imaging (CMR) may be useful to detect subendocardial ischemia due to 
abnormalities in coronary vascular function. We tested the sensitivity of CMR in women 
with angina and open coronary arteries for the diagnosis of microvascular angina using 
CRT as gold standard.
Methods: Forty women with clinical evidence of ischemia and non-obstructed coronary 
disease were referred for CRT and CMR. Women with myocardial bridging (n=1), left 
ventricular hypertrophy (n=1), obstructive coronary disease (n=2) and anomalous coronary 
(n=1) were excluded. CRT included intra-coronary artery adenosine coronary ﬂow 
reserve (CFR) (non-endothelial microvascular function), changes in coronary blood ﬂow 
and vessel diameter following intra-coronary acetylcholine (endothelial dependent macro 
and microvascular function) and vasodilatation following intra-coronary nitroglycerine 
(non-endothelial dependent macrovascular function). CMR included adenosine stress 
and rest perfusion using a 17 segment myocardial model with visual interpretation by two 
observers blinded t the CRT and angiography ﬁndings.
Results: The mean age of women was 54 ± 9.3 years, 19% were non-white, 48% 
dyslipidemic, 34% hypertensive, 46% had history of smoking. An abnormal CRT was 
found in 91%, and 68% had abnormalities in CMR subendocardial stress perfusion with 
normal delayed enhancement and ventricular function. The sensitivity of CMR to CRT 
deﬁned vascular dysfunction was 69% with a positive predictive value (PPV) of 92%. For 
the quantitative read, scoring the % ischemic myocardium of q10% by CMR resulted in a 
sensitivity of 68% and PPV of 88%.
Conclusions: Women with ischemia and open coronary arteries have a high rate of 
CRT and CMR abnormalities. CMR appears to have a fair sensitivity and good PPV for 
microvascular angina. Further study is indicated.
11:00 a.m.
1031-70 Effect of Enhanced External Counterpulsation on 
Ejection Fraction in Patients with Ischemic Heart 
Disease
William E. Lawson, Himanshu Padh, Subramanian Ramasamy, John CK Hui, Samarpan 
Heart Hospital and Research Center, Jamnagar, India, The People’s College of Medical 
Sciences, Jamnagar, India
Background: Enhanced External Counterpulsation (EECP) has been shown to decrease 
symptoms of myocardial ischemia, improve perfusion, endovascular function, and 
exercise capacity. There are no large studies evaluating the effect of EECP on ejection 
fraction (EF) in patients with ischemic heart disease.
Methods: Two-dimensional transthoracic echocardiography was performed on 505 
patients with ischemic heart disease 1 week before their 35 hours (1 hour daily) of EECP 
treatment and repeated within 1 week after completion of treatment. Patients were divided 
into two groups, one with baseline EF>35% (N=360) and the other with EFa35% (N=145). 
Pre- and post echo parameters were compared in both groups using a 2-tailed paired 
t-test with signiﬁcance at p<0.05.
Results: The EF>35% group was slightly younger than EFa35% group (58.1 versus 61.3 
years), predominately male (86 versus 88%), with similar percentage with diabetes (55 
versus 50%), hypertension (75 versus 72%), hypercholesterolemia (64 versus 61%), MI 
(48 versus 49%), CABG (21 versus 31%) and PCI (13% versus 8%). In the EFa35% group, 
the EF and stroke volume (SV) increased signiﬁcantly from a baseline of 29.3±6.3% and 
67.7±8.4 ml to 45.1±7.9% and 75.0±9.2 ml (p< 0.001), with no signiﬁcant change in 
heart rate (78±13 to 77± 13 beats/min). Surprisingly, the mean EF and SV of the >35% 
group also increased from 48.1±7.4% and 78.4±8.2 ml at baseline to 56.3±5.5% and 
85.6±9.3 ml post-EECP (p<0.001). The improvement in EF and SV was mainly from a 
signiﬁcant reduction of end systolic volume from 59.3±10.4 to 53.6±8.4 ml (p<0.001) in 
the EFa35% group and from 54.6±7.6 ml to 50.4±6.0 ml in the EF>35% group, without 
signiﬁcant change in end diastolic volumes (127.0±10.8 to 128.6 ±10.9ml and 133.8±11.8 
to 136.0±10.4 ml respectively).
Conclusions: EECP treatment signiﬁcantly increased ejection fraction and stroke volume, 
mainly due to a decrease in end systolic volume. Potential underlying mechanisms include 
improvement in left ventricular contractility due to improved myocardial perfusion and/or 
afterload reduction secondary to normalization of endovascular tone and function.
11:00 a.m.
1031-71 Cardiac Magnetic Resonance Imaging and Coronary 
Reactivity Testing: A Useful Noninvasive Tool
Chrisandra L. Shufelt, Saibal Kar, Melissa Slivka, Louise Thomson, Yuching Yang, Daniel 
Berman, Donna Polk, Kristen Tolstrup, C. Noel Bairey Merz, Cedars-Sinai Medical 
Center, Los Angeles, CA
Background: Coronary reactivity testing (CRT) is used in the diagnosis of microvascular 
dysfunction based on endothelial and non-endothelial dependent markers. Adenosine 
stress cardiac magnetic resonance imaging (CMR) may be a useful non-invasive method 
to detect subendocardial ischemia. We sought to determine the relationship between CRT 
and CMR abnormalities in a selected population of women.
Methods: Thirty-ﬁve women with clinical evidence of ischemia and open coronary 
arteries by angiogram underwent both a CRT and CMR. Four markers of microvascular 
dysfunction measured during CRT included intra-coronary artery adenosine coronary 
ﬂow reserve (CFR) (non-endothelial microvascular function), changes in coronary blood 
ﬂow (CBF) and coronary artery diameter with intra-coronary acetylcholine (endothelial 
micro- and macrovascular function, respectively) and vasodilatation following intra-
coronary nitroglycerine injection (non-endothelial macrovascular function). CMR was 
assessed for perfusion abnormality using a 17 segment visual scoring. We performed 
uni- and multivariate linear regression analysis with CMR perfusion abnormality and CRT 
variables.
Results: The mean age was 54 ± 9.3 years, 19% were non-white, 48% were dyslipidemic, 
34% hypertensive, 46% had a history of smoking. None were current smokers and there 
were no diabetics. Univariate analyses demonstrated that CFR and CBF predicted 
CMR perfusion abnormality (coefﬁcient = -7.43, p=0.045 and coefﬁcient = 5.3, p=0.048, 
respectively). There was no statistical associated trend found with either acetylcholine or 
nitroglycerine (p=0.19, p=0.58, resp). By multivariate analysis the association between 
CBF and CFR with CMR abnormality became nonsigniﬁcant; however both continued to 
show trends toward predicting CMR perfusion abnormality (p=0.09, 0.07, resp).
Conclusions: In women with clinical evidence of ischemia and open coronary arteries, 
there is a relationship between abnormalities in CBF, CFR and the percent of stress 
perfusion abnormalities by CMR. This observation suggests CMR may be a useful tool 
in evaluation of suspected abnormal CFR and study in a larger group including normal 
controls is needed.
11:00 a.m.
1031-72 Accurate Detection of Coronary Artery Disease 
without use of Radiation using Non-Stress 
Magnetocardiography
Indraneil Ray, Amelia Young, David Gallegos, Linn Defensor, Robert J. Siegel, Kirsten 
Tolstrup, Cedars Sinai Medical Center, Los Angeles, CA
Background: Early diagnosis of coronary artery disease (CAD) is complicated by the poor 
sensitivity of standard tests (ECG and troponin) and the contraindication for stress testing 
in unstable angina patients. Currently used diagnostic tests carry risks that involve stress 
provocation, injection of medication, use of nuclear tracer, contrast, or radiation, as well 
as the possibility of invasive catheterization. MagnetoCardioGraphy (MCG) is a no risk 
technology developed for the rapid, non-invasive evaluation and detection of ventricular 
repolarization abnormalities at rest.
Methods: 111 patients with stable angina, asymptomatic chronic ischemic heart disease 
or acute chest pain and 29 normal controls were studied with unshielded 9 channel MCG 
in a general clinical setting. Scan time was 6 minutes. The MCG data were processed 
utilizing an automated MCG analysis program and results were available immediately. All 
patients were angina free at the time of scanning.
Results: The patient mean age was 59 ± 13 years and 68% were men. Most had normal 
ECG (79%) and normal troponin I (88%). A diagnosis of CAD was established in 38% of 
patients after non-invasive and invasive testing. A normal MCG was seen in all controls. 
MCG detected CAD with high degree of accuracy (p<0.0001) and high diagnostic value: 
sensitivity 88%, speciﬁcity 80%, positive (PPV) and negative predictive value (NPV) of 



















73% and 92%, respectively. In comparison, the sensitivity, speciﬁcity, PPV and NPV of 
stress SPECT was 90%, 68%, 68% and 90%, respectively.
Conclusion: MCG is a rapid risk free method for detection of coronary artery disease 
without the use of radiation, contrast or stress testing.
11:00 a.m.
1031-73 Deﬁbrillation Threshold Decreases With Repeated 
Episodes of Long Duration Fibrillation
Derek J. Dosdall, Jose Osorio, Gregory P. Walcott, Raymond E. Ideker, University of 
Alabama at Birmingham, Birmingham, AL
Background: Many patients with sudden cardiac arrest persist in ventricular ﬁbrillation 
(VF) for several minutes before deﬁbrillation, and reﬁbrillation is common. However, most 
deﬁbrillation studies have examined only short duration VF (SDVF). The aim of this study 
was to determine if the deﬁbrillation threshold (DFT) is different after long duration VF 
(LDVF) compared to SDVF.
Methods: In 9 swine, during 5 alternating episodes of electrically induced SDVF (10 s) 
and LDVF (150 s) external biphasic shocks of increasing strength were delivered until 
VF was terminated. The shock that terminated VF was used as an approximation of the 
DFT. Between episodes of VF, the animals were allowed 5 or 30 min after SDVF or LDVF, 
respectively, to achieve hemodynamic and metabolic stability. During a 6th VF episode 
(n=6), shocks at the DFT for the 5th LDVF episode were delivered every 15 s until VF 
was terminated.
Results: While the SDVF DFT did not change, the LDVF DFT decreased signiﬁcantly after 
successive VF episodes (see ﬁgure). A repeated measures test showed that treatment 
group (SDVF vs. LDVF) was a signiﬁcant factor in DFT level. In the 6th LDVF episode, VF 
was terminated with 32±10 J after 137±41 s.
Conclusions: The DFT of LDVF, but not SDVF, decreases markedly after successive 
episodes. This decline may occur after 120-150 s of VF. Further studies into the 
mechanism of this reduction in LDVF DFT may lead to more effective deﬁbrillation 
strategies for clinically relevant scenarios of LDVF.
11:00 a.m.
1031-74 Clinical Relevance of Hemolysis During Circulatory 
Support With Percutaneously Implantable Axial Flow 
Pumps
Markus Ferrari, Markus Schlosser, Ruediger Pfeifer, Gerald S. Werner, Hans R. Figulla, 
Clinic of Internal Medicine 1, Friedrich-Schiller-University, Jena, Germany, Clinic of 
Internal Medicine 1, Darmstadt, Germany
Background & Objectives: Percutaneously implantable axial ﬂow pumps (pAFP) provide 
continuous circulatory support independently of cardiac rhythm. They are ideal devices for 
intermediate term circulatory support in cardiogenic shock. However, extend of use was 
limited due to hemolysis so far. We therefore evaluated the hemolysis rate during long term 
use of pAFP.
Methods: We included 14 patients who had circulatory support with pAFP (Impella recover 
LP2.5, or AMED LVAD 16F). Repetitive blood samples (free hemoglobin: fHb, ULN < 3.1 
µmol/l) were taken every 4 hours during pAFP support, and every 8 hours after removal 
of the device for additional 3 days.
Results: The pAFP was implanted in 8 patients due to severe cardiogenic shock (4 pts. 
were on IABP before), for high risk coronary angioplasty (5 pts.), and weaning from 
emergency cardio-pulmonary bypass (1 pt.). The mean age was 70 +/- 7.3 years, all 
male, duration of circulatory support was 27.3 +/- 38.36 hours (10 - 140 hours). The 
fHb increased from 2.9 +/- 2.13 µmol/l to a maximum of 27.9 +/- 30.84 µmol/l within 4 
hours of pump support. The serum level of fHb decreased to 13.9 +/- 12.10 µmol/l after 
8 hours, and remained on this level until removal of the pAFP. Afterwards, we observed 
a normalization of fHb within 48 hours. Blood transfusions were necessary in 6 patients 
(42.9 %). All patients were successfully weaned from pAFP. The 1-month survival rate 
was 78.6% (11 pts.).
Conclusions: The initial maximum of hemolysis within the ﬁrst 4 hours of pAFP support 
is partly reversible. However, no further increase in hemolysis should be expected 
afterwards. Signs of hemolysis should not result in termination of circulatory support. 
The beneﬁt of hemodynamic improvement overweighs the need for blood transfusion as 
observed in less than half of the patients.
11:00 a.m.
1031-75 Resuscitated Cardiac Arrest is Associated with 
Reduced In-Hospital, but not Long-term Survival in 
Acute Coronary Syndrome
Benjamin K. Dundon, Luan T. Huynh, Stephen G. Worthley, Ashish Soman, David B. 
Brieger, Derek P. Chew, University of Adelaide, Adelaide, Australia, Flinders University, 
Adelaide, Australia
Introduction: Acute Coronary Syndrome (ACS) complicated by pre-hospital Cardiac Arrest 
(CA) is commonly associated with poor clinical outcomes. Data regarding longer term 
prognosis and the effects of contemporary therapies are lacking in this cohort. We sought 
to assess the impact of successfully resuscitated Cardiac Arrest on ACS outcomes in 
routine clinical practice.
Methods: The Australian Collaborative Acute Coronary Syndromes Prospective Audit 
(ACACIA, n=3402, PML0051) is a prospective multi-centre registry of ST-segment 
elevation myocardial infarction and intermediate- to high-risk non-ST-segment elevation 
ACS patients, involving 39 Australian metropolitan and rural sites. ACS patients presenting 
following successfully resuscitated cardiac arrest were the focus of this investigation. 
Patient characteristics, management and clinical outcomes were assessed.
Results: In the seventy-nine patients assessed, successfully resuscitated, pre-hospital 
CA strongly predicted in-hospital mortality (HR 17.2, 95% CI 8.9-33.1, p<0.0001). 
Admission glomerular ﬁltration rate (eGFR) <60mL/minute was strongly associated with 
increased in-hospital mortality following CA (HR 4.7, 2.5-8.8, p<0.0001), but an invasive 
management strategy was associated with a marked reduction in in-hospital mortality (HR 
0.42, 0.23-0.79, p=0.007) despite multivariate adjustment and exclusion of patients dying 
within 24-hours of hospital presentation. Notwithstanding a poor short-term prognosis, no 
incremental hazard was seen at 12-month follow-up in ACS patients surviving to hospital 
discharge following CA (HR 1.2, 0.29-4.9, p=0.79).
Conclusions: Resuscitated CA prior to hospitalisation strongly predicted in-hospital 
mortality, but not post-discharge survival. The substantial in-hospital survival advantage 
conferred by early invasive therapy lends further support to the routine invasive 
management of such high-risk ACS patients.
11:00 a.m.
1031-76 Loss of Heart Rate and Blood Pressure Variability in 
Murine Sepsis
Anupam Gupta, Bryan Foley, Josh Weinstock, Karine Hageboutros, Jad Skaf, Joseph E. 
Parrillo, Sergio Zanotti, Steven M. Hollenberg, Cooper University Hospital, Camden, NJ
Background: Nonlinear analysis of beta-to-beat heart rate and blood pressure variability 
may provide insights into disease pathophysiology not available from standard linear 
measures. Calculation of volatility (standard deviation (SD) variability) is a means of 
assessing variability that may minimize artifact-induced error. We compared heart rate 
and blood pressure volatility in a murine model of resuscitated sepsis.
Methods: Radiotelemeters for noninvasive measurement of blood pressure were 
implanted into the ascending aorta of C57Bl/6 mice (8-12 weeks, n=23). After 5 to 7 
days of recovery post-implantation, baseline data were collected for 24 hours. The mice 
were then made septic by cecal ligation and puncture and resuscitated with ﬂuids and 
antibiotics every 6 hours; controls underwent sham ligation. Heart rate and blood pressure 
SDs were calculated for 1 minute and 5 minute intervals. For each animal, the SD cutoff 
of both heart rate and blood pressure that represented the lowest 5% was determined, 
and the % of low SDs (low volatility) in the entire experimental period was deﬁned by this 
cutoff. The % of low volatility periods was calculated over 1-hour and 4-hour intervals to 
generate time courses.
Results: Intervals with low heart rate and blood pressure volatility were increased in septic 
animals compared to controls (heart rate, 45.5±32% vs 4.7±4%, blood pressure 39.2±19% 
vs 11.7±5%, both p<0.05). Heart rate volatility decreased early in sepsis, and remained 
low in both septic survivors and non-survivors. Blood pressure volatility decreased early, 
but returned to control values in survivors and remained low in non-survivors.
Conclusion: Analysis of volatility is less susceptible to artifact than other nonlinear 
analytic measurements. These techniques show dramatic differences between septic 
and control animals. Heart rate volatility is a sensitive leading indicator of hemodynamic 
decompensation, while blood pressure volatility measures something distinct and may be 
a marker for failure to resolve organ dysfunction. Extrapolation of this methodology to the 
bedside has the potential to provide novel markers of hemodynamic decompensation in 
critically ill patients.
11:00 a.m.
1031-77 Resuscitation with Intraosseous Infusion of Liposome-
Encapsulated Hemoglobin (Artiﬁcial Oxygen Carrier 
Named TRM645) from Lethal Hemorrhagic Shock
Bonpei Takase, Satoshi Shono, Manabu Kinoshita, Yashiro Nogam, Yoshitaka Ogata, 
Hidemi Hattori, Masayuki Ishihara, National Defense Medical College, Tokorozawa, 
Japan, Terumo R&D Center, Ashigarakami-gun, Japan
Background: Liposome-encapsulated hemoglobin (TRM645), which is similar to natural 
red blood cells (RBC) except smaller size (250 nm), can serve as blood substitutes of 
oxygen-carrying capacity comparable to RBC. Intraosseous blood infusion (IOI), which is 
alternative to peripheral i.v. infusion, is expected as an important ﬁeld treatment in military 
and civilian emergency because intramedullary blood vessels in the bone marrow do not 
collapse in shock.
Methods: Study 1: We performed graded blood exchange experiment up to 75% blood 
loss in 16 mice (C57BL/6). Eight mice were gradually exchanged blood with 5% Albumin 
(Alb group) through superior vena cava while 8 mice exchanged with TRM645 (TRM645 




group). Study 2: Total 70% hemorrhagic shock was induced by femoral vein bleeding. 
Immediately after bleeding, 17 mice were resuscitated with tibial bone IOI of 5% Albumin 
(5% Albumin), 18 mice resuscitated with mouse-washed RBC (wash RBC) and 14 mice 
resuscitated with TRM645 (TRM-645). Survival rates were compared.
Results: Study 1: All mice died in Alb group whereas all survived in TRM645 group. Study 
2: All mice survived 48 h after IOI of TRM645 whereas only 47% and 45% mice survived 
in 5% Albumin and wash RBC, respectively (Fig. 1).The changes in RBC levels after IOI 
were not different among 3 groups (Fig. 2).
Conclusions: TRM645 has a salutary anti-shock effect in both i.v. and IOI. Especially, 
TRM645 is more effective than wash RBC in IOI probably due to smaller size. IOI of 
TRM645 could be useful in disaster medicine. 
11:00 a.m.
1031-78 A Systematic Review and Meta-analysis of the Value 
of Intra Aortic Balloon Pump Therapy in ST-elevation 
Myocardial Infarction Patients. Should we change the 
Guidelines?
Krischan D. Sjauw, Annemarie E. Engström, Jan G.P. Tijssen, Jan J. Piek, José P.S. 
Henriques, Academic Medical Center, University of Amsterdam, Amsterdam, The 
Netherlands
Background: Intra-aortic counterpulsation (IABP) in STEMI complicated by cardiogenic 
shock (CS) is listed in the ACC/AHA guidelines as a class IB recommendation. We 
performed meta-analysis in order to analyse the evidence in favour of concomitant IABP 
versus no support in high risk STEMI and in STEMI with CS.
Methods: Medical literature databases were scrutinized to identify randomized controlled 
trials (RCTs) of IABP therapy in acute high risk STEMI. Additionally, in the absence of 
RCTs, observational studies in STEMI with CS were identiﬁed. Two separate meta-
analysis were performed respectively. Random-effect absolute risk differences (ARD) 
were computed.
Results: Meta-analysis 1, which included 7 RCTs investigating IABP therapy in high risk 
STEMI patients (n=1009), showed no mortality difference (ARD 0.01 CI [-0.03, 0.04]; 
p=0.75). However, the rates of major bleeding and stroke were signiﬁcantly higher in 
IABP treated patients.
Meta-analysis 2, which included 9 observational studies in STEMI patients with CS 
(n=10329) showed a survival beneﬁt of IABP therapy (ARD -0.11 CI [-0.13, -0.09]; 
p<0.0001). However, signiﬁcant heterogeneity existed. Subsequent, subgroup analysis 
revealed a mortality beneﬁt in patients who received IABP adjunctive to thrombolysis 
(ARD -0.19 CI [-0.21, -0.16]; p<0.0001). However, amongst others, higher rates of rescue 
PCI and CABG in patients receiving IABP in this subgroup, were identiﬁed as important 
confounders. In the subgroup of patients treated by primary PCI, IABP was associated 
with a higher mortality (ARD 0.06 CI [0.06, 0.10]; p<0.0001).
Conclusion: There is no evidence for routine IABP therapy in patients with high risk 
STEMI. Although IABP therapy may be beneﬁcial as an adjunct to thrombolysis in STEMI 
patients with CS, this is only supported by observational data which importantly seems 
affected by confounders. The observational data did not support IABP adjunctive to 
primary PCI in STEMI patients with CS. However, meta-analysis of observational data 
should be seen as hypothesis generating. There is no scientiﬁc evidence supporting a 
class 1 recommendation for IABP therapy in STEMI with or without CS. This study will 
impact on current guidelines.
11:00 a.m.
1031-79 Epidemiology of Cardiogenic Shock Requiring 
Intensive Care Admission in Olmsted County, 
Minnesota
Amir H. Shoja, Rodrigo Cartin-Ceba, Mohammed Ahmed, Jaise Poulose, Girish Mour, 
Javier Cabello-Garza, Harpreet Suri, Ognjen Gajic, Daryl Kor, Mayo Epidemiology 
and Translational Research in Intensive Care (M.E.T.R.I.C.), Mayo Clinic College of 
Medicine, Rochester, MN
Background: While the incidence of Cardiogenic Shock (CS) following an acute coronary 
syndrome has been described, the epidemiology of all-cause CS requiring an Intensive 
Care Unit (ICU) admission is not, to our knowledge, known. The purpose of this study was 
to evaluate the epidemiology of CS in residents of Olmsted county, MN.
Methods: This was a retrospective cohort study of all Olmsted County residents admitted 
to the ICU’s of Mayo Clinic, Rochester, MN. This is the only center capable of providing 
continuous ICU services for patient’s in this demographic. A random quarter sample of 
the population was selected for analysis. We excluded patients who denied research 
authorization, were less than 18 years of age and who needed vasoactive support in 
the immediate post-cardiopulmonary bypass period. Those with prior withdrawal of care 
orders or a “mixed” distributive and CS picture were also excluded.
CS was deﬁned as a patient having 1. A shock index >1 or Systolic Blood Pressue (SBP) 
persistently <90 mmHg or need for vasoactive infusions to maintain a SBP >90 mmHg, 2. 
Evidence of end organ hypoperfusion and 3. Evidence of elevated ﬁlling pressures.
Results: The adult population of Olmsted County in 2006 was 100,716. During this one 
year evaluation, 88 patients developed 100 episodes of CS.
Median age of the patients with CS was 76 (IQR 63.5-81) of which 64% were females. 
The median BMI was 25.2 (IQR 22.7-34.1). The all cause in-hospital mortality following 
CS was 45% (95%CI 35-65).
CS was caused by NSTEMI in 40%, STEMI in 20% and other causes (arrhythmias, 
valvular disease, decompensated heart failure) in the remaining 40%.
The cumulative incidence of CS was 99 episodes (95%CI 68-147) per 100000 person-
years at risk. This translates to one episode of CS for every 1007 patient years. For a 
national life expectancy of 77.9 years, approximately one in 13 patients would develop 
CS in the course of his or her life in Olmsted county.
Conclusions: The incidence of cardiogenic shock in the community appears to be 
higher than previously reported. This may be explained by our use of more sensitive 
shock criteria. The in-hospital mortality was lower than expected, possibly due to recent 
improvements in our therapeutic approach.
11:00 a.m.
1031-80 Clinical Proﬁles of Patients Undergoing Coronary 
Artery Bypass Surgery or Percutaneous Coronary 
Intervention in California: A Comparative Analysis of 
Over 60,000 Patients
Zhongmin Li, Khung-Keong Yeo, Richard White, Geeta Mahendra, Ezra Amsterdam, 
University of California, Davis Medical Center, Sacramento, CA
Background: The clinical characteristics and peri-procedural outcomes among patients 
undergoing either Coronary Artery Bypass Surgery (CABG) or Percutaneous Coronary 
Intervention (PCI) have not been well deﬁned.
Methods: Using the California hospital discharge data, after excluding patients with 
emergent or salvage acuity, the preoperative risk proﬁles of all patients who had either 
PCI or CABG in 2004 were compared. Differences in peri-procedural myocardial infarction 
(MI), and re-admission for CABG and death were also determined.
Results: 61,641 patients had PCI (42,232, 68.5%) or CABG (19,409, 31.5%). Compared 
to PCI, CABG patients were more likely non-white and had more hypertension, diabetes, 
peripheral arterial disease, cerebrovascular disease, heart failure, dysrhythmia, chronic 
obstructive pulmonary disease, obesity, hepatic failure, mitral insufﬁciency and anemia 
(all p<0.001). However, CABG patients were less likely to: be female, have an urgent 
procedure, or have a history of prior MI/cardiac surgery/PCI (all p<0.001). On peri-
procedural outcomes, CABG patients had lower odds of procedure-related MI (OR: 0.57, 
95%CI: 0.53-0.62) or follow-up CABG (OR: 0.11, 95% CI: 0.08-0.15) but did have higher 
peri-procedural mortality (OR: 2.55, 95% CI: 2.25-2.88).
Conclusions: The clinical characteristics of patients undergoing CABG and PCI differed 
signiﬁcantly. CABG had higher peri-procedural mortality but less peri-procedural MI and 
need for a follow-up CABG.
# 
Clinical characteristics, outcomes and multivariate analyses in patients 








Age, yrs (mean) 66.6 67.5 0.000 1.003 1.001 1.005
Female 33.1% 28.3% <.0001 0.699 0.672 0.727
Non-white 28.7% 32.0% <.0001 1.194 1.149 1.241
Non-scheduled 61.1% 51.1% <.0001 0.642 0.620 0.665
‘Do not resuscitate’ 0.8% 0.9% 0.971 0.996 0.824 1.205
Hypertension 72.8% 76.3% <.0001 1.152 1.104 1.201
Diabetes 35.1% 41.0% <.0001 1.193 1.149 1.239
Peripheral arterial 
disease 11.2% 14.4% 0.007 1.079 1.021 1.140
Cerebrovascular 
disease 8.1% 12.3% <.0001 1.407 1.326 1.492
Heart failure 18.8% 26.3% <.0001 1.283 1.224 1.345
Heart block 7.8% 7.2% <.0001 0.745 0.695 0.798
Dysrhythmia 14.2% 19.1% <.0001 1.289 1.228 1.353
Chronic lung 
disease 13.5% 18.9% <.0001 1.321 1.258 1.387
Prior myocardial 
infarction 21.2% 20.6% <.0001 0.819 0.784 0.856
Dialysis 2.4% 2.5% 0.001 0.798 0.700 0.909
Renal failure 4.6% 5.7% 0.519 0.971 0.886 1.063
Obesity 1.6% 3.0% <.0001 1.867 1.664 2.094
Hepatic failure 0.8% 1.1% <.0001 1.447 1.211 1.728




AMI, % 7.61 4.52 <.0001 0.57 0.53 0.62
2) Re-Admission 
for CABG, % 2.07 0.23 <.0001 0.11 0.08 0.15
3) Operative 
Deaths, % 1.15 2.88 <.0001 2.55 2.25 2.88
1) or 2) or 3) 8.62 7.31 <.0001 0.84 0.78 0.89




















1031-83 Predicted Impact of Nesiritide on Dialysis and All-
Cause Hospital Mortality in Patients Undergoing 
Cardiac Surgery by Demonstrated Improvement in 
Post-Operative Glomerular Filtration Rate
Jinghua He, Almut G. Winterstein, Thomas M. Beaver, Department of Pharmacy Health 
Care Administration, College of Pharmacy, University of Florida, Gainesville, FL, 
Division of Thoracic and Cardiovascular Surgery, College of Medicine, University of 
Florida, Gainesville, FL
Background: The Nesiritide Administered Peri-anesthesia in Patients Undergoing Cardiac 
Surgery (NAPA) trial showed that nesiritide preserved renal function in cardiac surgery 
patients. Due to the small sample size, efﬁcacy estimates on dialysis and mortality were 
inconclusive.
Method: We built a decision tree model to predict the impact of nesiritide on dialysis 
and all-cause hospital mortality based on the post-operative glomerular ﬁltration rate 
change ($GFR) in the NAPA trial. The probabilities for dialysis and hospital mortality were 
obtained from a meta-analytic review of the literature. Analyses were performed in three 
scenarios: I. Full probabilistic analysis, repeatedly sampled probabilities for all variables 
from distributions based on 95% conﬁdence intervals (CI); II. Best-case nesiritide analysis, 
used the 95% CI boundary values of $GFR favoring nesiritide; III. Best-case placebo 
analysis, used the 95% CI boundary values of $GFR favoring placebo. 1000 consecutive 
Monte Carlo simulations for cohorts of 1000 hypothetical patients were performed for each 
analysis. Incremental dialysis rate (IDR) and incremental hospital mortality rate (IMR) 
for nesiritide versus placebo were calculated for total NAPA sample and two subgroups 
stratiﬁed by presence of pre-operative renal dysfunction, respectively.
Results: For the total sample, the model indicated signiﬁcantly lower dialysis and mortality 
rates in nesiritide group (P < 0.05) in all three scenarios (IDR: -2.90%, -5.10%, -0.70%; 
IMR -2.10%, -3.70%, -0.51%). The improvement was more pronounced in the stratum with 
pre-operative renal dysfunction (P < 0.05) (IDR: -4.60%, -7.90%, -1.20%; IMR: -3.40%, 
-6.10%, -0.88%). In the stratum without pre-operative renal dysfunction, the protective 
effect of nesiritide was signiﬁcant in scenario I and II (P < 0.05), but reversed in scenario 
III (IDR: -1.90%, -4.00%, 0.25%; IMR: -1.30%, -3.00%, 0.20%).
Conclusion: If demonstrated preservation of GFR can be extrapolated, nesiritide may 
reduce dialysis and all-cause hospital mortality rates; however, this effect does not exhibit 
robust superiority over placebo in patients without pre-operative renal dysfunction.
11:00 a.m.
1031-84 Chronic Olive Oil Consumption Is Associated With 
Better Short-Term Prognosis of Patients After Open 
Heart Surgery
Melina Sifakaki, Akrivi Lysikatou, Demosthenes B. Panagiotakos, Athanassios 
Manginas, George Stavrides, Maria Kotiou, Peter Alivizatos, Panagiotis Karioﬁllis, 
Dennis V. Cokkinos, Onassis Cardiac Surgery Center, Athens, Greece, Harokopio 
University, Athens, Greece
Background: Although the role of olive oil in the primary prevention of cardiovascular 
disease (CVD) has been studied and seems to be protective, research concerning its 
role in secondary prevention is rather limited. The aim of this work was to evaluate the 
association between olive oil intake and CVD risk after open heart surgery.
Methods: We enrolled 216 consecutive patients undergoing scheduled open-heart surgery; 
There were 163 men (62±12 years) and 53 women (65±10 years). Consumption of olive 
oil, vegetable seed oils, butter and margarines was assessed, by asking the patients 
about consumption in daily cooking. Quantiﬁcation of olive oil intake was determined 
as: a) low (<1spoon per use), b) moderate (2-3spoons per use), c) large (>3spoons per 
use). Patients were categorized as a) only olive oil consumers, b) olive oil plus other 
oils consumers, c) non- olive oil consumers. Clinical and biological characteristics were 
also measured. Multiple logistic regression models were used to evaluate the association 
between olive oil intake and the 30 day outcome (death or re-hospitalization due to CVD), 
after adjusting for various potential confounders.
Results: The 30 day CVD event rate following surgery was 13.4 per 100 patients (gender-
speciﬁc event rate: 14.7% in males vs. 9.2% in females, p=0.23). Only 4 cases were fatal 
(1.9%). Exclusive olive oil consumers were less likely to experience an adverse cardiac 
event within 30-days following surgery (p=0.02). Moreover, patients who reported plentiful 
olive oil consumption were almost 4 times less likely to have an adverse event during the 
follow-up period (p=0.001).
These ﬁndings were independent of sociodemographic, clinical and other lifestyle 
characteristics, including the Euroscore.
Conclusion: Our ﬁndings support the protective role of daily olive oil consumption in the 
short term prognosis of patients who had had open heart surgery. The wide range of 
antiatherogenic effects associated with olive oil consumption could explain its beneﬁcial 
effects in secondary prevention.
11:00 a.m.
1031-85 Intravascular Imaging Using Combined Intravascular 
Ultrasound and Photoacoustic Catheters in a Rabbit 
Atherosclerotic Model
Cezar A. Iliescu, Shriram Sethuraman, James Amirian, Silvio H. Litovsky, Bo Wang, 
Salavat Aglyamov, Andrew Hamilton, Stanislav Y. Emelianov, Richard W. Smalling, The 
University of Texas Health Science Center, Houston, TX
Background: Adverse clinical cardiovascular are frequently caused by rupture of plaques 
considered insigniﬁcant on coronary angiography. An integrated IVUS and intravascular 
photoacoustic (IVPA) imaging system improves visualization of both structural and 
functional properties of the atherosclerotic plaque.
Methods: A total of 12 New Zealand rabbits were fed a low cholesterol diet (0.1%) over 
6-12 months, high cholesterol diet (0.8%) over 3-4 months and created atherosclerotic 
lesions. IVUS (40 MHz) pullback was recorded in the descending thoracic aorta. The 
combined IVUS/IVPA imaging with spatially co-registered and temporally adjacent 
ultrasonic and photoacoustic beams acquired to generate one complete image was then 
performed ex vivo sample. The specimens were processed for H&E, collagen (picrosirius 
red) and macrophage activity (RAM11) histological staining.
Results: The combination of IVUS and IVPA imaging was technically possible and 
photoacoustic imaging complemented the structural data obtained with IVUS which 
correlated with tissue histology. The IVPA image demarcates the presence of lipids (lipid 
pool-1), ﬁbrous collagen (2), macrophages (3) and normal collagen (4).
Conclusions: IVUS/IVPA imaging can detect lipid ﬁlled vulnerable plaque and plaque 
containing macrophage foam cells, suggesting that IVUS/IVPA imaging system may 
provide a superior clinical tool in cardiovascular medicine. 
11:00 a.m.
1031-86 Emergent Coronary Bypass Surgery Following 
Percutaneous Coronary Intervention: Incidence, 
Predictors and Outcomes
Probal Roy, Teruo Okabe, Tina L. Pinto Slottow, Saquib Samee, Daniel H. Steinberg, 
Kimberly Smith, Zhenyi Xue, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, 
Augusto D. Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Technical advances have allowed percutaneous coronary intervention (PCI) 
to be performed with increasing safety. PCI is more commonly being performed at sites 
without surgical back-up. This study aimed to identify predictors of emergent coronary 
artery bypass graft (CABG) surgery since stent approval.
Methods: The study population consisted of 9164 unselected patients who underwent 
PCI since August 1994. Of this group 117 patients required CABG within 24 hours of PCI. 
Comparisons were made between CABG and no-CABG groups and logistic regression 
analysis was then performed to identify predictors of urgent CABG.
Results: The incidence of emergent CABG was 1.3%. Patients in the CABG group were 
younger (61.8±13.6 vs. 64.2±12.1, p=0.04), had more diseased vessels (2.3±0.7 vs. 
2.0±0.9 p<0.001), more prior PCI (44.4% vs.30.7% p=0.001), greater Type C lesions 
(49.7% vs. 28.0% p<0.001) and more restenotic lesions (18.7% vs.10.1% p<0.001). 
Independent predictors of emergent CABG are listed. See table. Patients requiring 
emergent CABG had signiﬁcantly worse in-hospital outcomes (cardiac death: 7.7% vs. 
0.6% p<0.001, Q-wave MI: 4.4% vs. 0.4% P<0.001, neurological events: 10.3% vs.1.1% 
p<0.001, renal insufﬁciency 19.6% vs.5.0% p<0.001).
Conclusions: Emergent CABG following PCI is infrequent but is associated with 
signiﬁcantly worse outcomes. Patients with multiple predictors of emergent CABG may 
identify those better treated at sites with surgical back-up. 
Odds ratio Conﬁdence intervals P
Prior PCI 1.77 1.13-2.79 0.01
Number of diseased vessels 1.62 1.28-2.04 <0.001
Left anterior descending artery 1.62 1.12-2.36 0.01
Type C lesion 2.52 1.74-3.66 <0.001
11:00 a.m.
1031-87 Magnetically Targeted Cell Delivery Improves 30-day 
Endothelialization of Synthetic Vascular Grafts
Adriana Harbuzariu, Danny Vo, Tyra Witt, Manju Kalra, David R. Holmes, Jr., Robert D. 
Simari, Gurpreet S. Sandhu, Mayo Clinic, Rochester, MN
Background: Synthetic vascular grafts often exhibit incomplete endothelialization and this 
has precluded their use in smaller vessels. Improvement of healing could lead to smaller 
caliber conduits for coronary applications. Superparamagnetic iron labeled autologous 
endothelial cells were coated on magnetized polyurethane grafts and implanted in pig 
carotids. We evaluated healing at 30 days.
Methods: 5g omental fat was cultured for 7d to obtain microvascular endothelial cells. 
These were labeled with 0.9u Bangs Labs SPIO (500 particles/cell) for 16h. TUNEL 
and BrdU assays conﬁrmed viability. A magnetic sheet was annealed circumferentially 
around 5mm grafts. Cells (106/ml) were placed within the grafts (n=3) for 10 min prior 
to surgical interposition in porcine carotids. Non-magnetic graft segments (n=3) were 
treated similarly.
Results: Magnetic and non-magnetic grafts had circumferential neointima (~1 mm 
thick). H&E staining showed excellent endothelialization, with well organized neointima 




in magnetic segments (A). Non-magnetic controls showed markedly disorganized 
neointima, along with patchy endothelialization (B). Prussian blue stain showed a faint 
ring of residual iron adjacent the inner graft surface.
Conclusions: Endothelial cell delivery to a magnetic graft resulted in signiﬁcantly improved 
healing. The superior endothelialization and neointimal organization may allow for the 
creation of smaller synthetic conduits for coronary and peripheral applications.
11:00 a.m.
1031-88 Long Term Clinical Outcomes of the Symmetry Aortic 
Connector Anastomotic Device in Coronary Artery 
Bypass Surgery
Gabriel Vorobiof, Angelo Pedulla, Stephen Minor, Peter Knight, Christopher J. Cove, 
University of Rochester, Rochester, NY
Background: The St. Jude Medical Symmetry Bypass System Aortic Connector device 
is a sutureless device that facilitates anastomosis of bypass grafts to the aorta during 
coronary bypass surgery (CABG) without the need for cross-clamping. Short and medium 
term clinical outcomes data suggest a higher graft occlusion rate in those who received 
this device. Data are lacking for the long-term clinical outcomes of this device.
Methods: To assess the long-term clinical outcomes of the Connector device, we 
performed a retrospective matched case-control analysis at our institution for patients 
who underwent implantation of at least one Connector device during their CABG between 
November 2001 and December 2002. We included 95 Connector patients and 120 
matched controls who underwent CABG using a traditional anastomotic technique.
Results: After a mean follow-up of 4.6 ± 1.6 years the primary composite endpoint of 
death, non-fatal MI and revascularization was signiﬁcantly more frequent in the Connector 
group (OR 2.18, 95% CI = 1.23 - 3.85, p<0.009). This was largely driven by a higher 
frequency of MI in the Connector group. No signiﬁcant differences were observed for 
the individual secondary endpoints of total mortality, non-fatal MI, ACS, stroke and CHF 
hospitalization.
Conclusions: In the most extensive follow-up data to date, signiﬁcantly higher rates of 
major adverse cardiovascular events were observed in patients receiving the Symmetry 
aortic connector device during CABG. This was largely driven by higher rates of non-fatal 
MI in the Connector group, which is consistent with the previously proposed mechanism of 
premature saphenous vein graft thrombosis and neointimal hyperplasia of the Connector 
device. We therefore recommend increased surveillance for patients who underwent 
CABG with this device.
